Clinical trial NCT02576938
Conditions: Atopic Dermatitis
Keywords: Atopic Eczema
Sponsor: Eli Lilly and Company
Start date: 2016-02-01; Completion date: 2017-03-01
Enrollment: 124 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of this study is to evaluate the safety and effectiveness of Baricitinib in eczema.

Detailed description:

Arms: arm 1: Administered once daily in multiple oral dose cohorts for 16 weeks

(Triamcinolone 0.1% topical also permitted) arm 2: Administered orally once daily, for 16 weeks

(Triamcinolone 0.1% topical also permitted)
Interventions: intervention 1: Baricitinib intervention 2: Placebo intervention 3: Triamcinolone (Optional)
Intervention descriptions: intervention 1: Administered orally intervention 2: Administered orally intervention 3: Administered topically

Protocol documents:
Prot_003.pdf: 
I4V-MC-JAHG Protocol Amendment (b)   
 
 
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety 
and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis. 
 
 
NCT ID: NCT02576938 
Approval Date: 07-March-2016 
 


I4V-MC-JAHG CSR Appendix Protocol 
Page 153 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 1 
 
 
Protocol I4V-MC-JAHG(b) 
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 
Study to Evaluate the Safety and Efficacy of Baricitinib in 
Patients with Moderate-to-Severe Atopic  Dermatitis 
 
 
 
 
 
 
 
Baricitinib 
 
 
 
 
Chorus, Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
 
 
 
Protocol Approval Date: 30-September-2015 
Amendment (a) Approval Date: 23-October-2015 
Amendment (b) Approval Date:   07-March-2016 
 
 
 
 
 
 
LY3009104 
Confidential Information 
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and  
should not be copied by or distributed to persons not involved in the clinical investigation of 
baricitinib, unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its  subsidiaries. 
Parallel, double-blinded, randomized placebo-controlled multiple dose study in patients with 
moderate-to-severe atopic dermatitis 


I4V-MC-JAHG CSR Appendix Protocol 
Page 154 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 2 
 
Table of Contents 
Section 
Page 
1. 
Protocol Synopsis ........................................................................................... 9 
2. 
Introduction .................................................................................................. 11 
2.1. 
Background ............................................................................................. 11 
2.2. 
Study Rationale ....................................................................................... 12 
3. 
Objectives and Endpoints ............................................................................. 13 
4. 
Study Design ................................................................................................ 15 
4.1. 
Overview of Study Design ...................................................................... 15 
4.2. 
Scientific Rationale for Study Design ..................................................... 15 
4.3. 
Justification for Dose .............................................................................. 16 
4.4. 
Benefit/Risk Assessment ......................................................................... 16 
5. 
Study Population .......................................................................................... 18 
5.1. 
Inclusion Criteria ..................................................................................... 18 
5.2. 
Exclusion Criteria ................................................................................... 18 
5.3. 
Screen Failures ........................................................................................ 22 
6. 
Treatment ..................................................................................................... 23 
6.1. 
Treatments Administered ........................................................................ 23 
6.2. 
Method of Treatment Assignment ........................................................... 23 
6.2.1. 
Selection and Timing of Doses ....................................................... 23 
6.3. 
Blinding .................................................................................................. 24 
6.4. 
Packaging and Labeling .......................................................................... 24 
6.5. 
Investigational Products Storage and Handling ...................................... 25 
6.6. 
Dose Modification ................................................................................... 25 
6.7. 
Treatment Compliance ............................................................................ 25 
6.8. 
Concomitant Therapy .............................................................................. 25 
6.9. 
Treatment after Study Completion .......................................................... 26 
6.9.1. 
Continued Access ........................................................................... 26 
7. 
Discontinuation Criteria ............................................................................... 27 
7.1. 
Discontinuation of Investigational Product ............................................. 27 
7.1.1. 
Temporary Interruption of Investigational Product ........................ 27 
7.1.2. 
Permanent Discontinuation of Investigational Product ............................................. 27 
7.1.3. 
Discontinuation of Inadvertently Enrolled Patients ........................ 28 
7.1.4. 
Permanent Discontinuation from the Study .................................... 28 
7.1.5. 
Patients Lost to Follow-Up ............................................................. 29 
8. 
Study Assessments and Procedures .............................................................. 30 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 155 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 3 
8.1. 
Efficacy Assessments ............................................................................. 30 
8.1.1. 
Primary Efficacy Assessments ....................................................... 30 
8.1.2. 
Secondary Efficacy Assessments ................................................... 30 
8.1.3. 
Appropriateness of Primary Efficacy Measure .............................. 31 
8.2. 
Adverse Events ....................................................................................... 32 
8.2.1. 
Adverse Events/Laboratory Results of Special Interest ........................................... 33 
8.2.2. 
Serious Adverse Events .................................................................. 33 
8.2.2.1. 
Suspected Unexpected Serious Adverse Reactions ............................................ 34 
8.2.3. 
Complaint Handling ....................................................................... 34 
8.3. 
Treatment of Overdose ........................................................................... 34 
8.4. 
Safety Assessments ................................................................................. 34 
8.4.1. 
Physical Examination ..................................................................... 35 
8.4.2. 
Electrocardiograms ......................................................................... 35 
8.4.3. 
Vital Signs ...................................................................................... 35 
8.4.4. 
Laboratory Tests ............................................................................. 35 
8.4.5. 
Hepatitis B virus (HBV) DNA monitoring .................................... 35 
8.4.6. 
Quick Inventory of Depressive Symptomatology-Self  Report 
16 (QIDS-SR16) ....................................................................................................... 36 
8.4.7. 
Safety Monitoring .......................................................................... 36 
8.5. 
Pharmacokinetics .................................................................................... 36 
8.5.1. 
PK Sample Collection .................................................................... 36 
8.5.2. 
PK Sample Assay ........................................................................... 38 
8.5.3. 
PK Sample Storage and Retention ................................................. 38 
8.6. 
Pharmacodynamics ................................................................................. 38 
8.7. 
Genetics .................................................................................................. 38 
8.8. 
Biomarkers .............................................................................................. 39 
8.8.1. 
Skin Biopsies .................................................................................. 39 
8.8.2. 
Nonpharmacogenetic Biomarkers .................................................. 39 
8.9. 
Health Economics ................................................................................... 40 
9. 
Statistical Considerations and Data Analysis .............................................. 41 
9.1. 
Determination of Sample Size ................................................................ 41 
9.2. 
General Statistical Considerations .......................................................... 41 
9.3. 
Treatment Group Comparability ............................................................ 41 
9.3.1. 
Patient Disposition ......................................................................... 41 
9.3.2. 
Patient Characteristics .................................................................... 42 
9.3.3. 
Concomitant Therapy ..................................................................... 42 
9.4. 
Primary and Secondary Analyses ........................................................... 42 
9.4.1. 
Primary Analyses ........................................................................... 42 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 156 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 4 
9.4.2. 
Secondary Analyses ....................................................................... 42 
9.4.3. 
Tertiary/Exploratory Analyses ....................................................... 42 
9.5. 
Safety Analyses ....................................................................................... 43 
9.6. 
Pharmacokinetic/Pharmacodynamic Analyses ....................................... 43 
9.7. 
Other Analyses ........................................................................................ 43 
9.7.1. 
Health Economics .......................................................................... 43 
9.7.2. 
Biomarkers ..................................................................................... 43 
9.8. 
Interim Analyses ..................................................................................... 43 
10. Study Governance Considerations ............................................................... 44 
10.1. Regulatory and Ethical Considerations, Including the  Informed 
Consent Process ................................................................................................................ 44 
10.1.1. 
Informed Consent ........................................................................... 44 
10.1.2. 
Ethical Review ............................................................................... 44 
10.1.3. 
Regulatory Considerations ............................................................. 44 
10.1.4. 
Investigator Information ................................................................. 45 
10.1.5. 
Protocol Signatures ........................................................................ 45 
10.1.6. 
Final Report Signature ................................................................... 45 
10.2. Data Quality Assurance .......................................................................... 45 
10.2.1. 
Data Capture System ...................................................................... 46 
10.3. Study and Site Closure............................................................................ 47 
10.3.1. 
Discontinuation of Study Sites ....................................................... 47 
10.3.2. 
Discontinuation of the Study .......................................................... 47 
11. References .................................................................................................... 48 
1 
Protocol Synopsis ............................................................................................................. 68 
4.1 
Overview of Study Design ................................................................................................ 69 
5.1 
Inclusion Criteria .................................................................................... 70 
5.2 
Exclusion Criteria ................................................................................... 70 
8.4.5.  Hepatitis B virus (HBV) DNA monitoring ....................................................................... 71 
9.1 
Determination of Sample Size ................................................................ 71 
9.2 
General Statistical Considerations .......................................................... 71 
9.8 
Interim Analyses ............................................................................................................... 72 
3 
Objectives and Endpoints ................................................................................................. 74 
5.2 
Exclusion Criteria ............................................................................................................. 75 
7. 
Discontinuation Criteria ............................................................................... 77 
7.1. 
Discontinuation of Investigational Product ............................................ 77 
7.1.1. 
Temporary Interruption of Investigational Product ....................... 77 
7.1.2. 
Permanent Discontinuation of Investigational Product ............................................ 77 
8.1.2 Secondary Efficacy Assessments ......................................................... 78 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 157 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 5 
 
8.4.6 
Quick Inventory of Depressive Symptomatology-Self  Report 
16 (QIDS-SR16) ....................................................................................................... 79 
11. References ............................................................................................................................... 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 158 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 6 
 
List of Tables 
Table 
Page 
Table JAHG.1.    Objectives and Endpoints ................................................................................... 13 
Table JAHG.2.    Treatment Regimens........................................................................................... 23 
Table JAHG.3.    Criteria for Temporary Interruption from Study Treatment ............................... 27 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product ................... 28 
Table  JAHG.5.     Timing  of  Dosing  and  Fasting  Requirements  for  PK  Sample  Collection 
Visits .................................................................................................................. 37 
Table JAHG.3.    Criteria for Temporary Interruption from Study Treatment ............................... 77 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product ................... 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 159 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 7 
 
List of Figures 
Figure 
Page 
Figure JAHG.1.   Illustration of study design for Clinical Protocol I4V-MC-JAHG. .................... 15 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 160 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 8 
 
List of Appendices 
Appendix 
Page 
Appendix 1. 
Abbreviations and Definitions ........................................................................... 51 
Appendix 2. 
Schedule of Activities ........................................................................................ 56 
Appendix 3. 
Clinical Laboratory Tests ................................................................................... 62 
Appendix 4. 
Hepatic Monitoring Tests for Treatment-Emergent Abnormality ...................... 65 
Appendix 5. 
Protocol I4V-MC-JAHG Signature Page ........................................................... 66 
Appendix 6. 
Protocol Amendment I4V-MC-JAHG(a) Summary  [A Randomized, 
Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the 
Safety and Efficacy of Baricitinib in Patients with  Moderate-to-Severe 
Atopic Dermatitis] ............................................................................................. 67 
Appendix 7. 
Protocol Amendment I4V-MC-JAHG(b) Summary  [A Randomized, 
Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the 
Safety and Efficacy of Baricitinib in Patients with  Moderate-to-Severe 
Atopic Dermatitis] ............................................................................................. 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 161 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 9 
 
1. Protocol Synopsis 
 
Title of Study: 
A randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of baricitinib in 
patients with moderate-to-severe atopic dermatitis. 
Rationale: 
Baricitinib is a JAK1/JAK2 selective inhibitor that is currently in development for treatment of inflammatory   
diseases such as rheumatoid arthritis and psoriasis. Baricitinib has been administered to healthy subjects and patients 
with rheumatoid arthritis (RA), moderate-to-severe plaque stage psoriasis, and diabetic nephropathy  (DN). 
In addition, baricitinib is also being developed for the treatment of atopic dermatitis (AD). This study will evaluate 
the safety and efficacy of baricitinib in patients with moderate-to-severe atopic  dermatitis. 
Objective(s)/Endpoints: 
 
Objectives 
Endpoints 
Primary 
To compare the proportion of moderate-to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose group (2 mg and 4 mg) and placebo 
when treated daily for 16 weeks 
Secondary 
To evaluate the absolute and percent change from baseline of the EASI with 
baricitinib compared to placebo at weeks 1 and 4 and monthly intervals  thereafter 
To evaluate the mean change from baseline of the SCORing Atopic Dermatitis 
(SCORAD) with baricitinib compared to placebo at weeks 1 and 4 and monthly 
intervals thereafter 
To evaluate the mean change from baseline of the Investigator’s Global 
Assessment (IGA) with baricitinib compared to placebo at weeks 1 and 4 and 
monthly intervals thereafter 
To assess quality of life based on the Dermatologic Life Quality Index (DLQI) at 
baseline, weeks 1 and 4 and monthly intervals  thereafter 
To assess itch using the itch numerical rating scale (NRS) at baseline, weeks 1 
and 4 and monthly intervals thereafter 
To evaluate the pharmacokinetics of baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 
 
Summary of Study Design: 
 
Study I4V-MC-JAHG is a multicenter, randomized, double-blind, parallel, placebo-controlled study designed to 
compare the efficacy and safety of baricitinib to placebo in patients with moderate-to-severe atopic dermatitis. 
Enrollment will be targeted at 120 patients to enable approximately 96 patients to complete the study. Patients who 
meet all eligibility criteria will be randomized to receive either placebo or baricitinib, administered as once daily   
oral doses of 2 mg or 4 mg.  Randomization will occur at the country  level. 
Treatment Arms and Duration: 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 162 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 10 
 
Three arms will be randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, respectively. Study drug will 
be administered as oral tablets to be taken once-daily (QD) for 16 weeks. A background therapy of a mid-potency 
topical corticosteroid (triamcinolone 0.1%) will be utilized during the 28-day standardization phase prior to 
randomization and continued throughout the study. This background therapy should be used according to the  
labeling provided by the manufacturer or as directed by the  investigator. 
Number of Patients:  120 
 
Statistical Analysis: 
 
Sample Size 
The study will plan to enroll 120 patients that will be randomized 4:3:3 to 
placebo, 2 mg baricitinib, or 4 mg baricitinib,  respectively. 
Primary Outcome & Methodology 
The primary outcome parameter is the proportion of patients achieving 
EASI-50 in each treatment arm. The placebo arm will be compared to each 
of the baricitinib arms using a two-sided chi-square test with alpha=0.05 to 
control the study-wise type 1 error rate; the comparison of the baricitinib 
arms with the placebo arm will be performed in a stepwise fashion.  The 
4-mg baricitinib arm will be compared with the placebo arm; if this test is 
statistically significant, then the 2-mg baricitinib arm will be compared with 
the placebo arm. Enrollment of 120 patients in a 4:3:3 ratio provides 
approximately 90% power for detecting a 35% difference in response rate 
between placebo and 4-mg baricitinib treatment. 
Interim Analysis 
An interim analysis is not planned for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 163 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 11 
 
 
 
2.1. Background 
2. Introduction 
Atopic dermatitis (AD) is a common skin disorder characterized clinically by chronic 
inflammation and altered skin barrier function, and histologically by skin infiltration of 
inflammatory cells. AD is characterized by excessive T-cell activation, with significant skin 
infiltration by T-cells and dendritic cells. Both Th2 and Th22 activation are hallmarks of AD, 
with some Th17 and Th1 components. Patients with moderate-to-severe AD are afflicted with a 
heavy disease burden including medical as well as psycho-social abnormalities. Patients often 
have bacterial- or viral-mediated cutaneous complications. AD is the most common chronic 
inflammatory skin disease (Schmitt, 2013) with a prevalence of 2%–10% among adults in 
western geographies (Bieber, 2010) and a prevalence of about 3% in Japan (Muto et al,   2003). 
Studies using genomic and histologic profiling of AD skin have defined sets of biomarkers for  
AD that include markers of epidermal hyperplasia (epidermal thickness, K16 and Ki67 staining), 
epidermal barrier components (filaggrin), specific cellular infiltrates, including T-cells (CD3+  
and CD8+) and several dendritic cell subsets (CD11c+, CD1a+, inflammatory dendritic   
epidermal cells). Serum biomarkers that correlate with disease activity include IgE, eosinophils, 
eosinophilic cationic protein, as well as the Th2 chemokines CCL17, CCL18, CCL22, CCL11, 
and CCL26, and the cytokines IL-13, IL-31, and IL-22 (Mansouri,  2015). 
Members of the Janus kinase (JAK) family of protein tyrosine kinases (JAK1, JAK2, JAK3, and 
TYK2), along with the signal transduction and activator of transcription (STAT) pathway, play   
an important role in signal transduction following cytokine and growth factor binding to their 
receptors (Pesu, 2008). Emerging data support the role of JAK and STAT in Th2 immunity, 
activating eosinophils, and suppressing regulatory T cells. The JAK-STAT pathway, activated by 
IL-4, plays a critical role in the pathogenesis of AD by upregulating epidermal chemokines, pro- 
inflammatory cytokines, and proangiogenic factors as well as by down-regulating antimicrobial 
peptides and factors responsible for skin barrier function (Bao, 2013). Consistent with the  
proposed role of IL-4 activation of the JAK-STAT pathway in AD, administration of a  
monoclonal antibody against the alpha subunit of the IL-4 receptor improved clinical endpoints 
associated with AD (Beck, 2014). 
Baricitinib (also previously known as LY3009104 and INCB028050) is a potent and selective 
small molecule inhibitor of JAK1 and JAK 2 enzymes that is currently under development for 
the treatment of inflammatory conditions such as rheumatoid arthritis, diabetic kidney disease, 
psoriasis, and AD. 
Through 04 June 2015, approximately 4300 subjects have received baricitinib. This group of 
subjects was comprised of healthy subjects and patients with rheumatoid arthritis, psoriasis, 
diabetic kidney disease, rare auto-inflammatory syndromes, various degrees of renal impairment, 
and hepatic dysfunction. Baricitinib has been administered as single doses ranging from 1 to 40 
mg, multiple doses of up to 20 mg QD for 10 days, 10 mg QD for 28 days or 5 mg twice daily    
for 28 days in healthy subjects; and as a single 10-mg or 5-mg dose to subjects with mild to 
moderate or severe renal impairment respectively, as well as a single 5-mg dose to patients   with 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 164 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 12 
 
end stage renal disease. Treatment duration has ranged from single doses in healthy volunteers  
to approximately 3.5 years in rheumatoid arthritis  patients. 
More information about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably anticipated adverse events (AEs) of baricitinib are to be found in the 
Investigator’s Brochure (IB). 
 
2.2. Study Rationale 
Inhibition of JAK-STAT signaling by targeting multiple AD-associated cytokine pathways has 
the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key 
immune cells. Treatment of six patients with AD with a JAK1 and JAK3 inhibitor, tofacitinib,  
led to marked improvement in both objective measures of dermatitis and pruritus and patient- 
reported pruritus (Levy, 2015). 
Baricitinib is a potent and selective small molecule inhibitor of JAK1/2 enzymes. In vitro, 
baricitinib inhibits JAK1 and JAK2 with IC50 values in the single-digit nM range, yet it does not 
significantly inhibit a diverse panel of 28 kinases when tested at 100-fold of the IC50 against  
JAK1 and JAK2. In healthy volunteers, baricitinib demonstrated dose and time-dependent 
inhibition of cytokine-induced pSTAT3 (Shi,  2014). 
Study I4V-MC-JAHG will evaluate the safety and efficacy of baricitinib in patients with 
moderate-to-severe atopic dermatitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 165 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 13 
 
3. Objectives and Endpoints 
Table JAHG.1 shows the objectives and endpoints of the  study. 
 
Table JAHG.1. 
Objectives and Endpoints 
 
Objectives 
Endpoints 
Primary 
 To compare the proportion of moderate- 
to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in 
the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose 
group (2 mg and 4 mg) and placebo when 
treated daily for 16 weeks 
 EASI-50 at 16 weeks 
Secondary 
 To evaluate the absolute and percent 
change from baseline of the EASI with 
baricitinib compared to placebo 
 EASI at Weeks 1, 4, 8, 12, and 16 
 To evaluate the mean change from 
baseline compared to placebo for the 
SCORing Atopic Dermatitis  (SCORAD) 
 SCORAD at  Weeks 1, 4, 8, 12, and  16 
 To evaluate the mean change from 
baseline compared to placebo for the 
Investigator’s Global Assessment  (IGA) 
 IGA at Weeks 1, 4, 8, 12, and 16 
 To assess quality of life based on the 
Dermatologic Life Quality Index (DLQI) 
 DLQI at Weeks 1, 4, 8, 12, and 16 
 
To assess itch based on the Itch 
Numerical Rating Scale (NRS) 
 Itch Numerical Rating Scale at Weeks 1, 
4, 8, 12, and 16 
 To characterize the pharmacokinetics of 
baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 Plasma pharmacokinetic data 
Exploratory 
 To evaluate EASI response in patients 
based on their baseline total serum  IgE 
 EASI at Weeks 1, 4, 8, 12 and 16; baseline 
total serum IgE 
 To evaluate total serum IgE over the 
course of treatment 
 Total serum IgE at baseline, Weeks 4, and 
16 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 166 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 14 
 
Exploratory (continued) 
 To evaluate changes in disease activity 
over the course of treatment 
 Patient-Oriented Eczema Measure (POEM) 
at  Weeks 1, 4, 8, 12, and 16 
 To evaluate changes in sleep quality over 
the course of treatment 
 Number of sleep disturbances and average 
percentage of sleep time from a wearable 
actigraphy device 
 To evaluate changes in nocturnal itch 
patterns over the course of treatment 
 Number of scratching events per night from 
a wearable actigraphy device 
 To evaluate EASI response relative to 
filaggrin genotype 
 EASI-50 and filaggrin genotype data from 
peripheral baseline blood sample 
 To assess tissue biomarkers from  biopsies 
 K16, Ki-67, and IL-4 will be assessed from 
each tissue biopsy (collected at baseline 
(lesion and non-lesion), at Week 4 (lesion), 
and at Week 16 (lesion and  non-lesion) 
 To assess peripheral biomarkers 
mechanistically related to inhibition of 
JAK 1/2 mechanism 
 Peripheral biomarkers collected at baseline, 
Weeks 4 and 16 
 To perform subgroup assessments of 
response based on patient and disease 
characteristics 
 Ad hoc evaluation of potential prognostic 
and predictive disease characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 167 
LY3009104 
 
 
4 mg baricitinib 
2 mg baricitinib 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 15 
 
4. Study Design 
4.1. Overview of Study Design 
I4V-MC-JAHG is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the 
safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The study 
design is illustrated in Figure JAHG.1. 
Standardization 
Treatment 
Follow-up 
 
 
 
 
120 AD 
Patients 
Placebo 
4 Weeks 
16 Weeks 
4 Weeks 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
Week: 
-4 
0 
1 
4 
8 
12 
16 
20 
Day: 
-28 
0 
7 
28 
56 
84 
112 
140 
 
 
 
Screening Randomization 
(4:3:3) 
Placebo : 2 mg baricitinib : 4 mg baricitinib 
 
Figure JAHG.1. 
Illustration of study design for Clinical Protocol I4V-MC-JAHG. 
 
 
 
4.2. Scientific Rationale for Study Design 
This study will enroll moderate-to-severe atopic dermatitis patients for whom a systemic 
treatment such as baricitinib may be appropriate. A 16-week course of treatment is expected to 
enable an optimal assessment of efficacy based on previous baricitinib studies in an 
inflammatory skin condition. 
Relatively high (20% to 50%) placebo responses have been observed in previously published 
atopic dermatitis studies (Bissonnette, 2012; Beck, 2014; Epstein and Pinski, 1964). Therefore, a 
4:3:3 randomization scheme of placebo, 2 mg baricitinib, and 4 mg baricitinib will be 
implemented.   Increased placebo enrollment across treatment groups has been reported to  
decrease placebo response and to also increase statistical power (Mallinckrodt,   2011). 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 168 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 16 
 
A standardization phase will be incorporated prior to randomization to minimize effects due to 
background treatment. Beginning at standardization and continuing throughout the study, 
patients will be provided a topical corticosteroid to be used as prescribed and may continue use 
of other allowed study-specified palliative care measures as specified in Section   6.8. 
The EASI and SCORAD are the best instruments available to measure clinical severity of AD 
(Schmitt, 2013). Several quality of life assessments are being utilized to evaluate the effect of 
baricitinib on patients’ quality of life. 
 
4.3. Justification for Dose 
This study will evaluate the safety and efficacy of 2-mg and 4-mg doses of baricitinib in patients 
with moderate-to-severe atopic dermatitis. The dose justification for AD is based on a Phase 2 
rheumatoid arthritis (RA) study (Study JADA), reported Phase 3 RA studies (Study JADW and 
Study JADX) and a Phase 2 psoriasis study (Study  JADP). 
In these studies, all doses were generally well tolerated based on the observed adverse event 
profile and infrequent discontinuations of baricitinib dosing. The anticipated on-target, dose- 
limiting effect is a small decline in hemoglobin and hematocrit values. As described in Section 
4.4, this likely results from inhibition of erythropoietin signals via the JAK2/STAT5 signal 
transduction pathway (Klingmüller, 1997; Vera, 2008). These hematologic effects occur in 
higher-dose groups (8 mg daily) upon initiation of treatment and then   stabilize. 
The 2-mg and 4-mg doses have shown efficacy in RA with an acceptable safety profile. There  
was no additional efficacy associated with an 8-mg dose in the Phase 2 RA study, thus only 4 mg 
and 2 mg have been studied in the RA Phase 3 program. Doses less than 2 mg were not clearly 
effective in RA. 
In patients with moderate-to-severe plaque stage psoriasis, doses of 4 mg to 10 mg were found to 
be associated with statistically significant reductions in Psoriasis Area and Severity Index (PASI) 
score, with greater efficacy at the higher doses; however, the 8-mg and 10-mg doses were 
associated with a higher rate of AEs related to laboratory abnormalities (decreases in    
hemoglobin, neutrophils, and lymphocytes). The 2-mg and 4-mg dose groups had a pattern of   
AEs similar to placebo. The 2-mg dose did show numeric reductions in PASI score compared   
with placebo and statistically significant reductions in itch. Thus, in AD, the highest dose to be 
tested will be 4 mg, which would be anticipated to show efficacy together with an acceptable  
safety profile, and also provide the opportunity to cross reference to the large safety database   
from the RA Phase 3 program. The lower dose of 2 mg also has the opportunity to show efficacy  
in AD, where itch is a major component of the disease and may provide data that may be useful    
in the future for patients less than 18 years of  age. 
 
4.4. Benefit/Risk Assessment 
Baricitinib is a specific inhibitor of JAK1/2 and may offer potential benefit to patients with 
moderate-to-severe AD. Increases in serum creatinine and in both LDL and HDL cholesterol 
have been observed in Phase 1 and 2 studies with baricitinib (see Investigator’s   Brochure). 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 169 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 17 
 
Baricitinib is a specific inhibitor of JAK1/2 that has shown to be well-tolerated and effective in 
chronic inflammatory conditions such as rheumatoid arthritis (Keystone, 2015) and psoriasis 
(Menter, 2014). Baricitinib may offer potential benefit in a chronic inflammatory dermatologic 
condition such as AD. 
Phase 1 and 2 studies with baricitinib showed increased levels of serum creatinine and LDL and 
HDL cholesterol (see Investigator’s Brochure). Similar increased levels of creatinine and 
cholesterol were also seen in tofacitinib, a JAK1/3 inhibitor (Fleischmann, 2012; Kremer, 2012). 
In addition, reductions in absolute neutrophil counts have been reported with both baricitinib and 
tofacitinib. Other pathways that signal through JAK include granulocyte macrophage colony 
stimulating factor and granulocyte colony stimulating factor signal and erythropoietin (JAK2) 
(Parganas, 1998). The assessment of safety of baricitinib in this study will therefore also include, 
but will not be limited to, monitoring of creatinine, cholesterol, neutrophil and granulocyte  
counts, hemoglobin levels, and rates of  infection. 
More information about the known and expected benefits, risks, and reasonably anticipated  
adverse events may be found in the Investigator’s Brochure. Information on adverse events 
expected to be related to the investigational product may be found in Section 7 (Development  
Core Safety Information) of the Investigator’s Brochure. Information on serious adverse events 
expected in the study population independent of drug exposure will be assessed by the sponsor in 
aggregate periodically during the course of the study and may be found in Section 6 (Effects in 
Humans) of the Investigator’s  Brochure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 170 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 18 
 
5. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, will not be  permitted. 
 
5.1. Inclusion Criteria 
Patients are eligible to be included in the study only if they meet all of the following   criteria: 
Type of Patient and Disease  Characteristics 
[1] Are at least 18 years of age at the time of Visit  1 
[2] Have moderate-to-severe AD, as determined by all of the  following: 
 EASI ≥12 at Visits 1 and 2 
 ≥10% of body surface area (BSA) involvement at Visits 1 and  2 
 Were diagnosed with AD at least 2 years before Visit  1 
With a history of inadequate clinical response, in the opinion of the 
investigator, to one or more of the three treatment categories listed below 
(used for at least 4 weeks): 
 Category 1: Hydration plus topical steroids and/or antibiotics (e.g., 
tetracycline, trimethoprim and sulfamethoxazole, cephalosporins) and/or 
topical immune modulators (e.g.,  tacrolimus/pimecrolimus) 
 Category 2:   Systemic steroids and/or phototherapy 
 Category 3: Cyclosporine and/or other immunomodulators (e.g., 
methotrexate, mycophenolate mofetal, and  azathioprine) 
[3] Agree to discontinue use of the following excluded medications for at least 4 
weeks prior to randomization (Visit 2) and throughout the  study 
 oral cyclosporine, steroids, and leukotriene  inhibitors 
 phototherapy 
 potent topical steroids (e.g., clobetasol) or topical immune modulators 
(e.g., tacrolimus/pimecrolimus). 
 cyclosporine and/or other immunomodulators (e.g., methotrexate, 
mycophenolate mofetal, and  azathioprine) 
 
5.2. Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
Medical Conditions 
[4] Are female subjects who are pregnant or  nursing 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 171 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 19 
 
[5] Are females of childbearing potential who do not agree to use 2 forms of  
highly effective methods of birth control or remain abstinent while enrolled in 
the study and for at least 28 days following the last dose of investigational 
product 
Note: Females of nonchildbearing potential are defined as women ≥60 years 
of age, or women >40 and <60 years of age who have had a cessation of 
menses for at least 12 months, or women who are congenitally or surgically 
sterile (that is, have had a hysterectomy or bilateral oophorectomy or tubal 
ligation). 
The following birth control methods are considered highly effective (the 
patient should choose 2): 
 Oral, injectable, or implanted hormonal  contraceptives 
 Condom with a spermicidal foam, gel, film, cream, or  suppository 
 Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal 
foam, gel, film, cream, or  suppository 
 Intrauterine device 
 Intrauterine system (for example, progestin-releasing  coil) 
 Vasectomized male (with appropriate post-vasectomy documentation 
of the absence of sperm in the  ejaculate). 
[6] 
Are males who do not agree to use 2 forms of highly effective birth control 
(see above) with female partners of childbearing potential while enrolled in 
the study, and for at least 28 days following the last dose of investigational 
product 
Are currently experiencing or have a history of any of the  following: 
[7] Other concomitant skin conditions (e.g., psoriasis, or lupus erythematosus) 
that would interfere with evaluations of the effect of study medication on 
atopic dermatitis 
[8] Erythrodermic, refractory or unstable skin disease that requires frequent 
hospitalizations and/or intravenous treatment for skin  infections 
[9] Immunocompromised and, in the opinion of the investigator, at an 
unacceptable risk for participating in the  study 
[10] Serious concomitant illness that could require the use of systemic 
corticosteroids or otherwise interfere with study participation or require active 
frequent monitoring (e.g., unstable chronic  asthma) 
[11] Organ transplant(s) (corneal transplant performed >3 months prior to 
screening may be allowed) 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 172 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 20 
 
[12] Clinically important deviation, in the opinion of the investigator, from normal 
limits in physical examination, vital sign measurements, and/or 
electrocardiograms, that is not associated with a chronic, well-controlled 
medical condition 
[13] Electrocardiogram (ECG) abnormalities at Visit 1 that, in the opinion of the 
investigator or the sponsor, are clinically significant and indicate an 
unacceptable risk for the patient’s participation in the study (Bazett’s 
corrected QT interval >470 msec for men and  women) 
[14] Have evidence of active or latent TB as documented by a positive PPD test 
(≥5 mm in duration between approximately 2 and 3 days after application, 
regardless of vaccination history), medical history, and chest x-ray at 
screening. Exceptions are patients with a history of latent TB who have 
documented evidence of completing a course of appropriate  treatment. 
 If the PPD test is positive or not conducted and the patient has no medical 
history or chest x-ray findings consistent with active or latent TB, the 
patient should have a QuantiFERON®-TB Gold test or the T-SPOT.TB® 
test. If either of these tests is positive or indeterminate (a single re-test is 
allowed), the patient is excluded from the  study. 
[15] Active or latent granulomatous disorders or a non-tuberculous mycobacterial 
infection or opportunistic systemic infection (e.g., Pneumocystis carinii, and 
aspergillosis) within 6 months prior to  screening 
[16] Uncompensated heart failure, fluid overload, myocardial infarction, or 
evidence of ischemic heart disease or other serious cardiac disease within 12 
weeks of Visit 1 
[17] Uncontrolled arterial hypertension characterized by a repeated systolic blood 
pressure >160mm Hg or diastolic blood pressure >100mm Hg at the time of 
Visit 1 
[18] Malignancy (except for basal or squamous cell carcinoma completely excised 
without evidence of recurrence) or lymphoproliferative diseases or have signs 
or symptoms suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly including  lymphoma 
Note: Patients with cervical carcinoma in situ that has been resected with no 
evidence of recurrence or metastatic disease, or with basal cell or squamous 
epithelial skin cancers that have been completely resected with no evidence of 
recurrence for at least 3 years may participate in the  study. 
[19] Evidence of HIV infection or are positive for HIV antibodies (based on 
history or point-of-care testing (POCT)) at Visit  1 
[20] Positive test for hepatitis B defined as: 
a) positive for hepatitis B surface antigen (HBsAg),  or 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 173 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 21 
 
b) positive for anti-hepatitis B core antibody (HBcAb) and positive for hepatitis B 
deoxyribonucleic acid (HBV DNA), or 
c) for patients enrolled in Japan only, positive for anti-hepatitis B core antibody 
(HBcAb) and/or positive for anti-hepatitis B surface antibody (HBsAb), and 
positive for hepatitis B deoxyribonucleic acid (HBV  DNA). 
 
If any of the hepatitis B tests have an indeterminate result, confirmatory testing will 
be performed by an alternate method. 
 
[21] Positive for anti-hepatitis C antibody with confirmed presence of hepatitis C 
virus, or chronic liver disease with the most recent available AST or ALT >2X 
the ULN 
[22] Serious and/or unstable mental and/or physical illness that, in the opinion of 
the investigator, poses an unacceptable risk for the patient’s participation in 
the study 
Prior/Concomitant Therapy 
[23] Received any oral JAK inhibitor (e.g., Xeljanz) within the past 6  months 
[24] Currently receiving any immunosuppressive therapy (e.g.,  cyclosporine) 
[25] Received any monoclonal antibody intended for AD (e.g., ustekinumab or 
dupilumab) within the past 6  months. 
[26] Currently using or expected to use concomitant medications or treatments for 
AD other than those allowed for use in the  protocol 
[27] Exposed to a live vaccine, including the nasal flu vaccine, within 12 weeks 
prior to planned enrollment (with the exception of herpes zoster vaccination; 
patients will be excluded if they were exposed to herpes zoster vaccination 
within 30 days of planned enrollment) or are expected to need/receive a live 
vaccine during the course of the  study. 
Prior/Concurrent Clinical Trial  Experience 
[28] Currently enrolled in any other clinical study involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this  study 
[29] Participated, within the last 30 days (for Japan, 4 months) in a clinical study 
involving an investigational product. If the previous investigational product 
has a long half-life (2 weeks or longer), at least 3 months or 5 half-lives 
(whichever is longer) should have  passed. 
[30] Previously completed or withdrawn from this  study 
Diagnostics Assessments 
Have any of the following specific abnormalities on screening laboratory   tests: 
[31] AST or ALT >2X the ULN 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 174 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 22 
 
[32] Total bilirubin ≥1.5X the ULN 
[33] Hemoglobin < LLN 
[34] Total white blood cell count <  LLN 
[35] Neutropenia (absolute neutrophil count <  LLN) 
[36] Lymphopenia (lymphocyte count <  LLN) 
[37] Thrombocytopenia (platelets < LLN) 
[38] eGFR <50 mL/min/1.73 m2 (based on CKD  EPI) 
Note: In the case of any of the aforementioned laboratory abnormalities, they may 
be repeated once within 1 week of the initial values, and values resulting from  
repeat testing may be used to assess enrollment  eligibility. 
Other Exclusions 
[39] 
Donated blood of more than 500 mL or blood products within 4 weeks 
prior to entry. 
[40] 
Unwilling to commit to refrain from donating blood or blood products 
during the study. 
[41] 
History of substance abuse (drug or alcohol) within the two years before 
screening. 
[42] 
Unable or unwilling to be available for the duration of the study and/or are 
unwilling to follow study  restrictions/procedures. 
[43] 
Unable or unwilling to have skin biopsies performed, unless exempted by 
the investigator. 
[44] 
Investigator site personnel directly affiliated with this study and/or their 
immediate families; immediate family is defined as a spouse, parent, child, 
or sibling, whether biological or legally  adopted. 
[45] 
Employees of the sponsor. 
 
5.3. Screen Failures 
Individuals who do not meet the criteria for participation in this study (screen failure) may be re- 
screened. Individuals may be re-screened once (time period from screen fail to re-screen to be 
determined by the investigator). If re-screening is performed, the individual must sign a new 
informed consent form (ICF) and will be assigned a new identification number. Additionally, all 
screening procedures must be conducted at re-screen to ensure all eligibility criteria are   met. 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 175 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 23 
 
6. Treatment 
6.1. Treatments Administered 
This study includes the treatment regimens outlined in Table JAHG.2 below. Doses of baricitinib 
or placebo will be administered orally. 
 
 
Table JAHG.2. 
Treatment Regimens 
 
    Treatment Group 
Dose (QD) 
Day 1 through Day 112 
2 mg LY 
(1  2-mg LY tab; 1  4-mg placebo tab) 
4 mg LY 
(1  2-mg placebo tab; 1  4-mg LY tab) 
Placebo 
(1  2-mg placebo tab; 1  4-mg placebo tab) 
Abbreviations:  tab = tablet; LY = baricitinib 
 
 
The investigator or his/her designee is responsible for the  following: 
 explaining and verifying the correct use of the investigational agent(s) to the 
patient and site personnel 
 maintaining accurate records of investigational product dispensing and   collection 
 returning, at the end of the study, all unused investigational product to the 
sponsor, or its designee, unless the sponsor and sites have agreed all unused 
medication is to be destroyed by the site, as allowed by local  law 
 
6.2. Method of Treatment Assignment 
Patients who meet all criteria for enrollment will be randomized to double-blind treatment at   
Visit 2. Assignment to treatment groups will be determined by a computer-generated random 
sequence using an interactive response technology (IRT) system. The IRT system will be used to 
assign blister packs containing double-blind investigational product to each patient. The IRT 
system will dispense a number of blister packs adequate for each visit   interval. 
The randomization will be stratified by  country. 
 
6.2.1. Selection and Timing of Doses 
Patient treatment assignments will be based on the randomization scheme as described   above. 
On PK sample collection days (Appendix 2), specific fasting and dose timing requirements are 
outlined in Table JAHG.5 (Section  8.5.1). 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 176 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 24 
 
6.3. Blinding 
This is a double-blind study in which the patients, investigator, and study site personnel will be 
blinded to treatment allocation. 
To preserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is   complete. 
Emergency unblinding for AEs may be performed through an IRT system, which may  
supplement or take the place of emergency codes generated by a computer drug-labeling system. 
This option may be used ONLY if the patient’s well-being requires knowledge of the patient’s 
treatment assignment. All calls resulting in an unblinding event are recorded and reported by the 
IRT system. 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warranted. Patient safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the sponsor CRP prior to  
unblinding a patient’s treatment  assignment. 
If an investigator, site personnel performing assessments, or patient is unblinded to the treatment 
code assignment, the sponsor must be contacted  immediately. 
 
6.4. Packaging and Labeling 
The sponsor (or its designee) will provide the following investigational   products: 
 tablets containing 2 mg of baricitinib 
 tablets containing 4 mg of baricitinib 
 placebo to match baricitinib 2 mg tablets 
 placebo to match baricitinib 4 mg tablets 
Additionally, the sponsor (or its designee) will also provide the following concomitant therapy 
product: 
 triamcinolone 0.1% cream which should be used according to the labeling provided 
by the manufacturer or as directed by the  investigator 
Investigational products and triamcinolone 0.1% cream will be dispensed to the patient at the 
investigator’s study site. 
Investigational product will be packaged in blister packs. Investigational product packaging will 
be labeled with a unique identifier for drug dispensing by the IRT system. Blister packs will 
contain additional tablets to allow for sufficient administration of investigational product within 
the allowed visit internal window. 
Investigational product will be labeled according to the country’s regulatory requirements. All 
investigational products will be stored, inventoried, reconciled, and destroyed according to 
applicable regulations. Investigational products will be manufactured and tested by the sponsor 
or its representative in accordance with current Good Manufacturing Practices   (cGMP) 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 177 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 25 
 
requirements for clinical studies, and will be supplied with lot numbers, expiry dates, and 
certificates of analysis (as applicable). 
 
6.5. Investigational Products Storage and  Handling 
Investigational products should be stored between 15°C and 30°C. All investigational products 
should be stored in a secure and locked area with strictly limited access and monitored for 
temperature and will be allocated and dispensed by appropriately trained   personnel. 
 
6.6. Dose Modification 
No dose modifications will be  allowed. 
 
6.7. Treatment Compliance 
Patient compliance with study medication will be assessed at each visit. Compliance will be 
assessed by counting returned tablets. Deviation(s) from the prescribed dosage regimen should 
be recorded in the CRF. 
The patient will be considered significantly noncompliant if he or she misses more than 20% of 
the prescribed doses during the study. Similarly, a patient will be considered significantly 
noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken 
more than the prescribed amount of  medication. 
Patients found to be noncompliant with investigational product should be assessed to determine 
the reason for noncompliance, and educated and/or managed as deemed appropriate by the 
investigator to improve compliance. 
 
6.8. Concomitant Therapy 
The use of triamcinolone 0.1% cream will be allowed throughout the trial. Patients will be 
instructed to apply the triamcinolone 0.1% cream according to the labeling provided by the 
manufacturer or as directed by the investigator. The triamcinolone 0.1% cream container will be 
weighed at each visit to assess usage. 
All other concomitant medication taken during the study must be recorded on the Concomitant 
Medication case report form (CRF). Treatment with concomitant atopic dermatitis therapies 
during the study is permitted only as outlined in the inclusion/exclusion criteria (Section 5.1 and 
Section 5.2) and as described in the paragraphs  below. 
Additional systemic drugs are to be avoided during the study, unless required to treat an   AE. 
Non-live seasonal vaccinations and/or emergency vaccination (such as rabies or tetanus 
vaccinations) are allowed. 
The following will be allowed as needed: use of topical antibiotics in the event of secondary 
infections of lesions; nonprescription shampoos; NSAIDs; diphenhydramine (50 mg); and 
topical moisturizers/emollients, bath oils, oatmeal bath preparations, bleach baths if using a  
stable regimen prior to enrollment, and salicylic acid preparations.  Patients will be instructed   to 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 178 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 26 
 
consult the investigator or other appropriate study personnel at the site before taking any new 
medications or supplements. 
 
6.9. Treatment after Study Completion 
6.9.1.   Continued Access 
The Investigational Product will not be made available to patients after the conclusion of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 179 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 27 
 
7. Discontinuation Criteria 
7.1. Discontinuation of Investigational  Product 
7.1.1. Temporary Interruption of Investigational  Product 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs   
or abnormal laboratory values as described in Table JAHG.3 that may have an unclear  
relationship to investigational product. Except in cases of emergency, it is recommended that the 
investigator consult with the sponsor (or its designee) before temporarily interrupting   therapy. 
The investigator must obtain approval from the sponsor (or its designee) before restarting 
investigational product that was temporarily discontinued because of an AE or abnormal 
laboratory value. Investigational product must be held in the following situations involving 
laboratory abnormalities and may be resumed as noted in Table  JAHG.3. 
 
Table JAHG.3. 
Criteria for Temporary Interruption from Study Treatment 
 
 
Hold Investigational Product if the Following 
Laboratory Test Results Occur: 
Investigational Product May Be Resumed after 
Approval from Lilly (or its Designee) and When: 
eGFR <40 mL/min/1.73 m2 (from serum 
 creatinine) 
eGFR 50 mL/min/1.73 m2 
ALT or AST >5 times the ULN 
ALT and AST return to <2 times the ULN, and 
investigational product is not considered to be the  cause 
of enzyme elevation 
Symptomatic herpes zoster 
All skin lesions have crusted and are resolving 
Severe infection that, in the opinion of the 
investigator, merits the investigational product 
 being discontinued 
Resolution of infection 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; min = minute; ULN = upper limit of normal; 
WBC = white blood cell. 
 
7.1.2. Permanent Discontinuation of Investigational  Product 
Any patient who is permanently discontinued from investigational product for an AE or  
abnormal laboratory result should have the reason for investigational product discontinuation 
reported as the AE or abnormal laboratory value. If any of the criteria listed in Section 7.1.1. 
above recur after investigational product is restarted, the investigator must obtain approval from 
the sponsor (or its designee) before restarting investigational product.  In addition, patients will  
be permanently discontinued from investigational product if they experience any of the criteria 
listed in Table JAHG.4. 
Any adverse event that is Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 
or higher will result in permanent discontinuation from the study except for transaminases and 
severe infection as noted in Table JAHG.3 and Table  JAHG.4. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 180 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 28 
 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product 
 
Permanently Discontinue Investigational Product if any of the Following are  Observed: 
ALT or AST >8 times the ULN 
ALT or AST >5 times the ULN persisting for more than 2 weeks after temporary interruption of investigational 
product 
ALT or AST >3 times the ULN and total bilirubin level >2 times the  ULN 
ALT or AST >3 times the ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) 
WBC count <3000 cells/L 
ANC <1500 cells/L 
Lymphocyte count <800 cells/L 
Hemoglobin <10 g/dL 
Platelet count <75,000/L 
Pregnancy 
Malignancy (except for successfully treated basal cell or squamous epithelial skin  cancers) 
HBV DNA ≥29 IU/mLa 
Score of 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any time during the   study 
 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; HBV DNA = hepatitis B virus deoxyribonucleic acid; ULN = upper limit of normal; 
WBC = white blood cell; QIDS-SR16 = Quick Inventory of Depressive Symptomatology-Self-Report   16. 
a If a HBV DNA result of ‘target detected’ 29 IU/mL or greater, then the patient should be referred to a hepatology 
specialist immediately. In selected cases, investigators may temporarily continue study drug in accordance with 
current immunomodulator management in the setting of HBV DNA positivity. This option may be considered in 
consultation with the sponsor (or its designee) and evaluation of individual patient risks and benefits. Refer to 
Section 8.4.5 for additional instruction on HBV DNA  monitoring. 
 
7.1.3. Discontinuation of Inadvertently Enrolled  Patients 
If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the sponsor CRP and the investigator to 
determine if the patient may continue in the study. If both agree it is medically appropriate to 
continue, the investigator must obtain documented approval from the sponsor CRP to allow the 
inadvertently enrolled patient to continue in the study with or without treatment with 
investigational product. 
 
7.1.4. Permanent Discontinuation from the  Study 
Some possible reasons that may lead to permanent discontinuation   include: 
 Enrollment in any other clinical study involving an investigational product or enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this study 
 Participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical practice   (GCP) 
 Investigator Decision 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 181 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 29 
 
o the investigator decides that the patient should be discontinued from the   study 
o if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new   agent 
 Patient  Decision 
Patients who discontinue the study early will have early termination (ET) procedures performed 
as shown in the Schedule of Activities (Appendix  2). 
 
7.1.5. Patients Lost to Follow-Up 
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make  
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 182 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 30 
 
8. Study Assessments and  Procedures 
Appendix 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for timing). 
Appendix 3 lists the laboratory tests that will be performed for this  study. 
Appendix 4 provides the hepatic monitoring tests for treatment-emergent   abnormalities. 
Additionally, a study addendum will be compiled to detail the capture of photographs from 
selected lesions for patients enrolled at up to three selected study sites. These photographs will 
permit documentation of the clinical response through sequential photography of a selected 
lesion or involved area before and following study drug  treatment. 
 
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results. Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards. 
 
8.1. Efficacy Assessments 
Study procedures and their timing are summarized in the Schedule of Activities (Appendix   2). 
 
8.1.1. Primary Efficacy Assessments 
The clinical outcome measure that will be used in this study is the EASI score (specifically, the 
proportion of patients achieving a 50% reduction in EASI or  EASI-50). 
 Eczema Area and Severity Index (EASI) scores: The EASI assesses extent of disease 
at four body sites and measures four clinical signs: (1) erythema, (2) 
induration/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3. 
EASI confers a maximum score of 72. EASI evaluates two dimensions of atopic 
dermatitis: disease extent and clinical signs.
 
8.1.2. Secondary Efficacy Assessments 
 Mean and Percentage change in Eczema Area and Severity Index (EASI) scores: See 
above.
 
 SCORing Atopic Dermatitis (SCORAD): The SCORAD index uses the rule of nines to 
assess disease extent and evaluates five clinical characteristics to determine disease 
severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) 
lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss 
with Visual Analogue Scales (VAS). These three aspects: extent of disease, disease 
severity and subjective symptoms combine to give a maximum possible score of 103.
 
 
Investigator’s Global Assessment (IGA): The IGA consists of a 6-point severity scale 
from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate 
disease, 4 = severe disease and 5 = very severe disease). IGA uses clinical characteristics
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 183 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 31 
 
of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall 
severity assessment. 
 
 
Dermatology Life Quality Index (DLQI): The DLQI is a simple, patient-administered, 
10-question, validated, quality-of-life questionnaire that covers 6 domains including 
symptoms and feelings, daily activities, leisure, work and school, personal relationships, 
and treatment. The recall period of this scale is over the “last week.” Response categories 
include “not at all,” “a lot,” and “very much,” with corresponding scores of 1, 2, and 3 
respectively and unanswered (“not relevant”) responses scored as 0. A DLQI total score 
of 0 to 1 is considered as having no effect on a patient’s health-related quality of life, and 
a 4-point change from baseline is considered as the minimal clinically important 
difference threshold (Khilji, 2002; Hongbo, 2005; Basra, 2015).
 
 
Itch Numerical Rating Scale (NRS): The Itch NRS is a patient-administered, 11 point 
horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 
representing “worst itch imaginable.”  Overall severity of a patient’s itching is 
indicated by circling the number that best describes the worst level of itching in the 
past 24 hours.
8.1.2.2 Exploratory Efficacy Assessments 
Data on the following exploratory efficacy measures will be collected at the times shown in the 
Schedule of Activities (Appendix 2): 
 Patient-Oriented Eczema Measure (POEM): The Patient-Oriented Eczema Measure 
(POEM) was originally developed to help address the imbalance between physician and 
patient-based outcome measures in eczema research. Patients answer simple questions 
about the frequency of seven symptoms: itch, sleep disturbance, skin bleeding, skin 
weeping/oozing, skin cracking, skin flaking, and skin dryness/roughness over the last 
week. The total score from this assessment reflects overall disease activity. The POEM 
utilizes a 5-point Likert scale for each question and is intended for ages 1-60 years. 
POEM scores can range from 0 to 28 where lower total scores reflect lower disease 
activity and higher scores reflect higher disease activity (Charman, 2004).
 
 Actigraphy Device: A hypoallergenic wrist watch-like device that is used to collect 
sleep/wake patterns and quantify nocturnal scratching events (Ferguson, 2015).
 
8.1.3. Appropriateness of Primary Efficacy  Measure 
 Eczema Area and Severity Index (EASI): The EASI is one of the best instruments 
available to measure clinical signs of AD. EASI utilizes objective physician estimates of 
disease extent and severity. The EASI is valid and internally consistent and has adequate 
intraobserver reliability, intermediate interobserver reliability, and adequate 
responsiveness. One advantage of the EASI is its unidimensionality; that is, it only 
measures clinical signs of AD and does not include symptoms. Another advantage of the 
EASI is that it measures the intensity of the lesions at multiple body parts (rather than 
relying on a representative lesion) (Schmitt, 2013).
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 184 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 32 
 
8.2. Adverse Events 
The investigator remains responsible for following, through an appropriate health care option,  
AEs that are (1) serious or otherwise medically important, (2) considered related to the 
investigational product or the study, or that (3) caused the patient to discontinue the  
investigational product before completing the study. The patient should be followed until the  
event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The 
frequency of follow-up evaluations of the AE is left to the discretion of the   investigator. 
The sponsor has standards for reporting AEs that are to be followed regardless of applicable 
regulatory requirements that may be less stringent. Study site personnel will record the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. All AEs collected in the study 
CRF will be validated and reported in the final study  report. 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect. 
After the ICF is signed, study site personnel will record, via the CRF/electronic data entry, the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. In addition, site personnel will 
record any change in the condition(s) and any new conditions as AEs. Investigators should  
record their assessment of the potential relatedness of each AE to protocol procedure or 
investigational product. 
Investigators must document their review of each laboratory safety  report. 
Any clinically significant findings from ECGs, laboratory tests, vital sign measurements, and 
other procedures that result in a diagnosis should be reported to the sponsor or its designee. In 
addition, all AEs occurring after the patient receives the first dose of the investigational product 
must be reported to the sponsor or its  designee. 
Investigators will be instructed to report to the sponsor or its designee their assessment of the 
potential relatedness of each AE to protocol procedure or investigational product via the case 
report form. 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the  study. 
Cases of pregnancy that occur during maternal or paternal exposures to the investigational   
product should be reported. Data on fetal outcome and breast-feeding are collected for regulatory 
reporting and drug safety evaluation. 
Study site personnel must alert the sponsor or its designee immediately of the investigator 
unblinding a patient’s treatment group assignment for any  reason. 
If a patient’s treatment is discontinued as a result of an AE, study site personnel must clearly 
report to the sponsor or its designee the circumstances and data leading to any such 
discontinuation of treatment. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 185 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 33 
 
8.2.1. Adverse Events/Laboratory Results of Special Interest  
Adverse events or laboratory results of special interest include infections; myelosuppressive 
events of anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia; thrombocytosis; 
hyperlipidemia; hypercholesterolemia; and elevations in ALT/AST (≥3X ULN) and total 
bilirubin (≥2X ULN). 
8.2.2. Serious Adverse Events 
Study site personnel must alert the sponsor or its designee of any SAE within 24 hours of 
investigator awareness of the event via a sponsor-approved method. Alerts issued via telephone 
are to be immediately followed with official notification on study-specific SAE   forms. 
All SAEs will be reported in the study CRF and on the approved study-specific SAE form by the 
study site personnel. In addition, the study-specific SAE forms will be collected by 
sponsor/designee and subsequently entered into the clinical study database and the study safety 
database. Investigators will be required to update the study-specific SAE forms when new 
information becomes available, and address questions from the sponsor/designee until the SAE  
has been fully resolved or explained to the satisfaction of the sponsor. The SAE data from both 
CRF and study-specific SAE forms will be validated and included in the final CSR. If the SAE 
cases are closed after the completion of database lock, such information may not be included in  
the final study report. Such additional information will continue to be collected in the study- 
specific SAE form, and be reported either in an amendment to study report if such information 
leads to clinically significant change(s) in the conclusion of the study; or in the annual 
Development Safety Update Report (DSUR) or IB update if the information from the SAE does 
not alter the overall conclusion of the  study. 
An SAE is any AE from this study that results in one of the following   outcomes: 
 death 
 initial or prolonged inpatient  hospitalization 
 a life-threatening experience (that is, immediate risk of  dying) 
 persistent or significant  disability/incapacity 
 congenital anomaly/birth defect 
 considered significant by the investigator for any other  reason 
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Previously planned (prior to signing of ICF) surgeries should  
not be reported as SAEs unless the underlying medical condition has worsened during the course 
of the study. 
SAEs occurring after a patient has taken the last dose of the investigational product will be 
collected in the pharmacovigilance system and clinical data collection database for 30 days after 
the last dose of the investigational product, regardless of the investigator’s opinion of   causation. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 186 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 34 
 
Thereafter, SAEs are not required to be reported unless the investigator feels the events were 
related to either investigational product, drug delivery system, or a protocol   procedure. 
Sponsor/designee has the option to request follow up information or clarification of existing 
information from the investigators up to closure of the case. SAEs should be followed by the 
investigator until resolution of all queries, clinical recovery is complete or until a stable clinical 
endpoint has been reached. Follow up may therefore continue after the patient has been  
discharged from the study. The type and extent of follow up undertaken will be determined for 
each individual case and depends upon the nature, severity, and medical significance of the  
report. The follow up may include supplemental investigations, additional laboratory tests, 
histopathological examinations, or consultations with other health care professionals. If a patient 
dies during participation in the study, the follow up may include a copy of any post-mortem 
findings, if available. 
The investigator site will be required to contact the patient in accordance with their procedures to 
obtain necessary information to provide updates to the study-specific SAE forms. Requests for 
outstanding information from the investigational site to patients should be maintained as part of  
the clinical study documents. 
8.2.2.1. 
Suspected Unexpected Serious Adverse  Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed   
in the IB and that the investigator identifies as related to investigational product or procedure. 
United States 21 CFR 312.32 and European Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participating countries  
require the reporting of SUSARs. The sponsor has procedures that will be followed for the 
recording and expedited reporting of SUSARs that are consistent with global regulations and the 
associated detailed guidances. 
 
8.2.3.   Complaint Handling 
The Sponsor collects product complaints on investigational products and drug delivery systems 
used in clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product  improvements. 
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be   assessed. 
 
8.3. Treatment of Overdose 
Refer to the baricitinib Investigator’s  Brochure. 
 
8.4. Safety Assessments 
Safety assessments include vital signs, physical examination, electrocardiograms, AEs, patient- 
reported scale data, and safety laboratory  testing. 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 187 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 35 
 
8.4.1. Physical Examination 
A complete physical examination will be performed during Visit 1 (screening). Directed physical 
examinations will be performed according to the Schedule of Activities (Appendix 2) and may    
be repeated at the investigator’s discretion any time a patient presents with physical   complaints. 
 
8.4.2. Electrocardiograms 
For each patient, an electrocardiogram (ECG) should be performed according to the Schedule of 
Activities (Appendix 2) and as deemed necessary by the  investigator. 
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient receives the first dose of the investigational treatment should be reported to Lilly or its 
designee as an AE via the CRF. 
 
8.4.3. Vital Signs 
For each patient, vital signs measurements should be conducted according to the Schedule of 
Activities (Appendix 2) and following study specific recommendations provided by the sponsor 
for the study. 
Any clinically significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
 
8.4.4. Laboratory Tests 
For each patient, laboratory tests detailed in (Appendix 3) should be conducted according to the 
Schedule of Activities (Appendix 2). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of investigational product should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
 
8.4.5. Hepatitis B virus (HBV) DNA  monitoring 
For US study sites, patients who are HBsAg negative, HBcAb positive, and HBV DNA negative 
(undetectable) at Visit 1 will require HBV DNA monitoring at Visits 5 and 8 or ET, regardless of 
their HBsAb status. 
For study sites in Japan only, patients who are HBsAg negative, HbcAb and/or HbsAb positive, 
and HBV DNA negative (undetectable) at Visit 1 will require HBV DNA monitoring at Visits 5 
and 8 or ET. 
If the HBV DNA result is ‘target detected’ ≥29 IU/mL at any point in the study, then the patient 
should be referred to a hepatology specialist immediately and discontinuation considered (refer   
to Table JAHG.4). In selected cases, investigators may temporarily continue study drug in 
accordance with current immunomodulator management in the setting of HBV DNA positivity. 
This option may be considered in consultation with the sponsor (or its designee) and evaluation  
of individual patient risks and  benefits. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 188 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 36 
 
8.4.6. Quick Inventory of Depressive Symptomatology-Self Report 16 
(QIDS-SR16) 
For each patient, the QIDS-SR16 should be administered according to the Schedule of Activities 
(Appendix 2). 
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and 
severity of symptoms of depression as listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (American 
Psychiatry Association [APA] 1994). The QIDS-SR16 scale is used to assess the potential  
impact of treatment on new onset or changes in depression, thoughts of death, and /or suicidal 
ideation severity. A patient is asked to consider each statement as it relates to the way they   have 
felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items 
corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, 
with higher scores denoting greater symptom severity. The domains assessed by the instrument 
include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) 
energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or   hypersomnia), 
(8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation (Rush,   2003). 
If an increase of 5 or more from the baseline QIDS-SR16 total score is noted, the patient should   
be evaluated on site for risk of suicide and/or referred to a mental health provider for   assessment. 
A patient who scores a 2 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be evaluated on site for risk of suicide and/or referred to a mental 
health provider for assessment. 
A patient who scores a 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be discontinued (Table  JAHG.4). 
 
8.4.7. Safety Monitoring 
The sponsor will periodically review evolving aggregate safety data within the study by 
appropriate methods. 
If a patient experiences elevated ALT ≥3X ULN, ALP ≥3X ULN, or elevated TBL ≥2X ULN, 
clinical and laboratory monitoring should be initiated by the investigator. Details for hepatic 
monitoring depend upon the severity and persistence of observed laboratory test abnormalities.  
To ensure patient safety and comply with regulatory guidance, the investigator is to consult with 
the sponsor CRP regarding collection of specific recommended clinical information and follow- 
up laboratory tests (Appendix 4). 
 
8.5. Pharmacokinetics 
8.5.1. PK Sample Collection 
A total of 6 venous blood samples (approximately 5 mL per sample) for the measurement of 
baricitinib concentrations will be drawn at visits scheduled within the time windows specified   in 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 189 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 37 
 
the Schedule of Activities (Appendix 2). Specific dosing and fasting requirements for each PK 
visit are described in Table JAHG.5  below. 
 
 
 
Table JAHG.5. 
Timing of Dosing and Fasting Requirements for  PK Sample 
Collection Visits 
Events 
Visit 
2 
4 
5 
6 
7 
ET 
Overnight 
(8-hr) fast 
Yes 
No 
No 
No 
Yes 
No 
Take study 
drug 
At clinic 
At home 
At home 
At clinic 
At clinic 
N/A 
Morning Fast 
Until PK 
samples are 
taken 
N/A 
N/A 
N/A 
Until PK 
sample is 
taken 
N/A 
Sample time 
windows 
relative to dose 
 
Pre-dose 
 
15-30min 
post-dose 
1.5 – 4 hr 
post-dose 
4 – 8 hr 
post-dose 
Pre-dose 
30-90 min 
post-dose 
N/A 
 
On all PK sample collection days, patients should take all study medication within 5   minutes. 
At Visits 2 and 7, patients will be asked to arrive at the study site after an overnight fast. Patients 
will receive an oral dose of placebo or baricitinib at the study site and will remain fasted until PK 
blood samples have been collected. A light snack will be provided after PK samples have been 
collected. 
At Visits 4 and 5, patients will be advised to take the study drug at home. Patients will then go  
to the study site in the scheduled time window for study  assessments. 
At Visit 6, patients will be advised to NOT take study drug prior to visiting the study site. A 
single blood sample will be collected prior to the patient taking their drug at the study   site. 
A single PK sample will be obtained, whenever possible, at the early termination visit. In the 
event of an SAE, up to 2 additional blood samples may be taken at the investigator’s discretion, 
up to 6 hours after the reported event and within 24 hours of the patient’s last   dose. 
For any PK sample taken, the actual date and time (24-hour clock) of PK sample collection as 
well as the date and time of the last 2 dose administrations prior to the PK sample should be 
recorded. 
The sponsor, or its designee, will provide instructions for the collection and handling of blood 
samples. 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 190 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 38 
 
8.5.2. PK Sample Assay 
Plasma samples will be assayed for baricitinib using a validated liquid chromatography with 
tandem mass spectrometry (LC/MS/MS) method at a laboratory approved by the sponsor. 
Samples from patients receiving baricitinib will be assayed. PK samples from patients on 
placebo are not planned to be assayed. 
 
8.5.3. PK Sample Storage and  Retention 
Bioanalytical samples collected to measure investigational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study. Pharmacokinetic samples will  
be kept in storage at a laboratory facility designated by the sponsor and may also be assayed for 
additional exploratory analyses. Pharmacokinetic results will not be provided to investigative   
sites or blinded personnel until the study has been  unblinded. 
 
8.6. Pharmacodynamics 
Further pharmacodynamic data, beyond efficacy and biomarker data, will not be   collected. 
 
8.7. Genetics 
A blood sample (approximately 10 mL) will be collected for pharmacogenetic analysis as 
specified in the Schedule of Activities (Appendix 2) where local regulations and ethical review 
boards (ERBs) allow. 
Samples will not be used to conduct unspecified disease or population genetic research either  
now or in the future. Samples will be used to investigate variable response to baricitinib and to 
investigate genetic variants thought to play a role in atopic dermatitis or other inflammatory skin 
disorders. Assessment of variable response may include evaluation of AEs or differences in 
efficacy.  These studies may include but are not limited to evaluate their association with  
observed response to baricitinib. 
All pharmacogenetic samples will be coded with the patient number. Only investigator site 
personnel can link these samples, and any data generated, back to the patient. Samples will be 
destroyed according to a process consistent with local  regulations. 
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or  
for a shorter period if local regulations and/or ERBs impose shorter time limits, at a facility 
selected by the sponsor. This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in drug development or when the drug is commercially  available. 
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, candidate gene studies, and epigenetic analyses. 
Regardless of technology utilized genotyping data generated will be used only for the specific 
research scope described here. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 191 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 39 
 
8.8. Biomarkers 
Skin biopsies, serum, plasma, and whole blood ribonucleic acid (RNA) samples for non-genetic 
biomarker research will be collected at the times specified in the Schedule of Activities 
(Appendix 2) where local regulations and ERBs  allow. 
Samples may be used for research on the drug target, disease process, pathways associated with 
atopic dermatitis, mechanism of action of baricitinib, and/or research method or in validating 
diagnostic tools or assay(s) related to atopic  dermatitis. 
All biomarker samples will be coded with the patient number. Only investigator site personnel 
can link these samples, and any data generated, back to the patient. Samples will be destroyed 
according to a process consistent with local  regulations. 
Samples will be retained for a maximum 15 years after the last patient visit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by   
the sponsor. This retention period enables use of new technologies, response to regulatory 
questions, and investigation of variable response that may not be observed until later in drug 
development or when the drug is commercially  available. 
 
8.8.1. Skin Biopsies 
Patients will be required to provide skin punch biopsy samples collected per the Schedule of 
Activities (Appendix 2), unless exempted by the  investigator. 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
and used to study biomarkers related to atopic dermatitis and/or related to the mechanism of  
action of baricitinib. Techniques used may include but are not limited to immunohistochemistry 
and microarray expression profiling. Samples will be de-identified as described in International 
Conference on Harmonisation (ICH) guideline E15, and may be used for exploratory microarray 
expression profiling or transcriptome sequencing. Detailed instructions for sample collection and 
handling will be provided by the sponsor. Samples will be sent to a sponsor-designated lab for 
immunohistochemistry. 
 
8.8.2. Nonpharmacogenetic  Biomarkers 
Peripheral serum samples (approximately 10 mL) will be collected at pre- and post-treatment 
time points for the assessment of biomarkers expected to be mechanistically related to JAK 1/2 
inhibition and/or the atopic dermatitis disease state. A blood sample for genotyping of filaggrin 
will also be collected. Sample processing and handling instructions will be provided by the 
sponsor. Samples will be sent to a sponsor-designated lab for  evaluation. 
Exploratory biomarker serum, plasma, and blood for mRNA samples will also be collected and 
stored at a sponsor-designated vendor. 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 192 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 40 
 
8.9.    Health Economics 
The self-reported questionnaires will be administered according to the Schedule of Activities 
(Appendix 2). The questionnaires will be administered in countries where they have been 
translated into the native language of the region and linguistically  validated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 193 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 41 
 
9. Statistical Considerations and Data  Analysis 
9.1. Determination of Sample Size 
Approximately 120 patients will be enrolled using a 4:3:3 randomization scheme of placebo,  
2 mg baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 
20%, approximately 96 patients will complete the  study. 
This sample size provides 90% power to detect a 35% difference in EASI-50 between placebo 
and the 4-mg baricitinib treatment group using a 2-sided chi-square test with alpha =   0.05. 
 
9.2. General Statistical Considerations 
Statistical analysis of this study will be the responsibility of the sponsor or its designee. A 
detailed statistical analysis plan (SAP) will be provided by the sponsor or its designee, and will 
be finalized prior to database lock and  unblinding. 
Investigator site data will be pooled for statistical analysis  purposes. 
All tests of treatment effects will be conducted at a 2-sided alpha level of 0.05, unless otherwise 
stated. 
Data analyses will be provided by treatment groups and for all study patients combined wherever 
appropriate. For continuous variables, summary statistics will include number of patients, mean, 
median, standard deviation, minimum, and maximum.  Categorical endpoints will be    
summarized using number of patients, frequency, and  percentages. 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report. Additional exploratory analyses of the data will be conducted as 
deemed appropriate. 
 
9.3. Treatment Group Comparability 
9.3.1. Patient Disposition 
All patients who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation will be 
given.  Data tabulations will summarize the following patient numbers, per treatment   group: 
 Enrolled 
 Received treatment 
 Violated the protocol 
 Completed the protocol 
 Withdrew because of: 
o Adverse event 
o Lack of efficacy 
o Consent withdrawal 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 194 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 42 
 
o Other reasons, as applicable 
A detailed description of patient disposition will be provided at the end of the   study. 
 
9.3.2. Patient Characteristics 
Baseline and demographic characteristics will be summarized descriptively by treatment group 
and overall. 
 
9.3.3. Concomitant Therapy 
Concomitant use of topical corticosteroids will be summarized by treatment   group. 
 
9.4. Primary and Secondary Analyses 
9.4.1. Primary Analyses 
The primary outcome will be the proportion of patients achieving EASI-50 in each treatment   
arm. The primary analysis will be performed using all randomized patients utilizing a Non- 
Responder Imputation (NRI) analysis. The proportion of patients achieving EASI-50 in the 
placebo arm will be compared to proportion of patients in each of the baricitinib arms using a two-
sided chi-square test with alpha=0.05. To control the study-wise type 1 error rate, the comparison 
of the baricitinib arms with the placebo arm will be performed in a stepwise fashion. The 4-mg 
baricitinib arm will be compared with the placebo arm; if this test is statistically significant, then 
the 2-mg baricitinib arm will be compared with the placebo arm. Enrollment of 120 patients in a 
4:3:3 ratio will provide approximately 90% power for detecting a 35%  difference in the EASI-50 
response rate between placebo and the 4-mg baricitinib treatment   arm. 
For EASI-50 endpoint, all Non-Responders, as well as all patients who discontinue study 
treatment at any time prior to the time point of interest or discontinue from the study for any 
reason, will be defined as Non-Responders for the NRI analysis. Randomized patients without at 
least 1 post-baseline observation will also be defined as Non-Responders for the NRI   analysis. 
 
9.4.2. Secondary Analyses 
Continuous secondary endpoints will be summarized and analyzed using treatment groups by use 
of a mixed effects model with treatment as the main factor and baseline values as covariates. The 
treatment (intercept) effects and their standard errors from the mixed effects model will be used   
to produce p-values and 90% confidence intervals for the treatment   comparison. 
For continuous endpoints collected longitudinally, missing data will assumed to be missing at 
random and a mixed model repeated measures (MMRM) approach will be used. Other 
imputation techniques, such as multiple imputation, may be utilized in sensitivity   analyses. 
Categorical secondary endpoints will be summarized and analyzed using a chi-square test or 
Fisher’s exact test, if needed. 
 
9.4.3. Tertiary/Exploratory Analyses 
Continuous secondary endpoints will be summarized and may be analyzed by use of a mixed 
effects model with treatment as the main factor and baseline values as covariates. The   treatment 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 195 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 43 
 
(intercept) effects and their standard errors from the mixed effects model will be used to produce 
p-values and 90% confidence intervals for the treatment  comparison. 
Categorical secondary endpoints will be summarized and may be analyzed using a chi-square 
test or Fisher’s exact test, if needed. 
 
9.5. Safety Analyses 
Safety analyses will be conducted on all patients who received at least one dose of study drug. 
No statistical comparisons of treatment groups will be completed for safety   endpoints. 
All adverse events will be summarized and listed. The incidence of symptoms for each treatment 
will be presented by severity and by association with study drug as perceived by the investigator. 
Symptoms reported to occur prior to enrollment will be distinguished from those reported as new 
or increased in severity during the  study. 
Additional safety parameters that will be assessed include safety lab parameters and vital signs. 
The parameters will be listed, and summarized using standard descriptive statistics. Additional 
analysis will be performed if warranted upon review of the  data. 
 
9.6. Pharmacokinetic/Pharmacodynamic  Analyses 
The pharmacokinetics of baricitinib will be assessed using population PK analysis techniques. 
The relationship between the primary and secondary efficacy endpoints and plasma exposure, 
race, and age of onset may be explored. PK and PD data may be combined with prior data for an 
integrated analysis. 
 
9.7. Other Analyses 
9.7.1. Health Economics 
Patient reported outcome endpoints will be summarized and analyzed using treatment groups by 
use of a mixed effects model with treatment as the main factor and baseline values as covariates. 
The treatment (intercept) effects and their standard errors from the mixed effects model will be 
used to produce p-values and 90% confidence intervals for the treatment   comparison. 
 
9.7.2. Biomarkers 
Biomarker data from all patients undergoing biomarker assessments will be analyzed. Biomarker 
data will be summarized and listed, and may be displayed  graphically. 
 
9.8.    Interim Analyses 
An interim analysis is not planned for this  study. 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 196 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 44 
 
10. Study Governance Considerations 
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process 
10.1.1. Informed Consent 
The investigator is responsible for ensuring  that: 
 the patient understands the potential risks and benefits of participating in the 
study 
 informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of 
investigational product. 
 any questions the patient may have throughout the study are answered and 
shares, in a timely manner, any new information that may be relevant to the 
patient’s willingness to continue his or her participation in the  study. 
 
10.1.2. Ethical Review 
The investigator or designee must give assurance that the ethical review board (ERB) was 
properly constituted and convened as required by International Conference on Harmonisation 
(ICH) guidelines and other applicable laws and  regulations. 
Documentation of ERB approval of the protocol and the ICF must be provided to the sponsor 
before the study may begin at the investigative site(s). The sponsor or its representatives must 
approve the ICF, including any changes made by the ERBs, before it is used at the investigative 
site(s).  All ICFs must be compliant with the ICH guideline on  GCP. 
The study site’s ERB(s) should be provided with the  following: 
 current IB and updates during the course of the  study 
 ICF 
 relevant curricula vitae 
10.1.3. Regulatory Considerations 
This study will be conducted in accordance  with: 
 consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of   
Medical Sciences (CIOMS) International Ethical  Guidelines 
 applicable ICH GCP Guidelines 
 applicable laws and regulations 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 197 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 45 
 
The investigator or designee will promptly submit the protocol to applicable   ERB(s). 
All or some of the obligations of the Sponsor may be assigned to a Contract Research 
Organization (CRO). 
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and/or other study-related 
data. 
 
10.1.4. Investigator Information 
Physicians with a specialty in dermatology will participate as investigators in this clinical   study. 
 
10.1.5. Protocol Signatures 
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a sponsor  representative. 
 
10.1.6. Final Report Signature 
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study. 
The investigator with the most enrolled patients will be requested to serve as the CSR 
coordinating investigator. If this investigator is unable to fulfill this function, another 
investigator will be chosen by the sponsor to serve as the CSR coordinating   investigator. 
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study. 
 
10.2. Data Quality Assurance 
To ensure accurate, complete, and reliable data, the sponsor/designee will perform the   following: 
 provide instructional material to the study sites, as  appropriate 
 sponsor start-up training to instruct the investigators and study coordinators. This 
training will give instruction on the protocol, the completion of the CRFs, and 
study procedures. 
 make periodic visits to the study site 
 be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 198 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 46 
 
 review and evaluate CRF data and use standard computer edits to detect errors in 
data collection 
 conduct a quality review of the  database 
In addition, the sponsor/designee will periodically check a sample of the patient data recorded 
against source documents at the study site. The sponsor/designee and/or regulatory agencies 
may audit the study at any time.  Investigators will be given notice before an audit   occurs. 
The investigator will keep records of all original source data.  This might include laboratory  
tests, medical records, and clinical notes. If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents. 
 
10.2.1. Data Capture System 
An electronic data capture (EDC) system will be used in this study. The site maintains a source 
for the data entered into the sponsor-designated EDC system, if collected external to the EDC 
system. 
Electronic patient-reported outcome (ePRO) measures (for example, a rating scale) or other data 
reported directly by the patient (for example, daily dosing schedule, event diary) may be entered 
into an ePRO instrument (for example, personal digital assistant [PDA]), or by means of an 
interactive response technology system (IRT) at the time the information is obtained. In these 
instances where there is no prior written or electronic source data at the site, the ePRO  
instrument record will serve as the  source. 
If ePRO records are stored at a third party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study 
for retention. 
Any data for which the ePRO instrument record will serve to collect source data will be 
identified and documented by each site in that site’s study  file. 
Case report form data will be encoded and stored in a clinical study  database. 
Case report form data collected by a third-party will be encoded by the third-party and stored 
electronically in the third-party’s database system. Validated data will subsequently be 
transferred to the sponsor designated  database. 
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system. Data will subsequently be transferred from the central 
vendor to the sponsor designated  database. 
Any data for which paper documentation provided by the patient will serve as the source  
document will be identified and documented by each site in that site’s study file. Paper 
documentation provided by the patient may include, for example, a paper diary to collect patient- 
reported outcome (PRO) measures (for example, a rating scale), a daily dosing schedule, or an 
event diary. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 199 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 47 
 
Data from complaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management  system. 
 
10.3. Study and Site Closure 
10.3.1. Discontinuation of Study Sites 
Study site participation may be discontinued if the sponsor or its designee, the investigator, or 
the ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons 
consistent with applicable laws, regulations, and  GCP. 
 
10.3.2. Discontinuation of the Study 
The study will be discontinued if the sponsor or its designee judges it necessary for medical, 
safety, regulatory, or other reasons consistent with applicable laws, regulations, and   GCP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 200 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 48 
 
11. References 
[APA] American Psychiatry Association. 1994. Diagnostic and Statistical Manual of Mental 
Disorders. 4th ed. Washington DC. 
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic 
inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul   1;2(3):e24137. 
Basra M.K.A, Salek MS, Camilleri L, Sturkey R, Finlay A.Y. Determining the Minimal 
Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index 
(DLQI):  Further Data.  Derm, 2015 Jan;  230:27-33. 
Beck, LA, Thaçi, D, Hamilton, JD, Graham, NM, Bieber, T, Rocklin, R, Ming, JE, Ren, H, Kao, 
R, Simpson, E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. 
New Engl. J. Med. 2014, 371,  130–139. 
Bieber, T. Atopic Dermatitis. Ann Derm. 2010,  125-137. 
Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy 
and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 
12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 
Apr;166(4):853-60. 
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Arch Dermatol. 2004  Dec;140(12):1513-9. 
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 
2009 (v4.03:  June 14, 2010).  http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 
14_QuickReference_5x7.pdf. Accessed March 7,  2016. 
Epstein E, Pinski JB. A blind study. Arch Dermatol 1964; 89:  548–549. 
Ferguson T, Rowlands AV, Olds T, Maher C. Validity of consumer-level, activity monitors in 
healthy adults worn in free-living conditions: a cross-sectional study. International Journal of 
Behavioral Nutrition and Physical Activity (2015)  12:42. 
 
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, 
Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of 
tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug   9;367(6):495-507. 
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality 
of life into practice: What do dermatology life quality index scores mean? J Invest   Dermatol. 
2005 Oct;125(4):659-64. 
Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus- 
Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib    
at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to 
methotrexate. Ann Rheum Dis. 2015  Feb;74(2):333-40. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 201 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 49 
 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol 2002; 147 (Suppl 62):  50. 
Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. 
Identification of a novel pathway important for proliferation and differentiation of primary 
erythroid progenitors. Proc Natl Acad Sci U S A. 1997 Apr  1;94(7):3016-21. 
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik 
KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging 
study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with 
background methotrexate in patients with active rheumatoid arthritis and an inadequate response 
to methotrexate alone. Arthritis Rheum. 2012  Apr;64(4):970-81. 
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015   Sep;73(3):395-9. 
Mallinckrodt C, Tamura RN, Tanaka Y. Recent developments in improving signal detection and 
reducing placebo response in psychiatric clinical trials. J Psychiatric Research 45 (2011) 1202- 
1207. 
Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of 
Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015 Apr   29;4(5):858-73. 
Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A phase 2b trial of baricitinib, an 
oral JAK inhibitor, in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2014 
May;70(5, Suppl 1): AB162. 
Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Brit J Derm. 2003; 
148: 117–121. 
Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, 
Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a 
variety of cytokine receptors. Cell. 1998 May  1;93(3):385-95. 
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus 
kinases. Immunol Rev. 2008  Jun;223:132-42. 
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan  
PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of 
Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a 
psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 
1;54(5):573-83. 
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P; 
Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of 
clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin 
Immunol.  2013 Dec;132(6):1337-47. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 202 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 50 
 
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S.  
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in 
healthy volunteers. J Clin Pharmacol. 2014  Dec;54(12):1354-61. 
Vera J, Bachmann J, Pfeifer AC, Becker V, Hormiga JA, Darias NV, Timmer J, Klingmüller U, 
Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 
signalling pathway. BMC Syst Biol. 2008 Apr  25;2:38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 203 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 51 
 
Appendix 1. 
Abbreviations and Definitions 
 
 
 
 
 
Term 
Definition 
AD 
Atopic Dermatitis 
AE 
adverse event: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product. 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
Audit 
A systematic and independent examination of the study-related activities and    
documents to determine whether the evaluated study-related activities were conducted, 
and the data were recorded, analyzed, and accurately reported according to the protocol, 
applicable standard operating procedures (SOPs), good clinical practice (GCP), and the 
applicable regulatory requirement(s). 
Blinding/masking 
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are  not. 
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received. 
BSA 
body surface area 
Chorus 
A semi-autonomous clinical development organization within Eli Lilly and  Company. 
CIOMS 
Council for International Organizations of Medical  Sciences 
CKD EPI 
Chronic Kidney Disease Epidemiology Collaboration 
Complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system. 
Compliance 
Adherence to all the study-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory  requirements. 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 204 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 52 
 
 
Confirmation 
A process used to confirm that laboratory test results meet the quality requirements 
defined by the laboratory generating the data and that Lilly is confident that results are 
accurate. Confirmation will either occur immediately after initial testing or will require 
that samples be held to be retested at some defined time point, depending on the steps 
required to obtain confirmed results. 
CRF/eCRF 
case report form/electronic case report form (sometimes referred to as clinical report 
form): A printed or electronic form for recording study participants’ data during a 
clinical study, as required by the protocol. 
CRO 
contract research organization 
CRP 
Clinical research physician:  individual responsible for the medical conduct of the 
study. Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical  officer. 
CRU 
clinical research unit 
CS 
Corticosteroid 
CSE 
clinically significant event.  A moderate-to-severe adverse event (AE), abnormal 
clinical sign, or clinical laboratory finding that may pose a risk to the well-being of the 
patient. 
CSR 
clinical study report 
DLQI 
Dermatologic Life Quality Index 
DMC 
data monitoring committee 
DN 
Diabetic Nephropathy 
DNA 
deoxyribonucleic acid 
DSUR 
Development Safety Update Report 
EASI 
Eczema Area and Severity Index 
ECG 
Electrocardiogram 
EDC 
Electronic data capture 
eGFR 
estimated glomerular filtration  rate 
End of study 
Date of the last visit or last scheduled procedure shown in the Study Schedule for the 
last active patient in the study 
Enroll 
The act of assigning a patient to a treatment. Patients who are enrolled in the study are 
those who have been assigned to a treatment. 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 205 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 53 
 
 
Enter 
Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives. 
ePRO 
electronic patient-reported outcome 
ERB/IRB 
ethical review board/institutional review board: a board or committee (institutional, 
regional, or national) composed of medical professionals and nonmedical members 
whose responsibility is to verify that the safety, welfare, and human rights of the 
patients participating in a clinical study are protected. 
e-source 
electronic source documentation 
FSH 
follicle stimulating hormone 
GCP 
good clinical practice 
GGT 
gamma glutamyltransferase 
H2 receptor 
histamine H2 receptor 
HBcAb 
hepatitis B core antibody 
HBsAb 
hepatitis B surface antibody 
HBsAg 
hepatitis B surface antigen 
HBV DNA 
hepatitis B virus DNA 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
IB 
Investigator’s Brochure 
IC50 
half-maximal inhibitory concentration 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IFN-γ 
interferon-gamma 
IGA 
Investigator’s Global Assessment 
IgE 
immunoglobulin E 
IL 
Interleukin 
INR 
international normalized ratio 
Informed consent 
A process by which a subject voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the subject's decision to participate. Informed consent is documented by 
means of a written, signed and dated informed consent  form. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 206 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 54 
 
 
Interim analysis 
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is  created/locked. 
Investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form. 
Investigator 
A person responsible for the conduct of the clinical study at a study site. If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal  investigator. 
ITT 
intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that treatment group irrespective of their 
compliance to the planned course of treatment. 
IRT 
interactive response technology system 
JAK 
Janus kinase 
JAK1, JAK2, JAK3 
kinases belonging to the Janus kinase family 
Legal Representative 
An individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical  study. 
Lilly 
Eli Lilly and Company 
LRL 
Lilly Research Laboratories 
MMRM 
mixed model repeated measures 
MOS 
margin of safety 
NRI 
non-responder imputation 
NRS 
numerical rating scale 
PASI 
Psoriasis Area and Severity Index 
Patient 
A study participant who has the disease or condition for which the investigational 
product is targeted. 
PK/PD 
pharmacokinetics/pharmacodynamics 
PO 
per os; oral administration 
POCT 
point-of-care testing 
POEM 
Patient-Oriented Eczema Measure 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 207 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 55 
 
 
PPD 
purified protein derivate 
PRO/ePRO 
patient-reported outcomes/electronic patient-reported  outcomes 
QIDS-SR16 
Quick Inventory of Depressive Symptomatology-Self Report  16 
QD 
once daily 
Randomize 
the process of assigning subjects to an experimental treatment group according to the 
randomization schedule for the study. 
RA 
Rheumatoid Arthritis 
RNA 
ribonucleic acid 
SAE 
serious adverse event; any untoward medical occurrence that at any dose results in 
death, is life threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect. 
SAP 
statistical analysis plan 
SCORAD 
SCORing of Atopic Dermatitis 
Screening 
The act of determining if an individual meets minimum requirements to become part of  
a pool of potential candidates for participation in a clinical  study. 
SUSARs 
suspected unexpected serious adverse reactions 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event: Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to  
have a causal relationship with this treatment. 
Th1, Th 2 
subsets of T helper cells; T lymphocytes expressing CD4 are also known as helper T 
cells 
TSH 
thyroid stimulating hormone. 
ULN 
upper limit of normal 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 208 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 56 
 
Appendix 2. 
Schedule of Activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 209 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 57 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable for 
PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs  later) 
X 
Read PPD (if applicable) 
X 
ECG (single) - Taken prior to all other 
assessments at V1 
X 
X 
X 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
continued on next page 
 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the evaluation of tuberculosis    
infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient will be 
excluded from the study. 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 210 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 58 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
Vital Signs (BP and pulse) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense topical corticosteroid (as needed) 
X 
X 
X 
X 
X 
X 
X 
Weigh and record topical corticosteroid 
container with cap 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discontinue all excluded AD medications 
X 
Pre-existing Conditions 
X 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational Product Package Dispensed 
X 
X 
X 
X 
X 
Investigational Product Package 
Returned/Compliance Assessed 
X 
X 
X 
X 
X 
X 
Dose administration at site 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
Itch NRS 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
X 
X 
X 
POEM 
X 
X 
X 
X 
X 
X 
X 
continued on next page 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 211 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 59 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 
days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device Dispensing 
X 
X 
X 
X 
X 
Biopsy performed (NL: non-lesion and L: lesion to 
be performed following Investigator and Patient rating 
scale assessments) 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non- 
PK samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HBsAb (including 
Quantitative HBsAb load assessment) 
X 
HBV DNA 
X 
 
continued on next page 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 212 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 60 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory 
Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 213 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 61 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Serum Immunoglobulin (IgA, IgG, IgM) 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 214 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 62 
 
Appendix 3. 
Clinical Laboratory Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 215 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 63 
 
 
Clinical Laboratory Tests 
Hematologya,b 
Clinical Chemistrya,b 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume 
Total bilirubin 
Mean cell hemoglobin concentration 
Direct bilirubin 
Leukocytes (WBC) 
Alkaline phosphatase 
Reticulocyte 
Alanine aminotransferase (ALT/SGPT) 
Absolute counts of: 
Aspartate aminotransferase (AST/SGOT) 
Neutrophils, segmented 
Blood urea nitrogen (BUN) 
Neutrophils, juvenile (bands) 
Creatinine 
Lymphocytes 
Uric acid 
Monocytes 
Calcium 
Eosinophils 
Glucose 
Basophils 
Albumin 
Platelets 
Total protein 
Cell morphology 
Estimated glomerular filtration rate (eGFR)e 
Creatine phosphokinase (CPK) 
Urinalysisa,b,d 
Color 
Other Testsa 
Specific gravity 
Hepatitis B Surface antigenf 
pH 
Anti-Hepatitis B Core antibodyf 
Protein 
Quantitative HBsAb load assessmenta 
Glucose 
Hepatitis B Surface antibodyf 
Ketones 
Human immunodeficiency virusf 
Bilirubin 
Hepatitis C antibodyf,g 
Urobilinogen 
Thyroid-stimulating hormonef 
Blood 
Thyroxinef 
Leukocyte esterase 
Pregnancy Testh 
Nitrite 
FSHf,i 
Serum immunoglobulin (IgA, IgG, and IgM) 
Lipid (Fasting) a,c 
PPD, QuantiFERON®-TB Gold or T-SPOT.TB® j 
Total cholesterol 
Low-density lipoprotein 
Baricitinib plasma levels 
High-density lipoprotein 
HBV DNA 
Triglycerides 
 
Abbreviations: CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; DNA = deoxyribonucleic   acid; 
FSH = folliclestimulatinghormone; HBV = Hepatitis B virus;; RBC =  red 
blood cells; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic 
pyruvic transaminase; TB = tuberculosis; WBC = white blood  cells. 
a Assayed by sponsor-designated laboratory. 
b Unscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed. 
c Fasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to  test. 
d Microscopic examination of sediment performed only if abnormalities are noted on the routine urinalysis.  
e eGFR for serum creatinine calculated by the central laboratory using the -CKD EPI  method. 
f Test required at Visit 1 only to determine eligibility of patient for the  study. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 216 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 64 
 
g A positive hepatitis C antibody (Hep C antibody) result will be confirmed with an alternate hepatitis C method.   
h For all women of childbearing potential, a serum pregnancy test will be performed at Visit 1 and a local   urine 
pregnancy test will be performed at all visits thereafter. 
i To confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an 
FSH test will be performed. Non-childbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of 
menses for at least 12 months. 
j The QuantiFERON®-TB Gold test is the preferred alternative to the PPD test for the evaluation of TB infection,   
and it may be used instead of the PPD test or T-SPOT.TB® test and may be read locally. If the QuantiFERON®- 
TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient is excluded from  
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 217 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 65 
 
Appendix 4. 
Hepatic Monitoring Tests for  Treatment- 
Emergent Abnormality 
 
 
 
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may be required in 
follow-up with patients in consultation with the sponsor, its designee, or clinical research  physician. 
 
Hepatic Monitoring Tests 
Hepatic Hematologya 
Haptoglobina 
Hemoglobin 
Hematocrit 
Hepatic Coagulationa 
RBC 
Prothrombin Time 
WBC 
Prothrombin Time, INR 
Neutrophils, segmented 
Lymphocytes 
Hepatic Serologiesa,b 
Monocytes 
Hepatitis A antibody, total 
Eosinophils 
Hepatitis A antibody, IgM 
Basophils 
Hepatitis B surface antigen 
Platelets 
Hepatitis B surface antibody 
Hepatitis B Core antibody 
Hepatic Chemistrya 
Hepatitis C antibody 
Total bilirubin 
Hepatitis E antibody, IgG 
Direct bilirubin 
Hepatitis E antibody, IgM 
Alkaline phosphatase 
ALT 
Anti-nuclear antibodya 
AST 
GGT 
Anti-smooth muscle antibodya 
Abbreviations: ALT = alanine aminotransferase; AST = aspirate aminotransferase; GGT = gamma-glutamyl 
transferase; Ig = immunoglobulin; INR = international normalised ratio; RBC = red blood cells; WBC = white 
blood cells. 
a Assayed by sponsor-designated or local laboratory. 
b Reflex/confirmation dependent on regulatory requirements and/or testing  availability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 218 
I4V-MC-JAHG(b) Clinical Protocol 
Page 66 
 
 
 
 
Appendix 5. 
Protocol I4V-MC-JAHG Signature  Page 
 
 
 
I confirm that I have read this protocol; I understand it and I will work according to this protocol.   
I will also work consistently with the ethical principles that have their origin in the Declaration    
of Helsinki and that are consistent with good clinical practices and applicable laws and  
regulations. I will accept the monitor’s overseeing of the study. I will abide by the publication  
plan set forth in my Agreement with the sponsor (Chorus, Eli Lilly and Company) or designee. I 
will promptly submit the protocol to applicable ethical review board(s). I confirm that if I or any  
of my staff are members of the ethical review board, we will abstain from voting on this    
protocol. 
 
 
Signature of Investigator 
Date 
 
 
Investigator Name (Title) 
 
 
Name of Facility 
 
 
Location of Facility 
(City, State (if applicable), Country) 
 
 
 
Signature of sponsor 
Date (dd-mmm-yyyy) 
Dr. Mark Deeg (Chief Medical Officer,  Chorus-Eli 
 Lilly and Company) 
 
Sponsor name (Title) 
 Eli Lilly and Company 
 
Name 
Lilly Corporate Center, Indianapolis, Indiana, USA 
Location (City, State (if applicable),  Country) 
 
 
LY3009104 
Instructions to the Investigator:  Please SIGN and DATE this signature page. PRINT  your 
name, title and the name of the facility in which the study will be conducted on both copies. 
Return 1 of the signed copies to the sponsor (Chorus, Eli Lilly and Company) or  designee. 


LY3009104 
 
 
PPD 
PPD 
14V-MC-JAHG CSR Appendix Protocol 
Page 219 
 
 
 
 
 
 
 
 
 
 
14 V-MC·J AHG(b) Clinical Protocol 
Page 66 
 
Appendix 5. 
Protocol 14V-MC-JAHG Signature Page 
 
 
 
I confirm that I have read this protocol; I understa nd it and I will work according to this protocol. 
I will also work consistently with the ethical principles that have their origin in the Declaration 
of Helsinki and that are consistent with good clinical practices and applicab le laws and 
regulations. I will accept the monitor's overseeing of thestudy. I will abide by the publication 
plan set forth in my Agreement with the sponsor (Chorus, Eli Lilly and Company) or designee. I 
will promptly submit the protocol to applicable ethical review board(s). I confirm that if I or any 
of my s taff are members of the ethica l rev iew board, we will abstain from voting on this 
protocol. 
Instructions to th& Investigator. PleaseSIGNandDATEthissignature page. PRINT your 
nam&,1itle at1d thename of thef&cilicyinwhich the study willhe conductedonboth copies. 
  Re.turn 1 of the si nedoo ies to thes    sor Chorus, Eliun andCan 
ordesi   nee.  
 
Signat ure of Investigator 
Date 
 
Investigator  Name (Title) 
 
Nameof Facility 
 
 
 
 
Date  (dd-mmm-yyyy) 
 
 
Eli Lill y and Company 
Name 
Lill y Corporate Center. Indianapolis. Indiana, USA 
Location (City.  State (if applicable), Country) 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 220 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 67 
 
Appendix 6. 
Protocol Amendment I4V-MC-JAHG(a) 
Summary [A Randomized, Double-Blind,  Placebo- 
Controlled, Phase 2 Study to Evaluate the Safety and 
Efficacy of Baricitinib in Patients with Moderate-to- 
Severe Atopic Dermatitis] 
 
 
 
Overview 
Protocol I4V-MC-JAHG [A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to 
Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic 
Dermatitis] has been amended. The new protocol is indicated by amendment (a) and will be  
used to conduct the study in place of any preceding version of the  protocol. 
The overall changes and rationale for the changes made to this protocol are as   follows: 
 The number of patients to be enrolled in this study has been increased from 90 to 120. 
The statistical analysis and power statements in the protocol have been revised to reflect 
this patient increase. The study diagram and all text related to the number of enrolled 
patients have been revised accordingly. 
 The original statistical analysis included two 1-sided tests for comparing the two 
baricitinib dose levels with placebo. The protocol has been revised to reflect a plan to 
control the type 1 error for the primary efficacy analysis at 5%, by including 2, 5% level, 
2-sided tests for testing the two baricitinib dose levels with placebo and a sequential 
testing strategy that first examines the highest dose relative to placebo and only tests the 
lower dose relative to placebo if there is statistical significance for the highest   dose. 
 
 The planned interim analysis has been removed based on the aforementioned statistical 
analysis strategy. 
 
 The description of hepatitis B testing was  revised. 
 
 The BSA inclusion criteria was changed from >10% BSA to ≥10%  BSA. 
 
 Minor textual edits were made for the purpose of clarification or  correction. 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 221 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 68 
 
Revised Protocol Sections 
 
Note: 
Deletions have been identified by strikethroughs or grayed out for  figures. 
Additions have been identified by the use of  underscore. 
1 
Protocol Synopsis 
Summary of Study Design: 
 
Study I4V-MC-JAHG is a multicenter, randomized, double-blind, parallel, placebo-controlled study designed to 
compare the efficacy and safety of baricitinib to placebo in patients with moderate-to-severe atopic dermatitis. 
Enrollment will be targeted at 90120 patients to enable approximately 7296 patients to complete the study. An 
interim analysis may be implemented and could result in up to an additional 30 patients being enrolled. Patients 
who meet all eligibility criteria will be randomized to receive either placebo or baricitinib, administered as once 
daily oral doses of 2 mg or 4 mg.  Randomization will occur at the country  level. 
Number of Patients:  90120 
 
Statistical Analysis: 
 
Sample Size 
The study will begin with a plan to enroll 90120 patients that will be 
randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, 
respectively. A maximum of 30 additional patients may be enrolled 
depending on the results of the interim analysis. 
Primary Outcome & Methodology 
The primary outcome parameter is the proportion of patients achieving 
EASI-50 in each treatment arm. The placebo arm will be compared to each 
of the baricitinib arms using a one two-sided chi-square test with 
alpha=0.05. To control the study-wise type 1 error rate, the comparison of 
the baricitinib arms with the placebo arm will be performed in a stepwise 
fashion. The 4 mg baricitinib arm will be compared with the placebo arm;  
if this test is statistically significant, then the 2 mg baricitinib arm will be 
compared with the placebo arm. As this is a proof of concept study,  there 
will not be any adjustment of alpha for multiple comparisons. Enrollment of 
120 90 patients in a 4:3:3 ratio provides approximately 90% power for 
detecting and a 35% difference in the EASI-50 response rate between 
placebo and either the 4-mg baricitinib treatment arm , statistical power is 
estimated to be apprxoimately 80%. 
Interim Analysis 
An interim analysis is not planned for this study. 
An interim analysis may be conducted to assess variability, effect size, and 
placebo effect during the course of the study in order to evaluate the 
potential need for an increase in the number of patients randomized (up to a 
total of 120) and/or a possible change in randomization ratio.  Details  
around this potential interim analysis will be described in the statistical 
analysis plan (SAP) or in interim analysis planning documentation,  as 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 222 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 69 
 
appropriate. 
 
 
 
4.1 
Overview of Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 223 
 
 
4 mg baricitinib 
2 mg baricitinib 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 70 
 
Standardization 
Treatment 
Follow-up 
 
 
 
 
120 AD 
Patients 
Placebo 
4 Weeks 
16 Weeks 
4 Weeks 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
Week: 
-4 
0 
1 
4 
8 
12 
16 
20 
Day: 
-28 
0 
7 
28 
56 
84 
112 
140 
 
 
 
Screening Randomization 
(4:3:3) 
Placebo : 2 mg baricitinib : 4 mg baricitinib 
Figure JAHG.1. 
Illustration of study design for Clinical Protocol  I4V-MC-JAHG. 
 
 
5.1 
Inclusion Criteria 
[2] Have moderate-to-severe AD, as determined by all of the  following: 
 EASI ≥12 at Visits 1 and 2 
 >≥10% of body surface area (BSA) involvement at Visits 1 and  2 
 Were diagnosed with AD at least 2 years before Visit  1 
 
5.2 
Exclusion Criteria 
[20] Positive test for hepatitis B defined as: 
a) positive for hepatitis B surface antigen (HBsAg),  or 
b) positive for anti-hepatitis B core antibody (HBcAb), but negative for hepatitis B 
surface antibody (HBsAb) or 
c) HBcAb positive and are HBV DNA positive  or 
d) for patients enrolled in Japan, positive for HBcAb and/or anti-hepatitis B surface 
antibody (HBsAb) and positive for hepatitis B deoxyribonucleic acid (HBV 
DNA). If any of the hepatitis B tests have an indeterminate result, confirmatory 
testing will be performed by an alternate  method. 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 224 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 71 
 
8.4.5. Hepatitis B virus (HBV) DNA  monitoring 
Patients who are HBcAb positive and HBV DNA negative (undetectable) at Visit 1 will require 
HBV DNA monitoring at Visits 5 and 8 or ET, every 3 months and at the patient’s last visit (V8   
or ET), regardless of their HBsAb status. If the HBV DNA result is ‘target detected’ ≥29 IU/mL, 
then the patient should be referred to a hepatology specialist immediately and discontinuation 
considered (refer to Table JAHG.4). In selected cases, investigators may temporarily continue 
study drug in accordance with current immunomodulator management in the setting of HBV   
DNA positivity. This option may be considered in consultation with the sponsor (or its designee) 
and evaluation of individual patient risks and benefits. The following actions should be taken in 
response to HBV DNA test results: 
 If a result of “target detected” is obtained at any time during the study with a value   of 
≥29 IU/mL, refer to Table JAHG.4. 
 
For patients enrolled at study sites in Japan only, if a patient is HbBsAb and/or HBcAb positive 
and negative for HBV DNA at Visit 1, HBV DNA needs to be monitored atVisits 5 and 8 or 
ETchecked at least monthly and at the patient’s last visit (V8or  ET). 
 
9.1 
Determination of Sample Size 
Approximately 90120 patients will be enrolled using a 4:3:3 randomization scheme of placebo,  
2 mg baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 
20%, approximately 7296 patients will complete the  study. 
This sample size provides 8090% power to see detect a 35% difference in EASI-50 between 
placebo and either the 4-mg baricitinib treatment group of 35%, assuming a placebo response 
rate of 40%, using a 12-sided chi-square test with alpha =  0.05. 
An interim analysis may be conducted to assess variability, effect size, and placebo effect to 
evaluate the need for an increase in the number of patients randomized up to a total of 120 and/or  
a possible change in randomization ratio. Details around this potential interim analysis will be 
described in the statistical analysis plan (SAP) or in interim analysis planning documentation, as 
appropriate. 
 
9.2 
General Statistical Considerations 
All tests of treatment effects will be conducted at a 12-sided alpha level of 0.05, unless otherwise 
stated. 
9.4.1  Primary Analyses 
The primary outcome will be the proportion of patients achieving EASI-50 in each treatment   
arm. The primary analysis will be performed using all randomized patients utilizing a Non- 
Responder Imputation (NRI) analysis. The proportion of patients achieving EASI-50 in the 
placebo arm will be compared to proportion of patients in each of the baricitinib arms using a 
onetwo-sided chi-square test with alpha=0.05. To control the study-wise type 1 error rate, the 
comparison of the baricitinib arms with the placebo arm will be performed in a stepwise   fashion. 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 225 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 72 
 
The 4-mg baricitinib arm will be compared with the placebo arm; if this test is statistically 
significant, then the 2-mg baricitinib arm will be compared with the placebo arm. Enrollment of 
120 patients in a 4:3:3 ratio will provide approximately 90% power for detecting a 35%  
difference in the EASI-50 response rate between placebo and 4-mg baricitinib treatment arm.As 
this is a proof of concept study, there will not be any adjustment of alpha for multiple 
comparisons. 
 
9.8 
Interim Analyses 
An interim analysis is not planned for this  study. 
A limited number of pre-identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan, prior to the interim or final database lock, in order to initiate the 
final  population pharmacokinetics/pharmacodynamics  (PK/PD) model  development  processes 
for interim or final analyses. Information that may unblind the study during the analyses will not 
be reported to study sites or blinded study team until the study has been   unblinded. 
An interim analysis may be conducted to assess variability of response, effect size, and placebo 
effect during the course of the study in order to evaluate the potential need for an increase in the 
number of patients randomized up to a total of 120 and/or a possible change in randomization 
ratio. Details around this potential interim analysis will be described in the statistical analysis 
plan (SAP) or in interim analysis planning documentation, as  appropriate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 226 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 73 
 
Appendix 7. 
Protocol Amendment I4V-MC-JAHG(b) 
Summary [A Randomized, Double-Blind,  Placebo- 
Controlled, Phase 2 Study to Evaluate the Safety and 
Efficacy of Baricitinib in Patients with Moderate-to- 
Severe Atopic Dermatitis] 
 
 
 
Overview 
Protocol I4V-MC-JAHG [A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to 
Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic 
Dermatitis] has been amended. The new protocol is indicated by amendment (b) and will be 
used to conduct the study in place of any preceding version of the  protocol. 
The overall changes and rationale for the changes made to this protocol are as   follows: 
 Exclusion Criteria, Temporary and Permanent Discontinuation Criteria, and ECG 
assessments have been updated to reflect FDA requested  changes. 
 Minor textual edits were made for the purpose of clarification or  correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 227 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 74 
 
Revised Protocol Sections 
 
Note: 
Deletions have been identified by strikethroughs or grayed out for  figures. 
Additions have been identified by the use of  underscore. 
3 
Objectives and Endpoints 
Table JAHG.1.  Objectives and Endpoints: 
 
Exploratory 
 To evaluate EASI response in patients 
based on their baseline total serum  IgE 
 EASI at Weeks 1, 4, 8, 12 and 16; baseline 
total serum IgE 
 To evaluate total serum IgE over the 
course of treatment 
 Total serum IgE at baseline, Weeks 4, and 
16 
 To evaluate changes in disease activity 
over the course of treatment 
 Patient-Oriented Eczema Measure (POEM) 
at  Weeks 1, 4, 8, 12, and 16 
 To evaluate changes in sleep quality over 
the course of treatment 
 Change from baselineNumber of sleep 
disturbances and average percentage of 
sleep time with datafrom a wearable 
actigraphy device 
 To evaluate changes in nocturnal itch 
patterns over the course of treatment 
 Change from baselineNumber of scratching 
events per night with datafrom a wearable 
actigraphy device 
 To evaluate EASI response relative to 
filaggrin genotype 
 EASI-50 and filaggrin genotype data from 
peripheral baseline blood sample 
 To assess tissue biomarkers from  biopsies 
 K16, Ki-67, and IL-4 will be assessed from 
each tissue biopsy (collected at baseline 
(lesion and non-lesion), at Week 4 (lesion), 
and at Week 16 (lesion and  non-lesion) 
 To assess peripheral biomarkers 
mechanistically related to inhibition of 
JAK 1/2 mechanism 
 Peripheral biomarkers collected at baseline, 
Weeks 4 and 16 
 To perform subgroup assessments of 
response based on patient and disease 
characteristics 
 Ad hoc evaluation of potential prognostic 
and predictive disease characteristics 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 228 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 75 
 
5.2 Exclusion Criteria 
[14] Have evidence of active or latent TB as documented by a positive PPD test 
(≥5 mm in duration between approximately 2 and 3 days after application, 
regardless of vaccination history), medical history, andor chest x-ray at 
screening. Exceptions are patients with a history of latent TB who have 
documented evidence of completing a course of appropriate  treatment. 
Diagnostics Assessments 
Have any of the following specific abnormalities on screening laboratory   tests: 
[31] AST or ALT >2X the ULN 
[32] Total bilirubin ≥1.5X the ULN 
[33] Hemoglobin < LLN11.0 g/dL (100.0  g/L) 
[34] Total white blood cell count < LLN2500  cells/µL 
[35] Neutropenia (absolute neutrophil count < LLN1200  cells/µL) 
[36] Lymphopenia (lymphocyte count < LLN750  cells/µL) 
[37] Thrombocytopenia (platelets <  LLN100,000/µL) 
[38] eGFR <50 mL/min/1.73 m2 (based on CKD  EPI) 
Note: In the case of any of the aforementioned laboratory abnormalities, they may  
be repeated once within 1 week of the initial values, and values resulting from 
repeat testing may be used to assess enrollment  eligibility. 
Other Exclusions 
[39] Donated blood of more than 500 mL or blood products within 4 weeks prior to 
entry. 
[40] Unwilling to commit to refrain from donating blood or blood products during 
the study. 
[41] History of substance abuse (drug or alcohol) within the two years before 
screening. 
[42] Unable or unwilling to be available for the duration of the study and/or are 
unwilling to follow study  restrictions/procedures. 
[43] Unable or unwilling to have skin biopsies performed, unless exempted by the 
investigator. 
[44] Investigator site personnel directly affiliated with this study and/or their 
immediate families; immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally  adopted. 
[45] Employees of the sponsor. 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 229 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 76 
 
[46] Unwilling or unable to comply with the use of all potential data collection 
devices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 230 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 77 
 
7.   Discontinuation Criteria 
7.1. Discontinuation of Investigational  Product 
7.1.1. Temporary Interruption of Investigational  Product 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs   
or abnormal laboratory values as described in Table JAHG.3 that may have an unclear  
relationship to investigational product. Except in cases of emergency, it is recommended that the 
investigator consult with the sponsor (or its designee) before temporarily interrupting   therapy. 
The investigator must obtain approval from the sponsor (or its designee) before restarting 
investigational product that was temporarily discontinued because of an AE or abnormal 
laboratory value. Investigational product must be held in the following situations involving 
laboratory abnormalities and may be resumed as noted in Table  JAHG.3. 
 
Table JAHG.6. 
Criteria for Temporary Interruption from Study Treatment 
 
 
Hold Investigational Product if the Following 
Laboratory Test Results Occur: 
Investigational Product May Be Resumed after 
Approval from Lilly (or its Designee) and When: 
WBC count <2000 cells/µL 
WBC count 2500 cells/µL 
ANC <1000 cells/L 
ANC >1200 cells/µL 
Lymphocyte count <500 cells/µL 
Lymphocyte count 750 cells/µL 
Platelet count <75,000/µL 
Platelet count 100,000/µL 
eGFR <40 mL/min/1.73 m2 (from serum 
 creatinine) 
eGFR 50 mL/min/1.73 m2 
ALT or AST >5 times the ULN 
ALT and AST return to <2 times the ULN, and 
investigational product is not considered to be the cause 
of enzyme elevation 
Hemoglobin <9 g/dL 
Hemoglobin 10 g/dL 
Symptomatic herpes zoster 
All skin lesions have crusted and are resolving 
Severe infection that, in the opinion of the 
investigator, merits the investigational product 
 being discontinued 
Resolution of infection 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; min = minute; ULN = upper limit of normal; 
WBC = white blood cell. 
 
7.1.2. Permanent Discontinuation of Investigational  Product 
Any patient who is permanently discontinued from investigational product for an AE or  
abnormal laboratory result should have the reason for investigational product discontinuation 
reported as the AE or abnormal laboratory value. If any of the criteria listed in Section 7.1.1. 
above recur after investigational product is restarted, the investigator must obtain approval from 
the sponsor (or its designee) before restarting investigational product.  In addition, patients   will 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 231 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 78 
 
be permanently discontinued from investigational product if they experience any of the criteria 
listed in Table JAHG.4. 
Any adverse event that is Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 
or higher will result in permanent discontinuation from the study except for transaminases and 
severe infection as noted in Tables JAHG.3 and  4. 
 
Table JAHG.7 
Criteria for Permanent Discontinuation of Investigational Product 
 
Permanently Discontinue Investigational Product if any of the Following are  Observed: 
ALT or AST >8 times the ULN 
ALT or AST >5 times the ULN persisting for more than 2 weeks after temporary interruption of investigational 
product 
ALT or AST >3 times the ULN and total bilirubin level >2 times the  ULN 
ALT or AST >3 times the ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) 
WBC count <31000 cells/L 
ANC <1500 cells/L 
Lymphocyte count <8200 cells/L 
Hemoglobin <108 g/dL 
Platelet count <75,000/L 
Pregnancy 
Malignancy (except for successfully treated basal cell or squamous epithelial skin  cancers) 
HBV DNA ≥29 IU/mLa 
Score of 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any time during the   study 
 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; HBV DNA = hepatitis B virus deoxyribonucleic acid; ULN = upper limit of normal; 
WBC = white blood cell; QIDS-SR16 = Quick Inventory of Depressive Symptomatology-Self-Report   16. 
a If a HBV DNA result of ‘target detected’ 29 IU/mL or greater, then the patient should be referred to a hepatology 
specialist immediately. In selected cases, investigators may temporarily continue study drug in accordance with 
current immunomodulator management in the setting of HBV DNA positivity. This option may be considered in 
consultation with the sponsor (or its designee) and evaluation of individual patient risks and benefits. Refer to 
Section 8.4.5 for additional instruction on HBV DNA  monitoring. 
 
8.1.2 Secondary Efficacy Assessments 
 
Mean and Percentage change in Eczema Area and Severity Index (EASI) scores: See 
above. 
 
 
SCORing Atopic Dermatitis (SCORAD): The SCORAD index uses the rule of nines to 
assess disease extent and evaluates five clinical characteristics to determine disease 
severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) 
lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss 
with Visual Analogue Scales (VAS). These three aspects: extent of disease, disease 
severity and subjective symptoms combine to give a maximum possible score of 103. 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 232 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 79 
 
 
Investigator’s Global Assessment (IGA): The IGA consists of a 6-point severity scale 
from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate 
disease, 4 = severe disease and 5 = very severe disease). IGA uses clinical characteristics 
of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall 
severity assessment. 
 
 
Dermatology Life Quality Index (DLQI): The DLQI is a simple, patient-administered, 
10-question, validated, quality-of-life questionnaire that covers 6 domains including 
symptoms and feelings, daily activities, leisure, work and school, personal relationships, 
and treatment. The recall period of this scale is over the “last week.” Response categories 
include “not at all,” “a lot,” and “very much,” with corresponding scores of 1, 2, and 3 
respectively and unanswered (“not relevant”) responses scored as 0. A DLQI total score 
of 0 to 1 is considered as having no effect on a patient’s health-related quality of life, and 
a 54-point change from baseline is considered as the minimal clinically important 
difference threshold (Finlay, 1994;Khilji, 2002; Hongbo, 2005; Basra, 2015). 
 
 
Itch Numerical Rating Scale (NRS): The Itch NRS is a patient-administered, 11 point 
horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 
representing “worst itch imaginable.”  Overall severity of a patient’s itching is 
indicated by circling the number that best describes the worst level of itching in the 
past 24 hours. Analyses were performed to support a responder definition tht was 
defined as proportion of patients achieving an Itch NRS >4 point reduction from 
baseline for patients who had baseline Itch NRS  >4. 
 
 
8.4.6  Quick Inventory of Depressive Symptomatology-Self  Report 16 
(QIDS-SR16) 
For each patient, the QIDS-SR16 should be administered according to the Schedule of Activities 
(Appendix 2). 
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and 
severity of symptoms of depression as listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (American 
Psychiatry Association [APA] 1994). The QIDS-SR16 scale is used to assess the potential  
impact of treatment on new onset or changes in depression, thoughts of death, and /or suicidal 
ideation severity. A patient is asked to consider each statement as it relates to the way they have 
felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items 
corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, 
with higher scores denoting greater symptom severity. The domains assessed by the instrument 
include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) 
energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or   hypersomnia), 
(8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation (Rush,   2003). 
If an increase of 5 or more from the baseline QIDS-SR16 total score is noted, the patient should   
be evaluated on site for risk of suicide and/or referred to a mental health provider for   assessment. 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 233 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 80 
 
A patient who scores a 2 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be evaluated on site for risk of suicide and/or referred to a mental 
health provider for assessment. 
A patient who scores a 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be discontinued (Table  JAHG.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 234 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 81 
 
11.  References 
[APA] American Psychiatry Association. 1994. Diagnostic and Statistical Manual of Mental 
Disorders. 4th ed. Washington DC. 
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic 
inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul   1;2(3):e24137. 
Basra M.K.A, Salek MS, Camilleri L, Sturkey R, Finlay A.Y. Determining the Minimal 
Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index 
(DLQI):  Further Data.  Derm, 2015 Jan;  230:27-33. 
Beck, LA, Thaçi, D, Hamilton, JD, Graham, NM, Bieber, T, Rocklin, R, Ming, JE, Ren, H, Kao, 
R, Simpson, E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. 
New Engl. J. Med. 2014, 371,  130–139. 
Bieber, T. Atopic Dermatitis. Ann Derm. 2010,  125-137. 
Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy 
and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 
12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 
Apr;166(4):853-60. 
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Arch Dermatol. 2004  Dec;140(12):1513-9. 
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 
2009 (v4.03: June 14, 2010). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 
14_QuickReference_5x7.pdf. Accessed March 7,  2016. 
Epstein E, Pinski JB. A blind study. Arch Dermatol 1964; 89:  548–549. 
Ferguson T, Rowlands AV, Olds T, Maher C. Validity of consumer-level, activity monitors in 
healthy adults worn in free-living conditions: a cross-sectional study. International Journal of 
Behavioral Nutrition and Physical Activity (2015)  12:42. 
 
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, 
Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of 
tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug   9;367(6):495-507. 
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for 
routine clinical use. Clin Exp Dermatol. 1994  May;19(3):210-6. 
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality 
of life into practice: What do dermatology life quality index scores mean? J Invest   Dermatol. 
2005 Oct;125(4):659-64. 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 235 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 82 
 
Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus- 
Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib    
at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to 
methotrexate. Ann Rheum Dis. 2015  Feb;74(2):333-40. 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol 2002; 147 (Suppl 62):  50. 
Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. 
Identification of a novel pathway important for proliferation and differentiation of primary 
erythroid progenitors. Proc Natl Acad Sci U S A. 1997 Apr  1;94(7):3016-21. 
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik 
KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging 
study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with 
background methotrexate in patients with active rheumatoid arthritis and an inadequate response 
to methotrexate alone. Arthritis Rheum. 2012  Apr;64(4):970-81. 
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015   Sep;73(3):395-9. 
Mallinckrodt C, Tamura RN, Tanaka Y. Recent developments in improving signal detection and 
reducing placebo response in psychiatric clinical trials. J Psychiatric Research 45 (2011) 1202- 
1207. 
Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of 
Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015 Apr   29;4(5):858-73. 
Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A phase 2b trial of baricitinib, an 
oral JAK inhibitor, in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2014 
May;70(5, Suppl 1): AB162. 
Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Brit J Derm. 2003; 
148: 117–121. 
Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, 
Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a 
variety of cytokine receptors. Cell. 1998 May  1;93(3):385-95. 
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus 
kinases. Immunol Rev. 2008  Jun;223:132-42. 
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan  
PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of 
Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a 
psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 
1;54(5):573-83. 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 236 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 83 
 
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P; 
Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of 
clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin 
Immunol.  2013 Dec;132(6):1337-47. 
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S.  
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in 
healthy volunteers. J Clin Pharmacol. 2014  Dec;54(12):1354-61. 
Vera J, Bachmann J, Pfeifer AC, Becker V, Hormiga JA, Darias NV, Timmer J, Klingmüller U, 
Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 
signalling pathway. BMC Syst Biol. 2008 Apr  25;2:38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 237 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 84 
 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Earl 
y 
Ter 
m 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of Investigational 
Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable 
for  PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs  later) 
X 
Read PPD (if applicable) 
X 
ECG (single) - Taken prior to all other assessments 
at V1 
X 
X 
X 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
continued on next page 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the 
evaluation of tuberculosis infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is 
allowed. If the retest is indeterminate, then the patient will be excluded from the study. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 238 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 85 
 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Earl 
y 
Ter 
m 
Study Visit 
V1 
V1a 
V 
2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of Investigational 
Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
Vital Signs (BP and pulse) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense topical corticosteroid (as needed) 
X 
X 
X 
X 
X 
X 
X 
Weigh and record topical corticosteroid container 
with cap 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discontinue all excluded AD medications 
X 
Pre-existing Conditions 
X 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational Product Package Dispensed 
X 
X 
X 
X 
X 
Investigational Product Package 
Returned/Compliance Assessed 
X 
X 
X 
X 
X 
X 
Dose administration at site 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 239 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 86 
 
Itch NRS 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
X 
X 
X 
POEM 
X 
X 
X 
X 
X 
X 
X 
continued on next page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 240 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 87 
 
 
 
 
Procedure 
Screening 
Treatment Period 
Washou 
t Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device DispensingDownload 
X 
X 
X 
X 
X 
X 
X 
Biopsy performed (NL: non-lesion and L: lesion to be 
performed following Investigator and Patient rating scale 
assessments) 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non-PK 
samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HBsAb (including Quantitative 
HBsAb load assessment) 
X 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 241 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 88 
 
HBV DNA 
X 
continued on next page 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 242 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 89 
 
 
 
Procedure 
Screening 
Treatment Period 
Washo 
ut 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of Investigational 
Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 
3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all non-PK 
samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory  Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 243 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(b) Clinical Protocol 
Page 90 
 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
Serum Immunoglobulin (IgA, IgG, IgM) 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 

Prot_005.pdf: 
I4V-MC-JAHG Protocol Amendment (d)   
 
 
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety 
and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis. 
 
 
NCT ID: NCT02576938 
Approval Date: 24-June-2016 
 


I4V-MC-JAHG CSR Appendix Protocol 
Page 2 
LY3009104 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 1 
 
 
Protocol I4V-MC-JAHG(d) 
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 
Study to Evaluate the Safety and Efficacy of Baricitinib in 
Patients with Moderate-to-Severe Atopic  Dermatitis 
 
 
 
 
 
 
 
Baricitinib 
 
 
 
 
Chorus, Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
 
 
Protocol Approval Date: 30-September-2015 
Amendment (a) Approval Date: 23-October-2015 
Amendment (b) Approval Date: 07-March-2016 
Amendment (c) Approval Date: 24-May-2016 
Amendment (d) Approval Date:   24-June-2016 
 
 
 
 
 
LY3009104 
Confidential Information 
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and  
should not be copied by or distributed to persons not involved in the clinical investigation of 
baricitinib, unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its  subsidiaries. 
Parallel, double-blinded, randomized placebo-controlled multiple dose study in patients with 
moderate-to-severe atopic dermatitis 


I4V-MC-JAHG CSR Appendix Protocol 
Page 3 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 2 
 
Table of Contents 
Section 
Page 
1. 
Protocol Synopsis ........................................................................................... 8 
2. 
Introduction .................................................................................................. 10 
2.1. 
Background ............................................................................................. 10 
2.2. 
Study Rationale ....................................................................................... 11 
3. 
Objectives and Endpoints ............................................................................. 12 
4. 
Study Design ................................................................................................ 14 
4.1. 
Overview of Study Design ...................................................................... 14 
4.2. 
Scientific Rationale for Study Design ..................................................... 14 
4.3. 
Justification for Dose .............................................................................. 15 
4.4. 
Benefit/Risk Assessment ......................................................................... 15 
5. 
Study Population .......................................................................................... 17 
5.1. 
Inclusion Criteria ..................................................................................... 17 
5.2. 
Exclusion Criteria ................................................................................... 17 
5.3. 
Screen Failures ........................................................................................ 21 
6. 
Treatment ..................................................................................................... 22 
6.1. 
Treatments Administered ........................................................................ 22 
6.2. 
Method of Treatment Assignment ........................................................... 22 
6.2.1. 
Selection and Timing of Doses ....................................................... 22 
6.3. 
Blinding .................................................................................................. 23 
6.4. 
Packaging and Labeling .......................................................................... 23 
6.5. 
Investigational Products Storage and Handling ...................................... 24 
6.6. 
Dose Modification ................................................................................... 24 
6.7. 
Treatment Compliance ............................................................................ 24 
6.8. 
Concomitant Therapy .............................................................................. 24 
6.9. 
Treatment after Study Completion .......................................................... 25 
6.9.1. 
Continued Access ........................................................................... 25 
7. 
Discontinuation Criteria ............................................................................... 26 
7.1. 
Discontinuation of Investigational Product ............................................. 26 
7.1.1. 
Temporary Interruption of Investigational Product ........................ 26 
7.1.2. 
Permanent Discontinuation of Investigational Product ............................................. 26 
7.1.3. 
Discontinuation of Inadvertently Enrolled Patients ........................ 27 
7.1.4. 
Permanent Discontinuation from the Study .................................... 27 
7.1.5. 
Patients Lost to Follow-Up ............................................................. 28 
8. 
Study Assessments and Procedures .............................................................. 29 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 4 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 3 
 
8.1. 
Efficacy Assessments .............................................................................. 29 
8.1.1. 
Primary Efficacy Assessments ........................................................ 29 
8.1.2. 
Secondary Efficacy Assessments .................................................... 29 
8.1.3. 
Appropriateness of Primary Efficacy Measure ............................... 30 
8.2. 
Adverse Events ....................................................................................... 31 
8.2.1. 
Adverse Events/Laboratory Results of Special Interest ............................................ 32 
8.2.2. 
Serious Adverse Events .................................................................. 32 
8.2.2.1. 
Suspected Unexpected Serious Adverse Reactions ............................................. 33 
8.2.3. 
Complaint Handling ....................................................................... 33 
8.3. 
Treatment of Overdose ............................................................................ 33 
8.4. 
Safety Assessments ................................................................................. 33 
8.4.1. 
Physical Examination ..................................................................... 34 
8.4.2. 
Electrocardiograms ......................................................................... 34 
8.4.3. 
Vital Signs ...................................................................................... 34 
8.4.4. 
Laboratory Tests ............................................................................. 34 
8.4.5. 
Hepatitis B virus (HBV) DNA monitoring ..................................... 34 
8.4.6. 
Quick Inventory of Depressive Symptomatology-Self  Report 
16 (QIDS-SR16) ....................................................................................................... 35 
8.4.7. 
Safety Monitoring ........................................................................... 35 
8.5. 
Pharmacokinetics .................................................................................... 35 
8.5.1. 
PK Sample Collection..................................................................... 35 
8.5.2. 
PK Sample Assay ........................................................................... 37 
8.5.3. 
PK Sample Storage and Retention .................................................. 37 
8.6. 
Pharmacodynamics ................................................................................. 37 
8.7. 
Genetics .................................................................................................. 37 
8.8. 
Biomarkers .............................................................................................. 38 
8.8.1. 
Skin Biopsies .................................................................................. 38 
8.8.2. 
Nonpharmacogenetic Biomarkers ................................................... 38 
8.9. 
Health Economics ................................................................................... 39 
9. 
Statistical Considerations and Data Analysis ............................................... 40 
9.1. 
Determination of Sample Size................................................................. 40 
9.2. 
General Statistical Considerations ........................................................... 40 
9.3. 
Treatment Group Comparability ............................................................. 40 
9.3.1. 
Patient Disposition .......................................................................... 40 
9.3.2. 
Patient Characteristics .................................................................... 41 
9.3.3. 
Concomitant Therapy ..................................................................... 41 
9.4. 
Primary and Secondary Analyses ............................................................ 41 
9.4.1. 
Primary Analyses ............................................................................ 41 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 5 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 4 
 
9.4.2. 
Secondary Analyses ........................................................................ 41 
9.4.3. 
Tertiary/Exploratory Analyses ........................................................ 41 
9.5. 
Safety Analyses ....................................................................................... 42 
9.6. 
Pharmacokinetic/Pharmacodynamic Analyses ........................................ 42 
9.7. 
Other Analyses ........................................................................................ 42 
9.7.1. 
Health Economics ........................................................................... 42 
9.7.2. 
Biomarkers ..................................................................................... 42 
9.8. 
Interim Analyses ..................................................................................... 42 
10. Study Governance Considerations ............................................................... 43 
10.1. Regulatory and Ethical Considerations, Including the  Informed 
Consent Process ................................................................................................................ 43 
10.1.1. 
Informed Consent ........................................................................... 43 
10.1.2. 
Ethical Review ................................................................................ 43 
10.1.3. 
Regulatory Considerations .............................................................. 43 
10.1.4. 
Investigator Information ................................................................. 44 
10.1.5. 
Protocol Signatures ......................................................................... 44 
10.1.6. 
Final Report Signature .................................................................... 44 
10.2. Data Quality Assurance ........................................................................... 44 
10.2.1. 
Data Capture System ...................................................................... 45 
10.3. Study and Site Closure ............................................................................ 46 
10.3.1. 
Discontinuation of Study Sites ....................................................... 46 
10.3.2. 
Discontinuation of the Study .......................................................... 46 
11. References .................................................................................................... 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 6 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 5 
 
List of Tables 
Table 
Page 
Table JAHG.1.    Objectives and Endpoints ................................................................................... 12 
Table JAHG.2.    Treatment Regimens........................................................................................... 22 
Table JAHG.3.    Criteria for Temporary Interruption from Study Treatment ............................... 26 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product ................... 27 
Table  JAHG.5.     Timing  of  Dosing  and  Fasting  Requirements  for  PK  Sample  Collection 
Visits .................................................................................................................. 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 7 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 6 
 
List of Figures 
Figure 
Page 
Figure JAHG.1.   Illustration of study design for Clinical Protocol I4V-MC-JAHG. .................... 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 8 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 7 
 
List of Appendices 
Appendix 
Page 
Appendix 1. 
Abbreviations and Definitions ........................................................................... 50 
Appendix 2. 
Schedule of Activities ........................................................................................ 55 
Appendix 3. 
Clinical Laboratory Tests ................................................................................... 61 
Appendix 4. 
Hepatic Monitoring Tests for Treatment-Emergent Abnormality ...................... 64 
Appendix 5. 
Protocol I4V-MC-JAHG Signature Page ........................................................... 65 
Appendix 6. 
Protocol Amendment I4V-MC-JAHG(c) Summary  [A Randomized, 
Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the 
Safety and Efficacy of Baricitinib in Patients with  Moderate-to-Severe 
Atopic Dermatitis] ............................................................................................. 66 
Appendix 7. 
Protocol Amendment I4V-MC-JAHG(d) Summary  [A Randomized, 
Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the 
Safety and Efficacy of Baricitinib in Patients with  Moderate-to-Severe 
Atopic Dermatitis] ............................................................................................. 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 9 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 8 
 
1. Protocol Synopsis 
 
Title of Study: 
A randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of baricitinib in 
patients with moderate-to-severe atopic dermatitis. 
Rationale: 
Baricitinib is a JAK1/JAK2 selective inhibitor that is currently in development for treatment of inflammatory   
diseases such as rheumatoid arthritis and psoriasis. Baricitinib has been administered to healthy subjects and patients 
with rheumatoid arthritis (RA), moderate-to-severe plaque stage psoriasis, and diabetic nephropathy  (DN). 
In addition, baricitinib is also being developed for the treatment of atopic dermatitis (AD). This study will evaluate 
the safety and efficacy of baricitinib in patients with moderate-to-severe atopic  dermatitis. 
Objective(s)/Endpoints: 
 
Objectives 
Endpoints 
Primary 
To compare the proportion of moderate-to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose group (2 mg and 4 mg) and placebo 
when treated daily for 16 weeks 
Secondary 
To evaluate the absolute and percent change from baseline of the EASI with 
baricitinib compared to placebo at weeks 1 and 4 and monthly intervals  thereafter 
To evaluate the mean change from baseline of the SCORing Atopic Dermatitis 
(SCORAD) with baricitinib compared to placebo at weeks 1 and 4 and monthly 
intervals thereafter 
To evaluate the mean change from baseline of the Investigator’s Global 
Assessment (IGA) with baricitinib compared to placebo at weeks 1 and 4 and 
monthly intervals thereafter 
To assess quality of life based on the Dermatologic Life Quality Index (DLQI) at 
baseline, weeks 1 and 4 and monthly intervals  thereafter 
To assess itch using the itch numerical rating scale (NRS) at baseline, weeks 1 
and 4 and monthly intervals thereafter 
To evaluate the pharmacokinetics of baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 
 
Summary of Study Design: 
 
Study I4V-MC-JAHG is a multicenter, randomized, double-blind, parallel, placebo-controlled study designed to 
compare the efficacy and safety of baricitinib to placebo in patients with moderate-to-severe atopic dermatitis. 
Enrollment will be targeted at 120 patients to enable approximately 96 patients to complete the study. Patients who 
meet all eligibility criteria will be randomized to receive either placebo or baricitinib, administered as once daily   
oral doses of 2 mg or 4 mg.  Randomization will occur at the country  level. 
Treatment Arms and Duration: 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 10 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 9 
 
Three arms will be randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, respectively. Study drug will 
be administered as oral tablets to be taken once-daily (QD) for 16 weeks. A background therapy of a mid-potency 
topical corticosteroid (triamcinolone 0.1%) will be utilized during the 28-day standardization phase prior to 
randomization and continued throughout the study. This background therapy should be used according to the  
labeling provided by the manufacturer or as directed by the  investigator. 
Number of Patients:  120 
 
Statistical Analysis: 
 
Sample Size 
The study will plan to enroll 120 patients that will be randomized 4:3:3 to 
placebo, 2 mg baricitinib, or 4 mg baricitinib,  respectively. 
Primary Outcome & Methodology 
The primary outcome parameter is the proportion of patients achieving 
EASI-50 in each treatment arm. The placebo arm will be compared to each 
of the baricitinib arms using a two-sided chi-square test with alpha=0.05 to 
control the study-wise type 1 error rate; the comparison of the baricitinib 
arms with the placebo arm will be performed in a stepwise fashion.  The 
4-mg baricitinib arm will be compared with the placebo arm; if this test is 
statistically significant, then the 2-mg baricitinib arm will be compared with 
the placebo arm. Enrollment of 120 patients in a 4:3:3 ratio provides 
approximately 90% power for detecting a 35% difference in response rate 
between placebo and 4-mg baricitinib treatment. 
Interim Analysis 
An interim analysis is not planned for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 11 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 10 
 
 
 
2.1. Background 
2. Introduction 
Atopic dermatitis (AD) is a common skin disorder characterized clinically by chronic 
inflammation and altered skin barrier function, and histologically by skin infiltration of 
inflammatory cells. AD is characterized by excessive T-cell activation, with significant skin 
infiltration by T-cells and dendritic cells. Both Th2 and Th22 activation are hallmarks of AD, 
with some Th17 and Th1 components. Patients with moderate-to-severe AD are afflicted with a 
heavy disease burden including medical as well as psycho-social abnormalities. Patients often 
have bacterial- or viral-mediated cutaneous complications. AD is the most common chronic 
inflammatory skin disease (Schmitt, 2013) with a prevalence of 2%–10% among adults in 
western geographies (Bieber, 2010) and a prevalence of about 3% in Japan (Muto et al,   2003). 
Studies using genomic and histologic profiling of AD skin have defined sets of biomarkers for  
AD that include markers of epidermal hyperplasia (epidermal thickness, K16 and Ki67 staining), 
epidermal barrier components (filaggrin), specific cellular infiltrates, including T-cells (CD3+  
and CD8+) and several dendritic cell subsets (CD11c+, CD1a+, inflammatory dendritic   
epidermal cells). Serum biomarkers that correlate with disease activity include IgE, eosinophils, 
eosinophilic cationic protein, as well as the Th2 chemokines CCL17, CCL18, CCL22, CCL11, 
and CCL26, and the cytokines IL-13, IL-31, and IL-22 (Mansouri,  2015). 
Members of the Janus kinase (JAK) family of protein tyrosine kinases (JAK1, JAK2, JAK3, and 
TYK2), along with the signal transduction and activator of transcription (STAT) pathway, play   
an important role in signal transduction following cytokine and growth factor binding to their 
receptors (Pesu, 2008). Emerging data support the role of JAK and STAT in Th2 immunity, 
activating eosinophils, and suppressing regulatory T cells. The JAK-STAT pathway, activated by 
IL-4, plays a critical role in the pathogenesis of AD by upregulating epidermal chemokines, pro- 
inflammatory cytokines, and proangiogenic factors as well as by down-regulating antimicrobial 
peptides and factors responsible for skin barrier function (Bao, 2013). Consistent with the  
proposed role of IL-4 activation of the JAK-STAT pathway in AD, administration of a  
monoclonal antibody against the alpha subunit of the IL-4 receptor improved clinical endpoints 
associated with AD (Beck, 2014). 
Baricitinib (also previously known as LY3009104 and INCB028050) is a potent and selective 
small molecule inhibitor of JAK1 and JAK 2 enzymes that is currently under development for 
the treatment of inflammatory conditions such as rheumatoid arthritis, diabetic kidney disease, 
psoriasis, and AD. 
Through 04 June 2015, approximately 4300 subjects have received baricitinib. This group of 
subjects was comprised of healthy subjects and patients with rheumatoid arthritis, psoriasis, 
diabetic kidney disease, rare auto-inflammatory syndromes, various degrees of renal impairment, 
and hepatic dysfunction. Baricitinib has been administered as single doses ranging from 1 to 40 
mg, multiple doses of up to 20 mg QD for 10 days, 10 mg QD for 28 days or 5 mg twice daily    
for 28 days in healthy subjects; and as a single 10-mg or 5-mg dose to subjects with mild to 
moderate or severe renal impairment respectively, as well as a single 5-mg dose to patients   with 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 12 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 11 
 
end stage renal disease. Treatment duration has ranged from single doses in healthy volunteers  
to approximately 3.5 years in rheumatoid arthritis  patients. 
More information about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably anticipated adverse events (AEs) of baricitinib are to be found in the 
Investigator’s Brochure (IB). 
 
2.2. Study Rationale 
Inhibition of JAK-STAT signaling by targeting multiple AD-associated cytokine pathways has 
the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key 
immune cells. Treatment of six patients with AD with a JAK1 and JAK3 inhibitor, tofacitinib,  
led to marked improvement in both objective measures of dermatitis and pruritus and patient- 
reported pruritus (Levy, 2015). 
Baricitinib is a potent and selective small molecule inhibitor of JAK1/2 enzymes. In vitro, 
baricitinib inhibits JAK1 and JAK2 with IC50 values in the single-digit nM range, yet it does not 
significantly inhibit a diverse panel of 28 kinases when tested at 100-fold of the IC50 against  
JAK1 and JAK2. In healthy volunteers, baricitinib demonstrated dose and time-dependent 
inhibition of cytokine-induced pSTAT3 (Shi,  2014). 
Study I4V-MC-JAHG will evaluate the safety and efficacy of baricitinib in patients with 
moderate-to-severe atopic dermatitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 13 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 12 
 
3. Objectives and Endpoints 
Table JAHG.1 shows the objectives and endpoints of the  study. 
 
Table JAHG.1. 
Objectives and Endpoints 
 
Objectives 
Endpoints 
Primary 
 To compare the proportion of moderate- 
to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in 
the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose 
group (2 mg and 4 mg) and placebo when 
treated daily for 16 weeks 
 EASI-50 at 16 weeks 
Secondary 
 To evaluate the absolute and percent 
change from baseline of the EASI with 
baricitinib compared to placebo 
 EASI at Weeks 1, 4, 8, 12, and 16 
 To evaluate the mean change from 
baseline compared to placebo for the 
SCORing Atopic Dermatitis  (SCORAD) 
 SCORAD at  Weeks 1, 4, 8, 12, and  16 
 To evaluate the mean change from 
baseline compared to placebo for the 
Investigator’s Global Assessment  (IGA) 
 IGA at Weeks 1, 4, 8, 12, and 16 
 To assess quality of life based on the 
Dermatologic Life Quality Index (DLQI) 
 DLQI at Weeks 1, 4, 8, 12, and 16 
 
To assess itch based on the Itch 
Numerical Rating Scale (NRS) 
 Itch Numerical Rating Scale at Weeks 1, 
4, 8, 12, and 16 
 To characterize the pharmacokinetics of 
baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 Plasma pharmacokinetic data 
Exploratory 
 To evaluate EASI response in patients 
based on their baseline total serum  IgE 
 EASI at Weeks 1, 4, 8, 12 and 16; baseline 
total serum IgE 
 To evaluate total serum IgE over the 
course of treatment 
 Total serum IgE at baseline, Weeks 4, and 
16 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 14 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 13 
 
Exploratory (continued) 
 To evaluate changes in disease activity 
over the course of treatment 
 Patient-Oriented Eczema Measure (POEM) 
at  Weeks 1, 4, 8, 12, and 16 
 To evaluate changes in sleep quality over 
the course of treatment 
 Number of sleep disturbances and average 
percentage of sleep time from a wearable 
actigraphy device 
 To evaluate changes in nocturnal itch 
patterns over the course of treatment 
 Number of scratching events per night from 
a wearable actigraphy device 
 To evaluate EASI response relative to 
filaggrin genotype 
 EASI-50 and filaggrin genotype data from 
peripheral baseline blood sample 
 To assess tissue biomarkers from  biopsies 
 K16, Ki-67, and IL-4 will be assessed from 
each tissue biopsy (collected at baseline 
(lesion and non-lesion), at Week 4 (lesion), 
and at Week 16 (lesion and  non-lesion) 
 To assess peripheral biomarkers 
mechanistically related to inhibition of 
JAK 1/2 mechanism 
 Peripheral biomarkers collected at baseline, 
Weeks 4 and 16 
 To perform subgroup assessments of 
response based on patient and disease 
characteristics 
 Ad hoc evaluation of potential prognostic 
and predictive disease characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 15 
LY3009104 
 
 
4 mg baricitinib 
2 mg baricitinib 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 14 
 
4. Study Design 
4.1. Overview of Study Design 
I4V-MC-JAHG is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the 
safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The study 
design is illustrated in Figure JAHG.1. 
Standardization 
Treatment 
Follow-up 
 
 
 
 
120 AD    
Patients 
 
Placebo 
4 Weeks 
16 Weeks 
4 Weeks 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
Week: 
-4 
0 
1 
4 
8 
12 
16 
20 
Day: 
-28 
0 
7 
28 
56 
84 
112 
140 
 
 
 
Screening Randomization 
(4:3:3) 
Placebo : 2 mg baricitinib : 4 mg baricitinib 
 
Figure JAHG.1. 
Illustration of study design for Clinical Protocol I4V-MC-JAHG. 
 
 
 
4.2. Scientific Rationale for Study Design 
This study will enroll moderate-to-severe atopic dermatitis patients for whom a systemic 
treatment such as baricitinib may be appropriate. A 16-week course of treatment is expected to 
enable an optimal assessment of efficacy based on previous baricitinib studies in an 
inflammatory skin condition. 
Relatively high (20% to 50%) placebo responses have been observed in previously published 
atopic dermatitis studies (Bissonnette, 2012; Beck, 2014; Epstein and Pinski, 1964). Therefore, a 
4:3:3 randomization scheme of placebo, 2 mg baricitinib, and 4 mg baricitinib will be 
implemented.   Increased placebo enrollment across treatment groups has been reported to  
decrease placebo response and to also increase statistical power (Mallinckrodt,   2011). 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 16 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 15 
 
A standardization phase will be incorporated prior to randomization to minimize effects due to 
background treatment. Beginning at standardization and continuing throughout the study, 
patients will be provided a topical corticosteroid to be used as prescribed and may continue use 
of other allowed study-specified palliative care measures as specified in Section   6.8. 
The EASI and SCORAD are the best instruments available to measure clinical severity of AD 
(Schmitt, 2013). Several quality of life assessments are being utilized to evaluate the effect of 
baricitinib on patients’ quality of life. 
 
4.3. Justification for Dose 
This study will evaluate the safety and efficacy of 2-mg and 4-mg doses of baricitinib in patients 
with moderate-to-severe atopic dermatitis. The dose justification for AD is based on a Phase 2 
rheumatoid arthritis (RA) study (Study JADA), reported Phase 3 RA studies (Study JADW and 
Study JADX) and a Phase 2 psoriasis study (Study  JADP). 
In these studies, all doses were generally well tolerated based on the observed adverse event 
profile and infrequent discontinuations of baricitinib dosing. The anticipated on-target, dose- 
limiting effect is a small decline in hemoglobin and hematocrit values. As described in Section 
4.4, this likely results from inhibition of erythropoietin signals via the JAK2/STAT5 signal 
transduction pathway (Klingmüller, 1997; Vera, 2008). These hematologic effects occur in 
higher-dose groups (8 mg daily) upon initiation of treatment and then   stabilize. 
The 2-mg and 4-mg doses have shown efficacy in RA with an acceptable safety profile. There  
was no additional efficacy associated with an 8-mg dose in the Phase 2 RA study, thus only 4 mg 
and 2 mg have been studied in the RA Phase 3 program. Doses less than 2 mg were not clearly 
effective in RA. 
In patients with moderate-to-severe plaque stage psoriasis, doses of 4 mg to 10 mg were found to 
be associated with statistically significant reductions in Psoriasis Area and Severity Index (PASI) 
score, with greater efficacy at the higher doses; however, the 8-mg and 10-mg doses were 
associated with a higher rate of AEs related to laboratory abnormalities (decreases in    
hemoglobin, neutrophils, and lymphocytes). The 2-mg and 4-mg dose groups had a pattern of   
AEs similar to placebo. The 2-mg dose did show numeric reductions in PASI score compared   
with placebo and statistically significant reductions in itch. Thus, in AD, the highest dose to be 
tested will be 4 mg, which would be anticipated to show efficacy together with an acceptable  
safety profile, and also provide the opportunity to cross reference to the large safety database   
from the RA Phase 3 program. The lower dose of 2 mg also has the opportunity to show efficacy  
in AD, where itch is a major component of the disease and may provide data that may be useful    
in the future for patients less than 18 years of  age. 
 
4.4. Benefit/Risk Assessment 
Baricitinib is a specific inhibitor of JAK1/2 and may offer potential benefit to patients with 
moderate-to-severe AD. Increases in serum creatinine and in both LDL and HDL cholesterol 
have been observed in Phase 1 and 2 studies with baricitinib (see Investigator’s   Brochure). 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 17 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 16 
 
Baricitinib is a specific inhibitor of JAK1/2 that has shown to be well-tolerated and effective in 
chronic inflammatory conditions such as rheumatoid arthritis (Keystone, 2015) and psoriasis 
(Menter, 2014). Baricitinib may offer potential benefit in a chronic inflammatory dermatologic 
condition such as AD. 
Phase 1 and 2 studies with baricitinib showed increased levels of serum creatinine and LDL and 
HDL cholesterol (see Investigator’s Brochure). Similar increased levels of creatinine and 
cholesterol were also seen in tofacitinib, a JAK1/3 inhibitor (Fleischmann, 2012; Kremer, 2012). 
In addition, reductions in absolute neutrophil counts have been reported with both baricitinib and 
tofacitinib. Other pathways that signal through JAK include granulocyte macrophage colony 
stimulating factor and granulocyte colony stimulating factor signal and erythropoietin (JAK2) 
(Parganas, 1998). The assessment of safety of baricitinib in this study will therefore also include, 
but will not be limited to, monitoring of creatinine, cholesterol, neutrophil and granulocyte  
counts, hemoglobin levels, and rates of  infection. 
More information about the known and expected benefits, risks, and reasonably anticipated  
adverse events may be found in the Investigator’s Brochure. Information on adverse events 
expected to be related to the investigational product may be found in Section 7 (Development  
Core Safety Information) of the Investigator’s Brochure. Information on serious adverse events 
expected in the study population independent of drug exposure will be assessed by the sponsor in 
aggregate periodically during the course of the study and may be found in Section 6 (Effects in 
Humans) of the Investigator’s  Brochure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 18 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 17 
 
5. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, will not be  permitted. 
 
5.1. Inclusion Criteria 
Patients are eligible to be included in the study only if they meet all of the following   criteria: 
Type of Patient and Disease  Characteristics 
[1] Are at least 18 years of age at the time of Visit  1 
[2] Have moderate-to-severe AD, as determined by all of the  following: 
 EASI ≥12 at Visits 1 and 2 
 ≥10% of body surface area (BSA) involvement at Visits 1 and  2 
 Were diagnosed with AD at least 2 years before Visit  1 
With a history of inadequate clinical response, in the opinion of the 
investigator, to one or more of the three treatment categories listed below 
(used for at least 4 weeks): 
 Category 1: Hydration plus topical steroids and/or antibiotics (e.g., 
tetracycline, trimethoprim and sulfamethoxazole, cephalosporins) and/or 
topical immune modulators (e.g.,  tacrolimus/pimecrolimus) 
 Category 2:   Systemic steroids and/or phototherapy 
 Category 3: Cyclosporine and/or other immunomodulators (e.g., 
methotrexate, mycophenolate mofetal, and  azathioprine) 
[3] Agree to discontinue use of the following excluded medications for at least 4 
weeks prior to randomization (Visit 2) and throughout the  study 
 oral cyclosporine, steroids, and leukotriene  inhibitors 
 phototherapy 
 potent topical steroids (e.g., clobetasol) or topical immune modulators 
(e.g., tacrolimus/pimecrolimus). 
 cyclosporine and/or other immunomodulators (e.g., methotrexate, 
mycophenolate mofetal, and  azathioprine) 
 
5.2. Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
Medical Conditions 
[4] Are female subjects who are pregnant or  nursing 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 19 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 18 
 
[5] Are females of childbearing potential who do not agree to use 2 forms of  
highly effective methods of birth control or remain abstinent while enrolled in 
the study and for at least 28 days following the last dose of investigational 
product 
Note: Females of nonchildbearing potential are defined as women ≥60 years 
of age, or women >40 and <60 years of age who have had a cessation of 
menses for at least 12 months, or women who are congenitally or surgically 
sterile (that is, have had a hysterectomy or bilateral oophorectomy or tubal 
ligation). 
The following birth control methods are considered highly effective (the 
patient should choose 2): 
 Oral, injectable, or implanted hormonal  contraceptives 
 Condom with a spermicidal foam, gel, film, cream, or  suppository 
 Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal 
foam, gel, film, cream, or  suppository 
 Intrauterine device 
 Intrauterine system (for example, progestin-releasing  coil) 
 Vasectomized male (with appropriate post-vasectomy documentation 
of the absence of sperm in the  ejaculate). 
[6] 
Are males who do not agree to use 2 forms of highly effective birth control 
(see above) with female partners of childbearing potential while enrolled in 
the study, and for at least 28 days following the last dose of investigational 
product 
Are currently experiencing or have a history of any of the  following: 
[7] Other concomitant skin conditions (e.g., psoriasis, or lupus erythematosus) 
that would interfere with evaluations of the effect of study medication on 
atopic dermatitis 
[8] Erythrodermic, refractory or unstable skin disease that requires frequent 
hospitalizations and/or intravenous treatment for skin  infections 
[9] Immunocompromised and, in the opinion of the investigator, at an 
unacceptable risk for participating in the  study 
[10] Serious concomitant illness that could require the use of systemic 
corticosteroids or otherwise interfere with study participation or require active 
frequent monitoring (e.g., unstable chronic  asthma) 
[11] Organ transplant(s) (corneal transplant performed >3 months prior to 
screening may be allowed) 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 20 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 19 
 
[12] Clinically important deviation, in the opinion of the investigator, from normal 
limits in physical examination, vital sign measurements, and/or 
electrocardiograms, that is not associated with a chronic, well-controlled 
medical condition 
[13] Electrocardiogram (ECG) abnormalities at Visit 1 that, in the opinion of the 
investigator or the sponsor, are clinically significant and indicate an 
unacceptable risk for the patient’s participation in the study (Bazett’s 
corrected QT interval >470 msec for men and  women) 
[14] Have evidence of active or latent TB as documented by a positive PPD test 
(≥5 mm in duration between approximately 2 and 3 days after application, 
regardless of vaccination history), medical history, and chest x-ray at 
screening. Exceptions are patients with a history of latent TB who have 
documented evidence of completing a course of appropriate  treatment. 
 If the PPD test is positive or not conducted and the patient has no medical 
history or chest x-ray findings consistent with active or latent TB, the 
patient should have a QuantiFERON®-TB Gold test or the T-SPOT.TB® 
test. If either of these tests is positive or indeterminate (a single re-test is 
allowed), the patient is excluded from the  study. 
[15] Active or latent granulomatous disorders or a non-tuberculous mycobacterial 
infection or opportunistic systemic infection (e.g., Pneumocystis carinii, and 
aspergillosis) within 6 months prior to  screening 
[16] Uncompensated heart failure, fluid overload, myocardial infarction, or 
evidence of ischemic heart disease or other serious cardiac disease within 12 
weeks of Visit 1 
[17] Uncontrolled arterial hypertension characterized by a repeated systolic blood 
pressure >160mm Hg or diastolic blood pressure >100mm Hg at the time of 
Visit 1 
[18] Have, or have a history of, lymphoproliferative disease; or signs or symptoms 
suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly; or active primary or recurrent malignant 
disease; or been in remission from clinically significant malignancy for less 
than 5 years. 
Note: Patients with cervical carcinoma in situ that has been resected with no 
evidence of recurrence or metastatic disease, or with basal cell or squamous 
epithelial skin cancers that have been completely resected with no evidence of 
recurrence for at least 3 years may participate in the  study. 
[19] Evidence of HIV infection or are positive for HIV antibodies (based on 
history or point-of-care testing (POCT) at Visit  1 
[20] Positive test for hepatitis B defined as: 
a) positive for hepatitis B surface antigen (HBsAg),  or 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 21 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 20 
 
b) positive for anti-hepatitis B core antibody (HBcAb) and positive for hepatitis B 
deoxyribonucleic acid (HBV DNA), or 
c) for patients enrolled in Japan only, positive for anti-hepatitis B core antibody 
(HBcAb) and/or positive for anti-hepatitis B surface antibody (HBsAb), and 
positive for hepatitis B deoxyribonucleic acid (HBV  DNA). 
 
If any of the hepatitis B tests have an indeterminate result, confirmatory testing will 
be performed by an alternate method. 
 
[21] Positive for anti-hepatitis C antibody with confirmed presence of hepatitis C 
virus, or chronic liver disease with the most recent available AST or ALT >2X 
the ULN 
[22] Serious and/or unstable mental and/or physical illness that, in the opinion of 
the investigator, poses an unacceptable risk for the patient’s participation in 
the study 
Prior/Concomitant Therapy 
[23] Received any oral JAK inhibitor (e.g., Xeljanz) within the past 6  months 
[24] Currently receiving any immunosuppressive therapy (e.g.,  cyclosporine) 
[25] Received any monoclonal antibody intended for AD (e.g., ustekinumab or 
dupilumab) within the past 6  months. 
[26] Currently using or expected to use concomitant medications or treatments for 
AD other than those allowed for use in the  protocol 
[27] Exposed to a live vaccine, including the nasal flu vaccine, within 12 weeks 
prior to planned enrollment (with the exception of herpes zoster vaccination; 
patients will be excluded if they were exposed to herpes zoster vaccination 
within 30 days of planned enrollment) or are expected to need/receive a live 
vaccine during the course of the  study. 
Prior/Concurrent Clinical Trial  Experience 
[28] Currently enrolled in any other clinical study involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this  study 
[29] Participated, within the last 30 days in a clinical study involving an 
investigational product. If the previous investigational product has a long 
half-life (2 weeks or longer), at least 3 months or 5 half-lives (whichever is 
longer) should have passed. 
[30] Previously completed or withdrawn from this  study 
Diagnostics Assessments 
Have any of the following specific abnormalities on screening laboratory   tests: 
[31] AST or ALT >2X the ULN 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 22 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 21 
 
[32] Total bilirubin ≥1.5X the ULN 
[33] Hemoglobin < LLN 
[34] Total white blood cell count <  LLN 
[35] Neutropenia (absolute neutrophil count <  LLN) 
[36] Lymphopenia (lymphocyte count <  LLN) 
[37] Thrombocytopenia (platelets < LLN) 
[38] eGFR <50 mL/min/1.73 m2 (based on CKD  EPI) 
Note: In the case of any of the aforementioned laboratory abnormalities, they may 
be repeated once within 1 week of the initial values, and values resulting from  
repeat testing may be used to assess enrollment  eligibility. 
Other Exclusions 
[39] 
Donated blood of more than 500 mL or blood products within 4 weeks 
prior to entry. 
[40] 
Unwilling to commit to refrain from donating blood or blood products 
during the study. 
[41] 
History of substance abuse (drug or alcohol) within the two years before 
screening. 
[42] 
Unable or unwilling to be available for the duration of the study and/or are 
unwilling to follow study  restrictions/procedures. 
[43] 
Unable or unwilling to have skin biopsies performed, unless exempted by 
the investigator. 
[44] 
Investigator site personnel directly affiliated with this study and/or their 
immediate families; immediate family is defined as a spouse, parent, child, 
or sibling, whether biological or legally  adopted. 
[45] 
Employees of the sponsor. 
 
5.3. Screen Failures 
Individuals who do not meet the criteria for participation in this study (screen failure) may be re- 
screened. Individuals may be re-screened once (time period from screen fail to re-screen to be 
determined by the investigator). If re-screening is performed, the individual must sign a new 
informed consent form (ICF) and will be assigned a new identification number. Additionally, all 
screening procedures must be conducted at re-screen to ensure all eligibility criteria are   met. 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 23 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 22 
 
6. Treatment 
6.1. Treatments Administered 
This study includes the treatment regimens outlined in Table JAHG.2 below. Doses of baricitinib 
or placebo will be administered orally. 
 
 
Table JAHG.2. 
Treatment Regimens 
 
    Treatment Group 
Dose (QD) 
Day 1 through Day 112 
2 mg LY 
(1  2-mg LY tab; 1  4-mg placebo tab) 
4 mg LY 
(1  2-mg placebo tab; 1  4-mg LY tab) 
Placebo 
(1  2-mg placebo tab; 1  4-mg placebo tab) 
Abbreviations:  tab = tablet; LY = baricitinib 
 
 
The investigator or his/her designee is responsible for the  following: 
 explaining and verifying the correct use of the investigational agent(s) to the 
patient and site personnel 
 maintaining accurate records of investigational product dispensing and   collection 
 returning, at the end of the study, all unused investigational product to the 
sponsor, or its designee, unless the sponsor and sites have agreed all unused 
medication is to be destroyed by the site, as allowed by local  law 
 
6.2. Method of Treatment Assignment 
Patients who meet all criteria for enrollment will be randomized to double-blind treatment at   
Visit 2. Assignment to treatment groups will be determined by a computer-generated random 
sequence using an interactive response technology (IRT) system. The IRT system will be used to 
assign blister packs containing double-blind investigational product to each patient. The IRT 
system will dispense a number of blister packs adequate for each visit   interval. 
The randomization will be stratified by  country. 
 
6.2.1. Selection and Timing of Doses 
Patient treatment assignments will be based on the randomization scheme as described   above. 
On PK sample collection days (Appendix 2), specific fasting and dose timing requirements are 
outlined in Table JAHG.5 (Section  8.5.1). 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 24 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 23 
 
6.3. Blinding 
This is a double-blind study in which the patients, investigator, and study site personnel will be 
blinded to treatment allocation. 
To preserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is   complete. 
Emergency unblinding for AEs may be performed through an IRT system, which may  
supplement or take the place of emergency codes generated by a computer drug-labeling system. 
This option may be used ONLY if the patient’s well-being requires knowledge of the patient’s 
treatment assignment. All calls resulting in an unblinding event are recorded and reported by the 
IRT system. 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warranted. Patient safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the sponsor CRP prior to  
unblinding a patient’s treatment  assignment. 
If an investigator, site personnel performing assessments, or patient is unblinded to the treatment 
code assignment, the sponsor must be contacted  immediately. 
 
6.4. Packaging and Labeling 
The sponsor (or its designee) will provide the following investigational   products: 
 tablets containing 2 mg of baricitinib 
 tablets containing 4 mg of baricitinib 
 placebo to match baricitinib 2 mg tablets 
 placebo to match baricitinib 4 mg tablets 
Additionally, the sponsor (or its designee) will also provide the following concomitant therapy 
product: 
 triamcinolone 0.1% cream which should be used according to the labeling provided 
by the manufacturer or as directed by the  investigator 
Investigational products and triamcinolone 0.1% cream will be dispensed to the patient at the 
investigator’s study site. 
Investigational product will be packaged in blister packs. Investigational product packaging will 
be labeled with a unique identifier for drug dispensing by the IRT system. Blister packs will 
contain additional tablets to allow for sufficient administration of investigational product within 
the allowed visit internal window. 
Investigational product will be labeled according to the country’s regulatory requirements. All 
investigational products will be stored, inventoried, reconciled, and destroyed according to 
applicable regulations. Investigational products will be manufactured and tested by the sponsor 
or its representative in accordance with current Good Manufacturing Practices   (cGMP) 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 25 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 24 
 
requirements for clinical studies, and will be supplied with lot numbers, expiry dates, and 
certificates of analysis (as applicable). 
 
6.5. Investigational Products Storage and  Handling 
Investigational products should be stored between 15°C and 30°C. All investigational products 
should be stored in a secure and locked area with strictly limited access and monitored for 
temperature and will be allocated and dispensed by appropriately trained   personnel. 
 
6.6. Dose Modification 
No dose modifications will be  allowed. 
 
6.7. Treatment Compliance 
Patient compliance with study medication will be assessed at each visit. Compliance will be 
assessed by counting returned tablets. Deviation(s) from the prescribed dosage regimen should 
be recorded in the CRF. 
The patient will be considered significantly noncompliant if he or she misses more than 20% of 
the prescribed doses during the study. Similarly, a patient will be considered significantly 
noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken 
more than the prescribed amount of  medication. 
Patients found to be noncompliant with investigational product should be assessed to determine 
the reason for noncompliance, and educated and/or managed as deemed appropriate by the 
investigator to improve compliance. 
 
6.8. Concomitant Therapy 
The use of triamcinolone 0.1% cream will be allowed throughout the trial. Patients will be 
instructed to apply the triamcinolone 0.1% cream according to the labeling provided by the 
manufacturer or as directed by the investigator. The triamcinolone 0.1% cream container will be 
weighed at each visit to assess usage. 
All other concomitant medication taken during the study must be recorded on the Concomitant 
Medication case report form (CRF). Treatment with concomitant atopic dermatitis therapies 
during the study is permitted only as outlined in the inclusion/exclusion criteria (Section 5.1 and 
Section 5.2) and as described in the paragraphs  below. 
Additional systemic drugs are to be avoided during the study, unless required to treat an   AE. 
Non-live seasonal vaccinations and/or emergency vaccination (such as rabies or tetanus 
vaccinations) are allowed. 
The following will be allowed as needed: use of topical antibiotics in the event of secondary 
infections of lesions; nonprescription shampoos; NSAIDs; antihistamines; and topical 
moisturizers/emollients, bath oils, oatmeal bath preparations, bleach baths if using a stable  
regimen prior to enrollment, and salicylic acid preparations.  Patients will be instructed to   consult 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 26 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 25 
 
the investigator or other appropriate study personnel at the site before taking any new 
medications or supplements. 
 
6.9. Treatment after Study Completion 
6.9.1.   Continued Access 
The Investigational Product will not be made available to patients after the conclusion of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 27 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 26 
 
7. Discontinuation Criteria 
7.1. Discontinuation of Investigational  Product 
7.1.1. Temporary Interruption of Investigational  Product 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs   
or abnormal laboratory values as described in Table JAHG.3 that may have an unclear  
relationship to investigational product. Except in cases of emergency, it is recommended that the 
investigator consult with the sponsor (or its designee) before temporarily interrupting   therapy. 
The investigator must obtain approval from the sponsor (or its designee) before restarting 
investigational product that was temporarily discontinued because of an AE or abnormal 
laboratory value. Investigational product must be held in the following situations involving 
laboratory abnormalities and may be resumed as noted in Table  JAHG.3. 
 
Table JAHG.3. 
Criteria for Temporary Interruption from Study Treatment 
 
 
Hold Investigational Product if the Following 
Laboratory Test Results Occur: 
Investigational Product May Be Resumed after 
Approval from Lilly (or its Designee) and When: 
eGFR <40 mL/min/1.73 m2 (from serum 
 creatinine) 
eGFR 50 mL/min/1.73 m2 
ALT or AST >5 times the ULN 
ALT and AST return to <2 times the ULN, and 
investigational product is not considered to be the  cause 
of enzyme elevation 
Symptomatic herpes zoster 
All skin lesions have crusted and are resolving 
Severe infection that, in the opinion of the 
investigator, merits the investigational product 
 being discontinued 
Resolution of infection 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; eGFR = estimated glomerular 
filtration rate; min = minute; ULN = upper limit of  normal. 
 
7.1.2. Permanent Discontinuation of Investigational  Product 
Any patient who is permanently discontinued from investigational product for an AE or  
abnormal laboratory result should have the reason for investigational product discontinuation 
reported as the AE or abnormal laboratory value. If any of the criteria listed in Section 7.1.1. 
above recur after investigational product is restarted, the investigator must obtain approval from 
the sponsor (or its designee) before restarting investigational product.  In addition, patients will  
be permanently discontinued from investigational product if they experience any of the criteria 
listed in Table JAHG.4. 
Any adverse event that is Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 
or higher will result in permanent discontinuation from the study except for transaminases and 
severe infection as noted in Table JAHG.3 and Table  JAHG.4. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 28 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 27 
 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product 
 
Permanently Discontinue Investigational Product if any of the Following are  Observed: 
ALT or AST >8 times the ULN 
ALT or AST >5 times the ULN persisting for more than 2 weeks after temporary interruption of investigational 
product 
ALT or AST >3 times the ULN and total bilirubin level >2 times the  ULN 
ALT or AST >3 times the ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) 
WBC count <3000 cells/L 
ANC <1500 cells/L 
Lymphocyte count <800 cells/L 
Hemoglobin <10 g/dL 
Platelet count <75,000/L 
Pregnancy 
Malignancy (except for successfully treated basal cell or squamous epithelial skin  cancers) 
HBV DNA ≥29 IU/mLa 
Score of 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any time during the   study 
 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; HBV DNA = hepatitis B virus deoxyribonucleic acid; ULN = upper limit of normal; 
WBC = white blood cell; QIDS-SR16 = Quick Inventory of Depressive Symptomatology-Self-Report   16. 
a If a HBV DNA result of ‘target detected’ 29 IU/mL or greater, then the patient should be referred to a hepatology 
specialist immediately. In selected cases, investigators may temporarily continue study drug in accordance with 
current immunomodulator management in the setting of HBV DNA positivity. This option may be considered in 
consultation with the sponsor (or its designee) and evaluation of individual patient risks and benefits. Refer to 
Section 8.4.5 for additional instruction on HBV DNA  monitoring. 
 
7.1.3. Discontinuation of Inadvertently Enrolled  Patients 
If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the sponsor CRP and the investigator to 
determine if the patient may continue in the study. If both agree it is medically appropriate to 
continue, the investigator must obtain documented approval from the sponsor CRP to allow the 
inadvertently enrolled patient to continue in the study with or without treatment with 
investigational product. 
 
7.1.4. Permanent Discontinuation from the  Study 
Some possible reasons that may lead to permanent discontinuation   include: 
 Enrollment in any other clinical study involving an investigational product or enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this study 
 Participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical practice   (GCP) 
 Investigator Decision 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 29 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 28 
 
o the investigator decides that the patient should be discontinued from the   study 
o if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new   agent 
 Patient  Decision 
Patients who discontinue the study early will have early termination (ET) procedures performed 
as shown in the Schedule of Activities (Appendix  2). 
 
7.1.5. Patients Lost to Follow-Up 
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make  
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 30 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 29 
 
8. Study Assessments and  Procedures 
Appendix 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for timing). 
Appendix 3 lists the laboratory tests that will be performed for this  study. 
Appendix 4 provides the hepatic monitoring tests for treatment-emergent   abnormalities. 
Additionally, a study addendum will be compiled to detail the capture of photographs from 
selected lesions for patients enrolled at up to three selected study sites. These photographs will 
permit documentation of the clinical response through sequential photography of a selected 
lesion or involved area before and following study drug  treatment. 
 
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results. Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards. 
 
8.1. Efficacy Assessments 
Study procedures and their timing are summarized in the Schedule of Activities (Appendix   2). 
 
8.1.1. Primary Efficacy Assessments 
The clinical outcome measure that will be used in this study is the EASI score (specifically, the 
proportion of patients achieving a 50% reduction in EASI or  EASI-50). 
 Eczema Area and Severity Index (EASI) scores: The EASI assesses extent of disease 
at four body sites and measures four clinical signs: (1) erythema, (2) 
induration/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3. 
EASI confers a maximum score of 72. EASI evaluates two dimensions of atopic 
dermatitis: disease extent and clinical signs.
 
8.1.2. Secondary Efficacy Assessments 
 Mean and Percentage change in Eczema Area and Severity Index (EASI) scores: See 
above.
 
 SCORing Atopic Dermatitis (SCORAD): The SCORAD index uses the rule of nines to 
assess disease extent and evaluates five clinical characteristics to determine disease 
severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) 
lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss 
with Visual Analogue Scales (VAS). These three aspects: extent of disease, disease 
severity and subjective symptoms combine to give a maximum possible score of 103.
 
 
Investigator’s Global Assessment (IGA): The IGA consists of a 6-point severity scale 
from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate 
disease, 4 = severe disease and 5 = very severe disease). IGA uses clinical characteristics
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 31 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 30 
 
of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall 
severity assessment. 
 
 
Dermatology Life Quality Index (DLQI): The DLQI is a simple, patient-administered, 
10-question, validated, quality-of-life questionnaire that covers 6 domains including 
symptoms and feelings, daily activities, leisure, work and school, personal relationships, 
and treatment. The recall period of this scale is over the “last week.” Response categories 
include “not at all,” “a lot,” and “very much,” with corresponding scores of 1, 2, and 3 
respectively and unanswered (“not relevant”) responses scored as 0. A DLQI total score 
of 0 to 1 is considered as having no effect on a patient’s health-related quality of life, and 
a 4-point change from baseline is considered as the minimal clinically important 
difference threshold (Khilji, 2002; Hongbo, 2005; Basra, 2015).
 
 
Itch Numerical Rating Scale (NRS): The Itch NRS is a patient-administered, 11 point 
horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 
representing “worst itch imaginable.”  Overall severity of a patient’s itching is 
indicated by circling the number that best describes the worst level of itching in the 
past 24 hours.
8.1.2.2 Exploratory Efficacy Assessments 
Data on the following exploratory efficacy measures will be collected at the times shown in the 
Schedule of Activities (Appendix 2): 
 Patient-Oriented Eczema Measure (POEM): The Patient-Oriented Eczema Measure 
(POEM) was originally developed to help address the imbalance between physician and 
patient-based outcome measures in eczema research. Patients answer simple questions 
about the frequency of seven symptoms: itch, sleep disturbance, skin bleeding, skin 
weeping/oozing, skin cracking, skin flaking, and skin dryness/roughness over the last 
week. The total score from this assessment reflects overall disease activity. The POEM 
utilizes a 5-point Likert scale for each question and is intended for ages 1-60 years. 
POEM scores can range from 0 to 28 where lower total scores reflect lower disease 
activity and higher scores reflect higher disease activity (Charman, 2004).
 
 Actigraphy Device: A hypoallergenic wrist watch-like device that is used to collect 
sleep/wake patterns and quantify nocturnal scratching events (Ferguson, 2015).
 
8.1.3. Appropriateness of Primary Efficacy  Measure 
 Eczema Area and Severity Index (EASI): The EASI is one of the best instruments 
available to measure clinical signs of AD. EASI utilizes objective physician estimates of 
disease extent and severity. The EASI is valid and internally consistent and has adequate 
intraobserver reliability, intermediate interobserver reliability, and adequate 
responsiveness. One advantage of the EASI is its unidimensionality; that is, it only 
measures clinical signs of AD and does not include symptoms. Another advantage of the 
EASI is that it measures the intensity of the lesions at multiple body parts (rather than 
relying on a representative lesion) (Schmitt, 2013).
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 32 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 31 
 
8.2. Adverse Events 
Investigators are responsible for monitoring the safety of patients who have entered this study 
and for alerting the sponsor or its designee to any event that seems unusual, even if this event 
may be considered an unanticipated benefit to the  patient. 
The investigator is responsible for the appropriate medical care of patients during the study. 
During and following a subject's participation in the trial, the investigator should ensure that 
adequate medical care is provided to a subject for any adverse events related to the trial. The 
investigator should inform a subject when medical care is needed for intercurrent illness(es) of 
which the investigator becomes aware. It is recommended that the investigator inform the 
subject's primary physician about the subject's participation in the trial if the subject has a 
primary physician and if the subject agrees to the primary physician being   informed. 
The investigator remains responsible for following, through an appropriate health care option,  
AEs that are (1) serious or otherwise medically important, (2) considered related to the 
investigational product or the study, or that (3) caused the patient to discontinue the  
investigational product before completing the study. The patient should be followed until the  
event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The 
frequency of follow-up evaluations of the AE is left to the discretion of the   investigator. 
The sponsor has standards for reporting AEs that are to be followed regardless of applicable 
regulatory requirements that may be less stringent. Study site personnel will record the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. All AEs collected in the study 
CRF will be validated and reported in the final study  report. 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect. 
After the ICF is signed, study site personnel will record, via the CRF/electronic data entry, the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. In addition, site personnel will 
record any change in the condition(s) and any new conditions as AEs. Investigators should  
record their assessment of the potential relatedness of each AE to protocol procedure or 
investigational product. 
Investigators must document their review of each laboratory safety  report. 
Any clinically significant findings from ECGs, laboratory tests, vital sign measurements, and  
other procedures that occur after the patient signs the ICF and that result in a diagnosis should be 
reported to the sponsor or its designee. 
Investigators will be instructed to report to the sponsor or its designee their assessment of the 
potential relatedness of each AE to protocol procedure or investigational product via the case 
report form. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 33 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 32 
 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the  study. 
Cases of pregnancy that occur during maternal or paternal exposures to the investigational  
product should be reported following the SAE process. Data on fetal outcome and breast-feeding 
are collected for regulatory reporting and drug safety  evaluation. 
Study site personnel must alert the sponsor or its designee immediately of the investigator 
unblinding a patient’s treatment group assignment for any  reason. 
If a patient’s treatment is discontinued as a result of an AE, study site personnel must clearly 
report to the sponsor or its designee the circumstances and data leading to any such 
discontinuation of treatment. 
 
8.2.1. Adverse Events/Laboratory Results of Special Interest  
Adverse events or laboratory results of special interest include infections; myelosuppressive 
events of anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia; thrombocytosis; 
hyperlipidemia; hypercholesterolemia; and elevations in ALT/AST (≥3X ULN) and total 
bilirubin (≥2X ULN). 
8.2.2. Serious Adverse Events 
Study site personnel must alert the sponsor or its designee of any SAE within 24 hours of 
investigator awareness of the event via a sponsor-approved method. Alerts issued via telephone 
are to be immediately followed with official notification on study-specific SAE forms. This 24- 
hour notification requirement refers to the initial SAE information and all follow-up SAE 
information. 
An SAE is any AE from this study that results in one of the following   outcomes: 
 death 
 initial or prolonged inpatient  hospitalization 
 a life-threatening experience (that is, immediate risk of  dying) 
 persistent or significant  disability/incapacity 
 congenital anomaly/birth defect 
 considered significant by the investigator for any other  reason 
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Previously planned (prior to signing of ICF) surgeries should  
not be reported as SAEs unless the underlying medical condition has worsened during the course 
of the study. 
Although all AEs occurring after signing the ICF are recorded in the CRF, SAE reporting begins 
after the patient has signed the ICF and has received investigational product.  However, if   an 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 34 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 33 
 
SAE occurs after signing the ICF, but prior to receiving investigational product, it needs to be 
reported ONLY if it is considered reasonably possibly related to study   procedure. 
SAEs occurring after a patient has taken the last dose of the investigational product will be 
collected in the pharmacovigilance system and clinical data collection database for 30 days after 
the last dose of the investigational product, regardless of the investigator’s opinion of causation. 
Thereafter, SAEs are not required to be reported unless the investigator feels the events were 
related to either investigational product, drug delivery system, or a protocol   procedure. 
Investigators are not obligated to actively seek AEs or SAEs in patients once they have been 
discontinued and/or completed the study (the patient summary CRF has been   completed). 
However, if the investigator learns of any SAE, including a death, at any time after a patient has 
been discharged from the study, and he/she considers the event reasonably possibly related to the 
study treatment or study participation, the investigator must promptly notify   Lilly. 
Pregnancy (during maternal or paternal exposure to investigational product) does not meet the 
definition of an SAE. However, to fulfil regulatory requirements, any pregnancy should be 
reported following the SAE process to collect data on the outcome for both mother and   fetus. 
8.2.2.1.    Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed   
in the IB and that the investigator identifies as related to investigational product or procedure. 
United States 21 CFR 312.32 and European Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participating countries  
require the reporting of SUSARs. The sponsor has procedures that will be followed for the 
recording and expedited reporting of SUSARs that are consistent with global regulations and the 
associated detailed guidances. 
 
8.2.3.   Complaint Handling 
The Sponsor collects product complaints on investigational products and drug delivery systems 
used in clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product  improvements. 
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be   assessed. 
 
8.3. Treatment of Overdose 
Refer to the baricitinib Investigator’s  Brochure. 
 
8.4. Safety Assessments 
Safety assessments include vital signs, physical examination, electrocardiograms, AEs, patient- 
reported scale data, and safety laboratory  testing. 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 35 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 34 
 
8.4.1. Physical Examination 
A complete physical examination will be performed during Visit 1 (screening). Directed physical 
examinations will be performed according to the Schedule of Activities (Appendix 2) and may    
be repeated at the investigator’s discretion any time a patient presents with physical   complaints. 
 
8.4.2. Electrocardiograms 
For each patient, an electrocardiogram (ECG) should be performed according to the Schedule of 
Activities (Appendix 2) and as deemed necessary by the  investigator. 
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient signs the ICF should be reported to Lilly or its designee as an AE via the   CRF. 
 
8.4.3. Vital Signs 
For each patient, vital signs measurements should be conducted according to the Schedule of 
Activities (Appendix 2) and following study specific recommendations provided by the sponsor 
for the study. 
Any clinically significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient signs the ICF should be reported to the sponsor or its designee as an 
AE via the CRF. 
 
8.4.4. Laboratory Tests 
For each patient, laboratory tests detailed in (Appendix 3) should be conducted according to the 
Schedule of Activities (Appendix 2). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient signs the ICF should be reported to the sponsor or its designee as an AE via the 
CRF. 
 
8.4.5. Hepatitis B virus (HBV) DNA  monitoring 
For US study sites, patients who are HBsAg negative, HBcAb positive, and HBV DNA negative 
(undetectable) at Visit 1 will require HBV DNA monitoring at Visits 5 and 8 or ET, regardless of 
their HBsAb status. 
For study sites in Japan only, patients who are HBsAg negative, HbcAb and/or HbsAb positive, 
and HBV DNA negative (undetectable) at Visit 1 will require HBV DNA monitoring at Visits 5 
and 8 or ET. 
If the HBV DNA result is ‘target detected’ ≥29 IU/mL at any point in the study, then the patient 
should be referred to a hepatology specialist immediately and discontinuation considered (refer   
to Table JAHG.4). In selected cases, investigators may temporarily continue study drug in 
accordance with current immunomodulator management in the setting of HBV DNA positivity. 
This option may be considered in consultation with the sponsor (or its designee) and evaluation  
of individual patient risks and  benefits. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 36 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 35 
 
8.4.6. Quick Inventory of Depressive Symptomatology-Self Report 16 
(QIDS-SR16) 
For each patient, the QIDS-SR16 should be administered according to the Schedule of Activities 
(Appendix 2). 
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and 
severity of symptoms of depression as listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (American 
Psychiatry Association [APA] 1994). The QIDS-SR16 scale is used to assess the potential  
impact of treatment on new onset or changes in depression, thoughts of death, and /or suicidal 
ideation severity. A patient is asked to consider each statement as it relates to the way they   have 
felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items 
corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, 
with higher scores denoting greater symptom severity. The domains assessed by the instrument 
include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) 
energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or   hypersomnia), 
(8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation (Rush,   2003). 
If an increase of 5 or more from the baseline QIDS-SR16 total score is noted, the patient should   
be evaluated on site for risk of suicide and/or referred to a mental health provider for   assessment. 
A patient who scores a 2 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be evaluated on site for risk of suicide and/or referred to a mental 
health provider for assessment. 
A patient who scores a 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be discontinued (Table  JAHG.4). 
 
8.4.7. Safety Monitoring 
The sponsor will periodically review evolving aggregate safety data within the study by 
appropriate methods. 
If a patient experiences elevated ALT ≥3X ULN, ALP ≥3X ULN, or elevated TBL ≥2X ULN, 
clinical and laboratory monitoring should be initiated by the investigator. Details for hepatic 
monitoring depend upon the severity and persistence of observed laboratory test abnormalities.  
To ensure patient safety and comply with regulatory guidance, the investigator is to consult with 
the sponsor CRP regarding collection of specific recommended clinical information and follow- 
up laboratory tests (Appendix 4). 
 
8.5. Pharmacokinetics 
8.5.1. PK Sample Collection 
A total of 6 venous blood samples (approximately 5 mL per sample) for the measurement of 
baricitinib concentrations will be drawn at visits scheduled within the time windows specified   in 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 37 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 36 
 
the Schedule of Activities (Appendix 2). Specific dosing and fasting requirements for each PK 
visit are described in Table JAHG.5  below. 
 
 
 
Table JAHG.5. 
Timing of Dosing and Fasting Requirements for PK Sample Collection   Visits 
Events 
Visit 
2 
4 
5 
6 
7 
ET 
Overnight 
(8-hr) fast 
Yes 
No 
No 
No 
Yes 
No 
Take study 
drug 
At clinic 
At home 
At home 
At clinic 
At clinic 
N/A 
Morning Fast 
Until PK 
samples are 
taken 
N/A 
N/A 
N/A 
Until PK 
sample is 
taken 
N/A 
Sample time 
windows 
relative to dose 
 
Pre-dose 
 
15-30min 
post-dose 
1.5 – 4 hr 
post-dose 
4 – 8 hr 
post-dose 
Pre-dose 
30-90 min 
post-dose 
N/A 
 
On all PK sample collection days, patients should take all study medication within 5   minutes. 
At Visits 2 and 7, patients will be asked to arrive at the study site after an overnight fast. Patients 
will receive an oral dose of placebo or baricitinib at the study site and will remain fasted until PK 
blood samples have been collected. A light snack will be provided after PK samples have been 
collected. 
At Visits 4 and 5, patients will be advised to take the study drug at home. Patients will then go  
to the study site in the scheduled time window for study  assessments. 
At Visit 6, patients will be advised to NOT take study drug prior to visiting the study site. A 
single blood sample will be collected prior to the patient taking their drug at the study   site. 
A single PK sample will be obtained, whenever possible, at the early termination visit. In the 
event of an SAE, up to 2 additional blood samples may be taken at the investigator’s discretion, 
up to 6 hours after the reported event and within 24 hours of the patient’s last   dose. 
For any PK sample taken, the actual date and time (24-hour clock) of PK sample collection as 
well as the date and time of the last 2 dose administrations prior to the PK sample should be 
recorded. 
The sponsor, or its designee, will provide instructions for the collection and handling of blood 
samples. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 38 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 37 
 
8.5.2. PK Sample Assay 
Plasma samples will be assayed for baricitinib using a validated liquid chromatography with 
tandem mass spectrometry (LC/MS/MS) method at a laboratory approved by the sponsor. 
Samples from patients receiving baricitinib will be assayed. PK samples from patients on 
placebo are not planned to be assayed. 
 
8.5.3. PK Sample Storage and  Retention 
Bioanalytical samples collected to measure investigational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study. Pharmacokinetic samples will  
be kept in storage at a laboratory facility designated by the sponsor and may also be assayed for 
additional exploratory analyses. Pharmacokinetic results will not be provided to investigative   
sites or blinded personnel until the study has been  unblinded. 
 
8.6. Pharmacodynamics 
Further pharmacodynamic data, beyond efficacy and biomarker data, will not be   collected. 
 
8.7. Genetics 
A blood sample (approximately 10 mL) will be collected for pharmacogenetic analysis as 
specified in the Schedule of Activities (Appendix 2) where local regulations and ethical review 
boards (ERBs) allow. 
Samples will not be used to conduct unspecified disease or population genetic research either  
now or in the future. Samples will be used to investigate variable response to baricitinib and to 
investigate genetic variants thought to play a role in atopic dermatitis or other inflammatory skin 
disorders. Assessment of variable response may include evaluation of AEs or differences in 
efficacy.  These studies may include but are not limited to evaluate their association with  
observed response to baricitinib. 
All pharmacogenetic samples will be coded with the patient number. Only investigator site 
personnel can link these samples, and any data generated, back to the patient. Samples will be 
destroyed according to a process consistent with local  regulations. 
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or  
for a shorter period if local regulations and/or ERBs impose shorter time limits, at a facility 
selected by the sponsor. This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in drug development or when the drug is commercially  available. 
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, candidate gene studies, and epigenetic analyses. 
Regardless of technology utilized genotyping data generated will be used only for the specific 
research scope described here. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 39 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 38 
 
8.8. Biomarkers 
Skin biopsies, serum, plasma, and whole blood ribonucleic acid (RNA) samples for non-genetic 
biomarker research will be collected at the times specified in the Schedule of Activities 
(Appendix 2) where local regulations and ERBs  allow. 
Samples may be used for research on the drug target, disease process, pathways associated with 
atopic dermatitis, mechanism of action of baricitinib, and/or research method or in validating 
diagnostic tools or assay(s) related to atopic  dermatitis. 
All biomarker samples will be coded with the patient number. Only investigator site personnel 
can link these samples, and any data generated, back to the patient. Samples will be destroyed 
according to a process consistent with local  regulations. 
Samples will be retained for a maximum 15 years after the last patient visit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by   
the sponsor. This retention period enables use of new technologies, response to regulatory 
questions, and investigation of variable response that may not be observed until later in drug 
development or when the drug is commercially  available. 
 
8.8.1. Skin Biopsies 
Patients will be required to provide 4mm skin punch biopsy samples collected per the Schedule 
of Activities (Appendix 2), unless exempted by the  investigator. 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
and used to study biomarkers related to atopic dermatitis and/or related to the mechanism of  
action of baricitinib. Techniques used may include but are not limited to immunohistochemistry 
and microarray expression profiling. Samples will be de-identified as described in International 
Conference on Harmonisation (ICH) guideline E15, and may be used for exploratory microarray 
expression profiling or transcriptome sequencing. Detailed instructions for sample collection and 
handling will be provided by the sponsor. Samples will be sent to a sponsor-designated lab for 
immunohistochemistry. 
 
8.8.2. Nonpharmacogenetic  Biomarkers 
Peripheral serum samples (approximately 10 mL) will be collected at pre- and post-treatment 
time points for the assessment of biomarkers expected to be mechanistically related to JAK 1/2 
inhibition and/or the atopic dermatitis disease state. A blood sample for genotyping of filaggrin 
will also be collected. Sample processing and handling instructions will be provided by the 
sponsor. Samples will be sent to a sponsor-designated lab for  evaluation. 
Exploratory biomarker serum, plasma, and blood for mRNA samples will also be collected and 
stored at a sponsor-designated vendor. 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 40 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 39 
 
8.9.    Health Economics 
The self-reported questionnaires will be administered according to the Schedule of Activities 
(Appendix 2). The questionnaires will be administered in countries where they have been 
translated into the native language of the region and linguistically validated, as   applicable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 41 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 40 
 
9. Statistical Considerations and Data  Analysis 
9.1. Determination of Sample Size 
Approximately 120 patients will be enrolled using a 4:3:3 randomization scheme of placebo,  
2 mg baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 
20%, approximately 96 patients will complete the  study. 
This sample size provides 90% power to detect a 35% difference in EASI-50 between placebo 
and the 4-mg baricitinib treatment group using a 2-sided chi-square test with alpha =   0.05. 
 
9.2. General Statistical Considerations 
Statistical analysis of this study will be the responsibility of the sponsor or its designee. A 
detailed statistical analysis plan (SAP) will be provided by the sponsor or its designee, and will 
be finalized prior to database lock and  unblinding. 
Investigator site data will be pooled for statistical analysis  purposes. 
All tests of treatment effects will be conducted at a 2-sided alpha level of 0.05, unless otherwise 
stated. 
Data analyses will be provided by treatment groups and for all study patients combined wherever 
appropriate. For continuous variables, summary statistics will include number of patients, mean, 
median, standard deviation, minimum, and maximum.  Categorical endpoints will be    
summarized using number of patients, frequency, and  percentages. 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report. Additional exploratory analyses of the data will be conducted as 
deemed appropriate. 
 
9.3. Treatment  Group Comparability 
9.3.1. Patient Disposition 
All patients who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation will be 
given.  Data tabulations will summarize the following patient numbers, per treatment   group: 
 Enrolled 
 Received treatment 
 Violated the protocol 
 Completed the protocol 
 Withdrew because of: 
o Adverse event 
o Lack of efficacy 
o Consent withdrawal 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 42 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 41 
 
o Other reasons, as applicable 
A detailed description of patient disposition will be provided at the end of the   study. 
 
9.3.2. Patient Characteristics 
Baseline and demographic characteristics will be summarized descriptively by treatment group 
and overall. 
 
9.3.3. Concomitant Therapy 
Concomitant use of topical corticosteroids will be summarized by treatment   group. 
 
9.4. Primary and Secondary Analyses 
9.4.1. Primary Analyses 
The primary outcome will be the proportion of patients achieving EASI-50 in each treatment   
arm. The primary analysis will be performed using all randomized patients utilizing a Non- 
Responder Imputation (NRI) analysis. The proportion of patients achieving EASI-50 in the 
placebo arm will be compared to proportion of patients in each of the baricitinib arms using a two-
sided chi-square test with alpha=0.05. To control the study-wise type 1 error rate, the comparison 
of the baricitinib arms with the placebo arm will be performed in a stepwise fashion. The 4-mg 
baricitinib arm will be compared with the placebo arm; if this test is statistically significant, then 
the 2-mg baricitinib arm will be compared with the placebo arm. Enrollment of 120 patients in a 
4:3:3 ratio will provide approximately 90% power for detecting a 35%  difference in the EASI-50 
response rate between placebo and the 4-mg baricitinib treatment   arm. 
For EASI-50 endpoint, all Non-Responders, as well as all patients who discontinue study 
treatment at any time prior to the time point of interest or discontinue from the study for any 
reason, will be defined as Non-Responders for the NRI analysis. Randomized patients without at 
least 1 post-baseline observation will also be defined as Non-Responders for the NRI   analysis. 
 
9.4.2. Secondary Analyses 
Continuous secondary endpoints will be summarized and analyzed using treatment groups by use 
of a mixed effects model with treatment as the main factor and baseline values as covariates. The 
treatment (intercept) effects and their standard errors from the mixed effects model will be used   
to produce p-values and 90% confidence intervals for the treatment   comparison. 
For continuous endpoints collected longitudinally, missing data will assumed to be missing at 
random and a mixed model repeated measures (MMRM) approach will be used. Other 
imputation techniques, such as multiple imputation, may be utilized in sensitivity   analyses. 
Categorical secondary endpoints will be summarized and analyzed using a chi-square test or 
Fisher’s exact test, if needed. 
 
9.4.3. Tertiary/Exploratory Analyses 
Continuous secondary endpoints will be summarized and may be analyzed by use of a mixed 
effects model with treatment as the main factor and baseline values as covariates. The   treatment 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 43 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 42 
 
(intercept) effects and their standard errors from the mixed effects model will be used to produce 
p-values and 90% confidence intervals for the treatment  comparison. 
Categorical secondary endpoints will be summarized and may be analyzed using a chi-square 
test or Fisher’s exact test, if needed. 
 
9.5. Safety Analyses 
Safety analyses will be conducted on all patients who received at least one dose of study drug. 
No statistical comparisons of treatment groups will be completed for safety   endpoints. 
All adverse events will be summarized and listed. The incidence of symptoms for each treatment 
will be presented by severity and by association with study drug as perceived by the investigator. 
Symptoms reported to occur prior to enrollment will be distinguished from those reported as new 
or increased in severity during the  study. 
Additional safety parameters that will be assessed include safety lab parameters and vital signs. 
The parameters will be listed, and summarized using standard descriptive statistics. Additional 
analysis will be performed if warranted upon review of the  data. 
 
9.6. Pharmacokinetic/Pharmacodynamic  Analyses 
The pharmacokinetics of baricitinib will be assessed using population PK analysis techniques. 
The relationship between the primary and secondary efficacy endpoints and plasma exposure, 
race, and age of onset may be explored. PK and PD data may be combined with prior data for an 
integrated analysis. 
 
9.7. Other Analyses 
9.7.1. Health Economics 
Patient reported outcome endpoints will be summarized and analyzed using treatment groups by 
use of a mixed effects model with treatment as the main factor and baseline values as covariates. 
The treatment (intercept) effects and their standard errors from the mixed effects model will be 
used to produce p-values and 90% confidence intervals for the treatment   comparison. 
 
9.7.2. Biomarkers 
Biomarker data from all patients undergoing biomarker assessments will be analyzed. Biomarker 
data will be summarized and listed, and may be displayed  graphically. 
 
9.8.    Interim Analyses 
An interim analysis is not planned for this study. However, a limited number of pre-identified 
individuals may gain access to limited unblinded data, as specified in the unblinding plan, prior   
to the final database lock, in order to enable business decision making.  Any or all of the   
available data may be reviewed. Information that may unblind the study during the analyses will 
not be reported to study sites or the blinded study team until the study has been   unblinded. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 44 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 43 
 
10. Study Governance Considerations 
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process 
10.1.1. Informed Consent 
The investigator is responsible for ensuring  that: 
 the patient understands the potential risks and benefits of participating in the 
study 
 informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of 
investigational product. 
 any questions the patient may have throughout the study are answered and 
shares, in a timely manner, any new information that may be relevant to the 
patient’s willingness to continue his or her participation in the  study. 
 
10.1.2. Ethical Review 
The investigator or designee must give assurance that the ethical review board (ERB) was 
properly constituted and convened as required by International Conference on Harmonisation 
(ICH) guidelines and other applicable laws and  regulations. 
Documentation of ERB approval of the protocol and the ICF must be provided to the sponsor 
before the study may begin at the investigative site(s). The sponsor or its representatives must 
approve the ICF, including any changes made by the ERBs, before it is used at the investigative 
site(s).  All ICFs must be compliant with the ICH guideline on  GCP. 
The study site’s ERB(s) should be provided with the  following: 
 current IB and updates during the course of the  study 
 ICF 
 relevant curricula vitae 
10.1.3. Regulatory Considerations 
This study will be conducted in accordance  with: 
 consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of   
Medical Sciences (CIOMS) International Ethical  Guidelines 
 applicable ICH GCP Guidelines 
 applicable laws and regulations 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 45 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 44 
 
The investigator or designee will promptly submit the protocol to applicable   ERB(s). 
All or some of the obligations of the Sponsor may be assigned to a Contract Research 
Organization (CRO). 
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and/or other study-related 
data. 
 
10.1.4. Investigator Information 
Physicians with a specialty in dermatology will participate as investigators in this clinical   study. 
 
10.1.5. Protocol Signatures 
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a sponsor  representative. 
 
10.1.6. Final Report Signature 
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study. 
Lilly will select a qualified investigator(s) from among investigators participating in the design, 
conduct, and/or analysis of the study to serve as the CSR coordinating   investigator. 
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study. 
 
10.2. Data Quality Assurance 
To ensure accurate, complete, and reliable data, the sponsor/designee will perform the   following: 
 provide instructional material to the study sites, as  appropriate 
 sponsor start-up training to instruct the investigators and study coordinators. This 
training will give instruction on the protocol, the completion of the CRFs, and 
study procedures. 
 make periodic visits to the study site 
 be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax 
 review and evaluate CRF data and use standard computer edits to detect errors in 
data collection 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 46 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 45 
 
 conduct a quality review of the  database 
In addition, the sponsor/designee will periodically check a sample of the patient data recorded 
against source documents at the study site. The sponsor/designee and/or regulatory agencies 
may audit the study at any time.  Investigators will be given notice before an audit   occurs. 
The investigator will keep records of all original source data.  This might include laboratory  
tests, medical records, and clinical notes. If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents. 
 
10.2.1. Data Capture System 
An electronic data capture (EDC) system will be used in this study. The site maintains a source 
for the data entered into the sponsor-designated EDC system, if collected external to the EDC 
system. 
Electronic patient-reported outcome (ePRO) measures (for example, a rating scale) or other data 
reported directly by the patient (for example, daily dosing schedule, event diary) may be entered 
into an ePRO instrument (for example, personal digital assistant [PDA]), or by means of an 
interactive response technology system (IRT) at the time the information is obtained. In these 
instances where there is no prior written or electronic source data at the site, the ePRO  
instrument record will serve as the  source. 
If ePRO records are stored at a third party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study 
for retention. 
Any data for which the ePRO instrument record will serve to collect source data will be 
identified and documented by each site in that site’s study  file. 
Case report form data will be encoded and stored in a clinical study  database. 
Case report form data collected by a third-party will be encoded by the third-party and stored 
electronically in the third-party’s database system. Validated data will subsequently be 
transferred to the sponsor designated  database. 
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system. Data will subsequently be transferred from the central 
vendor to the sponsor designated  database. 
Any data for which paper documentation provided by the patient will serve as the source  
document will be identified and documented by each site in that site’s study file. Paper 
documentation provided by the patient may include, for example, a paper diary to collect patient- 
reported outcome (PRO) measures (for example, a rating scale), a daily dosing schedule, or an 
event diary. 
Data from complaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management  system. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 47 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 46 
 
10.3. Study and Site Closure 
10.3.1. Discontinuation of Study Sites 
Study site participation may be discontinued if the sponsor or its designee, the investigator, or 
the ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons 
consistent with applicable laws, regulations, and  GCP. 
 
10.3.2. Discontinuation of the Study 
The study will be discontinued if the sponsor or its designee judges it necessary for medical, 
safety, regulatory, or other reasons consistent with applicable laws, regulations, and   GCP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 48 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 47 
 
11. References 
[APA] American Psychiatry Association. 1994. Diagnostic and Statistical Manual of Mental 
Disorders. 4th ed. Washington DC. 
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic 
inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul   1;2(3):e24137. 
Basra M.K.A, Salek MS, Camilleri L, Sturkey R, Finlay A.Y. Determining the Minimal 
Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index 
(DLQI):  Further Data.  Derm, 2015 Jan;  230:27-33. 
Beck, LA, Thaçi, D, Hamilton, JD, Graham, NM, Bieber, T, Rocklin, R, Ming, JE, Ren, H, Kao, 
R, Simpson, E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. 
New Engl. J. Med. 2014, 371,  130–139. 
Bieber, T. Atopic Dermatitis. Ann Derm. 2010,  125-137. 
Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy 
and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 
12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 
Apr;166(4):853-60. 
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Arch Dermatol. 2004  Dec;140(12):1513-9. 
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 
2009 (v4.03:  June 14, 2010).  http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 
14_QuickReference_5x7.pdf. Accessed March 7,  2016. 
Epstein E, Pinski JB. A blind study. Arch Dermatol 1964; 89:  548–549. 
Ferguson T, Rowlands AV, Olds T, Maher C. Validity of consumer-level, activity monitors in 
healthy adults worn in free-living conditions: a cross-sectional study. International Journal of 
Behavioral Nutrition and Physical Activity (2015)  12:42. 
 
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, 
Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of 
tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug   9;367(6):495-507. 
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality 
of life into practice: What do dermatology life quality index scores mean? J Invest   Dermatol. 
2005 Oct;125(4):659-64. 
Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus- 
Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib    
at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to 
methotrexate. Ann Rheum Dis. 2015  Feb;74(2):333-40. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 49 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 48 
 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol 2002; 147 (Suppl 62):  50. 
Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. 
Identification of a novel pathway important for proliferation and differentiation of primary 
erythroid progenitors. Proc Natl Acad Sci U S A. 1997 Apr  1;94(7):3016-21. 
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik 
KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging 
study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with 
background methotrexate in patients with active rheumatoid arthritis and an inadequate response 
to methotrexate alone. Arthritis Rheum. 2012  Apr;64(4):970-81. 
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015   Sep;73(3):395-9. 
Mallinckrodt C, Tamura RN, Tanaka Y. Recent developments in improving signal detection and 
reducing placebo response in psychiatric clinical trials. J Psychiatric Research 45 (2011) 1202- 
1207. 
Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of 
Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015 Apr   29;4(5):858-73. 
Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A phase 2b trial of baricitinib, an 
oral JAK inhibitor, in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2014 
May;70(5, Suppl 1): AB162. 
Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Brit J Derm. 2003; 
148: 117–121. 
Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, 
Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a 
variety of cytokine receptors. Cell. 1998 May  1;93(3):385-95. 
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus 
kinases. Immunol Rev. 2008  Jun;223:132-42. 
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan  
PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of 
Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a 
psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 
1;54(5):573-83. 
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P; 
Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of 
clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin 
Immunol.  2013 Dec;132(6):1337-47. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 50 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 49 
 
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S.  
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in 
healthy volunteers. J Clin Pharmacol. 2014  Dec;54(12):1354-61. 
Vera J, Bachmann J, Pfeifer AC, Becker V, Hormiga JA, Darias NV, Timmer J, Klingmüller U, 
Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 
signalling pathway. BMC Syst Biol. 2008 Apr  25;2:38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 51 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 50 
 
Appendix 1. 
Abbreviations and Definitions 
 
 
 
 
 
Term 
Definition 
AD 
Atopic Dermatitis 
AE 
adverse event: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational)  product. 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
Audit 
A systematic and independent examination of the study-related activities and    
documents to determine whether the evaluated study-related activities were conducted, 
and the data were recorded, analyzed, and accurately reported according to the protocol, 
applicable standard operating procedures (SOPs), good clinical practice (GCP), and the 
applicable regulatory requirement(s). 
Blinding/masking 
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are  not. 
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received. 
BSA 
body surface area 
Chorus 
A semi-autonomous clinical development organization within Eli Lilly and  Company. 
CIOMS 
Council for International Organizations of Medical  Sciences 
CKD EPI 
Chronic Kidney Disease Epidemiology Collaboration 
Complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system. 
Compliance 
Adherence to all the study-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory  requirements. 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 52 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 51 
 
 
Confirmation 
A process used to confirm that laboratory test results meet the quality requirements 
defined by the laboratory generating the data and that Lilly is confident that results are 
accurate. Confirmation will either occur immediately after initial testing or will require 
that samples be held to be retested at some defined time point, depending on the steps 
required to obtain confirmed results. 
CRF/eCRF 
case report form/electronic case report form (sometimes referred to as clinical report 
form): A printed or electronic form for recording study participants’ data during a 
clinical study, as required by the protocol. 
CRO 
contract research organization 
CRP 
Clinical research physician:  individual responsible for the medical conduct of the 
study. Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical  officer. 
CRU 
clinical research unit 
CS 
Corticosteroid 
CSE 
clinically significant event.  A moderate-to-severe adverse event (AE), abnormal 
clinical sign, or clinical laboratory finding that may pose a risk to the well-being of the 
patient. 
CSR 
clinical study report 
DLQI 
Dermatologic Life Quality Index 
DMC 
data monitoring committee 
DN 
Diabetic Nephropathy 
DNA 
deoxyribonucleic acid 
DSUR 
Development Safety Update Report 
EASI 
Eczema Area and Severity Index 
ECG 
Electrocardiogram 
EDC 
Electronic data capture 
eGFR 
estimated glomerular filtration  rate 
End of study 
Date of the last visit or last scheduled procedure shown in the Study Schedule for the 
last active patient in the study 
Enroll 
The act of assigning a patient to a treatment. Patients who are enrolled in the study are 
those who have been assigned to a treatment. 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 53 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 52 
 
 
Enter 
Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives. 
ePRO 
electronic patient-reported outcome 
ERB/IRB 
ethical review board/institutional review board: a board or committee (institutional, 
regional, or national) composed of medical professionals and nonmedical members 
whose responsibility is to verify that the safety, welfare, and human rights of the 
patients participating in a clinical study are protected. 
e-source 
electronic source documentation 
FSH 
follicle stimulating hormone 
GCP 
good clinical practice 
GGT 
gamma glutamyltransferase 
H2 receptor 
histamine H2 receptor 
HBcAb 
hepatitis B core antibody 
HBsAb 
hepatitis B surface antibody 
HBsAg 
hepatitis B surface antigen 
HBV DNA 
hepatitis B virus DNA 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
IB 
Investigator’s Brochure 
IC50 
half-maximal inhibitory concentration 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IFN-γ 
interferon-gamma 
IGA 
Investigator’s Global Assessment 
IgE 
immunoglobulin E 
IL 
Interleukin 
INR 
international normalized ratio 
Informed consent 
A process by which a subject voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the subject's decision to participate. Informed consent is documented by 
means of a written, signed and dated informed consent  form. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 54 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 53 
 
 
Interim analysis 
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is  created/locked. 
Investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form. 
Investigator 
A person responsible for the conduct of the clinical study at a study site. If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal  investigator. 
ITT 
intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that treatment group irrespective of their 
compliance to the planned course of treatment. 
IRT 
interactive response technology system 
JAK 
Janus kinase 
JAK1, JAK2, JAK3 
kinases belonging to the Janus kinase family 
Legal Representative 
An individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical  study. 
Lilly 
Eli Lilly and Company 
LRL 
Lilly Research Laboratories 
MMRM 
mixed model repeated measures 
MOS 
margin of safety 
NRI 
non-responder imputation 
NRS 
numerical rating scale 
PASI 
Psoriasis Area and Severity Index 
Patient 
A study participant who has the disease or condition for which the investigational 
product is targeted. 
PK/PD 
pharmacokinetics/pharmacodynamics 
PO 
per os; oral administration 
POCT 
point-of-care testing 
POEM 
Patient-Oriented Eczema Measure 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 55 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 54 
 
 
PPD 
purified protein derivate 
PRO/ePRO 
patient-reported outcomes/electronic patient-reported  outcomes 
QIDS-SR16 
Quick Inventory of Depressive Symptomatology-Self Report  16 
QD 
once daily 
Randomize 
the process of assigning subjects to an experimental treatment group according to the 
randomization schedule for the study. 
RA 
Rheumatoid Arthritis 
RNA 
ribonucleic acid 
SAE 
serious adverse event; any untoward medical occurrence that at any dose results in 
death, is life threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect. 
SAP 
statistical analysis plan 
SCORAD 
SCORing of Atopic Dermatitis 
Screening 
The act of determining if an individual meets minimum requirements to become part of  
a pool of potential candidates for participation in a clinical  study. 
SUSARs 
suspected unexpected serious adverse reactions 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event: Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to  
have a causal relationship with this treatment. 
Th1, Th 2 
subsets of T helper cells; T lymphocytes expressing CD4 are also known as helper T 
cells 
TSH 
thyroid stimulating hormone. 
ULN 
upper limit of normal 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 56 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 55 
 
Appendix 2. 
Schedule of Activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 57 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 56 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable for 
PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs  later) 
X 
Read PPD (if applicable) 
X 
ECG (single) 
X 
X 
X 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the evaluation of tuberculosis    
infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient will be 
excluded from the study. 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 58 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 57 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
Vital Signs (BP and pulse) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense topical corticosteroid (as needed) 
X 
X 
X 
X 
X 
X 
X 
Weigh and record topical corticosteroid 
container with cap 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discontinue all excluded AD medications 
X 
Pre-existing Conditions 
X 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational Product Package Dispensed 
X 
X 
X 
X 
X 
Investigational Product Package 
Returned/Compliance Assessed 
X 
X 
X 
X 
X 
X 
Dose administration at site 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
Itch NRS 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
X 
X 
X 
POEM 
X 
X 
X 
X 
X 
X 
X 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 59 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 58 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 
days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device Dispensing 
X 
X 
X 
X 
X 
Biopsy performed 
4mm; NL: non-lesion and L: lesion 
At Visit 2, to be performed following confirmation of 
Inclusion Criteria being met 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non- 
PK samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HBsAb (including 
Quantitative HBsAb load assessment) 
X 
HBV DNA 
X 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 60 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 59 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
X 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory 
Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 61 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 60 
 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Serum Immunoglobulin (IgA, IgG, IgM) 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 62 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 61 
 
Appendix 3. 
Clinical Laboratory Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 63 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 62 
 
 
Clinical Laboratory Tests 
Hematologya,b 
Clinical Chemistrya,b 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume 
Total bilirubin 
Mean cell hemoglobin concentration 
Direct bilirubin 
Leukocytes (WBC) 
Alkaline phosphatase 
Reticulocyte 
Alanine aminotransferase (ALT/SGPT) 
Absolute counts of: 
Aspartate aminotransferase (AST/SGOT) 
Neutrophils, segmented 
Blood urea nitrogen (BUN) 
Neutrophils, juvenile (bands) 
Creatinine 
Lymphocytes 
Uric acid 
Monocytes 
Calcium 
Eosinophils 
Glucose 
Basophils 
Albumin 
Platelets 
Total protein 
Cell morphology 
Estimated glomerular filtration rate (eGFR)e 
Creatine phosphokinase (CPK) 
Urinalysisa,b,d 
Color 
Other Testsa 
Specific gravity 
Hepatitis B Surface antigenf 
pH 
Anti-Hepatitis B Core antibodyf 
Protein 
Quantitative HBsAb load assessmenta 
Glucose 
Hepatitis B Surface antibodyf 
Ketones 
Human immunodeficiency virusf 
Bilirubin 
Hepatitis C antibodyf,g 
Urobilinogen 
Thyroid-stimulating hormone 
Blood 
Thyroxine 
Leukocyte esterase 
Pregnancy Testh 
Nitrite 
FSHf,i 
Serum immunoglobulin (IgA, IgG, and IgM) 
Lipid (Fasting) a,c 
PPD, QuantiFERON®-TB Gold or T-SPOT.TB® j 
Total cholesterol 
Low-density lipoprotein 
Baricitinib plasma levels 
High-density lipoprotein 
HBV DNA 
Triglycerides 
 
Abbreviations: CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; DNA = deoxyribonucleic   acid; 
FSH = folliclestimulatinghormone; HBV = Hepatitis B virus;; RBC =  red 
blood cells; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic 
pyruvic transaminase; TB = tuberculosis; WBC = white blood  cells. 
a Assayed by sponsor-designated laboratory. 
b Unscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed. 
c Fasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to  test. 
d Microscopic examination of sediment performed only if abnormalities are noted on the routine urinalysis.  
e eGFR for serum creatinine calculated by the central laboratory using the -CKD EPI  method. 
f Test required at Visit 1 only to determine eligibility of patient for the  study. 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 64 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 63 
 
g A positive hepatitis C antibody (Hep C antibody) result will be confirmed with an alternate hepatitis C method.   
h For all women of childbearing potential, a serum pregnancy test will be performed at Visit 1 and a local   urine 
pregnancy test will be performed at all visits thereafter. 
i To confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an 
FSH test will be performed. Non-childbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of 
menses for at least 12 months. 
j The QuantiFERON®-TB Gold test is the preferred alternative to the PPD test for the evaluation of TB infection,   
and it may be used instead of the PPD test or T-SPOT.TB® test and may be read locally. If the QuantiFERON®- 
TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient is excluded from  
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 65 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 64 
 
Appendix 4. 
Hepatic Monitoring Tests for  Treatment- 
Emergent Abnormality 
 
 
 
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may be required in 
follow-up with patients in consultation with the sponsor, its designee, or clinical research  physician. 
 
Hepatic Monitoring Tests 
Hepatic Hematologya 
Haptoglobina 
Hemoglobin 
Hematocrit 
Hepatic Coagulationa 
RBC 
Prothrombin Time 
WBC 
Prothrombin Time, INR 
Neutrophils, segmented 
Lymphocytes 
Hepatic Serologiesa,b 
Monocytes 
Hepatitis A antibody, total 
Eosinophils 
Hepatitis A antibody, IgM 
Basophils 
Hepatitis B surface antigen 
Platelets 
Hepatitis B surface antibody 
Hepatitis B Core antibody 
Hepatic Chemistrya 
Hepatitis C antibody 
Total bilirubin 
Hepatitis E antibody, IgG 
Direct bilirubin 
Hepatitis E antibody, IgM 
Alkaline phosphatase 
ALT 
Anti-nuclear antibodya 
AST 
GGT 
Anti-smooth muscle antibodya 
Abbreviations: ALT = alanine aminotransferase; AST = aspirate aminotransferase; GGT = gamma-glutamyl 
transferase; Ig = immunoglobulin; INR = international normalised ratio; RBC = red blood cells; WBC = white 
blood cells. 
a Assayed by sponsor-designated or local laboratory. 
b Reflex/confirmation dependent on regulatory requirements and/or testing  availability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
 
 
14V-MC-JAHG  CSR Appendix Protocol 
Page 66 
 
 
 
 
 
 
 
 
14V-MC.JAHG(d) !Clinical Protocol 
Page 65 
 
Appendix 5. 
Protocol 14V-MC-JAHG Signature Page 
 
 
 
I confinn that I have read this protocol; I understand it and I will work according to this protocol. 
I will also work consistently with the ethical p1inciples that have their origin in the Declaration 
of Helsinki and that are consistent with good clinical practices and applicable laws and 
regulations. I will accept the monitor's overseeingof the study. I will abide bythe publication 
plan set forth in my Agreement with the sponsor (Choms, Eli Lilly and Company) or designee. I 
will promptly submit the protocol to applicable ethical review board(s). I confirm that ifl or any 
of mystaff are members of the ethical review board, we will abstain from voting on this 
protocol. 
 
 
Signature of Investigator 
Date 
 
 
Investigator Name (Title) 
 
 
Name of Facility 
 
 
Location of Facility 
(City, State(if applicable), Country) 
 
 
 
Signature of sponsor 
Date (dd-m1mn-yyyy) 
PD 
(Chief Medical Officer, Choms-Eli 
  Lilly and Company) 
 
Sponsor name (Title) 
 
   Eli Lilly and Company 
 
Name 
Lilly Coroorate Center. Indianapolis, Indiana. USA 
Location (City, State (if applicable), Country) 
 
 
LY3009104 
Instructionsto the Investigator: Please SIGNand DATEthis signature page. PRINT your 
name, tiUe andthe nameof thefacility in which thestudy will beconductedon both copies. 
Return 1 of the·s    nedco iesto the 
nsor  Chorus, Eli Lil   and Corn   n   or desi nee. 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 67 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 66 
 
Appendix 6. 
Protocol  Amendment I4V-MC-JAHG(c) 
Summary [A Randomized, Double-Blind, Placebo- 
Controlled, Phase 2 Study to Evaluate the Safety and 
Efficacy of Baricitinib in Patients with Moderate-to-Severe 
Atopic Dermatitis] 
 
 
 
Overview 
Protocol I4V-MC-JAHG [A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to 
Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic 
Dermatitis] has been amended. The new protocol is indicated by amendment (c) and will be  
used to conduct the study in place of any preceding version of the  protocol. 
The overall changes and rationale for the changes made to this protocol are as   follows: 
 Exclusion Criteria #18 has been updated to clarify malignancy exclusion as well as 
remission timing acceptability. 
 Thyroid Function Tests assessments have been added at Visit 7 or ET to reflect FDA 
requested change to assess at end of  treatment. 
 Minor textual edits were made for the purpose of clarification or  correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 68 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 67 
 
Revised Protocol Sections 
 
Note: 
Deletions have been identified by strikethroughs or grayed out for  figures. 
Additions have been identified by the use of  underscore. 
5.2 
Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
[18] Have, or have a history of, lymphoproliferative disease; or signs or symptoms 
suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly; or active primary or recurrent malignant 
disease; or been in remission from clinically significant malignancy for less 
than 5 years. 
Malignancy (except for basal or squamous cell carcinoma completely excised 
without evidence of recurrence) or lymphoproliferative diseases or have signs 
or symptoms suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly including  lymphoma 
Note: Patients with cervical carcinoma in situ that has been resected with no 
evidence of recurrence or metastatic disease, or with basal cell or squamous 
epithelial skin cancers that have been completely resected with no evidence of 
recurrence for at least 3 years may participate in the  study. 
 
 
8.8.1  Skin Biopsies 
Patients will be required to provide 4mm skin punch biopsy samples collected per the Schedule 
of Activities (Appendix 2), unless exempted by the  investigator. 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
and used to study biomarkers related to atopic dermatitis and/or related to the mechanism of  
action of baricitinib. Techniques used may include but are not limited to immunohistochemistry 
and microarray expression profiling. Samples will be de-identified as described in International 
Conference on Harmonisation (ICH) guideline E15, and may be used for exploratory microarray 
expression profiling or transcriptome sequencing. Detailed instructions for sample collection and 
handling will be provided by the sponsor. Samples will be sent to a sponsor-designated lab for 
immunohistochemistry. 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 69 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 68 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable for 
PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs  later) 
X 
Read PPD (if applicable) 
X 
ECG (single) - Taken prior to all other 
assessments at V1 
X 
X 
X 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the evaluation of tuberculosis    
infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient will be 
excluded from the study. 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 70 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 69 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 
days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device Dispensing 
X 
X 
X 
X 
X 
Biopsy performed 
(4mm; NL: non-lesion and L: lesion to be performed 
following Investigator and Patient rating scale 
assessments) 
At Visit 2, to be performed following confirmation of 
Inclusion Criteria being met 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non- 
PK samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HBsAb (including 
Quantitative HBsAb load assessment) 
X 
HBV DNA 
X 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 71 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 70 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
X 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory 
Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 72 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 71 
 
Clinical Laboratory Tests 
Hematologya,b 
Clinical Chemistrya,b 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume 
Total bilirubin 
Mean cell hemoglobin concentration 
Direct bilirubin 
Leukocytes (WBC) 
Alkaline phosphatase 
Reticulocyte 
Alanine aminotransferase (ALT/SGPT) 
Absolute counts of: 
Aspartate aminotransferase (AST/SGOT) 
Neutrophils, segmented 
Blood urea nitrogen (BUN) 
Neutrophils, juvenile (bands) 
Creatinine 
Lymphocytes 
Uric acid 
Monocytes 
Calcium 
Eosinophils 
Glucose 
Basophils 
Albumin 
Platelets 
Total protein 
Cell morphology 
Estimated glomerular filtration rate (eGFR)e 
Creatine phosphokinase (CPK) 
Urinalysisa,b,d 
Color 
Other Testsa 
Specific gravity 
Hepatitis B Surface antigenf 
pH 
Anti-Hepatitis B Core antibodyf 
Protein 
Quantitative HBsAb load assessmenta 
Glucose 
Hepatitis B Surface antibodyf 
Ketones 
Human immunodeficiency virusf 
Bilirubin 
Hepatitis C antibodyf,g 
Urobilinogen 
Thyroid-stimulating hormonef 
Blood 
Thyroxinef 
Leukocyte esterase 
Pregnancy Testh 
Nitrite 
FSHf,i 
Serum immunoglobulin (IgA, IgG, and IgM) 
Lipid (Fasting) a,c 
PPD, QuantiFERON®-TB Gold or T-SPOT.TB® j 
Total cholesterol 
Low-density lipoprotein 
Baricitinib plasma levels 
High-density lipoprotein 
HBV DNA 
Triglycerides 
 
Abbreviations: CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; DNA = deoxyribonucleic   acid; 
FSH = folliclestimulatinghormone; HBV = Hepatitis B virus;; RBC =  red 
blood cells; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic 
pyruvic transaminase; TB = tuberculosis; WBC = white blood  cells. 
a Assayed by sponsor-designated laboratory. 
b Unscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed. 
c Fasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to  test. 
d Microscopic examination of sediment performed only if abnormalities are noted on the routine urinalysis.  
e eGFR for serum creatinine calculated by the central laboratory using the -CKD EPI  method. 
f Test required at Visit 1 only to determine eligibility of patient for the  study. 
g A positive hepatitis C antibody (Hep C antibody) result will be confirmed with an alternate hepatitis C   method. 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 73 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 72 
 
h For all women of childbearing potential, a serum pregnancy test will be performed at Visit 1 and a local urine 
pregnancy test will be performed at all visits thereafter. 
i To confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an 
FSH test will be performed. Non-childbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of 
menses for at least 12 months. 
j The QuantiFERON®-TB Gold test is the preferred alternative to the PPD test for the evaluation of TB infection,   
and it may be used instead of the PPD test or T-SPOT.TB® test and may be read locally. If the QuantiFERON®- 
TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient is excluded from  
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 74 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 73 
 
Appendix 7. 
Protocol  Amendment I4V-MC-JAHG(d) 
Summary [A Randomized, Double-Blind, Placebo- 
Controlled, Phase 2 Study to Evaluate the Safety and 
Efficacy of Baricitinib in Patients with Moderate-to-Severe 
Atopic Dermatitis] 
 
 
 
Overview 
Protocol I4V-MC-JAHG [A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to 
Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic 
Dermatitis] has been amended. The new protocol is indicated by amendment (d) and will be 
used to conduct the study in place of any preceding version of the  protocol. 
The overall changes and rationale for the changes made to this protocol are as   follows: 
 Exclusion Criteria #29 has been modified to remove the separate requirement (prior 
clinical trial experience) for Japan patients as this was template language that was 
inadvertently included. 
 Section 6.8 Concomitant Therapy was updated to clarify the allowed use of 
antihistamines. 
 Section 8.2 Adverse Events and Section 8.2.2 Serious Adverse Events verbiage was 
updated. 
 Section 9.8 Interim Analyses verbiage was  updated. 
 Section 10.1.6 Final Report Signature verbiage was  updated. 
 Concomitant Medications collection at Visit 8 was added to the Appendix 2 Study 
Schedule. 
 Minor textual edits were made for the purpose of clarification or  correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 75 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 74 
 
Revised Protocol Sections 
 
Note: 
Deletions have been identified by strikethroughs or grayed out for  figures. 
Additions have been identified by the use of  underscore. 
5.2 
Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
[29] Participated, within the last 30 days (for Japan, 4 months) in a clinical study 
involving an investigational product. If the previous investigational product 
has a long half-life (2 weeks or longer), at least 3 months or 5 half-lives 
(whichever is longer) should have  passed. 
 
6.8 
Concomitant Therapy 
The use of triamcinolone 0.1% cream will be allowed throughout the trial. Patients will be 
instructed to apply the triamcinolone 0.1% cream according to the labeling provided by the 
manufacturer or as directed by the investigator. The triamcinolone 0.1% cream container will be 
weighed at each visit to assess usage. 
All other concomitant medication taken during the study must be recorded on the Concomitant 
Medication case report form (CRF). Treatment with concomitant atopic dermatitis therapies 
during the study is permitted only as outlined in the inclusion/exclusion criteria (Section 5.1 and 
Section 5.2) and as described in the paragraphs  below. 
Additional systemic drugs are to be avoided during the study, unless required to treat an   AE. 
Non-live seasonal vaccinations and/or emergency vaccination (such as rabies or tetanus 
vaccinations) are allowed. 
The following will be allowed as needed: use of topical antibiotics in the event of secondary 
infections of lesions; nonprescription shampoos; NSAIDs; antihistaminesdiphenhydramine (50 
mg); and topical moisturizers/emollients, bath oils, oatmeal bath preparations, bleach baths if  
using a stable regimen prior to enrollment, and salicylic acid preparations. Patients will be 
instructed to consult the investigator or other appropriate study personnel at the site before taking 
any new medications or supplements. 
 
8.2 
Adverse Events 
Investigators are responsible for monitoring the safety of patients who have entered this study 
and for alerting the sponsor or its designee to any event that seems unusual, even if this event 
may be considered an unanticipated benefit to the  patient. 
The investigator is responsible for the appropriate medical care of patients during the study. 
During and following a subject's participation in the trial, the investigator should ensure that 
adequate medical care is provided to a subject for any adverse events related to the trial. The 
investigator should inform a subject when medical care is needed for intercurrent illness(es)   of 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 76 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 75 
 
which the investigator becomes aware. It is recommended that the investigator inform the 
subject's primary physician about the subject's participation in the trial if the subject has a 
primary physician and if the subject agrees to the primary physician being   informed. 
The investigator remains responsible for following, through an appropriate health care option,  
AEs that are (1) serious or otherwise medically important, (2) considered related to the 
investigational product or the study, or that (3) caused the patient to discontinue the  
investigational product before completing the study. The patient should be followed until the  
event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The 
frequency of follow-up evaluations of the AE is left to the discretion of the   investigator. 
The sponsor has standards for reporting AEs that are to be followed regardless of applicable 
regulatory requirements that may be less stringent. Study site personnel will record the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. All AEs collected in the study 
CRF will be validated and reported in the final study  report. 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect. 
After the ICF is signed, study site personnel will record, via the CRF/electronic data entry, the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. In addition, site personnel will 
record any change in the condition(s) and any new conditions as AEs. Investigators should  
record their assessment of the potential relatedness of each AE to protocol procedure or 
investigational product. 
Investigators must document their review of each laboratory safety  report. 
Any clinically significant findings from ECGs, laboratory tests, vital sign measurements, and  
other procedures that occur after the patient signs the ICF and that result in a diagnosis should be 
reported to the sponsor or its designee. In addition, all AEs occurring after the patient receives   
the first dose of the investigational product must be reported to the sponsor or its   designee. 
Investigators will be instructed to report to the sponsor or its designee their assessment of the 
potential relatedness of each AE to protocol procedure or investigational product via the case 
report form. 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the  study. 
Cases of pregnancy that occur during maternal or paternal exposures to the investigational  
product should be reported following the SAE process. Data on fetal outcome and breast-feeding 
are collected for regulatory reporting and drug safety  evaluation. 
Study site personnel must alert the sponsor or its designee immediately of the investigator 
unblinding a patient’s treatment group assignment for any  reason. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 77 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 76 
 
If a patient’s treatment is discontinued as a result of an AE, study site personnel must clearly 
report to the sponsor or its designee the circumstances and data leading to any such 
discontinuation of treatment. 
 
 
8.2.2 
Serious Adverse Events 
Study site personnel must alert the sponsor or its designee of any SAE within 24 hours of 
investigator awareness of the event via a sponsor-approved method. Alerts issued via telephone 
are to be immediately followed with official notification on study-specific SAE forms. This 24- 
hour notification requirement refers to the initial SAE information and all follow-up SAE 
information. 
All SAEs will be reported in the study CRF and on the approved study-specific SAE form by the 
study site personnel. In addition, the study-specific SAE forms will be collected by 
sponsor/designee and subsequently entered into the clinical study database and the study safety 
database. Investigators will be required to update the study-specific SAE forms when new 
information becomes available, and address questions from the sponsor/designee until the SAE  
has been fully resolved or explained to the satisfaction of the sponsor. The SAE data from both 
CRF and study-specific SAE forms will be validated and included in the final CSR. If the SAE 
cases are closed after the completion of database lock, such information may not be included in  
the final study report. Such additional information will continue to be collected in the study- 
specific SAE form, and be reported either in an amendment to study report if such information 
leads to clinically significant change(s) in the conclusion of the study; or in the annual 
Development Safety Update Report (DSUR) or IB update if the information from the SAE does 
not alter the overall conclusion of the  study. 
An SAE is any AE from this study that results in one of the following   outcomes: 
 death 
 initial or prolonged inpatient  hospitalization 
 a life-threatening experience (that is, immediate risk of  dying) 
 persistent or significant  disability/incapacity 
 congenital anomaly/birth defect 
 considered significant by the investigator for any other  reason 
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Previously planned (prior to signing of ICF) surgeries should  
not be reported as SAEs unless the underlying medical condition has worsened during the course 
of the study. 
Although all AEs and SAEs occurring after signing the ICF are recorded in the CRF, SAE 
reporting begins after the patient has signed the ICF and has received investigational   product. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 78 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 77 
 
However, if an SAE occurs after signing the ICF, but prior to receiving investigational product, it 
needs to be reported ONLY if it is considered reasonable possibly related to study   procedure. 
SAEs occurring after a patient has taken the last dose of the investigational product will be 
collected in the pharmacovigilance system and clinical data collection database for 30 days after 
the last dose of the investigational product, regardless of the investigator’s opinion of causation. 
Thereafter, SAEs are not required to be reported unless the investigator feels the events were 
related to either investigational product, drug delivery system, or a protocol   procedure. 
Investigators are not obligated to actively seek AEs or SAEs in patients once they have been 
discontinued and/or completed the study (the patient summary CRF has been   completed). 
However, if the investigator learns of any SAE, including a death, at any time after a patient has 
been discharged from the study, and he/she considers the event reasonably possibly related to the 
study treatment or study participation, the investigator must promptly notify   Lilly. 
Pregnancy (during maternal or paternal exposure to investigational product) does not meet the 
definition of an SAE. However, to fulfil regulatory requirements, any pregnancy should be 
reported following the SAE process to collect data on the outcome for both mother and   fetus. 
Sponsor/designee has the option to request follow up information or clarification of existing 
information from the investigators up to closure of the case. SAEs should be followed by the 
investigator until resolution of all queries, clinical recovery is complete or until a stable clinical 
endpoint has been reached. Follow up may therefore continue after the patient has been  
discharged from the study. The type and extent of follow up undertaken will be determined for 
each individual case and depends upon the nature, severity, and medical significance of the  
report. The follow up may include supplemental investigations, additional laboratory tests, 
histopathological examinations, or consultations with other health care professionals. If a patient 
dies during participation in the study, the follow up may include a copy of any post-mortem 
findings, if available. 
The investigator site will be required to contact the patient in accordance with their procedures to 
obtain necessary information to provide updates to the study-specific SAE forms. Requests for 
outstanding information from the investigational site to patients should be maintained as part of  
the clinical study documents. 
 
 
8.4.2 
Electrocardiograms 
For each patient, an electrocardiogram (ECG) should be performed according to the Schedule of 
Activities (Appendix 2) and as deemed necessary by the  investigator. 
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient receives the first dose of the investigational treatmentsigns the ICF should be reported to 
Lilly or its designee as an AE via the  CRF. 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 79 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 78 
 
8.4.3 
Vital Signs 
For each patient, vital signs measurements should be conducted according to the Schedule of 
Activities (Appendix 2) and following study specific recommendations provided by the sponsor 
for the study. 
Any clinically significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatmentsigns the ICF should be 
reported to the sponsor or its designee as an AE via the CRFdesignated data transmission 
methods. 
 
8.4.4 
Laboratory Tests 
For each patient, laboratory tests detailed in (Appendix 3) should be conducted according to the 
Schedule of Activities (Appendix 2). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of investigational productsigns the ICF should be reported 
to the sponsor or its designee as an AE via the CRFdesignated data transmission   methods. 
 
8.9 
Health Economics 
The self-reported questionnaires will be administered according to the Schedule of Activities 
(Appendix 2). The questionnaires will be administered in countries where they have been 
translated into the native language of the region and linguistically validated, as   applicable. 
 
9.8 
Interim Analyses 
An interim analysis is not planned for this study. However, a limited number of pre-identified 
individuals may gain access to limited unblinded data, as specified in the unblinding plan, prior   
to the final database lock, in order to enable business decision making.  Any or all of the   
available data may be reviewed. Information that may unblind the study during the analyses will 
not be reported to study sites or the blinded study team until the study has been   unblinded. 
 
10.1.6  Final Report Signature 
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study. 
Lilly will select a qualified investigator(s) from among investigators participating in the design, 
conduct, and/or analysis of the study to serve as the CSR coordinating   investigator. 
The investigator with the most enrolled patients will be requested to serve as the CSR 
coordinating investigator. If this investigator is unable to fulfill this function, another 
investigator will be chosen by the sponsor to serve as the CSR coordinating   investigator. 
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study. 
 
 
LY3009104 


LY3009104 
 
 
I4V-MC-JAHG CSR Appendix Protocol 
Page 80 
 
 
 
 
I4V-MC-JAHG(d) Clinical Protocol 
Page 79 
 
 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V 
2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
Vital Signs (BP and pulse) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense topical corticosteroid (as 
needed) 
X 
X 
X 
X 
X 
X 
X 
Weigh and record topical corticosteroid 
container with cap 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discontinue all excluded AD medications 
X 
Pre-existing Conditions 
X 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational Product Package 
Dispensed 
X 
X 
X 
X 
X 
Investigational Product Package 
Returned/Compliance Assessed 
X 
X 
X 
X 
X 
X 
Dose administration at site 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
Itch NRS 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
X 
X 
X 
POEM 
X 
X 
X 
X 
X 
X 
X 
LY3009104 

Prot_002.pdf: 
I4V-MC-JAHG Protocol Amendment (a)   
 
 
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety 
and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis. 
 
 
NCT ID: NCT02576938 
Approval Date: 23-October-2015 
 


I4V-MC-JAHG CSR Appendix Protocol 
Page 244 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 1 
 
 
Protocol I4V-MC-JAHG(a) 
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 
Study to Evaluate the Safety and Efficacy of Baricitinib in 
Patients with Moderate-to-Severe Atopic  Dermatitis 
 
 
 
 
 
 
 
Baricitinib 
 
 
 
 
Chorus, Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
 
 
 
Protocol Approval Date: 30-September-2015 
Amendment (a) Approval Date:  23-October-2015 
 
 
 
 
 
 
 
LY3009104 
Confidential Information 
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and  
should not be copied by or distributed to persons not involved in the clinical investigation of 
baricitinib, unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its  subsidiaries. 
Parallel, double-blinded, randomized placebo-controlled multiple dose study in patients with 
moderate-to-severe atopic dermatitis 


I4V-MC-JAHG CSR Appendix Protocol 
Page 245 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 2 
 
Table of Contents 
Section 
Page 
1. 
Protocol Synopsis ........................................................................................... 8 
2. 
Introduction .................................................................................................. 10 
2.1. 
Background ............................................................................................. 10 
2.2. 
Study Rationale ....................................................................................... 11 
3. 
Objectives and Endpoints ............................................................................. 12 
4. 
Study Design ................................................................................................ 14 
4.1. 
Overview of Study Design ...................................................................... 14 
4.2. 
Scientific Rationale for Study Design ..................................................... 14 
4.3. 
Justification for Dose .............................................................................. 15 
4.4. 
Benefit/Risk Assessment ......................................................................... 15 
5. 
Study Population .......................................................................................... 17 
5.1. 
Inclusion Criteria ..................................................................................... 17 
5.2. 
Exclusion Criteria ................................................................................... 17 
5.3. 
Screen Failures ........................................................................................ 21 
6. 
Treatment ..................................................................................................... 22 
6.1. 
Treatments Administered ........................................................................ 22 
6.2. 
Method of Treatment Assignment ........................................................... 22 
6.2.1. 
Selection and Timing of Doses ....................................................... 22 
6.3. 
Blinding .................................................................................................. 23 
6.4. 
Packaging and Labeling .......................................................................... 23 
6.5. 
Investigational Products Storage and Handling ...................................... 24 
6.6. 
Dose Modification ................................................................................... 24 
6.7. 
Treatment Compliance ............................................................................ 24 
6.8. 
Concomitant Therapy .............................................................................. 24 
6.9. 
Treatment after Study Completion .......................................................... 25 
6.9.1. 
Continued Access ........................................................................... 25 
7. 
Discontinuation Criteria ............................................................................... 26 
7.1. 
Discontinuation of Investigational Product ............................................. 26 
7.1.1. 
Temporary Interruption of Investigational Product ........................ 26 
7.1.2. 
Permanent Discontinuation of Investigational Product ............................................. 26 
7.1.3. 
Discontinuation of Inadvertently Enrolled Patients ........................ 27 
7.1.4. 
Permanent Discontinuation from the Study .................................... 27 
7.1.5. 
Patients Lost to Follow-Up ............................................................. 28 
8. 
Study Assessments and Procedures .............................................................. 29 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 246 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 3 
 
8.1. 
Efficacy Assessments .............................................................................. 29 
8.1.1. 
Primary Efficacy Assessments ........................................................ 29 
8.1.2. 
Secondary Efficacy Assessments .................................................... 29 
8.1.3. 
Appropriateness of Primary Efficacy Measure ............................... 30 
8.2. 
Adverse Events ....................................................................................... 31 
8.2.1. 
Adverse Events/Laboratory Results of Special Interest ............................................ 32 
8.2.2. 
Serious Adverse Events .................................................................. 32 
8.2.2.1. 
Suspected Unexpected Serious Adverse Reactions ............................................. 33 
8.2.3. 
Complaint Handling ....................................................................... 33 
8.3. 
Treatment of Overdose ............................................................................ 33 
8.4. 
Safety Assessments ................................................................................. 33 
8.4.1. 
Physical Examination ..................................................................... 34 
8.4.2. 
Electrocardiograms ......................................................................... 34 
8.4.3. 
Vital Signs ...................................................................................... 34 
8.4.4. 
Laboratory Tests ............................................................................. 34 
8.4.5. 
Hepatitis B virus (HBV) DNA monitoring ..................................... 34 
8.4.6. 
Quick Inventory of Depressive Symptomatology-Self  Report 
16 (QIDS-SR16) ....................................................................................................... 35 
8.4.7. 
Safety Monitoring ........................................................................... 35 
8.5. 
Pharmacokinetics .................................................................................... 35 
8.5.1. 
PK Sample Collection..................................................................... 35 
8.5.2. 
PK Sample Assay ........................................................................... 36 
8.5.3. 
PK Sample Storage and Retention .................................................. 37 
8.6. 
Pharmacodynamics ................................................................................. 37 
8.7. 
Genetics .................................................................................................. 37 
8.8. 
Biomarkers .............................................................................................. 37 
8.8.1. 
Skin Biopsies .................................................................................. 38 
8.8.2. 
Nonpharmacogenetic Biomarkers ................................................... 38 
8.9. 
Health Economics ................................................................................... 38 
9. 
Statistical Considerations and Data Analysis ............................................... 39 
9.1. 
Determination of Sample Size................................................................. 39 
9.2. 
General Statistical Considerations ........................................................... 39 
9.3. 
Treatment Group Comparability ............................................................. 39 
9.3.1. 
Patient Disposition .......................................................................... 39 
9.3.2. 
Patient Characteristics .................................................................... 40 
9.3.3. 
Concomitant Therapy ..................................................................... 40 
9.4. 
Primary and Secondary Analyses ............................................................ 40 
9.4.1. 
Primary Analyses ............................................................................ 40 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 247 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 4 
 
9.4.2. 
Secondary Analyses ........................................................................ 40 
9.4.3. 
Tertiary/Exploratory Analyses ........................................................ 40 
9.5. 
Safety Analyses ....................................................................................... 41 
9.6. 
Pharmacokinetic/Pharmacodynamic Analyses ........................................ 41 
9.7. 
Other Analyses ........................................................................................ 41 
9.7.1. 
Health Economics ........................................................................... 41 
9.7.2. 
Biomarkers ..................................................................................... 41 
9.8. 
Interim Analyses ..................................................................................... 41 
10. Study Governance Considerations ............................................................... 42 
10.1. Regulatory and Ethical Considerations, Including the  Informed 
Consent Process ................................................................................................................ 42 
10.1.1. 
Informed Consent ........................................................................... 42 
10.1.2. 
Ethical Review ................................................................................ 42 
10.1.3. 
Regulatory Considerations .............................................................. 42 
10.1.4. 
Investigator Information ................................................................. 43 
10.1.5. 
Protocol Signatures ......................................................................... 43 
10.1.6. 
Final Report Signature .................................................................... 43 
10.2. Data Quality Assurance ........................................................................... 43 
10.2.1. 
Data Capture System ...................................................................... 44 
10.3. Study and Site Closure ............................................................................ 45 
10.3.1. 
Discontinuation of Study Sites ....................................................... 45 
10.3.2. 
Discontinuation of the Study .......................................................... 45 
11. References .................................................................................................... 46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 248 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 5 
 
List of Tables 
Table 
Page 
Table JAHG.1.    Objectives and Endpoints ................................................................................... 12 
Table JAHG.2.    Treatment Regimens........................................................................................... 22 
Table JAHG.3.    Criteria for Temporary Interruption from Study Treatment ............................... 26 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product ................... 27 
Table  JAHG.5.     Timing  of  Dosing  and  Fasting  Requirements  for  PK  Sample  Collection 
Visits .................................................................................................................. 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 249 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 6 
 
List of Figures 
Figure 
Page 
Figure JAHG.1.   Illustration of study design for Clinical Protocol I4V-MC-JAHG. .................... 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 250 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 7 
 
List of Appendices 
Appendix 
Page 
Appendix 1. 
Abbreviations and Definitions ........................................................................... 49 
Appendix 2. 
Schedule of Activities ........................................................................................ 54 
Appendix 3. 
Clinical Laboratory Tests ................................................................................... 59 
Appendix 4. 
Hepatic Monitoring Tests for Treatment-Emergent Abnormality ...................... 62 
Appendix 5. 
Protocol I4V-MC-JAHG Signature Page ........................................................... 63 
Appendix 6. 
Protocol Amendment I4V-MC-JAHG(a) Summary  [A Randomized, 
Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the 
Safety and Efficacy of Baricitinib in Patients with  Moderate-to-Severe 
Atopic Dermatitis] ............................................................................................. 64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 251 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 8 
 
1. Protocol Synopsis 
 
Title of Study: 
A randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of baricitinib in 
patients with moderate-to-severe atopic dermatitis. 
Rationale: 
Baricitinib is a JAK1/JAK2 selective inhibitor that is currently in development for treatment of inflammatory   
diseases such as rheumatoid arthritis and psoriasis. Baricitinib has been administered to healthy subjects and patients 
with rheumatoid arthritis (RA), moderate-to-severe plaque stage psoriasis, and diabetic nephropathy  (DN). 
In addition, baricitinib is also being developed for the treatment of atopic dermatitis (AD). This study will evaluate 
the safety and efficacy of baricitinib in patients with moderate-to-severe atopic  dermatitis. 
Objective(s)/Endpoints: 
 
Objectives 
Endpoints 
Primary 
To compare the proportion of moderate-to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose group (2 mg and 4 mg) and placebo 
when treated daily for 16 weeks 
Secondary 
To evaluate the absolute and percent change from baseline of the EASI with 
baricitinib compared to placebo at weeks 1 and 4 and monthly intervals  thereafter 
To evaluate the mean change from baseline of the SCORing Atopic Dermatitis 
(SCORAD) with baricitinib compared to placebo at weeks 1 and 4 and monthly 
intervals thereafter 
To evaluate the mean change from baseline of the Investigator’s Global 
Assessment (IGA) with baricitinib compared to placebo at weeks 1 and 4 and 
monthly intervals thereafter 
To assess quality of life based on the Dermatologic Life Quality Index (DLQI) at 
baseline, weeks 1 and 4 and monthly intervals  thereafter 
To assess itch using the itch numerical rating scale (NRS) at baseline, weeks 1 
and 4 and monthly intervals thereafter 
To evaluate the pharmacokinetics of baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 
 
Summary of Study Design: 
 
Study I4V-MC-JAHG is a multicenter, randomized, double-blind, parallel, placebo-controlled study designed to 
compare the efficacy and safety of baricitinib to placebo in patients with moderate-to-severe atopic dermatitis. 
Enrollment will be targeted at 120 patients to enable approximately 96 patients to complete the study. Patients who 
meet all eligibility criteria will be randomized to receive either placebo or baricitinib, administered as once daily   
oral doses of 2 mg or 4 mg.  Randomization will occur at the country  level. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 252 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 9 
 
Treatment Arms and Duration: 
 
Three arms will be randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, respectively. Study drug will 
be administered as oral tablets to be taken once-daily (QD) for 16 weeks. A background therapy of a mid-potency 
topical corticosteroid (triamcinolone 0.1%) will be utilized during the 28-day standardization phase prior to 
randomization and continued throughout the study. This background therapy should be used according to the  
labeling provided by the manufacturer or as directed by the  investigator. 
Number of Patients:  120 
 
Statistical Analysis: 
 
Sample Size 
The study will plan to enroll 120 patients that will be randomized 4:3:3 to 
placebo, 2 mg baricitinib, or 4 mg baricitinib,  respectively. 
Primary Outcome & Methodology 
The primary outcome parameter is the proportion of patients achieving 
EASI-50 in each treatment arm. The placebo arm will be compared to each 
of the baricitinib arms using a two-sided chi-square test with alpha=0.05 to 
control the study-wise type 1 error rate; the comparison of the baricitinib 
arms with the placebo arm will be performed in a stepwise fashion.  The 
4-mg baricitinib arm will be compared with the placebo arm; if this test is 
statistically significant, then the 2-mg baricitinib arm will be compared with 
the placebo arm. Enrollment of 120 patients in a 4:3:3 ratio provides 
approximately 90% power for detecting a 35% difference in response rate 
between placebo and 4-mg baricitinib treatment. 
Interim Analysis 
An interim analysis is not planned for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 253 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 10 
 
 
 
2.1. Background 
2. Introduction 
Atopic dermatitis (AD) is a common skin disorder characterized clinically by chronic 
inflammation and altered skin barrier function, and histologically by skin infiltration of 
inflammatory cells. AD is characterized by excessive T-cell activation, with significant skin 
infiltration by T-cells and dendritic cells. Both Th2 and Th22 activation are hallmarks of AD, 
with some Th17 and Th1 components. Patients with moderate-to-severe AD are afflicted with a 
heavy disease burden including medical as well as psycho-social abnormalities. Patients often 
have bacterial- or viral-mediated cutaneous complications. AD is the most common chronic 
inflammatory skin disease (Schmitt, 2013) with a prevalence of 2%–10% among adults in 
western geographies (Bieber, 2010) and a prevalence of about 3% in Japan (Muto et al,   2003). 
Studies using genomic and histologic profiling of AD skin have defined sets of biomarkers for  
AD that include markers of epidermal hyperplasia (epidermal thickness, K16 and Ki67 staining), 
epidermal barrier components (filaggrin), specific cellular infiltrates, including T-cells (CD3+  
and CD8+) and several dendritic cell subsets (CD11c+, CD1a+, inflammatory dendritic   
epidermal cells). Serum biomarkers that correlate with disease activity include IgE, eosinophils, 
eosinophilic cationic protein, as well as the Th2 chemokines CCL17, CCL18, CCL22, CCL11, 
and CCL26, and the cytokines IL-13, IL-31, and IL-22 (Mansouri,  2015). 
Members of the Janus kinase (JAK) family of protein tyrosine kinases (JAK1, JAK2, JAK3, and 
TYK2), along with the signal transduction and activator of transcription (STAT) pathway, play   
an important role in signal transduction following cytokine and growth factor binding to their 
receptors (Pesu, 2008). Emerging data support the role of JAK and STAT in Th2 immunity, 
activating eosinophils, and suppressing regulatory T cells. The JAK-STAT pathway, activated by 
IL-4, plays a critical role in the pathogenesis of AD by upregulating epidermal chemokines, pro- 
inflammatory cytokines, and proangiogenic factors as well as by down-regulating antimicrobial 
peptides and factors responsible for skin barrier function (Bao, 2013). Consistent with the  
proposed role of IL-4 activation of the JAK-STAT pathway in AD, administration of a  
monoclonal antibody against the alpha subunit of the IL-4 receptor improved clinical endpoints 
associated with AD (Beck, 2014). 
Baricitinib (also previously known as LY3009104 and INCB028050) is a potent and selective 
small molecule inhibitor of JAK1 and JAK 2 enzymes that is currently under development for 
the treatment of inflammatory conditions such as rheumatoid arthritis, diabetic kidney disease, 
psoriasis, and AD. 
Through 04 June 2015, approximately 4300 subjects have received baricitinib. This group of 
subjects was comprised of healthy subjects and patients with rheumatoid arthritis, psoriasis, 
diabetic kidney disease, rare auto-inflammatory syndromes, various degrees of renal impairment, 
and hepatic dysfunction. Baricitinib has been administered as single doses ranging from 1 to 40 
mg, multiple doses of up to 20 mg QD for 10 days, 10 mg QD for 28 days or 5 mg twice daily    
for 28 days in healthy subjects; and as a single 10-mg or 5-mg dose to subjects with mild to 
moderate or severe renal impairment respectively, as well as a single 5-mg dose to patients   with 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 254 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 11 
 
end stage renal disease. Treatment duration has ranged from single doses in healthy volunteers  
to approximately 3.5 years in rheumatoid arthritis  patients. 
More information about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably anticipated adverse events (AEs) of baricitinib are to be found in the 
Investigator’s Brochure (IB). 
 
2.2. Study Rationale 
Inhibition of JAK-STAT signaling by targeting multiple AD-associated cytokine pathways has 
the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key 
immune cells. Treatment of six patients with AD with a JAK1 and JAK3 inhibitor, tofacitinib,  
led to marked improvement in both objective measures of dermatitis and pruritus and patient- 
reported pruritus (Levy, 2015). 
Baricitinib is a potent and selective small molecule inhibitor of JAK1/2 enzymes. In vitro, 
baricitinib inhibits JAK1 and JAK2 with IC50 values in the single-digit nM range, yet it does not 
significantly inhibit a diverse panel of 28 kinases when tested at 100-fold of the IC50 against  
JAK1 and JAK2. In healthy volunteers, baricitinib demonstrated dose and time-dependent 
inhibition of cytokine-induced pSTAT3 (Shi,  2014). 
Study I4V-MC-JAHG will evaluate the safety and efficacy of baricitinib in patients with 
moderate-to-severe atopic dermatitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 255 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 12 
 
3. Objectives and Endpoints 
Table JAHG.1 shows the objectives and endpoints of the  study. 
 
Table JAHG.1. 
Objectives and Endpoints 
 
Objectives 
Endpoints 
Primary 
 To compare the proportion of moderate- 
to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in 
the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose 
group (2 mg and 4 mg) and placebo when 
treated daily for 16 weeks 
 EASI-50 at 16 weeks 
Secondary 
 To evaluate the absolute and percent 
change from baseline of the EASI with 
baricitinib compared to placebo 
 EASI at Weeks 1, 4, 8, 12, and 16 
 To evaluate the mean change from 
baseline compared to placebo for the 
SCORing Atopic Dermatitis  (SCORAD) 
 SCORAD at  Weeks 1, 4, 8, 12, and  16 
 To evaluate the mean change from 
baseline compared to placebo for the 
Investigator’s Global Assessment  (IGA) 
 IGA at Weeks 1, 4, 8, 12, and 16 
 To assess quality of life based on the 
Dermatologic Life Quality Index (DLQI) 
 DLQI at Weeks 1, 4, 8, 12, and 16 
 
To assess itch based on the Itch 
Numerical Rating Scale (NRS) 
 Itch Numerical Rating Scale at Weeks 1, 
4, 8, 12, and 16 
 To characterize the pharmacokinetics of 
baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 Plasma pharmacokinetic data 
Exploratory 
 To evaluate EASI response in patients 
based on their baseline total serum  IgE 
 EASI at Weeks 1, 4, 8, 12 and 16; baseline 
total serum IgE 
 To evaluate total serum IgE over the 
course of treatment 
 Total serum IgE at baseline, Weeks 4, and 
16 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 256 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 13 
 
Exploratory (continued) 
 To evaluate changes in disease activity 
over the course of treatment 
 Patient-Oriented Eczema Measure (POEM) 
at  Weeks 1, 4, 8, 12, and 16 
 To evaluate changes in sleep quality over 
the course of treatment 
 Change from baseline with data from a 
wearable actigraphy device 
 To evaluate changes in nocturnal itch 
patterns over the course of treatment 
 Change from baseline with data from a 
wearable actigraphy device 
 To evaluate EASI response relative to 
filaggrin genotype 
 EASI-50 and filaggrin genotype data from 
peripheral baseline blood sample 
 To assess tissue biomarkers from  biopsies 
 K16, Ki-67, and IL-4 will be assessed from 
each tissue biopsy (collected at baseline 
(lesion and non-lesion), at Week 4 (lesion), 
and at Week 16 (lesion and  non-lesion) 
 To assess peripheral biomarkers 
mechanistically related to inhibition of 
JAK 1/2 mechanism 
 Peripheral biomarkers collected at baseline, 
Weeks 4 and 16 
 To perform subgroup assessments of 
response based on patient and disease 
characteristics 
 Ad hoc evaluation of potential prognostic 
and predictive disease characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 257 
LY3009104 
 
 
4 mg baricitinib 
2 mg baricitinib 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 14 
 
4. Study Design 
4.1. Overview of Study Design 
I4V-MC-JAHG is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the 
safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The study 
design is illustrated in Figure JAHG.1. 
Standardization 
Treatment 
Follow-up 
 
 
 
 
120 AD 
Patients 
Placebo 
4 Weeks 
16 Weeks 
4 Weeks 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
Week: 
-4 
0 
1 
4 
8 
12 
16 
20 
Day: 
-28 
0 
7 
28 
56 
84 
112 
140 
 
 
 
Screening Randomization 
(4:3:3) 
Placebo : 2 mg baricitinib : 4 mg baricitinib 
 
Figure JAHG.1. 
Illustration of study design for Clinical Protocol I4V-MC-JAHG. 
 
 
 
4.2. Scientific Rationale for Study Design 
This study will enroll moderate-to-severe atopic dermatitis patients for whom a systemic 
treatment such as baricitinib may be appropriate. A 16-week course of treatment is expected to 
enable an optimal assessment of efficacy based on previous baricitinib studies in an 
inflammatory skin condition. 
Relatively high (20% to 50%) placebo responses have been observed in previously published 
atopic dermatitis studies (Bissonnette, 2012; Beck, 2014; Epstein and Pinski, 1964). Therefore, a 
4:3:3 randomization scheme of placebo, 2 mg baricitinib, and 4 mg baricitinib will be 
implemented.   Increased placebo enrollment across treatment groups has been reported to  
decrease placebo response and to also increase statistical power (Mallinckrodt,   2011). 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 258 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 15 
 
A standardization phase will be incorporated prior to randomization to minimize effects due to 
background treatment. Beginning at standardization and continuing throughout the study, 
patients will be provided a topical corticosteroid to be used as prescribed and may continue use 
of other allowed study-specified palliative care measures as specified in Section   6.8. 
The EASI and SCORAD are the best instruments available to measure clinical severity of AD 
(Schmitt, 2013). Several quality of life assessments are being utilized to evaluate the effect of 
baricitinib on patients’ quality of life. 
 
4.3. Justification for Dose 
This study will evaluate the safety and efficacy of 2-mg and 4-mg doses of baricitinib in patients 
with moderate-to-severe atopic dermatitis. The dose justification for AD is based on a Phase 2 
rheumatoid arthritis (RA) study (Study JADA), reported Phase 3 RA studies (Study JADW and 
Study JADX) and a Phase 2 psoriasis study (Study  JADP). 
In these studies, all doses were generally well tolerated based on the observed adverse event 
profile and infrequent discontinuations of baricitinib dosing. The anticipated on-target, dose- 
limiting effect is a small decline in hemoglobin and hematocrit values. As described in Section 
4.4, this likely results from inhibition of erythropoietin signals via the JAK2/STAT5 signal 
transduction pathway (Klingmüller, 1997; Vera, 2008). These hematologic effects occur in 
higher-dose groups (8 mg daily) upon initiation of treatment and then   stabilize. 
The 2-mg and 4-mg doses have shown efficacy in RA with an acceptable safety profile. There  
was no additional efficacy associated with an 8-mg dose in the Phase 2 RA study, thus only 4 mg 
and 2 mg have been studied in the RA Phase 3 program. Doses less than 2 mg were not clearly 
effective in RA. 
In patients with moderate-to-severe plaque stage psoriasis, doses of 4 mg to 10 mg were found to 
be associated with statistically significant reductions in Psoriasis Area and Severity Index (PASI) 
score, with greater efficacy at the higher doses; however, the 8-mg and 10-mg doses were 
associated with a higher rate of AEs related to laboratory abnormalities (decreases in    
hemoglobin, neutrophils, and lymphocytes). The 2-mg and 4-mg dose groups had a pattern of   
AEs similar to placebo. The 2-mg dose did show numeric reductions in PASI score compared   
with placebo and statistically significant reductions in itch. Thus, in AD, the highest dose to be 
tested will be 4 mg, which would be anticipated to show efficacy together with an acceptable  
safety profile, and also provide the opportunity to cross reference to the large safety database   
from the RA Phase 3 program. The lower dose of 2 mg also has the opportunity to show efficacy  
in AD, where itch is a major component of the disease and may provide data that may be useful    
in the future for patients less than 18 years of  age. 
 
4.4. Benefit/Risk Assessment 
Baricitinib is a specific inhibitor of JAK1/2 and may offer potential benefit to patients with 
moderate-to-severe AD. Increases in serum creatinine and in both LDL and HDL cholesterol 
have been observed in Phase 1 and 2 studies with baricitinib (see Investigator’s   Brochure). 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 259 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 16 
 
Baricitinib is a specific inhibitor of JAK1/2 that has shown to be well-tolerated and effective in 
chronic inflammatory conditions such as rheumatoid arthritis (Keystone, 2015) and psoriasis 
(Menter, 2014). Baricitinib may offer potential benefit in a chronic inflammatory dermatologic 
condition such as AD. 
Phase 1 and 2 studies with baricitinib showed increased levels of serum creatinine and LDL and 
HDL cholesterol (see Investigator’s Brochure). Similar increased levels of creatinine and 
cholesterol were also seen in tofacitinib, a JAK1/3 inhibitor (Fleischmann, 2012; Kremer, 2012). 
In addition, reductions in absolute neutrophil counts have been reported with both baricitinib and 
tofacitinib. Other pathways that signal through JAK include granulocyte macrophage colony 
stimulating factor and granulocyte colony stimulating factor signal and erythropoietin (JAK2) 
(Parganas, 1998). The assessment of safety of baricitinib in this study will therefore also include, 
but will not be limited to, monitoring of creatinine, cholesterol, neutrophil and granulocyte  
counts, hemoglobin levels, and rates of  infection. 
More information about the known and expected benefits, risks, and reasonably anticipated  
adverse events may be found in the Investigator’s Brochure. Information on adverse events 
expected to be related to the investigational product may be found in Section 7 (Development  
Core Safety Information) of the Investigator’s Brochure. Information on serious adverse events 
expected in the study population independent of drug exposure will be assessed by the sponsor in 
aggregate periodically during the course of the study and may be found in Section 6 (Effects in 
Humans) of the Investigator’s  Brochure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 260 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 17 
 
5. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, will not be  permitted. 
 
5.1. Inclusion Criteria 
Patients are eligible to be included in the study only if they meet all of the following   criteria: 
Type of Patient and Disease  Characteristics 
[1] Are at least 18 years of age at the time of Visit  1 
[2] Have moderate-to-severe AD, as determined by all of the  following: 
 EASI ≥12 at Visits 1 and 2 
 ≥10% of body surface area (BSA) involvement at Visits 1 and  2 
 Were diagnosed with AD at least 2 years before Visit  1 
With a history of inadequate clinical response, in the opinion of the 
investigator, to one or more of the three treatment categories listed below 
(used for at least 4 weeks): 
 Category 1: Hydration plus topical steroids and/or antibiotics (e.g., 
tetracycline, trimethoprim and sulfamethoxazole, cephalosporins) and/or 
topical immune modulators (e.g.,  tacrolimus/pimecrolimus) 
 Category 2:   Systemic steroids and/or phototherapy 
 Category 3: Cyclosporine and/or other immunomodulators (e.g., 
methotrexate, mycophenolate mofetal, and  azathioprine) 
[3] Agree to discontinue use of the following excluded medications for at least 4 
weeks prior to randomization (Visit 2) and throughout the  study 
 oral cyclosporine, steroids, and leukotriene  inhibitors 
 phototherapy 
 potent topical steroids (e.g., clobetasol) or topical immune modulators 
(e.g., tacrolimus/pimecrolimus). 
 cyclosporine and/or other immunomodulators (e.g., methotrexate, 
mycophenolate mofetal, and  azathioprine) 
 
5.2. Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
Medical Conditions 
[4] Are female subjects who are pregnant or  nursing 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 261 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 18 
 
[5] Are females of childbearing potential who do not agree to use 2 forms of  
highly effective methods of birth control or remain abstinent while enrolled in 
the study and for at least 28 days following the last dose of investigational 
product 
Note: Females of nonchildbearing potential are defined as women ≥60 years 
of age, or women >40 and <60 years of age who have had a cessation of 
menses for at least 12 months, or women who are congenitally or surgically 
sterile (that is, have had a hysterectomy or bilateral oophorectomy or tubal 
ligation). 
The following birth control methods are considered highly effective (the 
patient should choose 2): 
 Oral, injectable, or implanted hormonal  contraceptives 
 Condom with a spermicidal foam, gel, film, cream, or  suppository 
 Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal 
foam, gel, film, cream, or  suppository 
 Intrauterine device 
 Intrauterine system (for example, progestin-releasing  coil) 
 Vasectomized male (with appropriate post-vasectomy documentation 
of the absence of sperm in the  ejaculate). 
[6] 
Are males who do not agree to use 2 forms of highly effective birth control 
(see above) with female partners of childbearing potential while enrolled in 
the study, and for at least 28 days following the last dose of investigational 
product 
Are currently experiencing or have a history of any of the  following: 
[7] Other concomitant skin conditions (e.g., psoriasis, or lupus erythematosus) 
that would interfere with evaluations of the effect of study medication on 
atopic dermatitis 
[8] Erythrodermic, refractory or unstable skin disease that requires frequent 
hospitalizations and/or intravenous treatment for skin  infections 
[9] Immunocompromised and, in the opinion of the investigator, at an 
unacceptable risk for participating in the  study 
[10] Serious concomitant illness that could require the use of systemic 
corticosteroids or otherwise interfere with study participation or require active 
frequent monitoring (e.g., unstable chronic  asthma) 
[11] Organ transplant(s) (corneal transplant performed >3 months prior to 
screening may be allowed) 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 262 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 19 
 
[12] Clinically important deviation, in the opinion of the investigator, from normal 
limits in physical examination, vital sign measurements, and/or 
electrocardiograms, that is not associated with a chronic, well-controlled 
medical condition 
[13] Electrocardiogram (ECG) abnormalities at Visit 1 that, in the opinion of the 
investigator or the sponsor, are clinically significant and indicate an 
unacceptable risk for the patient’s participation in the study (Bazett’s 
corrected QT interval >470 msec for men and  women) 
[14] Have evidence of active or latent TB as documented by a positive PPD test   
(≥5 mm in duration between approximately 2 and 3 days after application, 
regardless of vaccination history), medical history, or chest x-ray at screening. 
Exceptions are patients with a history of latent TB who have documented 
evidence of completing a course of appropriate  treatment. 
 If the PPD test is positive or not conducted and the patient has no medical 
history or chest x-ray findings consistent with active or latent TB, the 
patient should have a QuantiFERON®-TB Gold test or the T-SPOT.TB® 
test. If either of these tests is positive or indeterminate (a single re-test is 
allowed), the patient is excluded from the  study. 
[15] Active or latent granulomatous disorders or a non-tuberculous mycobacterial 
infection or opportunistic systemic infection (e.g., Pneumocystis carinii, and 
aspergillosis) within 6 months prior to  screening 
[16] Uncompensated heart failure, fluid overload, myocardial infarction, or 
evidence of ischemic heart disease or other serious cardiac disease within 12 
weeks of Visit 1 
[17] Uncontrolled arterial hypertension characterized by a repeated systolic blood 
pressure >160mm Hg or diastolic blood pressure >100mm Hg at the time of 
Visit 1 
[18] Malignancy (except for basal or squamous cell carcinoma completely excised 
without evidence of recurrence) or lymphoproliferative diseases or have signs 
or symptoms suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly including  lymphoma 
Note: Patients with cervical carcinoma in situ that has been resected with no 
evidence of recurrence or metastatic disease, or with basal cell or squamous 
epithelial skin cancers that have been completely resected with no evidence of 
recurrence for at least 3 years may participate in the  study. 
[19] Evidence of HIV infection or are positive for HIV antibodies (based on 
history or point-of-care testing (POCT)) at Visit  1 
[20] Positive test for hepatitis B defined as: 
a) positive for hepatitis B surface antigen (HBsAg),  or 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 263 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 20 
 
b) positive for anti-hepatitis B core antibody (HBcAb) and positive for hepatitis B 
deoxyribonucleic acid (HBV DNA), or 
c) for sites in Japan only, positive for HBcAb and/or positive for anti-hepatitis B 
surface antibody (HBsAb), and positive for HBV  DNA. 
 
If any of the hepatitis B tests have an indeterminate result, confirmatory testing will 
be performed by an alternate method. 
 
[21] Positive for anti-hepatitis C antibody with confirmed presence of hepatitis C 
virus, or chronic liver disease with the most recent available AST or ALT >2X 
the ULN 
[22] Serious and/or unstable mental and/or physical illness that, in the opinion of 
the investigator, poses an unacceptable risk for the patient’s participation in 
the study 
Prior/Concomitant Therapy 
[23] Received any oral JAK inhibitor (e.g., Xeljanz) within the past 6  months 
[24] Currently receiving any immunosuppressive therapy (e.g.,  cyclosporine) 
[25] Received any monoclonal antibody intended for AD (e.g., ustekinumab or 
dupilumab) within the past 6  months. 
[26] Currently using or expected to use concomitant medications or treatments for 
AD other than those allowed for use in the  protocol 
[27] Exposed to a live vaccine, including the nasal flu vaccine, within 12 weeks 
prior to planned enrollment (with the exception of herpes zoster vaccination; 
patients will be excluded if they were exposed to herpes zoster vaccination 
within 30 days of planned enrollment) or are expected to need/receive a live 
vaccine during the course of the  study. 
Prior/Concurrent Clinical Trial  Experience 
[28] Currently enrolled in any other clinical study involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this  study 
[29] Participated, within the last 30 days (for Japan, 4 months) in a clinical study 
involving an investigational product. If the previous investigational product 
has a long half-life (2 weeks or longer), at least 3 months or 5 half-lives 
(whichever is longer) should have  passed. 
[30] Previously completed or withdrawn from this  study 
Diagnostics Assessments 
Have any of the following specific abnormalities on screening laboratory   tests: 
[31] AST or ALT >2X the ULN 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 264 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 21 
 
[32] Total bilirubin ≥1.5X the ULN 
[33] Hemoglobin <11.0 g/dL (100.0 g/L) 
[34] Total white blood cell count <2500  cells/µL 
[35] Neutropenia (absolute neutrophil count <1200  cells/µL) 
[36] Lymphopenia (lymphocyte count <750  cells/µL) 
[37] Thrombocytopenia  (platelets <100,000/µL) 
[38] eGFR <50 mL/min/1.73 m2 (based on CKD  EPI) 
Note: In the case of any of the aforementioned laboratory abnormalities, they may 
be repeated once within 1 week of the initial values, and values resulting from  
repeat testing may be used to assess enrollment  eligibility. 
Other Exclusions 
[39] Donated blood of more than 500 mL or blood products within 4 weeks prior to 
entry. 
[40] Unwilling to commit to refrain from donating blood or blood products during 
the study. 
[41] History of substance abuse (drug or alcohol) within the two years before 
screening. 
[42] Unable or unwilling to be available for the duration of the study and/or are 
unwilling to follow study  restrictions/procedures. 
[43] Unable or unwilling to have skin biopsies performed, unless exempted by the 
investigator. 
[44] Investigator site personnel directly affiliated with this study and/or their 
immediate families; immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally  adopted. 
[45] Employees of the sponsor. 
[46] Unwilling or unable to comply with the use of all potential data collection 
devices. 
 
5.3. Screen Failures 
Individuals who do not meet the criteria for participation in this study (screen failure) may be re- 
screened. Individuals may be re-screened once (time period from screen fail to re-screen to be 
determined by the investigator). If re-screening is performed, the individual must sign a new 
informed consent form (ICF) and will be assigned a new identification number. Additionally, all 
screening procedures must be conducted at re-screen to ensure all eligibility criteria are   met. 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 265 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 22 
 
6. Treatment 
6.1. Treatments Administered 
This study includes the treatment regimens outlined in Table JAHG.2 below. Doses of baricitinib 
or placebo will be administered orally. 
 
 
Table JAHG.2. 
Treatment Regimens 
 
    Treatment Group 
Dose (QD) 
Day 1 through Day 112 
2 mg LY 
(1  2-mg LY tab; 1  4-mg placebo tab) 
4 mg LY 
(1  2-mg placebo tab; 1  4-mg LY tab) 
Placebo 
(1  2-mg placebo tab; 1  4-mg placebo tab) 
Abbreviations:  tab = tablet; LY = baricitinib 
 
 
The investigator or his/her designee is responsible for the  following: 
 explaining and verifying the correct use of the investigational agent(s) to the 
patient and site personnel 
 maintaining accurate records of investigational product dispensing and   collection 
 returning, at the end of the study, all unused investigational product to the 
sponsor, or its designee, unless the sponsor and sites have agreed all unused 
medication is to be destroyed by the site, as allowed by local  law 
 
6.2. Method of Treatment Assignment 
Patients who meet all criteria for enrollment will be randomized to double-blind treatment at   
Visit 2. Assignment to treatment groups will be determined by a computer-generated random 
sequence using an interactive response technology (IRT) system. The IRT system will be used to 
assign blister packs containing double-blind investigational product to each patient. The IRT 
system will dispense a number of blister packs adequate for each visit   interval. 
The randomization will be stratified by  country. 
 
6.2.1. Selection and Timing of Doses 
Patient treatment assignments will be based on the randomization scheme as described   above. 
On PK sample collection days (Appendix 2), specific fasting and dose timing requirements are 
outlined in Table JAHG.5 (Section  8.5.1). 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 266 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 23 
 
6.3. Blinding 
This is a double-blind study in which the patients, investigator, and study site personnel will be 
blinded to treatment allocation. 
To preserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is   complete. 
Emergency unblinding for AEs may be performed through an IRT system, which may  
supplement or take the place of emergency codes generated by a computer drug-labeling system. 
This option may be used ONLY if the patient’s well-being requires knowledge of the patient’s 
treatment assignment. All calls resulting in an unblinding event are recorded and reported by the 
IRT system. 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warranted. Patient safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the sponsor CRP prior to  
unblinding a patient’s treatment  assignment. 
If an investigator, site personnel performing assessments, or patient is unblinded to the treatment 
code assignment, the sponsor must be contacted  immediately. 
 
6.4. Packaging and Labeling 
The sponsor (or its designee) will provide the following investigational   products: 
 tablets containing 2 mg of baricitinib 
 tablets containing 4 mg of baricitinib 
 placebo to match baricitinib 2 mg tablets 
 placebo to match baricitinib 4 mg tablets 
Additionally, the sponsor (or its designee) will also provide the following concomitant therapy 
product: 
 triamcinolone 0.1% cream which should be used according to the labeling provided 
by the manufacturer or as directed by the  investigator 
Investigational products and triamcinolone 0.1% cream will be dispensed to the patient at the 
investigator’s study site. 
Investigational product will be packaged in blister packs. Investigational product packaging will 
be labeled with a unique identifier for drug dispensing by the IRT system. Blister packs will 
contain additional tablets to allow for sufficient administration of investigational product within 
the allowed visit internal window. 
Investigational product will be labeled according to the country’s regulatory requirements. All 
investigational products will be stored, inventoried, reconciled, and destroyed according to 
applicable regulations. Investigational products will be manufactured and tested by the sponsor 
or its representative in accordance with current Good Manufacturing Practices   (cGMP) 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 267 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 24 
 
requirements for clinical studies, and will be supplied with lot numbers, expiry dates, and 
certificates of analysis (as applicable). 
 
6.5. Investigational Products Storage and  Handling 
Investigational products should be stored between 15°C and 30°C. All investigational products 
should be stored in a secure and locked area with strictly limited access and monitored for 
temperature and will be allocated and dispensed by appropriately trained   personnel. 
 
6.6. Dose Modification 
No dose modifications will be  allowed. 
 
6.7. Treatment Compliance 
Patient compliance with study medication will be assessed at each visit. Compliance will be 
assessed by counting returned tablets. Deviation(s) from the prescribed dosage regimen should 
be recorded in the CRF. 
The patient will be considered significantly noncompliant if he or she misses more than 20% of 
the prescribed doses during the study. Similarly, a patient will be considered significantly 
noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken 
more than the prescribed amount of  medication. 
Patients found to be noncompliant with investigational product should be assessed to determine 
the reason for noncompliance, and educated and/or managed as deemed appropriate by the 
investigator to improve compliance. 
 
6.8. Concomitant Therapy 
The use of triamcinolone 0.1% cream will be allowed throughout the trial. Patients will be 
instructed to apply the triamcinolone 0.1% cream according to the labeling provided by the 
manufacturer or as directed by the investigator. The triamcinolone 0.1% cream container will be 
weighed at each visit to assess usage. 
All other concomitant medication taken during the study must be recorded on the Concomitant 
Medication case report form (CRF). Treatment with concomitant atopic dermatitis therapies 
during the study is permitted only as outlined in the inclusion/exclusion criteria (Section 5.1 and 
Section 5.2) and as described in the paragraphs  below. 
Additional systemic drugs are to be avoided during the study, unless required to treat an   AE. 
Non-live seasonal vaccinations and/or emergency vaccination (such as rabies or tetanus 
vaccinations) are allowed. 
The following will be allowed as needed: use of topical antibiotics in the event of secondary 
infections of lesions; nonprescription shampoos; NSAIDs; diphenhydramine (50 mg); and 
topical moisturizers/emollients, bath oils, oatmeal bath preparations, bleach baths if using a  
stable regimen prior to enrollment, and salicylic acid preparations.  Patients will be instructed   to 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 268 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 25 
 
consult the investigator or other appropriate study personnel at the site before taking any new 
medications or supplements. 
 
6.9. Treatment after Study Completion 
6.9.1.   Continued Access 
The Investigational Product will not be made available to patients after the conclusion of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 269 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 26 
 
7. Discontinuation Criteria 
7.1. Discontinuation of Investigational  Product 
7.1.1. Temporary Interruption of Investigational  Product 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs   
or abnormal laboratory values as described in Table JAHG.3 that may have an unclear  
relationship to investigational product. Except in cases of emergency, it is recommended that the 
investigator consult with the sponsor (or its designee) before temporarily interrupting   therapy. 
The investigator must obtain approval from the sponsor (or its designee) before restarting 
investigational product that was temporarily discontinued because of an AE or abnormal 
laboratory value. Investigational product must be held in the following situations involving 
laboratory abnormalities and may be resumed as noted in Table  JAHG.3. 
Table JAHG.3. 
Criteria for Temporary Interruption from Study Treatment 
 
 
Hold Investigational Product if the Following 
Laboratory Test Results Occur: 
Investigational Product May Be Resumed after 
Approval from Lilly (or its Designee) and When: 
WBC count <2000 cells/µL 
WBC count 2500 cells/µL 
ANC <1000 cells/L 
ANC >1200 cells/µL 
Lymphocyte count <500 cells/µL 
Lymphocyte count 750 cells/µL 
Platelet count <75,000/µL 
Platelet count 100,000/µL 
eGFR <40 mL/min/1.73 m2 (from serum 
 creatinine) 
eGFR 50 mL/min/1.73 m2 
ALT or AST >5 times the ULN 
ALT and AST return to <2 times the ULN, and 
investigational product is not considered to be the cause 
of enzyme elevation 
Hemoglobin <9 g/dL 
Hemoglobin 10 g/dL 
Symptomatic herpes zoster 
All skin lesions have crusted and are resolving 
Severe infection that, in the opinion of the 
investigator, merits the investigational product 
 being discontinued 
Resolution of infection 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; min = minute; ULN = upper limit of normal; 
WBC = white blood cell. 
 
 
7.1.2. Permanent Discontinuation of Investigational  Product 
Any patient who is permanently discontinued from investigational product for an AE or  
abnormal laboratory result should have the reason for investigational product discontinuation 
reported as the AE or abnormal laboratory value. If any of the criteria listed in Section 7.1.1. 
above recur after investigational product is restarted, the investigator must obtain approval from 
the sponsor (or its designee) before restarting investigational product.  In addition, patients   will 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 270 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 27 
 
be permanently discontinued from investigational product if they experience any of the criteria 
listed in Table JAHG.4. 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product 
 
Permanently Discontinue Investigational Product if any of the Following are  Observed: 
ALT or AST >8 times the ULN 
ALT or AST >5 times the ULN persisting for more than 2 weeks after temporary interruption of investigational 
product 
ALT or AST >3 times the ULN and total bilirubin level >2 times the  ULN 
ALT or AST >3 times the ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) 
WBC count <1000 cells/L 
ANC <500 cells/L 
Lymphocyte count <200 cells/L 
Hemoglobin <8 g/dL 
Pregnancy 
Malignancy (except for successfully treated basal cell or squamous epithelial skin  cancers) 
HBV DNA ≥29 IU/mLa 
 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; HBV DNA = hepatitis B virus deoxyribonucleic acid; ULN = upper limit of normal; 
WBC = white blood cell. 
a If a HBV DNA result of ‘target detected’ 29 IU/mL or greater, then the patient should be referred to a hepatology 
specialist immediately. In selected cases, investigators may temporarily continue study drug in accordance with 
current immunomodulator management in the setting of HBV DNA positivity. This option may be considered in 
consultation with the sponsor (or its designee) and evaluation of individual patient risks and benefits. Refer to 
Section 8.4.5 for additional instruction on HBV DNA  monitoring. 
 
7.1.3. Discontinuation of Inadvertently Enrolled  Patients 
If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the sponsor CRP and the investigator to 
determine if the patient may continue in the study. If both agree it is medically appropriate to 
continue, the investigator must obtain documented approval from the sponsor CRP to allow the 
inadvertently enrolled patient to continue in the study with or without treatment with 
investigational product. 
 
7.1.4. Permanent Discontinuation from the  Study 
Some possible reasons that may lead to permanent discontinuation   include: 
 Enrollment in any other clinical study involving an investigational product or enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this study 
 Participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical practice   (GCP) 
 Investigator Decision 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 271 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 28 
 
o the investigator decides that the patient should be discontinued from the   study 
o if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new   agent 
 Patient  Decision 
Patients who discontinue the study early will have early termination (ET) procedures performed 
as shown in the Schedule of Activities (Appendix  2). 
 
7.1.5. Patients Lost to Follow-Up 
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make  
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 272 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 29 
 
8. Study Assessments and  Procedures 
Appendix 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for timing). 
Appendix 3 lists the laboratory tests that will be performed for this  study. 
Appendix 4 provides the hepatic monitoring tests for treatment-emergent   abnormalities. 
Additionally, a study addendum will be compiled to detail the capture of photographs from 
selected lesions for patients enrolled at up to three selected study sites. These photographs will 
permit documentation of the clinical response through sequential photography of a selected 
lesion or involved area before and following study drug  treatment. 
 
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results. Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards. 
 
8.1. Efficacy Assessments 
Study procedures and their timing are summarized in the Schedule of Activities (Appendix   2). 
 
8.1.1. Primary Efficacy Assessments 
The clinical outcome measure that will be used in this study is the EASI score (specifically, the 
proportion of patients achieving a 50% reduction in EASI or  EASI-50). 
 Eczema Area and Severity Index (EASI) scores: The EASI assesses extent of disease 
at four body sites and measures four clinical signs: (1) erythema, (2) 
induration/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3. 
EASI confers a maximum score of 72. EASI evaluates two dimensions of atopic 
dermatitis: disease extent and clinical signs.
 
8.1.2. Secondary Efficacy Assessments 
 Mean and Percentage change in Eczema Area and Severity Index (EASI) scores: See 
above.
 
 SCORing Atopic Dermatitis (SCORAD): The SCORAD index uses the rule of nines to 
assess disease extent and evaluates five clinical characteristics to determine disease 
severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) 
lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss 
with Visual Analogue Scales (VAS). These three aspects: extent of disease, disease 
severity and subjective symptoms combine to give a maximum possible score of 103.
 
 
Investigator’s Global Assessment (IGA): The IGA consists of a 6-point severity scale 
from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate 
disease, 4 = severe disease and 5 = very severe disease). IGA uses clinical characteristics
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 273 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 30 
 
of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall 
severity assessment. 
 
 
Dermatology Life Quality Index (DLQI): The DLQI is a simple, patient-administered, 
10-question, validated, quality-of-life questionnaire that covers 6 domains including 
symptoms and feelings, daily activities, leisure, work and school, personal relationships, 
and treatment. The recall period of this scale is over the “last week.” Response categories 
include “not at all,” “a lot,” and “very much,” with corresponding scores of 1, 2, and 3 
respectively and unanswered (“not relevant”) responses scored as 0. A DLQI total score 
of 0 to 1 is considered as having no effect on a patient’s health-related quality of life, and 
a 5-point change from baseline is considered as the minimal clinically important 
difference threshold (Finlay, 1994; Khilji, 2002; Hongbo, 2005).
 
 
Itch Numerical Rating Scale (NRS): The Itch NRS is a patient-administered, 11 point 
horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 
representing “worst itch imaginable.”  Overall severity of a patient’s itching is 
indicated by circling the number that best describes the worst level of itching in the 
past 24 hours. Analyses were performed to support a responder definition that was 
defined as proportion of patients achieving an Itch NRS ≥4-point reduction from 
baseline for patients who had baseline Itch NRS  ≥4.
8.1.2.2 Exploratory Efficacy Assessments 
Data on the following exploratory efficacy measures will be collected at the times shown in the 
Schedule of Activities (Appendix 2): 
 Patient-Oriented Eczema Measure (POEM): The Patient-Oriented Eczema Measure 
(POEM) was originally developed to help address the imbalance between physician and 
patient-based outcome measures in eczema research. Patients answer simple questions 
about the frequency of seven symptoms: itch, sleep disturbance, skin bleeding, skin 
weeping/oozing, skin cracking, skin flaking, and skin dryness/roughness over the last 
week. The total score from this assessment reflects overall disease activity. The POEM 
utilizes a 5-point Likert scale for each question and is intended for ages 1-60 years. 
POEM scores can range from 0 to 28 where lower total scores reflect lower disease 
activity and higher scores reflect higher disease activity (Charman, 2004).
 
 Actigraphy Device: A hypoallergenic wrist watch-like device that is used to collect 
sleep/wake patterns and quantify nocturnal scratching events (Ferguson, 2015).
 
8.1.3. Appropriateness of Primary Efficacy  Measure 
 Eczema Area and Severity Index (EASI): The EASI is one of the best instruments 
available to measure clinical signs of AD. EASI utilizes objective physician estimates of 
disease extent and severity. The EASI is valid and internally consistent and has adequate 
intraobserver reliability, intermediate interobserver reliability, and adequate 
responsiveness. One advantage of the EASI is its unidimensionality; that is, it only 
measures clinical signs of AD and does not include symptoms. Another advantage of the
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 274 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 31 
 
EASI is that it measures the intensity of the lesions at multiple body parts (rather than 
relying on a representative lesion) (Schmitt, 2013). 
 
8.2. Adverse Events 
The investigator remains responsible for following, through an appropriate health care option,  
AEs that are (1) serious or otherwise medically important, (2) considered related to the 
investigational product or the study, or that (3) caused the patient to discontinue the  
investigational product before completing the study. The patient should be followed until the  
event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The 
frequency of follow-up evaluations of the AE is left to the discretion of the   investigator. 
The sponsor has standards for reporting AEs that are to be followed regardless of applicable 
regulatory requirements that may be less stringent. Study site personnel will record the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. All AEs collected in the study 
CRF will be validated and reported in the final study  report. 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect. 
After the ICF is signed, study site personnel will record, via the CRF/electronic data entry, the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. In addition, site personnel will 
record any change in the condition(s) and any new conditions as AEs. Investigators should  
record their assessment of the potential relatedness of each AE to protocol procedure or 
investigational product. 
Investigators must document their review of each laboratory safety  report. 
Any clinically significant findings from ECGs, laboratory tests, vital sign measurements, and 
other procedures that result in a diagnosis should be reported to the sponsor or its designee. In 
addition, all AEs occurring after the patient receives the first dose of the investigational product 
must be reported to the sponsor or its  designee. 
Investigators will be instructed to report to the sponsor or its designee their assessment of the 
potential relatedness of each AE to protocol procedure or investigational product via the case 
report form. 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the  study. 
Cases of pregnancy that occur during maternal or paternal exposures to the investigational   
product should be reported. Data on fetal outcome and breast-feeding are collected for regulatory 
reporting and drug safety evaluation. 
Study site personnel must alert the sponsor or its designee immediately of the investigator 
unblinding a patient’s treatment group assignment for any  reason. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 275 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 32 
 
If a patient’s treatment is discontinued as a result of an AE, study site personnel must clearly 
report to the sponsor or its designee the circumstances and data leading to any such 
discontinuation of treatment. 
 
8.2.1. Adverse Events/Laboratory Results of Special Interest  
Adverse events or laboratory results of special interest include infections; myelosuppressive 
events of anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia; thrombocytosis; 
hyperlipidemia; hypercholesterolemia; and elevations in ALT/AST (≥3X ULN) and total 
bilirubin (≥2X ULN). 
8.2.2. Serious Adverse Events 
Study site personnel must alert the sponsor or its designee of any SAE within 24 hours of 
investigator awareness of the event via a sponsor-approved method. Alerts issued via telephone 
are to be immediately followed with official notification on study-specific SAE   forms. 
All SAEs will be reported in the study CRF and on the approved study-specific SAE form by the 
study site personnel. In addition, the study-specific SAE forms will be collected by 
sponsor/designee and subsequently entered into the clinical study database and the study safety 
database. Investigators will be required to update the study-specific SAE forms when new 
information becomes available, and address questions from the sponsor/designee until the SAE  
has been fully resolved or explained to the satisfaction of the sponsor. The SAE data from both 
CRF and study-specific SAE forms will be validated and included in the final CSR. If the SAE 
cases are closed after the completion of database lock, such information may not be included in  
the final study report. Such additional information will continue to be collected in the study- 
specific SAE form, and be reported either in an amendment to study report if such information 
leads to clinically significant change(s) in the conclusion of the study; or in the annual 
Development Safety Update Report (DSUR) or IB update if the information from the SAE does 
not alter the overall conclusion of the  study. 
An SAE is any AE from this study that results in one of the following   outcomes: 
 death 
 initial or prolonged inpatient  hospitalization 
 a life-threatening experience (that is, immediate risk of  dying) 
 persistent or significant  disability/incapacity 
 congenital anomaly/birth defect 
 considered significant by the investigator for any other  reason 
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Previously planned (prior to signing of ICF) surgeries should  
not be reported as SAEs unless the underlying medical condition has worsened during the course 
of the study. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 276 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 33 
 
SAEs occurring after a patient has taken the last dose of the investigational product will be 
collected in the pharmacovigilance system and clinical data collection database for 30 days after 
the last dose of the investigational product, regardless of the investigator’s opinion of causation. 
Thereafter, SAEs are not required to be reported unless the investigator feels the events were 
related to either investigational product, drug delivery system, or a protocol   procedure. 
Sponsor/designee has the option to request follow up information or clarification of existing 
information from the investigators up to closure of the case. SAEs should be followed by the 
investigator until resolution of all queries, clinical recovery is complete or until a stable clinical 
endpoint has been reached. Follow up may therefore continue after the patient has been  
discharged from the study. The type and extent of follow up undertaken will be determined for 
each individual case and depends upon the nature, severity, and medical significance of the  
report. The follow up may include supplemental investigations, additional laboratory tests, 
histopathological examinations, or consultations with other health care professionals. If a patient 
dies during participation in the study, the follow up may include a copy of any post-mortem 
findings, if available. 
The investigator site will be required to contact the patient in accordance with their procedures to 
obtain necessary information to provide updates to the study-specific SAE forms. Requests for 
outstanding information from the investigational site to patients should be maintained as part of  
the clinical study documents. 
8.2.2.1. 
Suspected Unexpected Serious Adverse  Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed   
in the IB and that the investigator identifies as related to investigational product or procedure. 
United States 21 CFR 312.32 and European Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participating countries  
require the reporting of SUSARs. The sponsor has procedures that will be followed for the 
recording and expedited reporting of SUSARs that are consistent with global regulations and the 
associated detailed guidances. 
 
8.2.3.   Complaint Handling 
The Sponsor collects product complaints on investigational products and drug delivery systems 
used in clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product  improvements. 
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be   assessed. 
 
8.3. Treatment of Overdose 
Refer to the baricitinib Investigator’s  Brochure. 
 
8.4. Safety Assessments 
Safety assessments include vital signs, physical examination, electrocardiograms, AEs, patient- 
reported scale data, and safety laboratory  testing. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 277 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 34 
 
 
 
8.4.1. Physical Examination 
A complete physical examination will be performed during Visit 1 (screening). Directed physical 
examinations will be performed according to the Schedule of Activities (Appendix 2) and may    
be repeated at the investigator’s discretion any time a patient presents with physical   complaints. 
 
8.4.2. Electrocardiograms 
For each patient, an electrocardiogram (ECG) should be performed according to the Schedule of 
Activities (Appendix 2) and as deemed necessary by the  investigator. 
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient receives the first dose of the investigational treatment should be reported to Lilly or its 
designee as an AE via the CRF. 
 
8.4.3. Vital Signs 
For each patient, vital signs measurements should be conducted according to the Schedule of 
Activities (Appendix 2) and following study specific recommendations provided by the sponsor 
for the study. 
Any clinically significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
 
8.4.4. Laboratory Tests 
For each patient, laboratory tests detailed in (Appendix 3) should be conducted according to the 
Schedule of Activities (Appendix 2). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of investigational product should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
 
8.4.5. Hepatitis B virus (HBV) DNA  monitoring 
Patients enrolled in the US who are HBsAg negative, HBcAb positive, and HBV DNA negative 
(undetectable) at Visit 1, will require HBV DNA monitoring at Visits 5 and 8 or ET, regardless  
of their HBsAb status. 
Patients enrolled in Japan who are HBsAg negative, HBcAb and/or HBsAb positive, and HBV 
DNA negative (undetectable) at Visit 1, will require HBV DNA monitoring at Visits 5 and 8 or 
ET. 
If the HBV DNA result is ‘target detected’ ≥29 IU/mL at any point in the study, then the patient 
should be referred to a hepatology specialist immediately and discontinuation considered (refer   
to Table JAHG.4). In selected cases, investigators may temporarily continue study drug in 
accordance with current immunomodulator management in the setting of HBV DNA   positivity. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 278 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 35 
 
This option may be considered in consultation with the sponsor (or its designee) and evaluation 
of individual patient risks and  benefits. 
 
8.4.6. Quick Inventory of Depressive Symptomatology-Self Report 16 
(QIDS-SR16) 
For each patient, the QIDS-SR16 should be administered according to the Schedule of Activities 
(Appendix 2). 
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and 
severity of symptoms of depression as listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (American 
Psychiatry Association [APA] 1994). The QIDS-SR16 scale is used to assess the potential  
impact of treatment on new onset or changes in depression, thoughts of death, and /or suicidal 
ideation severity. A patient is asked to consider each statement as it relates to the way they   have 
felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items 
corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, 
with higher scores denoting greater symptom severity. The domains assessed by the instrument 
include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) 
energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or   hypersomnia), 
(8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation (Rush,   2003). 
 
8.4.7. Safety Monitoring 
The sponsor will periodically review evolving aggregate safety data within the study by 
appropriate methods. 
If a patient experiences elevated ALT ≥3X ULN, ALP ≥3X ULN, or elevated TBL ≥2X ULN, 
clinical and laboratory monitoring should be initiated by the investigator. Details for hepatic 
monitoring depend upon the severity and persistence of observed laboratory test abnormalities.  
To ensure patient safety and comply with regulatory guidance, the investigator is to consult with 
the sponsor CRP regarding collection of specific recommended clinical information and follow- 
up laboratory tests (Appendix 4). 
 
8.5. Pharmacokinetics 
8.5.1. PK Sample Collection 
A total of 6 venous blood samples (approximately 5 mL per sample) for the measurement of 
baricitinib concentrations will be drawn at visits scheduled within the time windows specified in 
the Schedule of Activities (Appendix 2). Specific dosing and fasting requirements for each PK 
visit are described in Table JAHG.5  below. 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 279 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 36 
 
Table JAHG.5. 
Timing of Dosing and Fasting Requirements for PK Sample 
Collection Visits 
 
Events 
Visit 
2 
4 
5 
6 
7 
ET 
Overnight 
(8-hr) fast 
Yes 
No 
No 
No 
Yes 
No 
Take study 
drug 
At clinic 
At home 
At home 
At clinic 
At clinic 
N/A 
Morning Fast 
Until PK 
samples are 
taken 
N/A 
N/A 
N/A 
Until PK 
sample is 
taken 
N/A 
Sample time 
windows 
relative to dose 
 
Pre-dose 
 
15-30min 
post-dose 
1.5 – 4 hr 
post-dose 
4 – 8 hr 
post-dose 
Pre-dose 
30-90 min 
post-dose 
N/A 
 
On all PK sample collection days, patients should take all study medication within 5   minutes. 
At Visits 2 and 7, patients will be asked to arrive at the study site after an overnight fast. Patients 
will receive an oral dose of placebo or baricitinib at the study site and will remain fasted until PK 
blood samples have been collected. A light snack will be provided after PK samples have been 
collected. 
At Visits 4 and 5, patients will be advised to take the study drug at home. Patients will then go  
to the study site in the scheduled time window for study  assessments. 
At Visit 6, patients will be advised to NOT take study drug prior to visiting the study site. A 
single blood sample will be collected prior to the patient taking their drug at the study   site. 
A single PK sample will be obtained, whenever possible, at the early termination visit. In the 
event of an SAE, up to 2 additional blood samples may be taken at the investigator’s discretion, 
up to 6 hours after the reported event and within 24 hours of the patient’s last   dose. 
For any PK sample taken, the actual date and time (24-hour clock) of PK sample collection as 
well as the date and time of the last 2 dose administrations prior to the PK sample should be 
recorded. 
The sponsor, or its designee, will provide instructions for the collection and handling of blood 
samples. 
 
8.5.2. PK Sample Assay 
Plasma samples will be assayed for baricitinib using a validated liquid chromatography with 
tandem mass spectrometry (LC/MS/MS) method at a laboratory approved by the   sponsor. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 280 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 37 
 
Samples from patients receiving baricitinib will be assayed. PK samples from patients on 
placebo are not planned to be assayed. 
 
8.5.3. PK Sample Storage and  Retention 
Bioanalytical samples collected to measure investigational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study. Pharmacokinetic samples will  
be kept in storage at a laboratory facility designated by the sponsor and may also be assayed for 
additional exploratory analyses. Pharmacokinetic results will not be provided to investigative   
sites or blinded personnel until the study has been  unblinded. 
 
8.6. Pharmacodynamics 
Further pharmacodynamic data, beyond efficacy and biomarker data, will not be   collected. 
 
8.7. Genetics 
A blood sample (approximately 10 mL) will be collected for pharmacogenetic analysis as 
specified in the Schedule of Activities (Appendix 2) where local regulations and ethical review 
boards (ERBs) allow. 
Samples will not be used to conduct unspecified disease or population genetic research either  
now or in the future. Samples will be used to investigate variable response to baricitinib and to 
investigate genetic variants thought to play a role in atopic dermatitis or other inflammatory skin 
disorders. Assessment of variable response may include evaluation of AEs or differences in 
efficacy.  These studies may include but are not limited to evaluate their association with  
observed response to baricitinib. 
All pharmacogenetic samples will be coded with the patient number. Only investigator site 
personnel can link these samples, and any data generated, back to the patient. Samples will be 
destroyed according to a process consistent with local  regulations. 
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or  
for a shorter period if local regulations and/or ERBs impose shorter time limits, at a facility 
selected by the sponsor. This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in drug development or when the drug is commercially  available. 
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, candidate gene studies, and epigenetic analyses. 
Regardless of technology utilized genotyping data generated will be used only for the specific 
research scope described here. 
 
8.8. Biomarkers 
Skin biopsies, serum, plasma, and whole blood ribonucleic acid (RNA) samples for non-genetic 
biomarker research will be collected at the times specified in the Schedule of Activities 
(Appendix 2) where local regulations and ERBs  allow. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 281 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 38 
 
Samples may be used for research on the drug target, disease process, pathways associated with 
atopic dermatitis, mechanism of action of baricitinib, and/or research method or in validating 
diagnostic tools or assay(s) related to atopic  dermatitis. 
All biomarker samples will be coded with the patient number. Only investigator site personnel 
can link these samples, and any data generated, back to the patient. Samples will be destroyed 
according to a process consistent with local  regulations. 
Samples will be retained for a maximum 15 years after the last patient visit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by   
the sponsor. This retention period enables use of new technologies, response to regulatory 
questions, and investigation of variable response that may not be observed until later in drug 
development or when the drug is commercially  available. 
 
8.8.1. Skin Biopsies 
Patients will be required to provide skin punch biopsy samples collected per the Schedule of 
Activities (Appendix 2), unless exempted by the  investigator. 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
and used to study biomarkers related to atopic dermatitis and/or related to the mechanism of  
action of baricitinib. Techniques used may include but are not limited to immunohistochemistry 
and microarray expression profiling. Samples will be de-identified as described in International 
Conference on Harmonisation (ICH) guideline E15, and may be used for exploratory microarray 
expression profiling or transcriptome sequencing. Detailed instructions for sample collection and 
handling will be provided by the sponsor. Samples will be sent to a sponsor-designated lab for 
immunohistochemistry. 
 
8.8.2. Nonpharmacogenetic  Biomarkers 
Peripheral serum samples (approximately 10 mL) will be collected at pre- and post-treatment 
time points for the assessment of biomarkers expected to be mechanistically related to JAK 1/2 
inhibition and/or the atopic dermatitis disease state. A blood sample for genotyping of filaggrin 
will also be collected. Sample processing and handling instructions will be provided by the 
sponsor. Samples will be sent to a sponsor-designated lab for  evaluation. 
Exploratory biomarker serum, plasma, and blood for mRNA samples will also be collected and 
stored at a sponsor-designated vendor. 
 
8.9.    Health Economics 
The self-reported questionnaires will be administered according to the Schedule of Activities 
(Appendix 2). The questionnaires will be administered in countries where they have been 
translated into the native language of the region and linguistically  validated. 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 282 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 39 
 
9. Statistical Considerations and Data  Analysis 
9.1. Determination of Sample Size 
Approximately 120 patients will be enrolled using a 4:3:3 randomization scheme of placebo,  
2 mg baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 
20%, approximately 96 patients will complete the  study. 
This sample size provides 90% power to detect a 35% difference in EASI-50 between placebo 
and the 4-mg baricitinib treatment group using a 2-sided chi-square test with alpha =   0.05. 
 
9.2. General Statistical Considerations 
Statistical analysis of this study will be the responsibility of the sponsor or its designee. A 
detailed statistical analysis plan (SAP) will be provided by the sponsor or its designee, and will 
be finalized prior to database lock and  unblinding. 
Investigator site data will be pooled for statistical analysis  purposes. 
All tests of treatment effects will be conducted at a 2-sided alpha level of 0.05, unless otherwise 
stated. 
Data analyses will be provided by treatment groups and for all study patients combined wherever 
appropriate. For continuous variables, summary statistics will include number of patients, mean, 
median, standard deviation, minimum, and maximum.  Categorical endpoints will be    
summarized using number of patients, frequency, and  percentages. 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report. Additional exploratory analyses of the data will be conducted as 
deemed appropriate. 
 
9.3. Treatment Group Comparability 
9.3.1. Patient Disposition 
All patients who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation will be 
given.  Data tabulations will summarize the following patient numbers, per treatment   group: 
 Enrolled 
 Received treatment 
 Violated the protocol 
 Completed the protocol 
 Withdrew because of: 
o Adverse event 
o Lack of efficacy 
o Consent withdrawal 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 283 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 40 
 
o Other reasons, as applicable 
A detailed description of patient disposition will be provided at the end of the   study. 
 
9.3.2. Patient Characteristics 
Baseline and demographic characteristics will be summarized descriptively by treatment group 
and overall. 
 
9.3.3. Concomitant Therapy 
Concomitant use of topical corticosteroids will be summarized by treatment   group. 
 
9.4. Primary and Secondary Analyses 
9.4.1. Primary Analyses 
The primary outcome will be the proportion of patients achieving EASI-50 in each treatment   
arm. The primary analysis will be performed using all randomized patients utilizing a Non- 
Responder Imputation (NRI) analysis. The proportion of patients achieving EASI-50 in the 
placebo arm will be compared to proportion of patients in each of the baricitinib arms using a two-
sided chi-square test with alpha=0.05. To control the study-wise type 1 error rate, the comparison 
of the baricitinib arms with the placebo arm will be performed in a stepwise fashion. The 4-mg 
baricitinib arm will be compared with the placebo arm; if this test is statistically significant, then 
the 2-mg baricitinib arm will be compared with the placebo arm. Enrollment of 120 patients in a 
4:3:3 ratio will provide approximately 90% power for detecting a 35%  difference in the EASI-50 
response rate between placebo and the 4-mg baricitinib treatment   arm. 
For EASI-50 endpoint, all Non-Responders, as well as all patients who discontinue study 
treatment at any time prior to the time point of interest or discontinue from the study for any 
reason, will be defined as Non-Responders for the NRI analysis. Randomized patients without at 
least 1 post-baseline observation will also be defined as Non-Responders for the NRI   analysis. 
 
9.4.2. Secondary Analyses 
Continuous secondary endpoints will be summarized and analyzed using treatment groups by use 
of a mixed effects model with treatment as the main factor and baseline values as covariates. The 
treatment (intercept) effects and their standard errors from the mixed effects model will be used   
to produce p-values and 90% confidence intervals for the treatment   comparison. 
For continuous endpoints collected longitudinally, missing data will assumed to be missing at 
random and a mixed model repeated measures (MMRM) approach will be used. Other 
imputation techniques, such as multiple imputation, may be utilized in sensitivity   analyses. 
Categorical secondary endpoints will be summarized and analyzed using a chi-square test or 
Fisher’s exact test, if needed. 
 
9.4.3. Tertiary/Exploratory Analyses 
Continuous secondary endpoints will be summarized and may be analyzed by use of a mixed 
effects model with treatment as the main factor and baseline values as covariates. The   treatment 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 284 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 41 
 
(intercept) effects and their standard errors from the mixed effects model will be used to produce 
p-values and 90% confidence intervals for the treatment  comparison. 
Categorical secondary endpoints will be summarized and may be analyzed using a chi-square 
test or Fisher’s exact test, if needed. 
 
9.5. Safety Analyses 
Safety analyses will be conducted on all patients who received at least one dose of study drug. 
No statistical comparisons of treatment groups will be completed for safety   endpoints. 
All adverse events will be summarized and listed. The incidence of symptoms for each treatment 
will be presented by severity and by association with study drug as perceived by the investigator. 
Symptoms reported to occur prior to enrollment will be distinguished from those reported as new 
or increased in severity during the  study. 
Additional safety parameters that will be assessed include safety lab parameters and vital signs. 
The parameters will be listed, and summarized using standard descriptive statistics. Additional 
analysis will be performed if warranted upon review of the  data. 
 
9.6. Pharmacokinetic/Pharmacodynamic  Analyses 
The pharmacokinetics of baricitinib will be assessed using population PK analysis techniques. 
The relationship between the primary and secondary efficacy endpoints and plasma exposure, 
race, and age of onset may be explored. PK and PD data may be combined with prior data for an 
integrated analysis. 
 
9.7. Other Analyses 
9.7.1. Health Economics 
Patient reported outcome endpoints will be summarized and analyzed using treatment groups by 
use of a mixed effects model with treatment as the main factor and baseline values as covariates. 
The treatment (intercept) effects and their standard errors from the mixed effects model will be 
used to produce p-values and 90% confidence intervals for the treatment   comparison. 
 
9.7.2. Biomarkers 
Biomarker data from all patients undergoing biomarker assessments will be analyzed. Biomarker 
data will be summarized and listed, and may be displayed  graphically. 
 
9.8.    Interim Analyses 
An interim analysis is not planned for this  study. 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 285 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 42 
 
10. Study Governance Considerations 
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process 
10.1.1. Informed Consent 
The investigator is responsible for ensuring  that: 
 the patient understands the potential risks and benefits of participating in the 
study 
 informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of 
investigational product. 
 any questions the patient may have throughout the study are answered and 
shares, in a timely manner, any new information that may be relevant to the 
patient’s willingness to continue his or her participation in the  study. 
 
10.1.2. Ethical Review 
The investigator or designee must give assurance that the ethical review board (ERB) was 
properly constituted and convened as required by International Conference on Harmonisation 
(ICH) guidelines and other applicable laws and  regulations. 
Documentation of ERB approval of the protocol and the ICF must be provided to the sponsor 
before the study may begin at the investigative site(s). The sponsor or its representatives must 
approve the ICF, including any changes made by the ERBs, before it is used at the investigative 
site(s).  All ICFs must be compliant with the ICH guideline on  GCP. 
The study site’s ERB(s) should be provided with the  following: 
 current IB and updates during the course of the  study 
 ICF 
 relevant curricula vitae 
10.1.3. Regulatory Considerations 
This study will be conducted in accordance  with: 
 consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of   
Medical Sciences (CIOMS) International Ethical  Guidelines 
 applicable ICH GCP Guidelines 
 applicable laws and regulations 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 286 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 43 
 
The investigator or designee will promptly submit the protocol to applicable   ERB(s). 
All or some of the obligations of the Sponsor may be assigned to a Contract Research 
Organization (CRO). 
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and/or other study-related 
data. 
 
10.1.4. Investigator Information 
Physicians with a specialty in dermatology will participate as investigators in this clinical   study. 
 
10.1.5. Protocol Signatures 
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a sponsor  representative. 
 
10.1.6. Final Report Signature 
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study. 
The investigator with the most enrolled patients will be requested to serve as the CSR 
coordinating investigator. If this investigator is unable to fulfill this function, another 
investigator will be chosen by the sponsor to serve as the CSR coordinating   investigator. 
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study. 
 
10.2. Data Quality Assurance 
To ensure accurate, complete, and reliable data, the sponsor/designee will perform the   following: 
 provide instructional material to the study sites, as  appropriate 
 sponsor start-up training to instruct the investigators and study coordinators. This 
training will give instruction on the protocol, the completion of the CRFs, and 
study procedures. 
 make periodic visits to the study site 
 be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 287 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 44 
 
 review and evaluate CRF data and use standard computer edits to detect errors in 
data collection 
 conduct a quality review of the  database 
In addition, the sponsor/designee will periodically check a sample of the patient data recorded 
against source documents at the study site. The sponsor/designee and/or regulatory agencies 
may audit the study at any time.  Investigators will be given notice before an audit   occurs. 
The investigator will keep records of all original source data.  This might include laboratory  
tests, medical records, and clinical notes. If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents. 
 
10.2.1. Data Capture System 
An electronic data capture (EDC) system will be used in this study. The site maintains a source 
for the data entered into the sponsor-designated EDC system, if collected external to the EDC 
system. 
Electronic patient-reported outcome (ePRO) measures (for example, a rating scale) or other data 
reported directly by the patient (for example, daily dosing schedule, event diary) may be entered 
into an ePRO instrument (for example, personal digital assistant [PDA]), or by means of an 
interactive response technology system (IRT) at the time the information is obtained. In these 
instances where there is no prior written or electronic source data at the site, the ePRO  
instrument record will serve as the  source. 
If ePRO records are stored at a third party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study 
for retention. 
Any data for which the ePRO instrument record will serve to collect source data will be 
identified and documented by each site in that site’s study  file. 
Case report form data will be encoded and stored in a clinical study  database. 
Case report form data collected by a third-party will be encoded by the third-party and stored 
electronically in the third-party’s database system. Validated data will subsequently be 
transferred to the sponsor designated  database. 
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system. Data will subsequently be transferred from the central 
vendor to the sponsor designated  database. 
Any data for which paper documentation provided by the patient will serve as the source  
document will be identified and documented by each site in that site’s study file. Paper 
documentation provided by the patient may include, for example, a paper diary to collect patient- 
reported outcome (PRO) measures (for example, a rating scale), a daily dosing schedule, or an 
event diary. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 288 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 45 
 
Data from complaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management  system. 
 
10.3. Study and Site Closure 
10.3.1. Discontinuation of Study Sites 
Study site participation may be discontinued if the sponsor or its designee, the investigator, or 
the ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons 
consistent with applicable laws, regulations, and  GCP. 
 
10.3.2. Discontinuation of the Study 
The study will be discontinued if the sponsor or its designee judges it necessary for medical, 
safety, regulatory, or other reasons consistent with applicable laws, regulations, and   GCP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 289 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 46 
 
11. References 
[APA] American Psychiatry Association. 1994. Diagnostic and Statistical Manual of Mental 
Disorders. 4th ed. Washington DC. 
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic 
inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul   1;2(3):e24137. 
Beck, LA, Thaçi, D, Hamilton, JD, Graham, NM, Bieber, T, Rocklin, R, Ming, JE, Ren, H, Kao, 
R, Simpson, E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. 
New Engl. J. Med. 2014, 371,  130–139. 
Bieber, T. Atopic Dermatitis. Ann Derm. 2010,  125-137. 
Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy 
and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 
12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 
Apr;166(4):853-60. 
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Arch Dermatol. 2004  Dec;140(12):1513-9. 
Epstein E, Pinski JB. A blind study. Arch Dermatol 1964; 89:  548–549. 
Ferguson T, Rowlands AV, Olds T, Maher C. Validity of consumer-level, activity monitors in 
healthy adults worn in free-living conditions: a cross-sectional study. International Journal of 
Behavioral Nutrition and Physical Activity (2015)  12:42. 
 
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for 
routine clinical use. Clin Exp Dermatol. 1994  May;19(3):210-6. 
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, 
Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of 
tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug   9;367(6):495-507. 
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality 
of life into practice: What do dermatology life quality index scores mean? J Invest   Dermatol. 
2005 Oct;125(4):659-64. 
Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus- 
Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib    
at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to 
methotrexate. Ann Rheum Dis. 2015  Feb;74(2):333-40. 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol 2002; 147 (Suppl 62):  50. 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 290 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 47 
 
Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. 
Identification of a novel pathway important for proliferation and differentiation of primary 
erythroid progenitors. Proc Natl Acad Sci U S A. 1997 Apr  1;94(7):3016-21. 
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik 
KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging 
study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with 
background methotrexate in patients with active rheumatoid arthritis and an inadequate response 
to methotrexate alone. Arthritis Rheum. 2012  Apr;64(4):970-81. 
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015   Sep;73(3):395-9. 
Mallinckrodt C, Tamura RN, Tanaka Y. Recent developments in improving signal detection and 
reducing placebo response in psychiatric clinical trials. J Psychiatric Research 45 (2011) 1202- 
1207. 
Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of 
Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015 Apr   29;4(5):858-73. 
Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A phase 2b trial of baricitinib, an 
oral JAK inhibitor, in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2014 
May;70(5, Suppl 1): AB162. 
Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Brit J Derm. 2003; 
148: 117–121. 
Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, 
Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a 
variety of cytokine receptors. Cell. 1998 May  1;93(3):385-95. 
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus 
kinases. Immunol Rev. 2008  Jun;223:132-42. 
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan  
PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of 
Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a 
psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 
1;54(5):573-83. 
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P; 
Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of 
clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin 
Immunol.  2013 Dec;132(6):1337-47. 
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S.  
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in 
healthy volunteers. J Clin Pharmacol. 2014  Dec;54(12):1354-61. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 291 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 48 
 
Vera J, Bachmann J, Pfeifer AC, Becker V, Hormiga JA, Darias NV, Timmer J, Klingmüller U, 
Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 
signalling pathway. BMC Syst Biol. 2008 Apr  25;2:38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 292 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 49 
 
Appendix 1. 
Abbreviations and Definitions 
 
 
 
 
 
Term 
Definition 
AD 
Atopic Dermatitis 
AE 
adverse event: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product. 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
Audit 
A systematic and independent examination of the study-related activities and    
documents to determine whether the evaluated study-related activities were conducted, 
and the data were recorded, analyzed, and accurately reported according to the protocol, 
applicable standard operating procedures (SOPs), good clinical practice (GCP), and the 
applicable regulatory requirement(s). 
Blinding/masking 
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are  not. 
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received. 
BSA 
body surface area 
Chorus 
A semi-autonomous clinical development organization within Eli Lilly and  Company. 
CIOMS 
Council for International Organizations of Medical  Sciences 
CKD EPI 
Chronic Kidney Disease Epidemiology Collaboration 
Complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system. 
Compliance 
Adherence to all the study-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory  requirements. 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 293 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 50 
 
 
Confirmation 
A process used to confirm that laboratory test results meet the quality requirements 
defined by the laboratory generating the data and that Lilly is confident that results are 
accurate. Confirmation will either occur immediately after initial testing or will require 
that samples be held to be retested at some defined time point, depending on the steps 
required to obtain confirmed results. 
CRF/eCRF 
case report form/electronic case report form (sometimes referred to as clinical report 
form): A printed or electronic form for recording study participants’ data during a 
clinical study, as required by the protocol. 
CRO 
contract research organization 
CRP 
Clinical research physician:  individual responsible for the medical conduct of the 
study. Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical  officer. 
CRU 
clinical research unit 
CS 
Corticosteroid 
CSE 
clinically significant event.  A moderate-to-severe adverse event (AE), abnormal 
clinical sign, or clinical laboratory finding that may pose a risk to the well-being of the 
patient. 
CSR 
clinical study report 
DLQI 
Dermatologic Life Quality Index 
DMC 
data monitoring committee 
DN 
Diabetic Nephropathy 
DNA 
deoxyribonucleic acid 
DSUR 
Development Safety Update Report 
EASI 
Eczema Area and Severity Index 
ECG 
Electrocardiogram 
EDC 
Electronic data capture 
eGFR 
estimated glomerular filtration  rate 
End of study 
Date of the last visit or last scheduled procedure shown in the Study Schedule for the 
last active patient in the study 
Enroll 
The act of assigning a patient to a treatment. Patients who are enrolled in the study are 
those who have been assigned to a treatment. 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 294 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 51 
 
 
Enter 
Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives. 
ePRO 
electronic patient-reported outcome 
ERB/IRB 
ethical review board/institutional review board: a board or committee (institutional, 
regional, or national) composed of medical professionals and nonmedical members 
whose responsibility is to verify that the safety, welfare, and human rights of the 
patients participating in a clinical study are protected. 
e-source 
electronic source documentation 
FSH 
follicle stimulating hormone 
GCP 
good clinical practice 
GGT 
gamma glutamyltransferase 
H2 receptor 
histamine H2 receptor 
HBcAb 
hepatitis B core antibody 
HBsAb 
hepatitis B surface antibody 
HBsAg 
hepatitis B surface antigen 
HBV DNA 
hepatitis B virus DNA 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
IB 
Investigator’s Brochure 
IC50 
half-maximal inhibitory concentration 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IFN-γ 
interferon-gamma 
IGA 
Investigator’s Global Assessment 
IgE 
immunoglobulin E 
IL 
Interleukin 
INR 
international normalized ratio 
Informed consent 
A process by which a subject voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the subject's decision to participate. Informed consent is documented by 
means of a written, signed and dated informed consent  form. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 295 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 52 
 
 
Interim analysis 
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is  created/locked. 
Investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form. 
Investigator 
A person responsible for the conduct of the clinical study at a study site. If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal  investigator. 
ITT 
intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that treatment group irrespective of their 
compliance to the planned course of treatment. 
IRT 
interactive response technology system 
JAK 
Janus kinase 
JAK1, JAK2, JAK3 
kinases belonging to the Janus kinase family 
Legal Representative 
An individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical  study. 
Lilly 
Eli Lilly and Company 
LRL 
Lilly Research Laboratories 
MMRM 
mixed model repeated measures 
MOS 
margin of safety 
NRI 
non-responder imputation 
NRS 
numerical rating scale 
PASI 
Psoriasis Area and Severity Index 
Patient 
A study participant who has the disease or condition for which the investigational 
product is targeted. 
PK/PD 
pharmacokinetics/pharmacodynamics 
PO 
per os; oral administration 
POCT 
point-of-care testing 
POEM 
Patient-Oriented Eczema Measure 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 296 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 53 
 
 
PPD 
purified protein derivate 
PRO/ePRO 
patient-reported outcomes/electronic patient-reported  outcomes 
QIDS-SR16 
Quick Inventory of Depressive Symptomatology-Self Report  16 
QD 
once daily 
Randomize 
the process of assigning subjects to an experimental treatment group according to the 
randomization schedule for the study. 
RA 
Rheumatoid Arthritis 
RNA 
ribonucleic acid 
SAE 
serious adverse event; any untoward medical occurrence that at any dose results in 
death, is life threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect. 
SAP 
statistical analysis plan 
SCORAD 
SCORing of Atopic Dermatitis 
Screening 
The act of determining if an individual meets minimum requirements to become part of  
a pool of potential candidates for participation in a clinical  study. 
SUSARs 
suspected unexpected serious adverse reactions 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event: Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to  
have a causal relationship with this treatment. 
Th1, Th 2 
subsets of T helper cells; T lymphocytes expressing CD4 are also known as helper T 
cells 
TSH 
thyroid stimulating hormone. 
ULN 
upper limit of normal 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 297 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 54 
 
Appendix 2. 
Schedule of Activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 298 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 55 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable for 
PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs  later) 
X 
Read PPD (if applicable) 
X 
ECG (single)-Taken prior to all other 
assessments at V1 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
continued on next page 
 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the evaluation of tuberculosis    
infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient will be 
excluded from the study. 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 299 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 56 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
Vital Signs (BP and pulse) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense topical corticosteroid (as needed) 
X 
X 
X 
X 
X 
X 
X 
Weigh and record topical corticosteroid 
container with cap 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discontinue all excluded AD medications 
X 
Pre-existing Conditions 
X 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational Product Package Dispensed 
X 
X 
X 
X 
X 
Investigational Product Package 
Returned/Compliance Assessed 
X 
X 
X 
X 
X 
X 
Dose administration at site 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
Itch NRS 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
X 
X 
X 
POEM 
X 
X 
X 
X 
X 
X 
X 
continued on next page 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 300 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 57 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 
days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device Download 
X 
X 
X 
X 
X 
X 
Biopsy performed (NL: non-lesion and L: lesion to 
be performed following Investigator and Patient rating 
scale assessments) 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non- 
PK samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HBsAb (including 
Quantitative HBsAb load assessment) 
X 
HBV DNA 
X 
 
continued on next page 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 301 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 58 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory 
Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 302 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 59 
 
Appendix 3. 
Clinical Laboratory Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 303 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 60 
 
 
Clinical Laboratory Tests 
Hematologya,b 
Clinical Chemistrya,b 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume 
Total bilirubin 
Mean cell hemoglobin concentration 
Direct bilirubin 
Leukocytes (WBC) 
Alkaline phosphatase 
Reticulocyte 
Alanine aminotransferase (ALT/SGPT) 
Absolute counts of: 
Aspartate aminotransferase (AST/SGOT) 
Neutrophils, segmented 
Blood urea nitrogen (BUN) 
Neutrophils, juvenile (bands) 
Creatinine 
Lymphocytes 
Uric acid 
Monocytes 
Calcium 
Eosinophils 
Glucose 
Basophils 
Albumin 
Platelets 
Total protein 
Cell morphology 
Estimated glomerular filtration rate (eGFR)e 
Creatine phosphokinase (CPK) 
Urinalysisa,b,d 
Color 
Other Testsa 
Specific gravity 
Hepatitis B Surface antigenf 
pH 
Anti-Hepatitis B Core antibodyf 
Protein 
Quantitative HBsAb load assessmenta 
Glucose 
Hepatitis B Surface antibodyf 
Ketones 
Human immunodeficiency virusf 
Bilirubin 
Hepatitis C antibodyf,g 
Urobilinogen 
Thyroid-stimulating hormonef 
Blood 
Thyroxinef 
Leukocyte esterase 
Pregnancy Testh 
Nitrite 
FSHf,i 
Serum immunoglobulin (IgA, IgG, and IgM) 
Lipid (Fasting) a,c 
PPD, QuantiFERON®-TB Gold or T-SPOT.TB® j 
Total cholesterol 
Low-density lipoprotein 
Baricitinib plasma levels 
High-density lipoprotein 
HBV DNA 
Triglycerides 
 
Abbreviations: CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; DNA = deoxyribonucleic   acid; 
FSH = folliclestimulatinghormone; HBV = Hepatitis B virus;; RBC =  red 
blood cells; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic 
pyruvic transaminase; TB = tuberculosis; WBC = white blood  cells. 
a Assayed by sponsor-designated laboratory. 
b Unscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed. 
c Fasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to  test. 
d Microscopic examination of sediment performed only if abnormalities are noted on the routine urinalysis.  
e eGFR for serum creatinine calculated by the central laboratory using the -CKD EPI   method. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 304 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 61 
 
f Test required at Visit 1 only to determine eligibility of patient for the  study. 
g A positive hepatitis C antibody (Hep C antibody) result will be confirmed with an alternate hepatitis C method.   
h For all women of childbearing potential, a serum pregnancy test will be performed at Visit 1 and a local   urine 
pregnancy test will be performed at all visits thereafter. 
i To confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an 
FSH test will be performed. Non-childbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of 
menses for at least 12 months. 
j The QuantiFERON®-TB Gold test is the preferred alternative to the PPD test for the evaluation of TB infection,   
and it may be used instead of the PPD test or T-SPOT.TB® test and may be read locally. If the QuantiFERON®- 
TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient is excluded from  
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 305 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 62 
 
Appendix 4. 
Hepatic Monitoring Tests for  Treatment- 
Emergent Abnormality 
 
 
 
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may be required in 
follow-up with patients in consultation with the sponsor, its designee, or clinical research  physician. 
 
Hepatic Monitoring Tests 
Hepatic Hematologya 
Haptoglobina 
Hemoglobin 
Hematocrit 
Hepatic Coagulationa 
RBC 
Prothrombin Time 
WBC 
Prothrombin Time, INR 
Neutrophils, segmented 
Lymphocytes 
Hepatic Serologiesa,b 
Monocytes 
Hepatitis A antibody, total 
Eosinophils 
Hepatitis A antibody, IgM 
Basophils 
Hepatitis B surface antigen 
Platelets 
Hepatitis B surface antibody 
Hepatitis B Core antibody 
Hepatic Chemistrya 
Hepatitis C antibody 
Total bilirubin 
Hepatitis E antibody, IgG 
Direct bilirubin 
Hepatitis E antibody, IgM 
Alkaline phosphatase 
ALT 
Anti-nuclear antibodya 
AST 
GGT 
Anti-smooth muscle antibodya 
Abbreviations: ALT = alanine aminotransferase; AST = aspirate aminotransferase; GGT = gamma-glutamyl 
transferase; Ig = immunoglobulin; INR = international normalised ratio; RBC = red blood cells; WBC = white 
blood cells. 
a Assayed by sponsor-designated or local laboratory. 
b Reflex/confirmation dependent on regulatory requirements and/or testing  availability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
 
 
14V-MC-JAHG  CSR Appendix Protocol 
Page 306 
 
 
 
 
 
 
14V -MC.J AHG( a ) C lini ca l Pro toco l 
P ag e 6 3 
 
Appendix 5. 
Protocol 14V-MC-JAHG Signature Page 
 
 
 
I confinn that I have read this protocol; I understandit and I will work according to this protocol. 
I will also work consistently with the ethical p1inciples that have their origin in the Declaration 
of Helsinki and that are consistent with good clinical practices and applicable laws and 
regulations. I will accept the monitor's overseeingof the study. I will abide bythe publication 
plan set forth in my Agreement with the sponsor (Choms, Eli Lilly and Company) or designee. I 
will promptly submit the protocol to applicable ethical review board(s). I confirm that ifl or any 
of mystaff are members of the ethical review board, we will abstain from voting on this 
protocol. 
 
 
Signature of Investigator 
Date 
 
 
Investigator Name (Title) 
 
 
Name of Facility 
 
 
Location of Facility 
(City, State(if applicable), Country) 
 
 
 
Signature of sponsor 
Date (dd-m1mn-yyyy) 
PD 
(Chief Medical Officer, Choms-Eli 
  Lilly and Company) 
 
Sponsor name (Title) 
 
   Eli Lilly and Company 
 
Name 
Lilly Coroorate Center. Indianapolis, Indiana. USA 
Location (City, State (if applicable), Country) 
 
 
LY3009104 
Instructionsto the Investigator: Please SIGNand DATEthis signaturepage. PRINT your 
name, tiUe andthe name of thefacility in which thestudy will beconductedon bothcopies. 
Return 1 of the·s   nedco iesto the 
nsor Chorus, Eli Lil  andCorn  n  or desi  nee. 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 307 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 64 
 
Appendix 6. 
Protocol  Amendment I4V-MC-JAHG(a) 
Summary [A Randomized, Double-Blind, Placebo- 
Controlled, Phase 2 Study to Evaluate the Safety and 
Efficacy of Baricitinib in Patients with Moderate-to- 
Severe Atopic Dermatitis] 
 
 
 
Overview 
Protocol I4V-MC-JAHG [A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to 
Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic 
Dermatitis] has been amended. The new protocol is indicated by amendment (a) and will be  
used to conduct the study in place of any preceding version of the  protocol. 
The overall changes and rationale for the changes made to this protocol are as   follows: 
 The number of patients to be enrolled in this study has been increased from 90 to 120. 
The statistical analysis and power statements in the protocol have been revised to reflect 
this patient increase. The study diagram and all text related to the number of enrolled 
patients have been revised accordingly. 
 The original statistical analysis included two 1-sided tests for comparing the two 
baricitinib dose levels with placebo. The protocol has been revised to reflect a plan to 
control the type 1 error for the primary efficacy analysis at 5%, by including 2, 5% level, 
2-sided tests for testing the two baricitinib dose levels with placebo and a sequential 
testing strategy that first examines the highest dose relative to placebo and only tests the 
lower dose relative to placebo if there is statistical significance for the highest   dose. 
 
 The planned interim analysis has been removed based on the aforementioned statistical 
analysis strategy. 
 
 The definition of a positive Hepatitis B test was clarified as were the HBV DNA 
monitoring criteria. 
 
 The BSA inclusion criteria was changed from >10% BSA to ≥10%  BSA. 
 
 Minor textual edits were made for the purpose of clarification or  correction. 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 308 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 65 
 
Revised Protocol Sections 
 
Note: 
Deletions have been identified by strikethroughs or grayed out for  figures. 
Additions have been identified by the use of  underscore. 
1 
Protocol Synopsis 
Summary of Study Design: 
 
Study I4V-MC-JAHG is a multicenter, randomized, double-blind, parallel, placebo-controlled study designed to 
compare the efficacy and safety of baricitinib to placebo in patients with moderate-to-severe atopic dermatitis. 
Enrollment will be targeted at 90120 patients to enable approximately 7296 patients to complete the study. An 
interim analysis may be implemented and could result in up to an additional 30 patients being enrolled. Patients 
who meet all eligibility criteria will be randomized to receive either placebo or baricitinib, administered as once 
daily oral doses of 2 mg or 4 mg.  Randomization will occur at the country  level. 
Number of Patients:  90120 
 
Statistical Analysis: 
 
Sample Size 
The study will begin with a plan to enroll 90120 patients that will be 
randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, 
respectively. A maximum of 30 additional patients may be enrolled 
depending on the results of the interim analysis. 
Primary Outcome & Methodology 
The primary outcome parameter is the proportion of patients achieving 
EASI-50 in each treatment arm. The placebo arm will be compared to each  
of the baricitinib arms using a one two-sided chi-square test with  
alpha=0.05. To control the study-wise type 1 error rate, the comparison of  
the baricitinib arms with the placebo arm will be performed in a stepwise 
fashion. The 4-mg baricitinib arm will be compared with the placebo arm;    
if this test is statistically significant, then the 2-mg baricitinib arm will be 
compared with the placebo arm. As this is a proof of concept study, there  
will not be any adjustment of alpha for multiple comparisons. Enrollment of 
120 90 patients in a 4:3:3 ratio provides approximately 90% power for 
detecting and a 35% difference in the EASI-50 response rate between 
placebo and either the 4-mg baricitinib treatment arm , statistical power is 
estimated to be apprxoimately 80%. 
Interim Analysis 
An interim analysis is not planned for this study. 
An interim analysis may be conducted to assess variability, effect size, and 
placebo effect during the course of the study in order to evaluate the 
potential need for an increase in the number of patients randomized (up to a 
total of 120) and/or a possible change in randomization ratio.  Details  
around this potential interim analysis will be described in the statistical 
analysis plan (SAP) or in interim analysis planning documentation,  as 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 309 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 66 
 
appropriate. 
 
 
4.1 
Overview of Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 310 
 
 
4 mg baricitinib 
2 mg baricitinib 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 67 
 
Standardization 
Treatment 
Follow-up 
 
 
 
 
120 AD 
Patients 
Placebo 
4 Weeks 
16 Weeks 
4 Weeks 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
Week: 
-4 
0 
1 
4 
8 
12 
16 
20 
Day: 
-28 
0 
7 
28 
56 
84 
112 
140 
 
 
 
Screening Randomization 
(4:3:3) 
Placebo : 2 mg baricitinib : 4 mg baricitinib 
Figure JAHG.1. 
Illustration of study design for Clinical Protocol  I4V-MC-JAHG. 
 
 
5.1 
Inclusion Criteria 
[2] Have moderate-to-severe AD, as determined by all of the  following: 
 EASI ≥12 at Visits 1 and 2 
 >≥10% of body surface area (BSA) involvement at Visits 1 and  2 
 Were diagnosed with AD at least 2 years before Visit  1 
5.2 
Exclusion Criteria 
[20] Positive test for hepatitis B defined as: 
a) positive for hepatitis B surface antigen (HBsAg),  or 
b) positive for anti-hepatitis B core antibody (HBcAb), but negative for hepatitis B 
surface antibody (HBsAb) or 
c)b) positive for anti-hepatitis B core antibody (HBcAb) positive and positive for 
hepatitis B deoxyribonucleic acid (HBV DNA) positive,  or 
d)c)for sites in Japan only, positive for HBcAb and/or anti-hepatitis B surface 
antibody (HBsAb) and positive for hepatitis B deoxyribonucleic acid (HBV 
DNA). 
 
If any of the hepatitis B tests have an indeterminate result, confirmatory testing will 
be performed by an alternate method. 
 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 311 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 68 
 
8.4.5. 
Hepatitis B virus (HBV) DNA  monitoring 
Patients enrolled in the US who are HBsAg negative, HBcAb positive, and HBV DNA negative 
(undetectable) at Visit 1 will require HBV DNA monitoring at Visits 5 and 8 or ET, every 3 
months and at the patient’s last visit (V8 or ET), regardless of their HBsAb   status. 
For patients enrolled at study sites in Japan onlyPatients enrolled in Japan who are HBsAg 
negative, HbBsAb and/or HBcAb positive, and negative for HBV DNA negative (undetectable) 
at Visit 1 will require HBV DNA needs to be monitoring atVisits 5 and 8 or ETchecked at least 
monthly and at the patient’s last visit (V8or  ET). 
In all geographies, if the HBV DNA result is ‘target detected’ ≥29 IU/mL, then the patient  
should be referred to a hepatology specialist immediately and discontinuation considered (refer  
to Table JAHG.4). In selected cases, investigators may temporarily continue study drug in 
accordance with current immunomodulator management in the setting of HBV DNA positivity. 
This option may be considered in consultation with the sponsor (or its designee) and evaluation 
of individual patient risks and benefits. The following actions should be taken in response to 
HBV DNA test results: 
* If a result of “target detected” is obtained at any time during the study with a value of ≥29 
IU/mL, refer to Table JAHG.4. 
 
9.1 
Determination of Sample Size 
Approximately 90120 patients will be enrolled using a 4:3:3 randomization scheme of placebo,  
2 mg baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 
20%, approximately 7296 patients will complete the  study. 
This sample size provides 8090% power to see detect a 35% difference in EASI-50 between 
placebo and either the 4-mg baricitinib treatment group of 35%, assuming a placebo response 
rate of 40%, using a 12-sided chi-square test with alpha =  0.05. 
An interim analysis may be conducted to assess variability, effect size, and placebo effect to 
evaluate the need for an increase in the number of patients randomized up to a total of 120 and/or  
a possible change in randomization ratio. Details around this potential interim analysis will be 
described in the statistical analysis plan (SAP) or in interim analysis planning documentation, as 
appropriate. 
9.2 
General Statistical Considerations 
All tests of treatment effects will be conducted at a 12-sided alpha level of 0.05, unless otherwise 
stated. 
9.4.1  Primary Analyses 
The primary outcome will be the proportion of patients achieving EASI-50 in each treatment 
arm. The primary analysis will be performed using all randomized patients utilizing a Non- 
Responder Imputation (NRI) analysis. The proportion of patients achieving EASI-50 in the 
placebo arm will be compared to proportion of patients in each of the baricitinib arms using   a 
 
LY3009104 


LY3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 312 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(a) Clinical Protocol 
Page 69 
 
onetwo-sided chi-square test with alpha=0.05. To control the study-wise type 1 error rate, the 
comparison of the baricitinib arms with the placebo arm will be performed in a stepwise fashion. 
The 4-mg baricitinib arm will be compared with the placebo arm; if this test is statistically 
significant, then the 2-mg baricitinib arm will be compared with the placebo arm. Enrollment of 
120 patients in a 4:3:3 ratio will provide approximately 90% power for detecting a 35%  
difference in the EASI-50 response rate between placebo and 4-mg baricitinib treatment arm.As 
this is a proof of concept study, there will not be any adjustment of alpha for multiple 
comparisons. 
9.8 
Interim Analyses 
An interim analysis is not planned for this  study. 
A limited number of pre-identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan, prior to the interim or final database lock, in order to initiate the 
final  population pharmacokinetics/pharmacodynamics  (PK/PD) model  development  processes 
for interim or final analyses. Information that may unblind the study during the analyses will not 
be reported to study sites or blinded study team until the study has been   unblinded. 
An interim analysis may be conducted to assess variability of response, effect size, and placebo 
effect during the course of the study in order to evaluate the potential need for an increase in the 
number of patients randomized up to a total of 120 and/or a possible change in randomization 
ratio. Details around this potential interim analysis will be described in the statistical analysis 
plan (SAP) or in interim analysis planning documentation, as  appropriate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
 
 
14V-MC-JAHG  CSR Appendix Protocol 
Page 313 
 
 
 
 
 
14V-MC-JAHG(a) Clinical Protocol 
Page 63 
 
Appendix 5. 
Protocol 14V-MC-JAHG Signature Page 
 
 
I confirm that I have read this protocol; I understand it and I will workaccording to this protocol. 
I will also work consistently with the ethical principles that have their origin in the Declaration 
of Helsinki and that are consistent with good clinical practices and applicable laws and 
regulations.I will accept the monitor's overseeingof the study. I will abide by the publication· 
plan set forth in my Agreement with the sponsor (Chorus, Eli Lilly and Company) or designee. I 
will promptly submit the protocol to applicable ethical review board(s). I confirm that ifI or any 
of my staff are members of the ethical review board, we will abstain from voting on this 
protocol. 
 
 
 
 
Signature ofl nvestigator 
Date 
 
 
Investigator Name (Title) 
 
 
Name of Facility 
 
 
Location ofF acility 
(City, Stale (if applicable), Country) 
 
PPD  
  
 
rt,c,1, a tneo- -pongo- p  p  o 
Date (dd-mmm-yyyy) 
PPD 
Medical Officer, Chorus-Eli 
:cmy ancfi 
pany) 
Sponsor name (Title) 
 
   Eli Lilly and Company 
Name 
Lilly Corporate Center, Indianapolis. Indiana, USA 
Location (City, State (if applicable), Country) 
 
 
LY3009104 
Instructions to the Investigator: Please SIGN and DATE thissignature page. PRINT your 
name, title and the name of the facility in which the study willbe conducted onboth copies. 
Return 1 of the s·.  ned co  ies to the s  onsor   Chorus, Eli Lill   and Com  an    or desi nee. 

Prot_004.pdf: 
I4V-MC-JAHG Protocol Amendment (c)   
 
 
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety 
and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis. 
 
 
NCT ID: NCT02576938 
Approval Date: 24-May-2016 
 


I4V-MC-JAHG CSR Appendix Protocol 
Page 81 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 1 
 
 
Protocol I4V-MC-JAHG(c) 
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 
Study to Evaluate the Safety and Efficacy of Baricitinib in 
Patients with Moderate-to-Severe Atopic  Dermatitis 
 
 
 
 
 
 
 
Baricitinib 
 
 
 
 
Chorus, Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
 
 
 
Protocol Approval Date: 30-September-2015 
Amendment (a) Approval Date: 23-October-2015 
Amendment (b) Approval Date: 07-March-2016 
Amendment (c) Approval Date:   24-May-2016 
 
 
 
 
 
LY3009104 
Confidential Information 
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and  
should not be copied by or distributed to persons not involved in the clinical investigation of 
baricitinib, unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its  subsidiaries. 
Parallel, double-blinded, randomized placebo-controlled multiple dose study in patients with 
moderate-to-severe atopic dermatitis 


I4V-MC-JAHG CSR Appendix Protocol 
Page 82 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 2 
 
Table of Contents 
Section 
Page 
1. 
Protocol Synopsis ........................................................................................... 8 
2. 
Introduction .................................................................................................. 10 
2.1. 
Background ............................................................................................. 10 
2.2. 
Study Rationale ....................................................................................... 11 
3. 
Objectives and Endpoints ............................................................................. 12 
4. 
Study Design ................................................................................................ 14 
4.1. 
Overview of Study Design ...................................................................... 14 
4.2. 
Scientific Rationale for Study Design ..................................................... 14 
4.3. 
Justification for Dose .............................................................................. 15 
4.4. 
Benefit/Risk Assessment ......................................................................... 15 
5. 
Study Population .......................................................................................... 17 
5.1. 
Inclusion Criteria ..................................................................................... 17 
5.2. 
Exclusion Criteria ................................................................................... 17 
5.3. 
Screen Failures ........................................................................................ 21 
6. 
Treatment ..................................................................................................... 22 
6.1. 
Treatments Administered ........................................................................ 22 
6.2. 
Method of Treatment Assignment ........................................................... 22 
6.2.1. 
Selection and Timing of Doses ....................................................... 22 
6.3. 
Blinding .................................................................................................. 23 
6.4. 
Packaging and Labeling .......................................................................... 23 
6.5. 
Investigational Products Storage and Handling ...................................... 24 
6.6. 
Dose Modification ................................................................................... 24 
6.7. 
Treatment Compliance ............................................................................ 24 
6.8. 
Concomitant Therapy .............................................................................. 24 
6.9. 
Treatment after Study Completion .......................................................... 25 
6.9.1. 
Continued Access ........................................................................... 25 
7. 
Discontinuation Criteria ............................................................................... 26 
7.1. 
Discontinuation of Investigational Product ............................................. 26 
7.1.1. 
Temporary Interruption of Investigational Product ........................ 26 
7.1.2. 
Permanent Discontinuation of Investigational Product ............................................. 26 
7.1.3. 
Discontinuation of Inadvertently Enrolled Patients ........................ 27 
7.1.4. 
Permanent Discontinuation from the Study .................................... 27 
7.1.5. 
Patients Lost to Follow-Up ............................................................. 28 
8. 
Study Assessments and Procedures .............................................................. 29 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 83 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 3 
8.1. 
Efficacy Assessments ............................................................................. 29 
8.1.1. 
Primary Efficacy Assessments ....................................................... 29 
8.1.2. 
Secondary Efficacy Assessments ................................................... 29 
8.1.3. 
Appropriateness of Primary Efficacy Measure .............................. 30 
8.2. 
Adverse Events ....................................................................................... 31 
8.2.1. 
Adverse Events/Laboratory Results of Special Interest ........................................... 32 
8.2.2. 
Serious Adverse Events .................................................................. 32 
8.2.2.1. 
Suspected Unexpected Serious Adverse Reactions ............................................ 33 
8.2.3. 
Complaint Handling ....................................................................... 33 
8.3. 
Treatment of Overdose ........................................................................... 33 
8.4. 
Safety Assessments ................................................................................. 33 
8.4.1. 
Physical Examination ..................................................................... 34 
8.4.2. 
Electrocardiograms ......................................................................... 34 
8.4.3. 
Vital Signs ...................................................................................... 34 
8.4.4. 
Laboratory Tests ............................................................................. 34 
8.4.5. 
Hepatitis B virus (HBV) DNA monitoring .................................... 34 
8.4.6. 
Quick Inventory of Depressive Symptomatology-Self  Report 
16 (QIDS-SR16) ....................................................................................................... 35 
8.4.7. 
Safety Monitoring .......................................................................... 35 
8.5. 
Pharmacokinetics .................................................................................... 35 
8.5.1. 
PK Sample Collection .................................................................... 35 
8.5.2. 
PK Sample Assay ........................................................................... 37 
8.5.3. 
PK Sample Storage and Retention ................................................. 37 
8.6. 
Pharmacodynamics ................................................................................. 37 
8.7. 
Genetics .................................................................................................. 37 
8.8. 
Biomarkers .............................................................................................. 38 
8.8.1. 
Skin Biopsies .................................................................................. 38 
8.8.2. 
Nonpharmacogenetic Biomarkers .................................................. 38 
8.9. 
Health Economics ................................................................................... 39 
9. 
Statistical Considerations and Data Analysis .............................................. 40 
9.1. 
Determination of Sample Size ................................................................ 40 
9.2. 
General Statistical Considerations .......................................................... 40 
9.3. 
Treatment Group Comparability ............................................................ 40 
9.3.1. 
Patient Disposition ......................................................................... 40 
9.3.2. 
Patient Characteristics .................................................................... 41 
9.3.3. 
Concomitant Therapy ..................................................................... 41 
9.4. 
Primary and Secondary Analyses ........................................................... 41 
9.4.1. 
Primary Analyses ........................................................................... 41 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 84 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 4 
9.4.2. 
Secondary Analyses ....................................................................... 41 
9.4.3. 
Tertiary/Exploratory Analyses ....................................................... 41 
9.5. 
Safety Analyses ....................................................................................... 42 
9.6. 
Pharmacokinetic/Pharmacodynamic Analyses ....................................... 42 
9.7. 
Other Analyses ........................................................................................ 42 
9.7.1. 
Health Economics .......................................................................... 42 
9.7.2. 
Biomarkers ..................................................................................... 42 
9.8. 
Interim Analyses ..................................................................................... 42 
10. Study Governance Considerations ............................................................... 43 
10.1. Regulatory and Ethical Considerations, Including the  Informed 
Consent Process ................................................................................................................ 43 
10.1.1. 
Informed Consent ........................................................................... 43 
10.1.2. 
Ethical Review ............................................................................... 43 
10.1.3. 
Regulatory Considerations ............................................................. 43 
10.1.4. 
Investigator Information ................................................................. 44 
10.1.5. 
Protocol Signatures ........................................................................ 44 
10.1.6. 
Final Report Signature ................................................................... 44 
10.2. Data Quality Assurance .......................................................................... 44 
10.2.1. 
Data Capture System ...................................................................... 45 
10.3. Study and Site Closure............................................................................ 46 
10.3.1. 
Discontinuation of Study Sites ....................................................... 46 
10.3.2. 
Discontinuation of the Study .......................................................... 46 
11. References .................................................................................................... 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 85 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 5 
 
List of Tables 
Table 
Page 
Table JAHG.1.    Objectives and Endpoints ................................................................................... 12 
Table JAHG.2.    Treatment Regimens........................................................................................... 22 
Table JAHG.3.    Criteria for Temporary Interruption from Study Treatment ............................... 26 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product ................... 27 
Table  JAHG.5.     Timing  of  Dosing  and  Fasting  Requirements  for  PK  Sample  Collection 
Visits .................................................................................................................. 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 86 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 6 
 
List of Figures 
Figure 
Page 
Figure JAHG.1.   Illustration of study design for Clinical Protocol I4V-MC-JAHG. .................... 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 87 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 7 
 
List of Appendices 
Appendix 
Page 
Appendix 1. 
Abbreviations and Definitions ........................................................................... 50 
Appendix 2. 
Schedule of Activities ........................................................................................ 55 
Appendix 3. 
Clinical Laboratory Tests ................................................................................... 61 
Appendix 4. 
Hepatic Monitoring Tests for Treatment-Emergent Abnormality ...................... 64 
Appendix 5. 
Protocol I4V-MC-JAHG Signature Page ........................................................... 65 
Appendix 6. 
Protocol Amendment I4V-MC-JAHG(c) Summary  [A Randomized, 
Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the 
Safety and Efficacy of Baricitinib in Patients with  Moderate-to-Severe 
Atopic Dermatitis] ............................................................................................. 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 88 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 8 
 
1. Protocol Synopsis 
 
Title of Study: 
A randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of baricitinib in 
patients with moderate-to-severe atopic dermatitis. 
Rationale: 
Baricitinib is a JAK1/JAK2 selective inhibitor that is currently in development for treatment of inflammatory   
diseases such as rheumatoid arthritis and psoriasis. Baricitinib has been administered to healthy subjects and patients 
with rheumatoid arthritis (RA), moderate-to-severe plaque stage psoriasis, and diabetic nephropathy  (DN). 
In addition, baricitinib is also being developed for the treatment of atopic dermatitis (AD). This study will evaluate 
the safety and efficacy of baricitinib in patients with moderate-to-severe atopic  dermatitis. 
Objective(s)/Endpoints: 
 
Objectives 
Endpoints 
Primary 
To compare the proportion of moderate-to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose group (2 mg and 4 mg) and placebo 
when treated daily for 16 weeks 
Secondary 
To evaluate the absolute and percent change from baseline of the EASI with 
baricitinib compared to placebo at weeks 1 and 4 and monthly intervals  thereafter 
To evaluate the mean change from baseline of the SCORing Atopic Dermatitis 
(SCORAD) with baricitinib compared to placebo at weeks 1 and 4 and monthly 
intervals thereafter 
To evaluate the mean change from baseline of the Investigator’s Global 
Assessment (IGA) with baricitinib compared to placebo at weeks 1 and 4 and 
monthly intervals thereafter 
To assess quality of life based on the Dermatologic Life Quality Index (DLQI) at 
baseline, weeks 1 and 4 and monthly intervals  thereafter 
To assess itch using the itch numerical rating scale (NRS) at baseline, weeks 1 
and 4 and monthly intervals thereafter 
To evaluate the pharmacokinetics of baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 
 
Summary of Study Design: 
 
Study I4V-MC-JAHG is a multicenter, randomized, double-blind, parallel, placebo-controlled study designed to 
compare the efficacy and safety of baricitinib to placebo in patients with moderate-to-severe atopic dermatitis. 
Enrollment will be targeted at 120 patients to enable approximately 96 patients to complete the study. Patients who 
meet all eligibility criteria will be randomized to receive either placebo or baricitinib, administered as once daily   
oral doses of 2 mg or 4 mg.  Randomization will occur at the country  level. 
Treatment Arms and Duration: 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 89 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 9 
 
Three arms will be randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, respectively. Study drug will 
be administered as oral tablets to be taken once-daily (QD) for 16 weeks. A background therapy of a mid-potency 
topical corticosteroid (triamcinolone 0.1%) will be utilized during the 28-day standardization phase prior to 
randomization and continued throughout the study. This background therapy should be used according to the  
labeling provided by the manufacturer or as directed by the  investigator. 
Number of Patients:  120 
 
Statistical Analysis: 
 
Sample Size 
The study will plan to enroll 120 patients that will be randomized 4:3:3 to 
placebo, 2 mg baricitinib, or 4 mg baricitinib,  respectively. 
Primary Outcome & Methodology 
The primary outcome parameter is the proportion of patients achieving 
EASI-50 in each treatment arm. The placebo arm will be compared to each 
of the baricitinib arms using a two-sided chi-square test with alpha=0.05 to 
control the study-wise type 1 error rate; the comparison of the baricitinib 
arms with the placebo arm will be performed in a stepwise fashion.  The 
4-mg baricitinib arm will be compared with the placebo arm; if this test is 
statistically significant, then the 2-mg baricitinib arm will be compared with 
the placebo arm. Enrollment of 120 patients in a 4:3:3 ratio provides 
approximately 90% power for detecting a 35% difference in response rate 
between placebo and 4-mg baricitinib treatment. 
Interim Analysis 
An interim analysis is not planned for this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 90 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 10 
 
 
 
2.1. Background 
2. Introduction 
Atopic dermatitis (AD) is a common skin disorder characterized clinically by chronic 
inflammation and altered skin barrier function, and histologically by skin infiltration of 
inflammatory cells. AD is characterized by excessive T-cell activation, with significant skin 
infiltration by T-cells and dendritic cells. Both Th2 and Th22 activation are hallmarks of AD, 
with some Th17 and Th1 components. Patients with moderate-to-severe AD are afflicted with a 
heavy disease burden including medical as well as psycho-social abnormalities. Patients often 
have bacterial- or viral-mediated cutaneous complications. AD is the most common chronic 
inflammatory skin disease (Schmitt, 2013) with a prevalence of 2%–10% among adults in 
western geographies (Bieber, 2010) and a prevalence of about 3% in Japan (Muto et al,   2003). 
Studies using genomic and histologic profiling of AD skin have defined sets of biomarkers for  
AD that include markers of epidermal hyperplasia (epidermal thickness, K16 and Ki67 staining), 
epidermal barrier components (filaggrin), specific cellular infiltrates, including T-cells (CD3+  
and CD8+) and several dendritic cell subsets (CD11c+, CD1a+, inflammatory dendritic   
epidermal cells). Serum biomarkers that correlate with disease activity include IgE, eosinophils, 
eosinophilic cationic protein, as well as the Th2 chemokines CCL17, CCL18, CCL22, CCL11, 
and CCL26, and the cytokines IL-13, IL-31, and IL-22 (Mansouri,  2015). 
Members of the Janus kinase (JAK) family of protein tyrosine kinases (JAK1, JAK2, JAK3, and 
TYK2), along with the signal transduction and activator of transcription (STAT) pathway, play   
an important role in signal transduction following cytokine and growth factor binding to their 
receptors (Pesu, 2008). Emerging data support the role of JAK and STAT in Th2 immunity, 
activating eosinophils, and suppressing regulatory T cells. The JAK-STAT pathway, activated by 
IL-4, plays a critical role in the pathogenesis of AD by upregulating epidermal chemokines, pro- 
inflammatory cytokines, and proangiogenic factors as well as by down-regulating antimicrobial 
peptides and factors responsible for skin barrier function (Bao, 2013). Consistent with the  
proposed role of IL-4 activation of the JAK-STAT pathway in AD, administration of a  
monoclonal antibody against the alpha subunit of the IL-4 receptor improved clinical endpoints 
associated with AD (Beck, 2014). 
Baricitinib (also previously known as LY3009104 and INCB028050) is a potent and selective 
small molecule inhibitor of JAK1 and JAK 2 enzymes that is currently under development for 
the treatment of inflammatory conditions such as rheumatoid arthritis, diabetic kidney disease, 
psoriasis, and AD. 
Through 04 June 2015, approximately 4300 subjects have received baricitinib. This group of 
subjects was comprised of healthy subjects and patients with rheumatoid arthritis, psoriasis, 
diabetic kidney disease, rare auto-inflammatory syndromes, various degrees of renal impairment, 
and hepatic dysfunction. Baricitinib has been administered as single doses ranging from 1 to 40 
mg, multiple doses of up to 20 mg QD for 10 days, 10 mg QD for 28 days or 5 mg twice daily    
for 28 days in healthy subjects; and as a single 10-mg or 5-mg dose to subjects with mild to 
moderate or severe renal impairment respectively, as well as a single 5-mg dose to patients   with 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 91 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 11 
 
end stage renal disease. Treatment duration has ranged from single doses in healthy volunteers  
to approximately 3.5 years in rheumatoid arthritis  patients. 
More information about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably anticipated adverse events (AEs) of baricitinib are to be found in the 
Investigator’s Brochure (IB). 
 
2.2. Study Rationale 
Inhibition of JAK-STAT signaling by targeting multiple AD-associated cytokine pathways has 
the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key 
immune cells. Treatment of six patients with AD with a JAK1 and JAK3 inhibitor, tofacitinib,  
led to marked improvement in both objective measures of dermatitis and pruritus and patient- 
reported pruritus (Levy, 2015). 
Baricitinib is a potent and selective small molecule inhibitor of JAK1/2 enzymes. In vitro, 
baricitinib inhibits JAK1 and JAK2 with IC50 values in the single-digit nM range, yet it does not 
significantly inhibit a diverse panel of 28 kinases when tested at 100-fold of the IC50 against  
JAK1 and JAK2. In healthy volunteers, baricitinib demonstrated dose and time-dependent 
inhibition of cytokine-induced pSTAT3 (Shi,  2014). 
Study I4V-MC-JAHG will evaluate the safety and efficacy of baricitinib in patients with 
moderate-to-severe atopic dermatitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 92 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 12 
 
3. Objectives and Endpoints 
Table JAHG.1 shows the objectives and endpoints of the  study. 
 
Table JAHG.1. 
Objectives and Endpoints 
 
Objectives 
Endpoints 
Primary 
 To compare the proportion of moderate- 
to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in 
the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose 
group (2 mg and 4 mg) and placebo when 
treated daily for 16 weeks 
 EASI-50 at 16 weeks 
Secondary 
 To evaluate the absolute and percent 
change from baseline of the EASI with 
baricitinib compared to placebo 
 EASI at Weeks 1, 4, 8, 12, and 16 
 To evaluate the mean change from 
baseline compared to placebo for the 
SCORing Atopic Dermatitis  (SCORAD) 
 SCORAD at  Weeks 1, 4, 8, 12, and  16 
 To evaluate the mean change from 
baseline compared to placebo for the 
Investigator’s Global Assessment  (IGA) 
 IGA at Weeks 1, 4, 8, 12, and 16 
 To assess quality of life based on the 
Dermatologic Life Quality Index (DLQI) 
 DLQI at Weeks 1, 4, 8, 12, and 16 
 
To assess itch based on the Itch 
Numerical Rating Scale (NRS) 
 Itch Numerical Rating Scale at Weeks 1, 
4, 8, 12, and 16 
 To characterize the pharmacokinetics of 
baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 Plasma pharmacokinetic data 
Exploratory 
 To evaluate EASI response in patients 
based on their baseline total serum  IgE 
 EASI at Weeks 1, 4, 8, 12 and 16; baseline 
total serum IgE 
 To evaluate total serum IgE over the 
course of treatment 
 Total serum IgE at baseline, Weeks 4, and 
16 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 93 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 13 
 
Exploratory (continued) 
 To evaluate changes in disease activity 
over the course of treatment 
 Patient-Oriented Eczema Measure (POEM) 
at  Weeks 1, 4, 8, 12, and 16 
 To evaluate changes in sleep quality over 
the course of treatment 
 Number of sleep disturbances and average 
percentage of sleep time from a wearable 
actigraphy device 
 To evaluate changes in nocturnal itch 
patterns over the course of treatment 
 Number of scratching events per night from 
a wearable actigraphy device 
 To evaluate EASI response relative to 
filaggrin genotype 
 EASI-50 and filaggrin genotype data from 
peripheral baseline blood sample 
 To assess tissue biomarkers from  biopsies 
 K16, Ki-67, and IL-4 will be assessed from 
each tissue biopsy (collected at baseline 
(lesion and non-lesion), at Week 4 (lesion), 
and at Week 16 (lesion and  non-lesion) 
 To assess peripheral biomarkers 
mechanistically related to inhibition of 
JAK 1/2 mechanism 
 Peripheral biomarkers collected at baseline, 
Weeks 4 and 16 
 To perform subgroup assessments of 
response based on patient and disease 
characteristics 
 Ad hoc evaluation of potential prognostic 
and predictive disease characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 94 
LY3009104 
 
 
4 mg baricitinib 
2 mg baricitinib 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 14 
 
4. Study Design 
4.1. Overview of Study Design 
I4V-MC-JAHG is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the 
safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The study 
design is illustrated in Figure JAHG.1. 
Standardization 
Treatment 
Follow-up 
 
 
 
 
120 AD 
Patients 
Placebo 
4 Weeks 
16 Weeks 
4 Weeks 
Visit: 
1 
2 
3 
4 
5 
6 
7 
8 
Week: 
-4 
0 
1 
4 
8 
12 
16 
20 
Day: 
-28 
0 
7 
28 
56 
84 
112 
140 
 
 
 
Screening Randomization 
(4:3:3) 
Placebo : 2 mg baricitinib : 4 mg baricitinib 
 
Figure JAHG.1. 
Illustration of study design for Clinical Protocol I4V-MC-JAHG. 
 
 
 
4.2. Scientific Rationale for Study Design 
This study will enroll moderate-to-severe atopic dermatitis patients for whom a systemic 
treatment such as baricitinib may be appropriate. A 16-week course of treatment is expected to 
enable an optimal assessment of efficacy based on previous baricitinib studies in an 
inflammatory skin condition. 
Relatively high (20% to 50%) placebo responses have been observed in previously published 
atopic dermatitis studies (Bissonnette, 2012; Beck, 2014; Epstein and Pinski, 1964). Therefore, a 
4:3:3 randomization scheme of placebo, 2 mg baricitinib, and 4 mg baricitinib will be 
implemented.   Increased placebo enrollment across treatment groups has been reported to  
decrease placebo response and to also increase statistical power (Mallinckrodt,   2011). 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 95 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 15 
 
A standardization phase will be incorporated prior to randomization to minimize effects due to 
background treatment. Beginning at standardization and continuing throughout the study, 
patients will be provided a topical corticosteroid to be used as prescribed and may continue use 
of other allowed study-specified palliative care measures as specified in Section   6.8. 
The EASI and SCORAD are the best instruments available to measure clinical severity of AD 
(Schmitt, 2013). Several quality of life assessments are being utilized to evaluate the effect of 
baricitinib on patients’ quality of life. 
 
4.3. Justification for Dose 
This study will evaluate the safety and efficacy of 2-mg and 4-mg doses of baricitinib in patients 
with moderate-to-severe atopic dermatitis. The dose justification for AD is based on a Phase 2 
rheumatoid arthritis (RA) study (Study JADA), reported Phase 3 RA studies (Study JADW and 
Study JADX) and a Phase 2 psoriasis study (Study  JADP). 
In these studies, all doses were generally well tolerated based on the observed adverse event 
profile and infrequent discontinuations of baricitinib dosing. The anticipated on-target, dose- 
limiting effect is a small decline in hemoglobin and hematocrit values. As described in Section 
4.4, this likely results from inhibition of erythropoietin signals via the JAK2/STAT5 signal 
transduction pathway (Klingmüller, 1997; Vera, 2008). These hematologic effects occur in 
higher-dose groups (8 mg daily) upon initiation of treatment and then   stabilize. 
The 2-mg and 4-mg doses have shown efficacy in RA with an acceptable safety profile. There  
was no additional efficacy associated with an 8-mg dose in the Phase 2 RA study, thus only 4 mg 
and 2 mg have been studied in the RA Phase 3 program. Doses less than 2 mg were not clearly 
effective in RA. 
In patients with moderate-to-severe plaque stage psoriasis, doses of 4 mg to 10 mg were found to 
be associated with statistically significant reductions in Psoriasis Area and Severity Index (PASI) 
score, with greater efficacy at the higher doses; however, the 8-mg and 10-mg doses were 
associated with a higher rate of AEs related to laboratory abnormalities (decreases in    
hemoglobin, neutrophils, and lymphocytes). The 2-mg and 4-mg dose groups had a pattern of   
AEs similar to placebo. The 2-mg dose did show numeric reductions in PASI score compared   
with placebo and statistically significant reductions in itch. Thus, in AD, the highest dose to be 
tested will be 4 mg, which would be anticipated to show efficacy together with an acceptable  
safety profile, and also provide the opportunity to cross reference to the large safety database   
from the RA Phase 3 program. The lower dose of 2 mg also has the opportunity to show efficacy  
in AD, where itch is a major component of the disease and may provide data that may be useful    
in the future for patients less than 18 years of  age. 
 
4.4. Benefit/Risk Assessment 
Baricitinib is a specific inhibitor of JAK1/2 and may offer potential benefit to patients with 
moderate-to-severe AD. Increases in serum creatinine and in both LDL and HDL cholesterol 
have been observed in Phase 1 and 2 studies with baricitinib (see Investigator’s   Brochure). 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 96 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 16 
 
Baricitinib is a specific inhibitor of JAK1/2 that has shown to be well-tolerated and effective in 
chronic inflammatory conditions such as rheumatoid arthritis (Keystone, 2015) and psoriasis 
(Menter, 2014). Baricitinib may offer potential benefit in a chronic inflammatory dermatologic 
condition such as AD. 
Phase 1 and 2 studies with baricitinib showed increased levels of serum creatinine and LDL and 
HDL cholesterol (see Investigator’s Brochure). Similar increased levels of creatinine and 
cholesterol were also seen in tofacitinib, a JAK1/3 inhibitor (Fleischmann, 2012; Kremer, 2012). 
In addition, reductions in absolute neutrophil counts have been reported with both baricitinib and 
tofacitinib. Other pathways that signal through JAK include granulocyte macrophage colony 
stimulating factor and granulocyte colony stimulating factor signal and erythropoietin (JAK2) 
(Parganas, 1998). The assessment of safety of baricitinib in this study will therefore also include, 
but will not be limited to, monitoring of creatinine, cholesterol, neutrophil and granulocyte  
counts, hemoglobin levels, and rates of  infection. 
More information about the known and expected benefits, risks, and reasonably anticipated  
adverse events may be found in the Investigator’s Brochure. Information on adverse events 
expected to be related to the investigational product may be found in Section 7 (Development  
Core Safety Information) of the Investigator’s Brochure. Information on serious adverse events 
expected in the study population independent of drug exposure will be assessed by the sponsor in 
aggregate periodically during the course of the study and may be found in Section 6 (Effects in 
Humans) of the Investigator’s  Brochure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 97 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 17 
 
5. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, will not be  permitted. 
 
5.1. Inclusion Criteria 
Patients are eligible to be included in the study only if they meet all of the following   criteria: 
Type of Patient and Disease  Characteristics 
[1] Are at least 18 years of age at the time of Visit  1 
[2] Have moderate-to-severe AD, as determined by all of the  following: 
 EASI ≥12 at Visits 1 and 2 
 ≥10% of body surface area (BSA) involvement at Visits 1 and  2 
 Were diagnosed with AD at least 2 years before Visit  1 
With a history of inadequate clinical response, in the opinion of the 
investigator, to one or more of the three treatment categories listed below 
(used for at least 4 weeks): 
 Category 1: Hydration plus topical steroids and/or antibiotics (e.g., 
tetracycline, trimethoprim and sulfamethoxazole, cephalosporins) and/or 
topical immune modulators (e.g.,  tacrolimus/pimecrolimus) 
 Category 2:   Systemic steroids and/or phototherapy 
 Category 3: Cyclosporine and/or other immunomodulators (e.g., 
methotrexate, mycophenolate mofetal, and  azathioprine) 
[3] Agree to discontinue use of the following excluded medications for at least 4 
weeks prior to randomization (Visit 2) and throughout the  study 
 oral cyclosporine, steroids, and leukotriene  inhibitors 
 phototherapy 
 potent topical steroids (e.g., clobetasol) or topical immune modulators 
(e.g., tacrolimus/pimecrolimus). 
 cyclosporine and/or other immunomodulators (e.g., methotrexate, 
mycophenolate mofetal, and  azathioprine) 
 
5.2. Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
Medical Conditions 
[4] Are female subjects who are pregnant or  nursing 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 98 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 18 
 
[5] Are females of childbearing potential who do not agree to use 2 forms of  
highly effective methods of birth control or remain abstinent while enrolled in 
the study and for at least 28 days following the last dose of investigational 
product 
Note: Females of nonchildbearing potential are defined as women ≥60 years 
of age, or women >40 and <60 years of age who have had a cessation of 
menses for at least 12 months, or women who are congenitally or surgically 
sterile (that is, have had a hysterectomy or bilateral oophorectomy or tubal 
ligation). 
The following birth control methods are considered highly effective (the 
patient should choose 2): 
 Oral, injectable, or implanted hormonal  contraceptives 
 Condom with a spermicidal foam, gel, film, cream, or  suppository 
 Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal 
foam, gel, film, cream, or  suppository 
 Intrauterine device 
 Intrauterine system (for example, progestin-releasing  coil) 
 Vasectomized male (with appropriate post-vasectomy documentation 
of the absence of sperm in the  ejaculate). 
[6] 
Are males who do not agree to use 2 forms of highly effective birth control 
(see above) with female partners of childbearing potential while enrolled in 
the study, and for at least 28 days following the last dose of investigational 
product 
Are currently experiencing or have a history of any of the  following: 
[7] Other concomitant skin conditions (e.g., psoriasis, or lupus erythematosus) 
that would interfere with evaluations of the effect of study medication on 
atopic dermatitis 
[8] Erythrodermic, refractory or unstable skin disease that requires frequent 
hospitalizations and/or intravenous treatment for skin  infections 
[9] Immunocompromised and, in the opinion of the investigator, at an 
unacceptable risk for participating in the  study 
[10] Serious concomitant illness that could require the use of systemic 
corticosteroids or otherwise interfere with study participation or require active 
frequent monitoring (e.g., unstable chronic  asthma) 
[11] Organ transplant(s) (corneal transplant performed >3 months prior to 
screening may be allowed) 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 99 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 19 
 
[12] Clinically important deviation, in the opinion of the investigator, from normal 
limits in physical examination, vital sign measurements, and/or 
electrocardiograms, that is not associated with a chronic, well-controlled 
medical condition 
[13] Electrocardiogram (ECG) abnormalities at Visit 1 that, in the opinion of the 
investigator or the sponsor, are clinically significant and indicate an 
unacceptable risk for the patient’s participation in the study (Bazett’s 
corrected QT interval >470 msec for men and  women) 
[14] Have evidence of active or latent TB as documented by a positive PPD test 
(≥5 mm in duration between approximately 2 and 3 days after application, 
regardless of vaccination history), medical history, and chest x-ray at 
screening. Exceptions are patients with a history of latent TB who have 
documented evidence of completing a course of appropriate  treatment. 
 If the PPD test is positive or not conducted and the patient has no medical 
history or chest x-ray findings consistent with active or latent TB, the 
patient should have a QuantiFERON®-TB Gold test or the T-SPOT.TB® 
test. If either of these tests is positive or indeterminate (a single re-test is 
allowed), the patient is excluded from the  study. 
[15] Active or latent granulomatous disorders or a non-tuberculous mycobacterial 
infection or opportunistic systemic infection (e.g., Pneumocystis carinii, and 
aspergillosis) within 6 months prior to  screening 
[16] Uncompensated heart failure, fluid overload, myocardial infarction, or 
evidence of ischemic heart disease or other serious cardiac disease within 12 
weeks of Visit 1 
[17] Uncontrolled arterial hypertension characterized by a repeated systolic blood 
pressure >160mm Hg or diastolic blood pressure >100mm Hg at the time of 
Visit 1 
[18] Have, or have a history of, lymphoproliferative disease; or signs or symptoms 
suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly; or active primary or recurrent malignant 
disease; or been in remission from clinically significant malignancy for less 
than 5 years. 
Note: Patients with cervical carcinoma in situ that has been resected with no 
evidence of recurrence or metastatic disease, or with basal cell or squamous 
epithelial skin cancers that have been completely resected with no evidence of 
recurrence for at least 3 years may participate in the  study. 
[19] Evidence of HIV infection or are positive for HIV antibodies (based on 
history or point-of-care testing (POCT)) at Visit  1 
[20] Positive test for hepatitis B defined as: 
a) positive for hepatitis B surface antigen (HBsAg),  or 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 100 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 20 
 
b) positive for anti-hepatitis B core antibody (HBcAb) and positive for hepatitis B 
deoxyribonucleic acid (HBV DNA), or 
c) for patients enrolled in Japan only, positive for anti-hepatitis B core antibody 
(HBcAb) and/or positive for anti-hepatitis B surface antibody (HBsAb), and 
positive for hepatitis B deoxyribonucleic acid (HBV  DNA). 
 
If any of the hepatitis B tests have an indeterminate result, confirmatory testing will 
be performed by an alternate method. 
 
[21] Positive for anti-hepatitis C antibody with confirmed presence of hepatitis C 
virus, or chronic liver disease with the most recent available AST or ALT >2X 
the ULN 
[22] Serious and/or unstable mental and/or physical illness that, in the opinion of 
the investigator, poses an unacceptable risk for the patient’s participation in 
the study 
Prior/Concomitant Therapy 
[23] Received any oral JAK inhibitor (e.g., Xeljanz) within the past 6  months 
[24] Currently receiving any immunosuppressive therapy (e.g.,  cyclosporine) 
[25] Received any monoclonal antibody intended for AD (e.g., ustekinumab or 
dupilumab) within the past 6  months. 
[26] Currently using or expected to use concomitant medications or treatments for 
AD other than those allowed for use in the  protocol 
[27] Exposed to a live vaccine, including the nasal flu vaccine, within 12 weeks 
prior to planned enrollment (with the exception of herpes zoster vaccination; 
patients will be excluded if they were exposed to herpes zoster vaccination 
within 30 days of planned enrollment) or are expected to need/receive a live 
vaccine during the course of the  study. 
Prior/Concurrent Clinical Trial  Experience 
[28] Currently enrolled in any other clinical study involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this  study 
[29] Participated, within the last 30 days (for Japan, 4 months) in a clinical study 
involving an investigational product. If the previous investigational product 
has a long half-life (2 weeks or longer), at least 3 months or 5 half-lives 
(whichever is longer) should have  passed. 
[30] Previously completed or withdrawn from this  study 
Diagnostics Assessments 
Have any of the following specific abnormalities on screening laboratory   tests: 
[31] AST or ALT >2X the ULN 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 101 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 21 
 
[32] Total bilirubin ≥1.5X the ULN 
[33] Hemoglobin < LLN 
[34] Total white blood cell count <  LLN 
[35] Neutropenia (absolute neutrophil count <  LLN) 
[36] Lymphopenia (lymphocyte count <  LLN) 
[37] Thrombocytopenia (platelets < LLN) 
[38] eGFR <50 mL/min/1.73 m2 (based on CKD  EPI) 
Note: In the case of any of the aforementioned laboratory abnormalities, they may 
be repeated once within 1 week of the initial values, and values resulting from  
repeat testing may be used to assess enrollment  eligibility. 
Other Exclusions 
[39] 
Donated blood of more than 500 mL or blood products within 4 weeks 
prior to entry. 
[40] 
Unwilling to commit to refrain from donating blood or blood products 
during the study. 
[41] 
History of substance abuse (drug or alcohol) within the two years before 
screening. 
[42] 
Unable or unwilling to be available for the duration of the study and/or are 
unwilling to follow study  restrictions/procedures. 
[43] 
Unable or unwilling to have skin biopsies performed, unless exempted by 
the investigator. 
[44] 
Investigator site personnel directly affiliated with this study and/or their 
immediate families; immediate family is defined as a spouse, parent, child, 
or sibling, whether biological or legally  adopted. 
[45] 
Employees of the sponsor. 
 
5.3. Screen Failures 
Individuals who do not meet the criteria for participation in this study (screen failure) may be re- 
screened. Individuals may be re-screened once (time period from screen fail to re-screen to be 
determined by the investigator). If re-screening is performed, the individual must sign a new 
informed consent form (ICF) and will be assigned a new identification number. Additionally, all 
screening procedures must be conducted at re-screen to ensure all eligibility criteria are   met. 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 102 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 22 
 
6. Treatment 
6.1. Treatments Administered 
This study includes the treatment regimens outlined in Table JAHG.2 below. Doses of baricitinib 
or placebo will be administered orally. 
 
 
Table JAHG.2. 
Treatment Regimens 
 
    Treatment Group 
Dose (QD) 
Day 1 through Day 112 
2 mg LY 
(1  2-mg LY tab; 1  4-mg placebo tab) 
4 mg LY 
(1  2-mg placebo tab; 1  4-mg LY tab) 
Placebo 
(1  2-mg placebo tab; 1  4-mg placebo tab) 
Abbreviations:  tab = tablet; LY = baricitinib 
 
 
The investigator or his/her designee is responsible for the  following: 
 explaining and verifying the correct use of the investigational agent(s) to the 
patient and site personnel 
 maintaining accurate records of investigational product dispensing and   collection 
 returning, at the end of the study, all unused investigational product to the 
sponsor, or its designee, unless the sponsor and sites have agreed all unused 
medication is to be destroyed by the site, as allowed by local  law 
 
6.2. Method of Treatment Assignment 
Patients who meet all criteria for enrollment will be randomized to double-blind treatment at   
Visit 2. Assignment to treatment groups will be determined by a computer-generated random 
sequence using an interactive response technology (IRT) system. The IRT system will be used to 
assign blister packs containing double-blind investigational product to each patient. The IRT 
system will dispense a number of blister packs adequate for each visit   interval. 
The randomization will be stratified by  country. 
 
6.2.1. Selection and Timing of Doses 
Patient treatment assignments will be based on the randomization scheme as described   above. 
On PK sample collection days (Appendix 2), specific fasting and dose timing requirements are 
outlined in Table JAHG.5 (Section  8.5.1). 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 103 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 23 
 
6.3. Blinding 
This is a double-blind study in which the patients, investigator, and study site personnel will be 
blinded to treatment allocation. 
To preserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is   complete. 
Emergency unblinding for AEs may be performed through an IRT system, which may  
supplement or take the place of emergency codes generated by a computer drug-labeling system. 
This option may be used ONLY if the patient’s well-being requires knowledge of the patient’s 
treatment assignment. All calls resulting in an unblinding event are recorded and reported by the 
IRT system. 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warranted. Patient safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the sponsor CRP prior to  
unblinding a patient’s treatment  assignment. 
If an investigator, site personnel performing assessments, or patient is unblinded to the treatment 
code assignment, the sponsor must be contacted  immediately. 
 
6.4. Packaging and Labeling 
The sponsor (or its designee) will provide the following investigational   products: 
 tablets containing 2 mg of baricitinib 
 tablets containing 4 mg of baricitinib 
 placebo to match baricitinib 2 mg tablets 
 placebo to match baricitinib 4 mg tablets 
Additionally, the sponsor (or its designee) will also provide the following concomitant therapy 
product: 
 triamcinolone 0.1% cream which should be used according to the labeling provided 
by the manufacturer or as directed by the  investigator 
Investigational products and triamcinolone 0.1% cream will be dispensed to the patient at the 
investigator’s study site. 
Investigational product will be packaged in blister packs. Investigational product packaging will 
be labeled with a unique identifier for drug dispensing by the IRT system. Blister packs will 
contain additional tablets to allow for sufficient administration of investigational product within 
the allowed visit internal window. 
Investigational product will be labeled according to the country’s regulatory requirements. All 
investigational products will be stored, inventoried, reconciled, and destroyed according to 
applicable regulations. Investigational products will be manufactured and tested by the sponsor 
or its representative in accordance with current Good Manufacturing Practices   (cGMP) 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 104 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 24 
 
requirements for clinical studies, and will be supplied with lot numbers, expiry dates, and 
certificates of analysis (as applicable). 
 
6.5. Investigational Products Storage and  Handling 
Investigational products should be stored between 15°C and 30°C. All investigational products 
should be stored in a secure and locked area with strictly limited access and monitored for 
temperature and will be allocated and dispensed by appropriately trained   personnel. 
 
6.6. Dose Modification 
No dose modifications will be  allowed. 
 
6.7. Treatment Compliance 
Patient compliance with study medication will be assessed at each visit. Compliance will be 
assessed by counting returned tablets. Deviation(s) from the prescribed dosage regimen should 
be recorded in the CRF. 
The patient will be considered significantly noncompliant if he or she misses more than 20% of 
the prescribed doses during the study. Similarly, a patient will be considered significantly 
noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken 
more than the prescribed amount of  medication. 
Patients found to be noncompliant with investigational product should be assessed to determine 
the reason for noncompliance, and educated and/or managed as deemed appropriate by the 
investigator to improve compliance. 
 
6.8. Concomitant Therapy 
The use of triamcinolone 0.1% cream will be allowed throughout the trial. Patients will be 
instructed to apply the triamcinolone 0.1% cream according to the labeling provided by the 
manufacturer or as directed by the investigator. The triamcinolone 0.1% cream container will be 
weighed at each visit to assess usage. 
All other concomitant medication taken during the study must be recorded on the Concomitant 
Medication case report form (CRF). Treatment with concomitant atopic dermatitis therapies 
during the study is permitted only as outlined in the inclusion/exclusion criteria (Section 5.1 and 
Section 5.2) and as described in the paragraphs  below. 
Additional systemic drugs are to be avoided during the study, unless required to treat an   AE. 
Non-live seasonal vaccinations and/or emergency vaccination (such as rabies or tetanus 
vaccinations) are allowed. 
The following will be allowed as needed: use of topical antibiotics in the event of secondary 
infections of lesions; nonprescription shampoos; NSAIDs; diphenhydramine (50 mg); and 
topical moisturizers/emollients, bath oils, oatmeal bath preparations, bleach baths if using a  
stable regimen prior to enrollment, and salicylic acid preparations.  Patients will be instructed   to 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 105 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 25 
 
consult the investigator or other appropriate study personnel at the site before taking any new 
medications or supplements. 
 
6.9. Treatment after Study Completion 
6.9.1.   Continued Access 
The Investigational Product will not be made available to patients after the conclusion of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 106 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 26 
 
7. Discontinuation Criteria 
7.1. Discontinuation of Investigational  Product 
7.1.1. Temporary Interruption of Investigational  Product 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs   
or abnormal laboratory values as described in Table JAHG.3 that may have an unclear  
relationship to investigational product. Except in cases of emergency, it is recommended that the 
investigator consult with the sponsor (or its designee) before temporarily interrupting   therapy. 
The investigator must obtain approval from the sponsor (or its designee) before restarting 
investigational product that was temporarily discontinued because of an AE or abnormal 
laboratory value. Investigational product must be held in the following situations involving 
laboratory abnormalities and may be resumed as noted in Table  JAHG.3. 
 
Table JAHG.3. 
Criteria for Temporary Interruption from Study Treatment 
 
 
Hold Investigational Product if the Following 
Laboratory Test Results Occur: 
Investigational Product May Be Resumed after 
Approval from Lilly (or its Designee) and When: 
eGFR <40 mL/min/1.73 m2 (from serum 
 creatinine) 
eGFR 50 mL/min/1.73 m2 
ALT or AST >5 times the ULN 
ALT and AST return to <2 times the ULN, and 
investigational product is not considered to be the  cause 
of enzyme elevation 
Symptomatic herpes zoster 
All skin lesions have crusted and are resolving 
Severe infection that, in the opinion of the 
investigator, merits the investigational product 
 being discontinued 
Resolution of infection 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; min = minute; ULN = upper limit of normal; 
WBC = white blood cell. 
 
7.1.2. Permanent Discontinuation of Investigational  Product 
Any patient who is permanently discontinued from investigational product for an AE or  
abnormal laboratory result should have the reason for investigational product discontinuation 
reported as the AE or abnormal laboratory value. If any of the criteria listed in Section 7.1.1. 
above recur after investigational product is restarted, the investigator must obtain approval from 
the sponsor (or its designee) before restarting investigational product.  In addition, patients will  
be permanently discontinued from investigational product if they experience any of the criteria 
listed in Table JAHG.4. 
Any adverse event that is Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 
or higher will result in permanent discontinuation from the study except for transaminases and 
severe infection as noted in Table JAHG.3 and Table  JAHG.4. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 107 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 27 
 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product 
 
Permanently Discontinue Investigational Product if any of the Following are  Observed: 
ALT or AST >8 times the ULN 
ALT or AST >5 times the ULN persisting for more than 2 weeks after temporary interruption of investigational 
product 
ALT or AST >3 times the ULN and total bilirubin level >2 times the  ULN 
ALT or AST >3 times the ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) 
WBC count <3000 cells/L 
ANC <1500 cells/L 
Lymphocyte count <800 cells/L 
Hemoglobin <10 g/dL 
Platelet count <75,000/L 
Pregnancy 
Malignancy (except for successfully treated basal cell or squamous epithelial skin  cancers) 
HBV DNA ≥29 IU/mLa 
Score of 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any time during the   study 
 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; HBV DNA = hepatitis B virus deoxyribonucleic acid; ULN = upper limit of normal; 
WBC = white blood cell; QIDS-SR16 = Quick Inventory of Depressive Symptomatology-Self-Report   16. 
a If a HBV DNA result of ‘target detected’ 29 IU/mL or greater, then the patient should be referred to a hepatology 
specialist immediately. In selected cases, investigators may temporarily continue study drug in accordance with 
current immunomodulator management in the setting of HBV DNA positivity. This option may be considered in 
consultation with the sponsor (or its designee) and evaluation of individual patient risks and benefits. Refer to 
Section 8.4.5 for additional instruction on HBV DNA  monitoring. 
 
7.1.3. Discontinuation of Inadvertently Enrolled  Patients 
If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the sponsor CRP and the investigator to 
determine if the patient may continue in the study. If both agree it is medically appropriate to 
continue, the investigator must obtain documented approval from the sponsor CRP to allow the 
inadvertently enrolled patient to continue in the study with or without treatment with 
investigational product. 
 
7.1.4. Permanent Discontinuation from the  Study 
Some possible reasons that may lead to permanent discontinuation   include: 
 Enrollment in any other clinical study involving an investigational product or enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this study 
 Participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical practice   (GCP) 
 Investigator Decision 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 108 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 28 
 
o the investigator decides that the patient should be discontinued from the   study 
o if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new   agent 
 Patient  Decision 
Patients who discontinue the study early will have early termination (ET) procedures performed 
as shown in the Schedule of Activities (Appendix  2). 
 
7.1.5. Patients Lost to Follow-Up 
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make  
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 109 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 29 
 
8. Study Assessments and  Procedures 
Appendix 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for timing). 
Appendix 3 lists the laboratory tests that will be performed for this  study. 
Appendix 4 provides the hepatic monitoring tests for treatment-emergent   abnormalities. 
Additionally, a study addendum will be compiled to detail the capture of photographs from 
selected lesions for patients enrolled at up to three selected study sites. These photographs will 
permit documentation of the clinical response through sequential photography of a selected 
lesion or involved area before and following study drug  treatment. 
 
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results. Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards. 
 
8.1. Efficacy Assessments 
Study procedures and their timing are summarized in the Schedule of Activities (Appendix   2). 
 
8.1.1. Primary Efficacy Assessments 
The clinical outcome measure that will be used in this study is the EASI score (specifically, the 
proportion of patients achieving a 50% reduction in EASI or  EASI-50). 
 Eczema Area and Severity Index (EASI) scores: The EASI assesses extent of disease 
at four body sites and measures four clinical signs: (1) erythema, (2) 
induration/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3. 
EASI confers a maximum score of 72. EASI evaluates two dimensions of atopic 
dermatitis: disease extent and clinical signs.
 
8.1.2. Secondary Efficacy Assessments 
 Mean and Percentage change in Eczema Area and Severity Index (EASI) scores: See 
above.
 
 SCORing Atopic Dermatitis (SCORAD): The SCORAD index uses the rule of nines to 
assess disease extent and evaluates five clinical characteristics to determine disease 
severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) 
lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss 
with Visual Analogue Scales (VAS). These three aspects: extent of disease, disease 
severity and subjective symptoms combine to give a maximum possible score of 103.
 
 
Investigator’s Global Assessment (IGA): The IGA consists of a 6-point severity scale 
from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate 
disease, 4 = severe disease and 5 = very severe disease). IGA uses clinical characteristics
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 110 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 30 
 
of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall 
severity assessment. 
 
 
Dermatology Life Quality Index (DLQI): The DLQI is a simple, patient-administered, 
10-question, validated, quality-of-life questionnaire that covers 6 domains including 
symptoms and feelings, daily activities, leisure, work and school, personal relationships, 
and treatment. The recall period of this scale is over the “last week.” Response categories 
include “not at all,” “a lot,” and “very much,” with corresponding scores of 1, 2, and 3 
respectively and unanswered (“not relevant”) responses scored as 0. A DLQI total score 
of 0 to 1 is considered as having no effect on a patient’s health-related quality of life, and 
a 4-point change from baseline is considered as the minimal clinically important 
difference threshold (Khilji, 2002; Hongbo, 2005; Basra, 2015).
 
 
Itch Numerical Rating Scale (NRS): The Itch NRS is a patient-administered, 11 point 
horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 
representing “worst itch imaginable.”  Overall severity of a patient’s itching is 
indicated by circling the number that best describes the worst level of itching in the 
past 24 hours.
8.1.2.2 Exploratory Efficacy Assessments 
Data on the following exploratory efficacy measures will be collected at the times shown in the 
Schedule of Activities (Appendix 2): 
 Patient-Oriented Eczema Measure (POEM): The Patient-Oriented Eczema Measure 
(POEM) was originally developed to help address the imbalance between physician and 
patient-based outcome measures in eczema research. Patients answer simple questions 
about the frequency of seven symptoms: itch, sleep disturbance, skin bleeding, skin 
weeping/oozing, skin cracking, skin flaking, and skin dryness/roughness over the last 
week. The total score from this assessment reflects overall disease activity. The POEM 
utilizes a 5-point Likert scale for each question and is intended for ages 1-60 years. 
POEM scores can range from 0 to 28 where lower total scores reflect lower disease 
activity and higher scores reflect higher disease activity (Charman, 2004).
 
 Actigraphy Device: A hypoallergenic wrist watch-like device that is used to collect 
sleep/wake patterns and quantify nocturnal scratching events (Ferguson, 2015).
 
8.1.3. Appropriateness of Primary Efficacy  Measure 
 Eczema Area and Severity Index (EASI): The EASI is one of the best instruments 
available to measure clinical signs of AD. EASI utilizes objective physician estimates of 
disease extent and severity. The EASI is valid and internally consistent and has adequate 
intraobserver reliability, intermediate interobserver reliability, and adequate 
responsiveness. One advantage of the EASI is its unidimensionality; that is, it only 
measures clinical signs of AD and does not include symptoms. Another advantage of the 
EASI is that it measures the intensity of the lesions at multiple body parts (rather than 
relying on a representative lesion) (Schmitt, 2013).
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 111 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 31 
 
8.2. Adverse Events 
The investigator remains responsible for following, through an appropriate health care option,  
AEs that are (1) serious or otherwise medically important, (2) considered related to the 
investigational product or the study, or that (3) caused the patient to discontinue the  
investigational product before completing the study. The patient should be followed until the  
event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The 
frequency of follow-up evaluations of the AE is left to the discretion of the   investigator. 
The sponsor has standards for reporting AEs that are to be followed regardless of applicable 
regulatory requirements that may be less stringent. Study site personnel will record the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. All AEs collected in the study 
CRF will be validated and reported in the final study  report. 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect. 
After the ICF is signed, study site personnel will record, via the CRF/electronic data entry, the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. In addition, site personnel will 
record any change in the condition(s) and any new conditions as AEs. Investigators should  
record their assessment of the potential relatedness of each AE to protocol procedure or 
investigational product. 
Investigators must document their review of each laboratory safety  report. 
Any clinically significant findings from ECGs, laboratory tests, vital sign measurements, and 
other procedures that result in a diagnosis should be reported to the sponsor or its designee. In 
addition, all AEs occurring after the patient receives the first dose of the investigational product 
must be reported to the sponsor or its  designee. 
Investigators will be instructed to report to the sponsor or its designee their assessment of the 
potential relatedness of each AE to protocol procedure or investigational product via the case 
report form. 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the  study. 
Cases of pregnancy that occur during maternal or paternal exposures to the investigational   
product should be reported. Data on fetal outcome and breast-feeding are collected for regulatory 
reporting and drug safety evaluation. 
Study site personnel must alert the sponsor or its designee immediately of the investigator 
unblinding a patient’s treatment group assignment for any  reason. 
If a patient’s treatment is discontinued as a result of an AE, study site personnel must clearly 
report to the sponsor or its designee the circumstances and data leading to any such 
discontinuation of treatment. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 112 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 32 
 
8.2.1. Adverse Events/Laboratory Results of Special Interest  
Adverse events or laboratory results of special interest include infections; myelosuppressive 
events of anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia; thrombocytosis; 
hyperlipidemia; hypercholesterolemia; and elevations in ALT/AST (≥3X ULN) and total 
bilirubin (≥2X ULN). 
8.2.2. Serious Adverse Events 
Study site personnel must alert the sponsor or its designee of any SAE within 24 hours of 
investigator awareness of the event via a sponsor-approved method. Alerts issued via telephone 
are to be immediately followed with official notification on study-specific SAE   forms. 
All SAEs will be reported in the study CRF and on the approved study-specific SAE form by the 
study site personnel. In addition, the study-specific SAE forms will be collected by 
sponsor/designee and subsequently entered into the clinical study database and the study safety 
database. Investigators will be required to update the study-specific SAE forms when new 
information becomes available, and address questions from the sponsor/designee until the SAE  
has been fully resolved or explained to the satisfaction of the sponsor. The SAE data from both 
CRF and study-specific SAE forms will be validated and included in the final CSR. If the SAE 
cases are closed after the completion of database lock, such information may not be included in  
the final study report. Such additional information will continue to be collected in the study- 
specific SAE form, and be reported either in an amendment to study report if such information 
leads to clinically significant change(s) in the conclusion of the study; or in the annual 
Development Safety Update Report (DSUR) or IB update if the information from the SAE does 
not alter the overall conclusion of the  study. 
An SAE is any AE from this study that results in one of the following   outcomes: 
 death 
 initial or prolonged inpatient  hospitalization 
 a life-threatening experience (that is, immediate risk of  dying) 
 persistent or significant  disability/incapacity 
 congenital anomaly/birth defect 
 considered significant by the investigator for any other  reason 
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Previously planned (prior to signing of ICF) surgeries should  
not be reported as SAEs unless the underlying medical condition has worsened during the course 
of the study. 
SAEs occurring after a patient has taken the last dose of the investigational product will be 
collected in the pharmacovigilance system and clinical data collection database for 30 days after 
the last dose of the investigational product, regardless of the investigator’s opinion of   causation. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 113 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 33 
 
Thereafter, SAEs are not required to be reported unless the investigator feels the events were 
related to either investigational product, drug delivery system, or a protocol   procedure. 
Sponsor/designee has the option to request follow up information or clarification of existing 
information from the investigators up to closure of the case. SAEs should be followed by the 
investigator until resolution of all queries, clinical recovery is complete or until a stable clinical 
endpoint has been reached. Follow up may therefore continue after the patient has been  
discharged from the study. The type and extent of follow up undertaken will be determined for 
each individual case and depends upon the nature, severity, and medical significance of the  
report. The follow up may include supplemental investigations, additional laboratory tests, 
histopathological examinations, or consultations with other health care professionals. If a patient 
dies during participation in the study, the follow up may include a copy of any post-mortem 
findings, if available. 
The investigator site will be required to contact the patient in accordance with their procedures to 
obtain necessary information to provide updates to the study-specific SAE forms. Requests for 
outstanding information from the investigational site to patients should be maintained as part of  
the clinical study documents. 
8.2.2.1. 
Suspected Unexpected Serious Adverse  Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed   
in the IB and that the investigator identifies as related to investigational product or procedure. 
United States 21 CFR 312.32 and European Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participating countries  
require the reporting of SUSARs. The sponsor has procedures that will be followed for the 
recording and expedited reporting of SUSARs that are consistent with global regulations and the 
associated detailed guidances. 
 
8.2.3.   Complaint Handling 
The Sponsor collects product complaints on investigational products and drug delivery systems 
used in clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product  improvements. 
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be   assessed. 
 
8.3. Treatment of Overdose 
Refer to the baricitinib Investigator’s  Brochure. 
 
8.4. Safety Assessments 
Safety assessments include vital signs, physical examination, electrocardiograms, AEs, patient- 
reported scale data, and safety laboratory  testing. 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 114 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 34 
 
8.4.1. Physical Examination 
A complete physical examination will be performed during Visit 1 (screening). Directed physical 
examinations will be performed according to the Schedule of Activities (Appendix 2) and may    
be repeated at the investigator’s discretion any time a patient presents with physical   complaints. 
 
8.4.2. Electrocardiograms 
For each patient, an electrocardiogram (ECG) should be performed according to the Schedule of 
Activities (Appendix 2) and as deemed necessary by the  investigator. 
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient receives the first dose of the investigational treatment should be reported to Lilly or its 
designee as an AE via the CRF. 
 
8.4.3. Vital Signs 
For each patient, vital signs measurements should be conducted according to the Schedule of 
Activities (Appendix 2) and following study specific recommendations provided by the sponsor 
for the study. 
Any clinically significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
 
8.4.4. Laboratory Tests 
For each patient, laboratory tests detailed in (Appendix 3) should be conducted according to the 
Schedule of Activities (Appendix 2). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of investigational product should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
 
8.4.5. Hepatitis B virus (HBV) DNA  monitoring 
For US study sites, patients who are HBsAg negative, HBcAb positive, and HBV DNA negative 
(undetectable) at Visit 1 will require HBV DNA monitoring at Visits 5 and 8 or ET, regardless of 
their HBsAb status. 
For study sites in Japan only, patients who are HBsAg negative, HbcAb and/or HbsAb positive, 
and HBV DNA negative (undetectable) at Visit 1 will require HBV DNA monitoring at Visits 5 
and 8 or ET. 
If the HBV DNA result is ‘target detected’ ≥29 IU/mL at any point in the study, then the patient 
should be referred to a hepatology specialist immediately and discontinuation considered (refer   
to Table JAHG.4). In selected cases, investigators may temporarily continue study drug in 
accordance with current immunomodulator management in the setting of HBV DNA positivity. 
This option may be considered in consultation with the sponsor (or its designee) and evaluation  
of individual patient risks and  benefits. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 115 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 35 
 
8.4.6. Quick Inventory of Depressive Symptomatology-Self Report 16 
(QIDS-SR16) 
For each patient, the QIDS-SR16 should be administered according to the Schedule of Activities 
(Appendix 2). 
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and 
severity of symptoms of depression as listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (American 
Psychiatry Association [APA] 1994). The QIDS-SR16 scale is used to assess the potential  
impact of treatment on new onset or changes in depression, thoughts of death, and /or suicidal 
ideation severity. A patient is asked to consider each statement as it relates to the way they   have 
felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16 items 
corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, 
with higher scores denoting greater symptom severity. The domains assessed by the instrument 
include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) 
energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or   hypersomnia), 
(8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation (Rush,   2003). 
If an increase of 5 or more from the baseline QIDS-SR16 total score is noted, the patient should   
be evaluated on site for risk of suicide and/or referred to a mental health provider for   assessment. 
A patient who scores a 2 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be evaluated on site for risk of suicide and/or referred to a mental 
health provider for assessment. 
A patient who scores a 3 for Item 12 (Thoughts of Death or Suicide) on the QIDS-SR16 at any 
time during the study should be discontinued (Table  JAHG.4). 
 
8.4.7. Safety Monitoring 
The sponsor will periodically review evolving aggregate safety data within the study by 
appropriate methods. 
If a patient experiences elevated ALT ≥3X ULN, ALP ≥3X ULN, or elevated TBL ≥2X ULN, 
clinical and laboratory monitoring should be initiated by the investigator. Details for hepatic 
monitoring depend upon the severity and persistence of observed laboratory test abnormalities.  
To ensure patient safety and comply with regulatory guidance, the investigator is to consult with 
the sponsor CRP regarding collection of specific recommended clinical information and follow- 
up laboratory tests (Appendix 4). 
 
8.5. Pharmacokinetics 
8.5.1. PK Sample Collection 
A total of 6 venous blood samples (approximately 5 mL per sample) for the measurement of 
baricitinib concentrations will be drawn at visits scheduled within the time windows specified   in 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 116 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 36 
 
the Schedule of Activities (Appendix 2). Specific dosing and fasting requirements for each PK 
visit are described in Table JAHG.5  below. 
 
 
 
Table JAHG.5. 
Timing of Dosing and Fasting Requirements for PK Sample Collection   Visits 
Events 
Visit 
2 
4 
5 
6 
7 
ET 
Overnight 
(8-hr) fast 
Yes 
No 
No 
No 
Yes 
No 
Take study 
drug 
At clinic 
At home 
At home 
At clinic 
At clinic 
N/A 
Morning Fast 
Until PK 
samples are 
taken 
N/A 
N/A 
N/A 
Until PK 
sample is 
taken 
N/A 
Sample time 
windows 
relative to dose 
 
Pre-dose 
 
15-30min 
post-dose 
1.5 – 4 hr 
post-dose 
4 – 8 hr 
post-dose 
Pre-dose 
30-90 min 
post-dose 
N/A 
 
On all PK sample collection days, patients should take all study medication within 5   minutes. 
At Visits 2 and 7, patients will be asked to arrive at the study site after an overnight fast. Patients 
will receive an oral dose of placebo or baricitinib at the study site and will remain fasted until PK 
blood samples have been collected. A light snack will be provided after PK samples have been 
collected. 
At Visits 4 and 5, patients will be advised to take the study drug at home. Patients will then go  
to the study site in the scheduled time window for study  assessments. 
At Visit 6, patients will be advised to NOT take study drug prior to visiting the study site. A 
single blood sample will be collected prior to the patient taking their drug at the study   site. 
A single PK sample will be obtained, whenever possible, at the early termination visit. In the 
event of an SAE, up to 2 additional blood samples may be taken at the investigator’s discretion, 
up to 6 hours after the reported event and within 24 hours of the patient’s last   dose. 
For any PK sample taken, the actual date and time (24-hour clock) of PK sample collection as 
well as the date and time of the last 2 dose administrations prior to the PK sample should be 
recorded. 
The sponsor, or its designee, will provide instructions for the collection and handling of blood 
samples. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 117 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 37 
 
8.5.2. PK Sample Assay 
Plasma samples will be assayed for baricitinib using a validated liquid chromatography with 
tandem mass spectrometry (LC/MS/MS) method at a laboratory approved by the sponsor. 
Samples from patients receiving baricitinib will be assayed. PK samples from patients on 
placebo are not planned to be assayed. 
 
8.5.3. PK Sample Storage and  Retention 
Bioanalytical samples collected to measure investigational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study. Pharmacokinetic samples will  
be kept in storage at a laboratory facility designated by the sponsor and may also be assayed for 
additional exploratory analyses. Pharmacokinetic results will not be provided to investigative   
sites or blinded personnel until the study has been  unblinded. 
 
8.6. Pharmacodynamics 
Further pharmacodynamic data, beyond efficacy and biomarker data, will not be   collected. 
 
8.7. Genetics 
A blood sample (approximately 10 mL) will be collected for pharmacogenetic analysis as 
specified in the Schedule of Activities (Appendix 2) where local regulations and ethical review 
boards (ERBs) allow. 
Samples will not be used to conduct unspecified disease or population genetic research either  
now or in the future. Samples will be used to investigate variable response to baricitinib and to 
investigate genetic variants thought to play a role in atopic dermatitis or other inflammatory skin 
disorders. Assessment of variable response may include evaluation of AEs or differences in 
efficacy.  These studies may include but are not limited to evaluate their association with  
observed response to baricitinib. 
All pharmacogenetic samples will be coded with the patient number. Only investigator site 
personnel can link these samples, and any data generated, back to the patient. Samples will be 
destroyed according to a process consistent with local  regulations. 
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or  
for a shorter period if local regulations and/or ERBs impose shorter time limits, at a facility 
selected by the sponsor. This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in drug development or when the drug is commercially  available. 
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, candidate gene studies, and epigenetic analyses. 
Regardless of technology utilized genotyping data generated will be used only for the specific 
research scope described here. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 118 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 38 
 
8.8. Biomarkers 
Skin biopsies, serum, plasma, and whole blood ribonucleic acid (RNA) samples for non-genetic 
biomarker research will be collected at the times specified in the Schedule of Activities 
(Appendix 2) where local regulations and ERBs  allow. 
Samples may be used for research on the drug target, disease process, pathways associated with 
atopic dermatitis, mechanism of action of baricitinib, and/or research method or in validating 
diagnostic tools or assay(s) related to atopic  dermatitis. 
All biomarker samples will be coded with the patient number. Only investigator site personnel 
can link these samples, and any data generated, back to the patient. Samples will be destroyed 
according to a process consistent with local  regulations. 
Samples will be retained for a maximum 15 years after the last patient visit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by   
the sponsor. This retention period enables use of new technologies, response to regulatory 
questions, and investigation of variable response that may not be observed until later in drug 
development or when the drug is commercially  available. 
 
8.8.1. Skin Biopsies 
Patients will be required to provide 4mm skin punch biopsy samples collected per the Schedule 
of Activities (Appendix 2), unless exempted by the  investigator. 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
and used to study biomarkers related to atopic dermatitis and/or related to the mechanism of  
action of baricitinib. Techniques used may include but are not limited to immunohistochemistry 
and microarray expression profiling. Samples will be de-identified as described in International 
Conference on Harmonisation (ICH) guideline E15, and may be used for exploratory microarray 
expression profiling or transcriptome sequencing. Detailed instructions for sample collection and 
handling will be provided by the sponsor. Samples will be sent to a sponsor-designated lab for 
immunohistochemistry. 
 
8.8.2. Nonpharmacogenetic  Biomarkers 
Peripheral serum samples (approximately 10 mL) will be collected at pre- and post-treatment 
time points for the assessment of biomarkers expected to be mechanistically related to JAK 1/2 
inhibition and/or the atopic dermatitis disease state. A blood sample for genotyping of filaggrin 
will also be collected. Sample processing and handling instructions will be provided by the 
sponsor. Samples will be sent to a sponsor-designated lab for  evaluation. 
Exploratory biomarker serum, plasma, and blood for mRNA samples will also be collected and 
stored at a sponsor-designated vendor. 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 119 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 39 
 
8.9.    Health Economics 
The self-reported questionnaires will be administered according to the Schedule of Activities 
(Appendix 2). The questionnaires will be administered in countries where they have been 
translated into the native language of the region and linguistically  validated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 120 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 40 
 
9. Statistical Considerations and Data  Analysis 
9.1. Determination of Sample Size 
Approximately 120 patients will be enrolled using a 4:3:3 randomization scheme of placebo,  
2 mg baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 
20%, approximately 96 patients will complete the  study. 
This sample size provides 90% power to detect a 35% difference in EASI-50 between placebo 
and the 4-mg baricitinib treatment group using a 2-sided chi-square test with alpha =   0.05. 
 
9.2. General Statistical Considerations 
Statistical analysis of this study will be the responsibility of the sponsor or its designee. A 
detailed statistical analysis plan (SAP) will be provided by the sponsor or its designee, and will 
be finalized prior to database lock and  unblinding. 
Investigator site data will be pooled for statistical analysis  purposes. 
All tests of treatment effects will be conducted at a 2-sided alpha level of 0.05, unless otherwise 
stated. 
Data analyses will be provided by treatment groups and for all study patients combined wherever 
appropriate. For continuous variables, summary statistics will include number of patients, mean, 
median, standard deviation, minimum, and maximum.  Categorical endpoints will be    
summarized using number of patients, frequency, and  percentages. 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report. Additional exploratory analyses of the data will be conducted as 
deemed appropriate. 
 
9.3. Treatment Group Comparability 
9.3.1. Patient Disposition 
All patients who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation will be 
given.  Data tabulations will summarize the following patient numbers, per treatment   group: 
 Enrolled 
 Received treatment 
 Violated the protocol 
 Completed the protocol 
 Withdrew because of: 
o Adverse event 
o Lack of efficacy 
o Consent withdrawal 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 121 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 41 
 
o Other reasons, as applicable 
A detailed description of patient disposition will be provided at the end of the   study. 
 
9.3.2. Patient Characteristics 
Baseline and demographic characteristics will be summarized descriptively by treatment group 
and overall. 
 
9.3.3. Concomitant Therapy 
Concomitant use of topical corticosteroids will be summarized by treatment   group. 
 
9.4. Primary and Secondary Analyses 
9.4.1. Primary Analyses 
The primary outcome will be the proportion of patients achieving EASI-50 in each treatment   
arm. The primary analysis will be performed using all randomized patients utilizing a Non- 
Responder Imputation (NRI) analysis. The proportion of patients achieving EASI-50 in the 
placebo arm will be compared to proportion of patients in each of the baricitinib arms using a two-
sided chi-square test with alpha=0.05. To control the study-wise type 1 error rate, the comparison 
of the baricitinib arms with the placebo arm will be performed in a stepwise fashion. The 4-mg 
baricitinib arm will be compared with the placebo arm; if this test is statistically significant, then 
the 2-mg baricitinib arm will be compared with the placebo arm. Enrollment of 120 patients in a 
4:3:3 ratio will provide approximately 90% power for detecting a 35%  difference in the EASI-50 
response rate between placebo and the 4-mg baricitinib treatment   arm. 
For EASI-50 endpoint, all Non-Responders, as well as all patients who discontinue study 
treatment at any time prior to the time point of interest or discontinue from the study for any 
reason, will be defined as Non-Responders for the NRI analysis. Randomized patients without at 
least 1 post-baseline observation will also be defined as Non-Responders for the NRI   analysis. 
 
9.4.2. Secondary Analyses 
Continuous secondary endpoints will be summarized and analyzed using treatment groups by use 
of a mixed effects model with treatment as the main factor and baseline values as covariates. The 
treatment (intercept) effects and their standard errors from the mixed effects model will be used   
to produce p-values and 90% confidence intervals for the treatment   comparison. 
For continuous endpoints collected longitudinally, missing data will assumed to be missing at 
random and a mixed model repeated measures (MMRM) approach will be used. Other 
imputation techniques, such as multiple imputation, may be utilized in sensitivity   analyses. 
Categorical secondary endpoints will be summarized and analyzed using a chi-square test or 
Fisher’s exact test, if needed. 
 
9.4.3. Tertiary/Exploratory Analyses 
Continuous secondary endpoints will be summarized and may be analyzed by use of a mixed 
effects model with treatment as the main factor and baseline values as covariates. The   treatment 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 122 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 42 
 
(intercept) effects and their standard errors from the mixed effects model will be used to produce 
p-values and 90% confidence intervals for the treatment  comparison. 
Categorical secondary endpoints will be summarized and may be analyzed using a chi-square 
test or Fisher’s exact test, if needed. 
 
9.5. Safety Analyses 
Safety analyses will be conducted on all patients who received at least one dose of study drug. 
No statistical comparisons of treatment groups will be completed for safety   endpoints. 
All adverse events will be summarized and listed. The incidence of symptoms for each treatment 
will be presented by severity and by association with study drug as perceived by the investigator. 
Symptoms reported to occur prior to enrollment will be distinguished from those reported as new 
or increased in severity during the  study. 
Additional safety parameters that will be assessed include safety lab parameters and vital signs. 
The parameters will be listed, and summarized using standard descriptive statistics. Additional 
analysis will be performed if warranted upon review of the  data. 
 
9.6. Pharmacokinetic/Pharmacodynamic  Analyses 
The pharmacokinetics of baricitinib will be assessed using population PK analysis techniques. 
The relationship between the primary and secondary efficacy endpoints and plasma exposure, 
race, and age of onset may be explored. PK and PD data may be combined with prior data for an 
integrated analysis. 
 
9.7. Other Analyses 
9.7.1. Health Economics 
Patient reported outcome endpoints will be summarized and analyzed using treatment groups by 
use of a mixed effects model with treatment as the main factor and baseline values as covariates. 
The treatment (intercept) effects and their standard errors from the mixed effects model will be 
used to produce p-values and 90% confidence intervals for the treatment   comparison. 
 
9.7.2. Biomarkers 
Biomarker data from all patients undergoing biomarker assessments will be analyzed. Biomarker 
data will be summarized and listed, and may be displayed  graphically. 
 
9.8.    Interim Analyses 
An interim analysis is not planned for this  study. 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 123 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 43 
 
10. Study Governance Considerations 
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process 
10.1.1. Informed Consent 
The investigator is responsible for ensuring  that: 
 the patient understands the potential risks and benefits of participating in the 
study 
 informed consent is given by each patient or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of 
investigational product. 
 any questions the patient may have throughout the study are answered and 
shares, in a timely manner, any new information that may be relevant to the 
patient’s willingness to continue his or her participation in the  study. 
 
10.1.2. Ethical Review 
The investigator or designee must give assurance that the ethical review board (ERB) was 
properly constituted and convened as required by International Conference on Harmonisation 
(ICH) guidelines and other applicable laws and  regulations. 
Documentation of ERB approval of the protocol and the ICF must be provided to the sponsor 
before the study may begin at the investigative site(s). The sponsor or its representatives must 
approve the ICF, including any changes made by the ERBs, before it is used at the investigative 
site(s).  All ICFs must be compliant with the ICH guideline on  GCP. 
The study site’s ERB(s) should be provided with the  following: 
 current IB and updates during the course of the  study 
 ICF 
 relevant curricula vitae 
10.1.3. Regulatory Considerations 
This study will be conducted in accordance  with: 
 consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of   
Medical Sciences (CIOMS) International Ethical  Guidelines 
 applicable ICH GCP Guidelines 
 applicable laws and regulations 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 124 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 44 
 
The investigator or designee will promptly submit the protocol to applicable   ERB(s). 
All or some of the obligations of the Sponsor may be assigned to a Contract Research 
Organization (CRO). 
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and/or other study-related 
data. 
 
10.1.4. Investigator Information 
Physicians with a specialty in dermatology will participate as investigators in this clinical   study. 
 
10.1.5. Protocol Signatures 
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a sponsor  representative. 
 
10.1.6. Final Report Signature 
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study. 
The investigator with the most enrolled patients will be requested to serve as the CSR 
coordinating investigator. If this investigator is unable to fulfill this function, another 
investigator will be chosen by the sponsor to serve as the CSR coordinating   investigator. 
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study. 
 
10.2. Data Quality Assurance 
To ensure accurate, complete, and reliable data, the sponsor/designee will perform the   following: 
 provide instructional material to the study sites, as  appropriate 
 sponsor start-up training to instruct the investigators and study coordinators. This 
training will give instruction on the protocol, the completion of the CRFs, and 
study procedures. 
 make periodic visits to the study site 
 be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 125 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 45 
 
 review and evaluate CRF data and use standard computer edits to detect errors in 
data collection 
 conduct a quality review of the  database 
In addition, the sponsor/designee will periodically check a sample of the patient data recorded 
against source documents at the study site. The sponsor/designee and/or regulatory agencies 
may audit the study at any time.  Investigators will be given notice before an audit   occurs. 
The investigator will keep records of all original source data.  This might include laboratory  
tests, medical records, and clinical notes. If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents. 
 
10.2.1. Data Capture System 
An electronic data capture (EDC) system will be used in this study. The site maintains a source 
for the data entered into the sponsor-designated EDC system, if collected external to the EDC 
system. 
Electronic patient-reported outcome (ePRO) measures (for example, a rating scale) or other data 
reported directly by the patient (for example, daily dosing schedule, event diary) may be entered 
into an ePRO instrument (for example, personal digital assistant [PDA]), or by means of an 
interactive response technology system (IRT) at the time the information is obtained. In these 
instances where there is no prior written or electronic source data at the site, the ePRO  
instrument record will serve as the  source. 
If ePRO records are stored at a third party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study 
for retention. 
Any data for which the ePRO instrument record will serve to collect source data will be 
identified and documented by each site in that site’s study  file. 
Case report form data will be encoded and stored in a clinical study  database. 
Case report form data collected by a third-party will be encoded by the third-party and stored 
electronically in the third-party’s database system. Validated data will subsequently be 
transferred to the sponsor designated  database. 
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system. Data will subsequently be transferred from the central 
vendor to the sponsor designated  database. 
Any data for which paper documentation provided by the patient will serve as the source  
document will be identified and documented by each site in that site’s study file. Paper 
documentation provided by the patient may include, for example, a paper diary to collect patient- 
reported outcome (PRO) measures (for example, a rating scale), a daily dosing schedule, or an 
event diary. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 126 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 46 
 
Data from complaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management  system. 
 
10.3. Study and Site Closure 
10.3.1. Discontinuation of Study Sites 
Study site participation may be discontinued if the sponsor or its designee, the investigator, or 
the ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons 
consistent with applicable laws, regulations, and  GCP. 
 
10.3.2. Discontinuation of the Study 
The study will be discontinued if the sponsor or its designee judges it necessary for medical, 
safety, regulatory, or other reasons consistent with applicable laws, regulations, and   GCP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 127 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 47 
 
11. References 
[APA] American Psychiatry Association. 1994. Diagnostic and Statistical Manual of Mental 
Disorders. 4th ed. Washington DC. 
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic 
inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul   1;2(3):e24137. 
Basra M.K.A, Salek MS, Camilleri L, Sturkey R, Finlay A.Y. Determining the Minimal 
Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index 
(DLQI):  Further Data.  Derm, 2015 Jan;  230:27-33. 
Beck, LA, Thaçi, D, Hamilton, JD, Graham, NM, Bieber, T, Rocklin, R, Ming, JE, Ren, H, Kao, 
R, Simpson, E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. 
New Engl. J. Med. 2014, 371,  130–139. 
Bieber, T. Atopic Dermatitis. Ann Derm. 2010,  125-137. 
Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy 
and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 
12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 
Apr;166(4):853-60. 
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Arch Dermatol. 2004  Dec;140(12):1513-9. 
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 
2009 (v4.03:  June 14, 2010).  http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06- 
14_QuickReference_5x7.pdf. Accessed March 7,  2016. 
Epstein E, Pinski JB. A blind study. Arch Dermatol 1964; 89:  548–549. 
Ferguson T, Rowlands AV, Olds T, Maher C. Validity of consumer-level, activity monitors in 
healthy adults worn in free-living conditions: a cross-sectional study. International Journal of 
Behavioral Nutrition and Physical Activity (2015)  12:42. 
 
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, 
Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of 
tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug   9;367(6):495-507. 
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality 
of life into practice: What do dermatology life quality index scores mean? J Invest   Dermatol. 
2005 Oct;125(4):659-64. 
Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus- 
Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib    
at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to 
methotrexate. Ann Rheum Dis. 2015  Feb;74(2):333-40. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 128 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 48 
 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol 2002; 147 (Suppl 62):  50. 
Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. 
Identification of a novel pathway important for proliferation and differentiation of primary 
erythroid progenitors. Proc Natl Acad Sci U S A. 1997 Apr  1;94(7):3016-21. 
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik 
KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging 
study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with 
background methotrexate in patients with active rheumatoid arthritis and an inadequate response 
to methotrexate alone. Arthritis Rheum. 2012  Apr;64(4):970-81. 
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015   Sep;73(3):395-9. 
Mallinckrodt C, Tamura RN, Tanaka Y. Recent developments in improving signal detection and 
reducing placebo response in psychiatric clinical trials. J Psychiatric Research 45 (2011) 1202- 
1207. 
Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of 
Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015 Apr   29;4(5):858-73. 
Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A phase 2b trial of baricitinib, an 
oral JAK inhibitor, in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2014 
May;70(5, Suppl 1): AB162. 
Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Brit J Derm. 2003; 
148: 117–121. 
Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, 
Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a 
variety of cytokine receptors. Cell. 1998 May  1;93(3):385-95. 
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus 
kinases. Immunol Rev. 2008  Jun;223:132-42. 
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan  
PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of 
Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a 
psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 
1;54(5):573-83. 
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P; 
Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of 
clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin 
Immunol.  2013 Dec;132(6):1337-47. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 129 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 49 
 
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S.  
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in 
healthy volunteers. J Clin Pharmacol. 2014  Dec;54(12):1354-61. 
Vera J, Bachmann J, Pfeifer AC, Becker V, Hormiga JA, Darias NV, Timmer J, Klingmüller U, 
Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 
signalling pathway. BMC Syst Biol. 2008 Apr  25;2:38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 130 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 50 
 
Appendix 1. 
Abbreviations and Definitions 
 
 
 
 
 
Term 
Definition 
AD 
Atopic Dermatitis 
AE 
adverse event: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product. 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
Audit 
A systematic and independent examination of the study-related activities and    
documents to determine whether the evaluated study-related activities were conducted, 
and the data were recorded, analyzed, and accurately reported according to the protocol, 
applicable standard operating procedures (SOPs), good clinical practice (GCP), and the 
applicable regulatory requirement(s). 
Blinding/masking 
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are  not. 
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received. 
BSA 
body surface area 
Chorus 
A semi-autonomous clinical development organization within Eli Lilly and  Company. 
CIOMS 
Council for International Organizations of Medical  Sciences 
CKD EPI 
Chronic Kidney Disease Epidemiology Collaboration 
Complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system. 
Compliance 
Adherence to all the study-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory  requirements. 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 131 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 51 
 
 
Confirmation 
A process used to confirm that laboratory test results meet the quality requirements 
defined by the laboratory generating the data and that Lilly is confident that results are 
accurate. Confirmation will either occur immediately after initial testing or will require 
that samples be held to be retested at some defined time point, depending on the steps 
required to obtain confirmed results. 
CRF/eCRF 
case report form/electronic case report form (sometimes referred to as clinical report 
form): A printed or electronic form for recording study participants’ data during a 
clinical study, as required by the protocol. 
CRO 
contract research organization 
CRP 
Clinical research physician:  individual responsible for the medical conduct of the 
study. Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical  officer. 
CRU 
clinical research unit 
CS 
Corticosteroid 
CSE 
clinically significant event.  A moderate-to-severe adverse event (AE), abnormal 
clinical sign, or clinical laboratory finding that may pose a risk to the well-being of the 
patient. 
CSR 
clinical study report 
DLQI 
Dermatologic Life Quality Index 
DMC 
data monitoring committee 
DN 
Diabetic Nephropathy 
DNA 
deoxyribonucleic acid 
DSUR 
Development Safety Update Report 
EASI 
Eczema Area and Severity Index 
ECG 
Electrocardiogram 
EDC 
Electronic data capture 
eGFR 
estimated glomerular filtration  rate 
End of study 
Date of the last visit or last scheduled procedure shown in the Study Schedule for the 
last active patient in the study 
Enroll 
The act of assigning a patient to a treatment. Patients who are enrolled in the study are 
those who have been assigned to a treatment. 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 132 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 52 
 
 
Enter 
Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives. 
ePRO 
electronic patient-reported outcome 
ERB/IRB 
ethical review board/institutional review board: a board or committee (institutional, 
regional, or national) composed of medical professionals and nonmedical members 
whose responsibility is to verify that the safety, welfare, and human rights of the 
patients participating in a clinical study are protected. 
e-source 
electronic source documentation 
FSH 
follicle stimulating hormone 
GCP 
good clinical practice 
GGT 
gamma glutamyltransferase 
H2 receptor 
histamine H2 receptor 
HBcAb 
hepatitis B core antibody 
HBsAb 
hepatitis B surface antibody 
HBsAg 
hepatitis B surface antigen 
HBV DNA 
hepatitis B virus DNA 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
IB 
Investigator’s Brochure 
IC50 
half-maximal inhibitory concentration 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IFN-γ 
interferon-gamma 
IGA 
Investigator’s Global Assessment 
IgE 
immunoglobulin E 
IL 
Interleukin 
INR 
international normalized ratio 
Informed consent 
A process by which a subject voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the subject's decision to participate. Informed consent is documented by 
means of a written, signed and dated informed consent  form. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 133 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 53 
 
 
Interim analysis 
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is  created/locked. 
Investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form. 
Investigator 
A person responsible for the conduct of the clinical study at a study site. If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal  investigator. 
ITT 
intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that treatment group irrespective of their 
compliance to the planned course of treatment. 
IRT 
interactive response technology system 
JAK 
Janus kinase 
JAK1, JAK2, JAK3 
kinases belonging to the Janus kinase family 
Legal Representative 
An individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical  study. 
Lilly 
Eli Lilly and Company 
LRL 
Lilly Research Laboratories 
MMRM 
mixed model repeated measures 
MOS 
margin of safety 
NRI 
non-responder imputation 
NRS 
numerical rating scale 
PASI 
Psoriasis Area and Severity Index 
Patient 
A study participant who has the disease or condition for which the investigational 
product is targeted. 
PK/PD 
pharmacokinetics/pharmacodynamics 
PO 
per os; oral administration 
POCT 
point-of-care testing 
POEM 
Patient-Oriented Eczema Measure 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 134 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 54 
 
 
PPD 
purified protein derivate 
PRO/ePRO 
patient-reported outcomes/electronic patient-reported  outcomes 
QIDS-SR16 
Quick Inventory of Depressive Symptomatology-Self Report  16 
QD 
once daily 
Randomize 
the process of assigning subjects to an experimental treatment group according to the 
randomization schedule for the study. 
RA 
Rheumatoid Arthritis 
RNA 
ribonucleic acid 
SAE 
serious adverse event; any untoward medical occurrence that at any dose results in 
death, is life threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect. 
SAP 
statistical analysis plan 
SCORAD 
SCORing of Atopic Dermatitis 
Screening 
The act of determining if an individual meets minimum requirements to become part of  
a pool of potential candidates for participation in a clinical  study. 
SUSARs 
suspected unexpected serious adverse reactions 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event: Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to  
have a causal relationship with this treatment. 
Th1, Th 2 
subsets of T helper cells; T lymphocytes expressing CD4 are also known as helper T 
cells 
TSH 
thyroid stimulating hormone. 
ULN 
upper limit of normal 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 135 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 55 
 
Appendix 2. 
Schedule of Activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 136 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 56 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable for 
PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs  later) 
X 
Read PPD (if applicable) 
X 
ECG (single) 
X 
X 
X 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the evaluation of tuberculosis    
infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient will be 
excluded from the study. 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 137 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 57 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
Vital Signs (BP and pulse) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense topical corticosteroid (as needed) 
X 
X 
X 
X 
X 
X 
X 
Weigh and record topical corticosteroid 
container with cap 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discontinue all excluded AD medications 
X 
Pre-existing Conditions 
X 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational Product Package Dispensed 
X 
X 
X 
X 
X 
Investigational Product Package 
Returned/Compliance Assessed 
X 
X 
X 
X 
X 
X 
Dose administration at site 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
Itch NRS 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
X 
X 
X 
POEM 
X 
X 
X 
X 
X 
X 
X 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 138 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 58 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 
days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device Dispensing 
X 
X 
X 
X 
X 
Biopsy performed 
4mm; NL: non-lesion and L: lesion 
At Visit 2, to be performed following confirmation of 
Inclusion Criteria being met 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non- 
PK samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HBsAb (including 
Quantitative HBsAb load assessment) 
X 
HBV DNA 
X 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 139 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 59 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
X 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory 
Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 140 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 60 
 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Serum Immunoglobulin (IgA, IgG, IgM) 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 141 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 61 
 
Appendix 3. 
Clinical Laboratory Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 142 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 62 
 
 
Clinical Laboratory Tests 
Hematologya,b 
Clinical Chemistrya,b 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume 
Total bilirubin 
Mean cell hemoglobin concentration 
Direct bilirubin 
Leukocytes (WBC) 
Alkaline phosphatase 
Reticulocyte 
Alanine aminotransferase (ALT/SGPT) 
Absolute counts of: 
Aspartate aminotransferase (AST/SGOT) 
Neutrophils, segmented 
Blood urea nitrogen (BUN) 
Neutrophils, juvenile (bands) 
Creatinine 
Lymphocytes 
Uric acid 
Monocytes 
Calcium 
Eosinophils 
Glucose 
Basophils 
Albumin 
Platelets 
Total protein 
Cell morphology 
Estimated glomerular filtration rate (eGFR)e 
Creatine phosphokinase (CPK) 
Urinalysisa,b,d 
Color 
Other Testsa 
Specific gravity 
Hepatitis B Surface antigenf 
pH 
Anti-Hepatitis B Core antibodyf 
Protein 
Quantitative HBsAb load assessmenta 
Glucose 
Hepatitis B Surface antibodyf 
Ketones 
Human immunodeficiency virusf 
Bilirubin 
Hepatitis C antibodyf,g 
Urobilinogen 
Thyroid-stimulating hormone 
Blood 
Thyroxine 
Leukocyte esterase 
Pregnancy Testh 
Nitrite 
FSHf,i 
Serum immunoglobulin (IgA, IgG, and IgM) 
Lipid (Fasting) a,c 
PPD, QuantiFERON®-TB Gold or T-SPOT.TB® j 
Total cholesterol 
Low-density lipoprotein 
Baricitinib plasma levels 
High-density lipoprotein 
HBV DNA 
Triglycerides 
 
Abbreviations: CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; DNA = deoxyribonucleic   acid; 
FSH = folliclestimulatinghormone; HBV = Hepatitis B virus;; RBC =  red 
blood cells; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic 
pyruvic transaminase; TB = tuberculosis; WBC = white blood  cells. 
a Assayed by sponsor-designated laboratory. 
b Unscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed. 
c Fasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to  test. 
d Microscopic examination of sediment performed only if abnormalities are noted on the routine urinalysis.  
e eGFR for serum creatinine calculated by the central laboratory using the -CKD EPI  method. 
f Test required at Visit 1 only to determine eligibility of patient for the  study. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 143 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 63 
 
g A positive hepatitis C antibody (Hep C antibody) result will be confirmed with an alternate hepatitis C method.   
h For all women of childbearing potential, a serum pregnancy test will be performed at Visit 1 and a local   urine 
pregnancy test will be performed at all visits thereafter. 
i To confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an 
FSH test will be performed. Non-childbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of 
menses for at least 12 months. 
j The QuantiFERON®-TB Gold test is the preferred alternative to the PPD test for the evaluation of TB infection,   
and it may be used instead of the PPD test or T-SPOT.TB® test and may be read locally. If the QuantiFERON®- 
TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient is excluded from  
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 144 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 64 
 
Appendix 4. 
Hepatic Monitoring Tests for  Treatment- 
Emergent Abnormality 
 
 
 
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may be required in 
follow-up with patients in consultation with the sponsor, its designee, or clinical research  physician. 
 
Hepatic Monitoring Tests 
Hepatic Hematologya 
Haptoglobina 
Hemoglobin 
Hematocrit 
Hepatic Coagulationa 
RBC 
Prothrombin Time 
WBC 
Prothrombin Time, INR 
Neutrophils, segmented 
Lymphocytes 
Hepatic Serologiesa,b 
Monocytes 
Hepatitis A antibody, total 
Eosinophils 
Hepatitis A antibody, IgM 
Basophils 
Hepatitis B surface antigen 
Platelets 
Hepatitis B surface antibody 
Hepatitis B Core antibody 
Hepatic Chemistrya 
Hepatitis C antibody 
Total bilirubin 
Hepatitis E antibody, IgG 
Direct bilirubin 
Hepatitis E antibody, IgM 
Alkaline phosphatase 
ALT 
Anti-nuclear antibodya 
AST 
GGT 
Anti-smooth muscle antibodya 
Abbreviations: ALT = alanine aminotransferase; AST = aspirate aminotransferase; GGT = gamma-glutamyl 
transferase; Ig = immunoglobulin; INR = international normalised ratio; RBC = red blood cells; WBC = white 
blood cells. 
a Assayed by sponsor-designated or local laboratory. 
b Reflex/confirmation dependent on regulatory requirements and/or testing  availability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
 
 
PPD 
14V-MC-JAHG CSR Appendix Protocol 
Page 145 
 
 
 
 
 
 
14V-MC-JAHG(c)!Clinical Protocol 
Page 65 
 
Appendix 5. 
Protocol 14V-MC-JAHG Signature Page 
 
 
I confirm that I have read this protocol; I understand itand I will work according to this protocol. 
I will alsowork consistently withtheethical principles that have their origin in the Declaration 
of Helsinki and that are consistent with good clinical practicesand applicable laws and 
regulations. I will accept the monitor's overseeing of the study. I will abide by the publication 
plan set forth in my Agreement with the sponsor (Chorus, Eli Lilly and Company) or designee. I 
will prompltysubmit the protocol to applicable ethical review board(s). I confirm that if I orany 
ofmystaff are members of the ethical review board, we will abstain from voting on this 
protocol. 
 
 
Signature of Investigator 
Date 
 
 
Investigator Name (Title) 
 
 
Name of Facility 
 
 
 
Location of Facility 
  
 
@y,  State @:!pplicable), Country) 
 
_ 
 
 
Date (dd-mmm-yyyy) 
 
 
Sponsor name (Title) 
 
Eli Lilly and Company 
Name 
Lilly Corporate Center. Indianapolis, Indiana, USA 
Location (City, State{if applicab,le) Country) 
 
 
LY30 09104 
Instructions to the Investigato.r Please SIGN and DATE this signaturepage. PRINT your 
name. title andthe nameof the facility in vmiththestudy willlie conducted C111l>Oth copies, 
Relum 1 of the sl 
co  esto the s onso, Chorus Ell Lil   and Com an  or desi n 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 146 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 66 
 
Appendix 6. 
Protocol Amendment I4V-MC-JAHG(c) 
Summary [A Randomized, Double-Blind,  Placebo- 
Controlled, Phase 2 Study to Evaluate the Safety and 
Efficacy of Baricitinib in Patients with Moderate-to- 
Severe Atopic Dermatitis] 
 
 
 
Overview 
Protocol I4V-MC-JAHG [A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to 
Evaluate the Safety and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic 
Dermatitis] has been amended. The new protocol is indicated by amendment (c) and will be  
used to conduct the study in place of any preceding version of the  protocol. 
The overall changes and rationale for the changes made to this protocol are as   follows: 
 Exclusion Criteria #18 has been updated to clarify malignancy exclusion as well as 
remission timing acceptability. 
 Thyroid Function Tests assessments have been added at Visit 7 or ET to reflect FDA 
requested change to assess at end of  treatment. 
 Minor textual edits were made for the purpose of clarification or  correction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 147 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 67 
 
Revised Protocol Sections 
 
Note: 
Deletions have been identified by strikethroughs or grayed out for  figures. 
Additions have been identified by the use of  underscore. 
5.2 
Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
[18] Have, or have a history of, lymphoproliferative disease; or signs or symptoms 
suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly; or active primary or recurrent malignant 
disease; or been in remission from clinically significant malignancy for less 
than 5 years. 
Malignancy (except for basal or squamous cell carcinoma completely excised 
without evidence of recurrence) or lymphoproliferative diseases or have signs 
or symptoms suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly including  lymphoma 
Note: Patients with cervical carcinoma in situ that has been resected with no 
evidence of recurrence or metastatic disease, or with basal cell or squamous 
epithelial skin cancers that have been completely resected with no evidence of 
recurrence for at least 3 years may participate in the  study. 
 
 
8.8.1  Skin Biopsies 
Patients will be required to provide 4mm skin punch biopsy samples collected per the Schedule 
of Activities (Appendix 2), unless exempted by the  investigator. 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
and used to study biomarkers related to atopic dermatitis and/or related to the mechanism of  
action of baricitinib. Techniques used may include but are not limited to immunohistochemistry 
and microarray expression profiling. Samples will be de-identified as described in International 
Conference on Harmonisation (ICH) guideline E15, and may be used for exploratory microarray 
expression profiling or transcriptome sequencing. Detailed instructions for sample collection and 
handling will be provided by the sponsor. Samples will be sent to a sponsor-designated lab for 
immunohistochemistry. 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 148 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 68 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable for 
PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs  later) 
X 
Read PPD (if applicable) 
X 
ECG (single) - Taken prior to all other 
assessments at V1 
X 
X 
X 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
continued on next page 
 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the evaluation of tuberculosis    
infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient will be 
excluded from the study. 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 149 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 69 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 
days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device Dispensing 
X 
X 
X 
X 
X 
Biopsy performed 
(4mm; NL: non-lesion and L: lesion to be performed 
following Investigator and Patient rating scale 
assessments) 
At Visit 2, to be performed following confirmation of 
Inclusion Criteria being met 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non- 
PK samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HBsAb (including 
Quantitative HBsAb load assessment) 
X 
HBV DNA 
X 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 150 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 70 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
X 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory 
Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 151 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 71 
 
Clinical Laboratory Tests 
Hematologya,b 
Clinical Chemistrya,b 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume 
Total bilirubin 
Mean cell hemoglobin concentration 
Direct bilirubin 
Leukocytes (WBC) 
Alkaline phosphatase 
Reticulocyte 
Alanine aminotransferase (ALT/SGPT) 
Absolute counts of: 
Aspartate aminotransferase (AST/SGOT) 
Neutrophils, segmented 
Blood urea nitrogen (BUN) 
Neutrophils, juvenile (bands) 
Creatinine 
Lymphocytes 
Uric acid 
Monocytes 
Calcium 
Eosinophils 
Glucose 
Basophils 
Albumin 
Platelets 
Total protein 
Cell morphology 
Estimated glomerular filtration rate (eGFR)e 
Creatine phosphokinase (CPK) 
Urinalysisa,b,d 
Color 
Other Testsa 
Specific gravity 
Hepatitis B Surface antigenf 
pH 
Anti-Hepatitis B Core antibodyf 
Protein 
Quantitative HBsAb load assessmenta 
Glucose 
Hepatitis B Surface antibodyf 
Ketones 
Human immunodeficiency virusf 
Bilirubin 
Hepatitis C antibodyf,g 
Urobilinogen 
Thyroid-stimulating hormonef 
Blood 
Thyroxinef 
Leukocyte esterase 
Pregnancy Testh 
Nitrite 
FSHf,i 
Serum immunoglobulin (IgA, IgG, and IgM) 
Lipid (Fasting) a,c 
PPD, QuantiFERON®-TB Gold or T-SPOT.TB® j 
Total cholesterol 
Low-density lipoprotein 
Baricitinib plasma levels 
High-density lipoprotein 
HBV DNA 
Triglycerides 
 
Abbreviations: CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; DNA = deoxyribonucleic   acid; 
FSH = folliclestimulatinghormone; HBV = Hepatitis B virus;; RBC =  red 
blood cells; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic 
pyruvic transaminase; TB = tuberculosis; WBC = white blood  cells. 
a Assayed by sponsor-designated laboratory. 
b Unscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed. 
c Fasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to  test. 
d Microscopic examination of sediment performed only if abnormalities are noted on the routine urinalysis.  
e eGFR for serum creatinine calculated by the central laboratory using the -CKD EPI  method. 
f Test required at Visit 1 only to determine eligibility of patient for the  study. 
g A positive hepatitis C antibody (Hep C antibody) result will be confirmed with an alternate hepatitis C   method. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 152 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG(c) Clinical Protocol 
Page 72 
 
h For all women of childbearing potential, a serum pregnancy test will be performed at Visit 1 and a local urine 
pregnancy test will be performed at all visits thereafter. 
i To confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an 
FSH test will be performed. Non-childbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of 
menses for at least 12 months. 
j The QuantiFERON®-TB Gold test is the preferred alternative to the PPD test for the evaluation of TB infection,   
and it may be used instead of the PPD test or T-SPOT.TB® test and may be read locally. If the QuantiFERON®- 
TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient is excluded from  
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 

Prot_001.pdf: 
I4V-MC-JAHG Protocol  
 
 
Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety 
and Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis. 
 
 
NCT ID: NCT02576938 
Approval Date: 30-September-2015 
 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 314 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 1 
 
 
Protocol I4V-MC-JAHG 
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 
Study to Evaluate the Safety and Efficacy of Baricitinib in 
Patients with Moderate-to-Severe Atopic  Dermatitis 
 
 
 
 
 
 
 
Baricitinib 
 
 
 
 
Chorus, Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
 
 
 
Protocol Approval Date:    30-September-2015 
 
 
 
 
 
 
 
 
LY3009104 
Confidential Information 
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and  
should not be copied by or distributed to persons not involved in the clinical investigation of 
baricitinib, unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subject to Freedom of Information Act (FOIA)  
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its  subsidiaries. 
Parallel, double-blinded, randomized placebo-controlled multiple dose study in patients with 
moderate-to-severe atopic dermatitis 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 315 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 2 
 
Table of Contents 
Section 
Page 
1. 
Protocol Synopsis ........................................................................................... 8 
2. 
Introduction .................................................................................................. 10 
2.1. 
Background ............................................................................................. 10 
2.2. 
Study Rationale ....................................................................................... 11 
3. 
Objectives and Endpoints ............................................................................. 12 
4. 
Study Design ................................................................................................ 14 
4.1. 
Overview of Study Design ...................................................................... 14 
4.2. 
Scientific Rationale for Study Design ..................................................... 14 
4.3. 
Justification for Dose .............................................................................. 15 
4.4. 
Benefit/Risk Assessment ......................................................................... 15 
5. 
Study Population .......................................................................................... 17 
5.1. 
Inclusion Criteria .................................................................................... 17 
5.2. 
Exclusion Criteria ................................................................................... 17 
5.3. 
Screen Failures ........................................................................................ 21 
6. 
Treatment ..................................................................................................... 22 
6.1. 
Treatments Administered ........................................................................ 22 
6.2. 
Method of Treatment Assignment ........................................................... 22 
6.2.1. 
Selection and Timing of Doses ....................................................... 22 
6.3. 
Blinding .................................................................................................. 23 
6.4. 
Packaging and Labelling ......................................................................... 23 
6.5. 
Investigational Products Storage and Handling ...................................... 24 
6.6. 
Dose Modification................................................................................... 24 
6.7. 
Treatment Compliance ............................................................................ 24 
6.8. 
Concomitant Therapy .............................................................................. 24 
6.9. 
Treatment after Study Completion .......................................................... 25 
6.9.1. 
Continued Access ........................................................................... 25 
7. 
Discontinuation Criteria ............................................................................... 26 
7.1. 
Discontinuation of Investigational Product ............................................. 26 
7.1.1. 
Temporary Interruption of Investigational Product .................................................. 26 
7.1.2. 
Permanent Discontinuation of Investigational Product ............................................. 26 
7.1.3. 
Discontinuation of Inadvertently Enrolled Patients .................................................. 27 
7.1.4. 
Permanent Discontinuation from the Study .................................... 27 
7.1.5. 
Patients Lost to Follow-Up ............................................................. 28 
8. 
Study Assessments and Procedures .............................................................. 29 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 316 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 3 
8.1. 
Efficacy Assessments ............................................................................. 29 
8.1.1. 
Primary Efficacy Assessments ....................................................... 29 
8.1.2. 
Secondary Efficacy Assessments ................................................... 29 
8.1.3. 
Appropriateness of Primary Efficacy Measure .............................. 30 
8.2. 
Adverse Events ....................................................................................... 31 
8.2.1. 
Adverse Events/Laboratory Results of Special Interest ........................................... 32 
8.2.2. 
Serious Adverse Events .................................................................. 32 
8.2.2.1. 
Suspected Unexpected Serious Adverse Reactions ............................................ 33 
8.2.3. 
Complaint Handling ....................................................................... 33 
8.3. 
Treatment of Overdose ........................................................................... 33 
8.4. 
Safety Assessments ................................................................................. 33 
8.4.1. 
Physical examination ...................................................................... 34 
8.4.2. 
Electrocardiograms ......................................................................... 34 
8.4.3. 
Vital Signs ...................................................................................... 34 
8.4.4. 
Laboratory Tests ............................................................................. 34 
8.4.5. 
Hepatitis B virus (HBV) DNA monitoring .................................... 34 
8.4.6. 
Quick Inventory of Depressive Symptomatology-Self  Report 
16 (QIDS-SR16) ....................................................................................................... 35 
8.4.7. 
Safety Monitoring .......................................................................... 35 
8.5. 
Pharmacokinetics .................................................................................... 35 
8.5.1. 
PK sample collection ...................................................................... 35 
8.5.2. 
PK sample assay ............................................................................. 37 
8.5.3. 
PK sample storage and retention .................................................... 37 
8.6. 
Pharmacodynamics ................................................................................. 37 
8.7. 
Genetics .................................................................................................. 37 
8.8. 
Biomarkers .............................................................................................. 38 
8.8.1. 
Skin Biopsies .................................................................................. 38 
8.8.2. 
Nonpharmacogenetic Biomarkers .................................................. 39 
8.9. 
Health Economics ................................................................................... 39 
9. 
Statistical Considerations and Data Analysis .............................................. 40 
9.1. 
Determination of Sample Size ................................................................ 40 
9.2. 
General Statistical Considerations .......................................................... 40 
9.3. 
Treatment Group Comparability ............................................................. 40 
9.3.1. 
Patient Disposition ......................................................................... 40 
9.3.2. 
Patient Characteristics .................................................................... 41 
9.3.3. 
Concomitant Therapy ..................................................................... 41 
9.4. 
Primary and Secondary Analyses ........................................................... 41 
9.4.1. 
Primary Analyses ........................................................................... 41 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 317 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 4 
9.4.2. 
Secondary Analyses ....................................................................... 41 
9.4.3. 
Tertiary/Exploratory Analyses ....................................................... 42 
9.5. 
Safety Analyses ....................................................................................... 42 
9.6. 
Pharmacokinetic/Pharmacodynamic Analyses ....................................... 42 
9.7. 
Other Analyses ........................................................................................ 42 
9.7.1. 
Health Economics .......................................................................... 42 
9.7.2. 
Biomarkers ..................................................................................... 42 
9.8. 
Interim Analyses ..................................................................................... 42 
10. Study Governance Considerations ............................................................... 44 
10.1. Regulatory and Ethical Considerations, Including the  Informed 
Consent Process ................................................................................................................ 44 
10.1.1. 
Informed Consent ........................................................................... 44 
10.1.2. 
Ethical Review ............................................................................... 44 
10.1.3. 
Regulatory Considerations ............................................................. 44 
10.1.4. 
Investigator Information ................................................................. 45 
10.1.5. 
Protocol Signatures ........................................................................ 45 
10.1.6. 
Final Report Signature ................................................................... 45 
10.2. Data Quality Assurance .......................................................................... 45 
10.2.1. 
Data Capture System ...................................................................... 46 
10.3. Study and Site Closure ........................................................................... 47 
10.3.1. 
Discontinuation of Study Sites ....................................................... 47 
10.3.2. 
Discontinuation of the Study .......................................................... 47 
11. References .................................................................................................... 48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 318 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 5 
 
List of Tables 
Table 
Page 
Table JAHG.1.    Objectives and Endpoints ................................................................................... 12 
Table JAHG.2.    Treatment Regimens .......................................................................................... 22 
Table JAHG.3.    Criteria for Temporary Interruption from  Study Treatment ............................... 26 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product ................... 27 
Table  JAHG.5.     Timing  of  Dosing  and  Fasting  Requirements  for  PK  Sample  Collection 
Visits .................................................................................................................. 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 319 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 6 
 
List of Figures 
Figure 
Page 
Figure JAHG.1.   Illustration of study design for Clinical Protocol I4V-MC-JAHG. .................... 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 320 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 7 
 
List of Appendices 
Appendix 
Page 
Appendix 1. 
Abbreviations and Definitions ........................................................................... 51 
Appendix 2. 
Schedule of Activities ........................................................................................ 56 
Appendix 3. 
Clinical Laboratory Tests ................................................................................... 61 
Appendix 4. 
Hepatic Monitoring Tests for Treatment-Emergent Abnormality ...................... 64 
Appendix 5. 
Protocol I4V-MC-JAHG Signature Page ........................................................... 65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 321 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 8 
 
1. Protocol Synopsis 
 
Title of Study: 
A randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of baricitinib in 
patients with moderate-to-severe atopic dermatitis. 
Rationale: 
Baricitinib is a JAK1/JAK2 selective inhibitor that is currently in development for treatment of inflammatory 
diseases such as rheumatoid arthritis and psoriasis. Baricitinib has been administered to healthy subjects and patients 
with rheumatoid arthritis (RA), moderate-to-severe plaque stage psoriasis, and diabetic nephropathy (DN). 
In addition, baricitinib is also being developed for the treatment of atopic dermatitis (AD). This study will evaluate 
the safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. 
Objective(s)/Endpoints: 
 
Objectives 
Endpoints 
Primary 
To compare the proportion of moderate-to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose group (2 mg and 4 mg) and placebo 
when treated daily for 16 weeks 
Secondary 
To evaluate the absolute and percent change from baseline of the EASI with 
baricitinib compared to placebo at weeks 1 and 4 and monthly intervals thereafter 
To evaluate the mean change from baseline of the SCORing Atopic Dermatitis 
(SCORAD) with baricitinib compared to placebo at weeks 1 and 4 and monthly 
intervals thereafter 
To evaluate the mean change from baseline of the Investigator’s Global 
Assessment (IGA) with baricitinib compared to placebo for the at weeks 1 and 4 
and monthly intervals thereafter 
To assess quality of life based on the Dermatologic Life Quality Index (DLQI) at 
baseline, weeks 1 and 4 and monthly intervals thereafter 
To assess itch using the itch numerical rating scale (NRS) at baseline, weeks 1 
and 4 and monthly intervals thereafter 
To evaluate the pharmacokinetics of baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 
 
Summary of Study Design: 
 
Study I4V-MC-JAHG is a multicenter, randomized, double-blind, parallel, placebo-controlled study designed to 
compare the efficacy and safety of baricitinib to placebo in patients with moderate-to-severe atopic dermatitis. 
Enrollment will be targeted at 90 patients to enable approximately 72 patients to complete the study. An interim 
analysis may be implemented and could result in up to an additional 30 patients being enrolled. Patients who meet 
all eligibility criteria will be randomized to receive either placebo or baricitinib, administered as once daily oral 
doses of 2 mg or 4 mg. Randomization will occur at the country level. 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 322 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 9 
 
Treatment Arms and Duration: 
 
Three arms will be randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, respectively. Study drug will 
be administered as oral tablets to be taken once-daily (QD) for 16 weeks. A background therapy of a mid-potency 
topical corticosteroid (triamcinolone 0.1%) will be utilized during the 28 day standardization phase prior to 
randomization and continued throughout the study. This background therapy should be used according to the 
labeling provided by the manufacturer or as directed by the investigator. 
Number of Patients: 90-120 
 
Statistical Analysis: 
 
Sample Size 
The study will begin with a plan to enroll 90 patients that will be 
randomized 4:3:3 to placebo, 2 mg baricitinib, or 4 mg baricitinib, 
respectively. A maximum of 30 additional patients may be enrolled 
depending on the results of the interim analysis. 
Primary Outcome & Methodology 
The primary outcome parameter is the proportion of patients achieving 
EASI-50 in each treatment arm. The placebo arm will be compared to each 
of the baricitinib arms using a one-sided chi-square test with alpha=0.05. As 
this is a proof of concept study, there will not be any adjustment of alpha for 
multiple comparisons. Based on 72 patients and a 35% difference in 
response rates between placebo and either treatment, statistical power is 
estimated to be approximately 80%. 
Interim Analysis 
An interim analysis may be conducted to assess variability, effect size, and 
placebo effect during the course of the study in order to evaluate the 
potential need for an increase in the number of patients randomized (up to a 
total of 120) and/or a possible change in randomization ratio. Details 
around this potential interim analysis will be described in the statistical 
analysis plan (SAP) or in interim analysis planning documentation, as 
appropriate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 323 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 10 
 
 
 
2.1. Background 
2. Introduction 
Atopic dermatitis (AD) is a common skin disorder characterized clinically by chronic 
inflammation and altered skin barrier function, and histologically by skin infiltration of 
inflammatory cells. AD is characterized by excessive T-cell activation, with significant skin 
infiltration by T-cells and dendritic cells. Both Th2 and Th22 activation are hallmarks of AD, 
with some Th17 and Th1 components. Patients with moderate-to-severe AD are afflicted with a 
heavy disease burden including medical as well as psycho-social abnormalities. Patients often 
have bacterial- or viral-mediated cutaneous complications. AD is the most common chronic 
inflammatory skin disease (Schmitt, 2013) with a prevalence of 2%–10% among adults in 
western geographies (Bieber, 2010) and a prevalence of about 3% in Japan (Muto et al,   2003). 
Studies using genomic and histologic profiling of AD skin have defined sets of biomarkers for   
AD that include markers of epidermal hyperplasia (epidermal thickness, K16 and Ki67 staining), 
epidermal barrier components (filaggrin), specific cellular infiltrates, including T-cells (CD3+  
and CD8+) and several dendritic cell subsets (CD11c+, CD1a+, inflammatory dendritic   
epidermal cells). Serum biomarkers that correlate with disease activity include IgE, eosinophils, 
eosinophilic cationic protein, as well as the Th2 chemokines CCL17, CCL18, CCL22, CCL11, 
and CCL26, and the cytokines IL-13, IL-31, and IL-22 (Mansouri,   2015). 
Members of the Janus kinase (JAK) family of protein tyrosine kinases (JAK1, JAK2, JAK3, and 
TYK2), along with the signal transduction and activator of transcription (STAT) pathway, play   
an important role in signal transduction following cytokine and growth factor binding to their 
receptors (Pesu, 2008). Emerging data support the role of JAK and STAT in Th2 immunity, 
activating eosinophils, and suppressing regulatory T cells. The JAK-STAT pathway, activated by 
IL-4, plays a critical role in the pathogenesis of AD by upregulating epidermal chemokines, pro- 
inflammatory cytokines, and proangiogenic factors as well as by down-regulating antimicrobial 
peptides and factors responsible for skin barrier function (Bao, 2013). Consistent with the  
proposed role of IL-4 activation of the JAK-STAT pathway in AD, administration of a  
monoclonal antibody against the alpha subunit of the IL-4 receptor improved clinical endpoints 
associated with AD (Beck, 2014). 
Baricitinib (also previously known as LY3009104 and INCB028050) is a potent and selective 
small molecule inhibitor of JAK1 and JAK 2 enzymes that is currently under development for 
the treatment of inflammatory conditions such as rheumatoid arthritis, diabetic kidney disease, 
psoriasis, and AD. 
Through 04 June 2015, approximately 4300 subjects have received baricitinib. This group of 
subjects was comprised of healthy subjects, and patients with rheumatoid arthritis, psoriasis, 
diabetic kidney disease, rare auto-inflammatory syndromes, various degrees of renal impairment, 
and hepatic dysfunction. Baricitinib has been administered as single doses ranging from 1 to 40 
mg, multiple doses of up to 20 mg QD for 10 days, 10 mg QD for 28 days or 5 mg twice daily     
for 28 days in healthy subjects; and as a single 10-mg or 5-mg dose to subjects with mild to 
moderate or severe renal impairment respectively, as well as a single 5-mg dose to patients   with 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 324 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 11 
 
end stage renal disease. Treatment duration has ranged from single doses in healthy volunteers  
to approximately 3.5 years in rheumatoid arthritis  patients. 
More information about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably anticipated adverse events (AEs) of baricitinib are to be found in the 
Investigator’s Brochure (IB). 
2.2. Study Rationale 
Inhibition of JAK-STAT signaling by targeting multiple AD-associated cytokine pathways has 
the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key 
immune cells. Treatment of six patients with AD with a JAK1 and JAK3 inhibitor, tofacitinib,  
led to marked improvement in both objective measures of dermatitis and pruritus and patient- 
reported pruritus (Levy, 2015). 
Baricitinib is a potent and selective small molecule inhibitor of JAK1/2 enzymes. In vitro, 
baricitinib inhibits JAK1 and JAK2 with IC50 values in the single-digit nM range, yet it does not 
significantly inhibit a diverse panel of 28 kinases when tested at 100-fold of the IC50 against  
JAK1 and JAK2. In healthy volunteers, baricitinib demonstrated dose and time-dependent 
inhibition of cytokine-induced pSTAT3  (Shi, 2014). 
Study I4V-MC-JAHG will evaluate the safety and efficacy of baricitinib in patients with 
moderate-to-severe atopic dermatitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 325 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 12 
 
3. Objectives and Endpoints 
Table JAHG.1 shows the objectives and endpoints of the  study. 
 
Table JAHG.1. 
Objectives and Endpoints 
 
Objectives 
Endpoints 
Primary 
 To compare the proportion of moderate- 
to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in 
the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose 
group (2 mg and 4 mg) and placebo when 
treated daily for 16 weeks 
 EASI-50 at 16 weeks 
Secondary 
 To evaluate the absolute and percent 
change from baseline of the EASI with 
baricitinib compared to placebo 
 EASI at Weeks 1, 4, 8, 12, and 16 
 To evaluate the mean change from 
baseline compared to placebo for the 
SCORing Atopic Dermatitis (SCORAD) 
 SCORAD at  Weeks 1, 4, 8, 12, and  16 
 To evaluate the mean change from 
baseline compared to placebo for the 
Investigator’s Global Assessment (IGA) 
 IGA at Weeks 1, 4, 8, 12, and  16 
 To assess quality of life based on the 
Dermatologic Life Quality Index (DLQI) 
 DLQI at Weeks 1, 4, 8, 12, and 16 
 
To assess itch using the itch numerical 
rating scale (NRS) 
 Itch Numerical Rating Scale at Week 1, 4, 
8, 12, and 16 
 To characterize the pharmacokinetics of 
baricitinib in patients with moderate-to- 
severe atopic dermatitis 
 Plasma pharmacokinetic data 
Exploratory 
 To evaluate EASI response in patients 
based on their baseline total serum  IgE 
 EASI at Weeks 1, 4, 8, 12 and 16; Baseline 
total serum IgE 
 To evaluate total serum IgE over the 
course of treatment 
 Total serum IgE at baseline, Weeks 4 and 
16 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 326 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 13 
 
 
Exploratory (continued) 
 To evaluate changes in disease activity 
over the course of treatment 
 Patient-Oriented Eczema Measure (POEM) 
at  Weeks 1, 4, 8, 12, and 16 
 To evaluate changes in sleep quality over 
the course of treatment 
 Change from baseline with data from a 
wearable actigraphy device 
 To evaluate changes in nocturnal itch 
patterns over the course of treatment 
 Data from a wearable actigraphy device 
 To evaluate EASI response relative to 
filaggrin genotype 
 EASI-50 and filaggrin genotype data from 
peripheral baseline blood sample 
 To assess tissue biomarkers from biopsies 
 K16, Ki-67, and IL-4 will be assessed from 
each tissue biopsy (collected at baseline 
(lesion and non-lesion), at Week 4 (lesion), 
and at Week 16 (lesion and non-lesion) 
 To assess peripheral biomarkers 
mechanistically related to inhibition of 
JAK 1/2 mechanism 
 Peripheral biomarkers collected at baseline, 
Weeks 4 and 16 
 To perform subgroup assessments of 
response based on patient and disease 
characteristics 
 Ad hoc evaluation of potential prognostic 
and predictive disease characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 327 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 14 
 
4. Study Design 
4.1. Overview of Study Design 
I4V-MC-JAHG is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the 
safety and efficacy of baricitinib in patients with moderate-to-severe atopic dermatitis. The study 
design is illustrated in Figure JAHG.1. 
Figure JAHG.1. 
Illustration of study design for Clinical Protocol I4V-MC-JAHG. 
 
 
4.2. Scientific Rationale for Study Design 
This study will enroll moderate-to-severe atopic dermatitis patients for whom a systemic 
treatment such as baricitinib may be appropriate. A 16-week course of treatment is expected to 
enable an optimal assessment of efficacy based on previous baricitinib studies in an  
inflammatory skin condition. 
Relatively high (20% to 50%) placebo responses have been observed in previously published 
atopic dermatitis studies (Bissonnette, 2012; Beck, 2014; Epstein and Pinski, 1964). Therefore, a 
4:3:3 randomization scheme of placebo, 2 mg baricitinib and 4 mg baricitinib will be  
implemented.   Increased placebo enrollment across treatment groups has been reported to  
decrease placebo response and to also increase statistical power (Mallinckrodt,   2011). 
A standardization phase will be incorporated prior to randomization to minimize effects due to 
background treatment.  Beginning at standardization and continuing throughout the   study. 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 328 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 15 
 
patients will be provided a topical corticosteroid to be used as prescribed and may continue use 
of other allowed study-specified palliative care measures as specified in Section   6.8. 
The EASI and SCORAD are the best instruments available to measure clinical severity of AD 
(Schmitt, 2013). Several quality of life assessments are being utilized to evaluate the effect of 
baricitinib on patients’ quality of life. 
4.3. Justification for Dose 
This study will evaluate the safety and efficacy of 2 mg and 4 mg doses of baricitinib in patients 
with moderate-to-severe atopic dermatitis. The dose justification for AD is based on the Phase 2 
rheumatoid arthritis (RA) study (Study JADA), the reported Phase 3 RA studies (Study JADW 
and Study JADX) and the Phase 2 psoriasis study (Study  JADP). 
In these studies, all doses were generally well tolerated based on the observed adverse event 
profile and infrequent discontinuations of baricitinib dosing. The anticipated on-target, dose- 
limiting effect is a small decline in hemoglobin and hematocrit values. As described in Section 
4.4, this likely results from inhibition of erythropoietin signals via the JAK2/STAT5 signal 
transduction pathway (Klingmüller, 1997; Vera, 2008). These hematologic effects occur in 
higher-dose groups (8 mg daily) upon initiation of treatment and then  stabilize. 
The 2-mg and 4-mg doses have shown efficacy in RA with an acceptable safety profile. There  
was no additional efficacy associated with an 8-mg dose in the Phase 2 RA study, thus only 4 mg 
and 2 mg have been studied in the RA Phase 3 program. Doses less than 2 mg were not clearly 
effective in RA. 
In patients with moderate-to-severe plaque stage psoriasis, doses of 4 mg to 10 mg were found to 
be associated with statistically significant reductions in Psoriasis Area and Severity Index (PASI) 
score, with greater efficacy at the higher doses; however, the 8-mg and 10-mg doses were 
associated with a higher rate of AEs related to laboratory abnormalities (decreases in    
hemoglobin, neutrophils, and lymphocytes). The 2-mg and 4-mg dose groups had a pattern of   
AEs similar to placebo. The 2-mg dose did show numeric reductions in PASI score compared   
with placebo and statistically significant reductions in itch. Thus, in AD, the highest dose to be 
tested will be 4 mg, which would be anticipated to show efficacy together with an acceptable   
safety profile, and also provide the opportunity to cross reference to the large safety database   
from the RA Phase 3 program. The lower dose of 2 mg also has the opportunity to show efficacy  
in AD, where itch is a major component of the disease and may provide data that may be useful    
in the future for patients less than 18 years of  age. 
4.4. Benefit/Risk Assessment 
Baricitinib is a specific inhibitor of JAK1/2 and may offer potential benefit to patients with 
moderate-to-severe AD. Increases in serum creatinine and in both LDL and HDL cholesterol 
have been observed in Phase 1 and 2 studies with baricitinib (see Investigator’s   Brochure). 
Baricitinib is a specific inhibitor of JAK1/2 that has shown to be well-tolerated and effective in 
chronic inflammatory conditions such as rheumatoid arthritis (Keystone, 2015) and   psoriasis 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 329 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 16 
 
(Menter, 2014). baricitinib may offer potential benefit in a chronic inflammatory dermatologic 
condition such as AD. 
Phase 1 and 2 studies with baricitinib showed increased levels of serum creatinine and LDL and 
HDL cholesterol (see Investigator’s Brochure). Similar increased levels of creatinine and 
cholesterol were also seen in tofacitinib, a JAK1/3 inhibitor (Fleischmann, 2012; Kremer, 2012).  
In addition, reductions in absolute neutrophil counts have been reported with both baricitinib and 
tofacitinib. Other pathways that signal through JAK include granulocyte macrophage colony 
stimulating factor and granulocyte colony stimulating factor signal and erythropoietin (JAK2) 
(Parganas, 1998). The assessment of safety of baricitinib in this study will therefore also include, 
but will not be limited to, monitoring of creatinine, cholesterol, neutrophil and granulocyte  
counts, hemoglobin levels and rates of  infection. 
More information about the known and expected benefits, risks, and reasonably anticipated 
adverse events may be found in the Investigator’s Brochure. Information on adverse events 
expected to be related to the investigational product may be found in Section 7 (Development  
Core Safety Information) of the Investigator’s Brochure. Information on serious adverse events 
expected in the study population independent of drug exposure will be assessed by the sponsor in 
aggregate periodically during the course of the study and may be found in Section 6 (Effects in 
Humans) of the Investigator’s Brochure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 330 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 17 
 
5. Study Population 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, will not be  permitted. 
 
5.1. Inclusion Criteria 
Patients are eligible to be included in the study only if they meet all of the following   criteria: 
Type of Patient and Disease  Characteristics 
[1] Are at least 18 years of age at the time of Visit  1 
[2] Have moderate-to-severe AD, as determined by all of the  following: 
 EASI ≥12 at Visits 1 and 2 
 >10% of body surface area (BSA) involvement at Visits 1 and  2 
 Were diagnosed with AD at least 2 years before Visit  1 
With a history of inadequate clinical response, in the opinion of the 
investigator, to one or more of the three treatment categories listed below 
(used for at least 4 weeks): 
 Category 1: Hydration plus topical steroids and/or antibiotics (e.g., 
tetracycline, trimethoprim and sulfamethoxazole, cephalosporins, etc.) 
and or topical immune modulators (e.g.,  tacrolimus/pimecrolimus) 
 Category 2:  Systemic steroids and/or  phototherapy 
 Category 3: Cyclosporine and/or other immunomodulators (e.g., 
methotrexate, mycophenolate mofetal, and  azathioprine) 
[3] Agree to discontinue use of the following excluded medications for at least 4 
weeks prior to randomization (Visit 2) and throughout the  study 
 oral cyclosporine, steroids, and leukotriene  inhibitors 
 phototherapy 
 potent topical steroids (e.g., clobetasol) or topical immune modulators 
(e.g.,tacrolimus/pimecrolimus). 
 cyclosporine and/or other immunomodulators (e.g., methotrexate, 
mycophenolate mofetal, and  azathioprine) 
 
5.2. Exclusion Criteria 
Patients will be excluded from participating in the study if they meet any of the following 
criteria: 
Medical Conditions 
[4] Are female subjects who are pregnant or  nursing 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 331 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 18 
 
[5] Are females of childbearing potential who do not agree to use 2 forms of  
highly effective methods of birth control or remain abstinent while enrolled in 
the study and for at least 28 days following the last dose of investigational 
product 
Note: Females of nonchildbearing potential are defined as women ≥60 years 
of age, or women >40 and <60 years of age who have had a cessation of 
menses for at least 12 months, or women who are congenitally or surgically 
sterile (that is, have had a hysterectomy or bilateral oophorectomy or tubal 
ligation). 
The following birth control methods are considered highly effective (the 
patient should choose 2): 
 Oral, injectable, or implanted hormonal  contraceptives 
 Condom with a spermicidal foam, gel, film, cream, or  suppository 
 Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal 
foam, gel, film, cream, or suppository 
 Intrauterine device 
 Intrauterine system (for example, progestin-releasing  coil) 
 Vasectomized male (with appropriate post-vasectomy documentation 
of the absence of sperm in the  ejaculate). 
[6] 
Are males who do not agree to use 2 forms of highly effective birth control 
(see above) with female partners of childbearing potential while enrolled in 
the study, and for at least 28 days following the last dose of investigational 
product 
Are currently experiencing or have a history of any of the  following: 
[7] Other concomitant skin conditions (e.g., psoriasis, or lupus erythematosus) 
that would interfere with evaluations of the effect of study medication on 
atopic dermatitis 
[8] Erythrodermic, refractory or unstable skin disease that requires frequent 
hospitalizations and/or intravenous treatment for skin  infections 
[9] Immunocompromised and, in the opinion of the investigator, at an 
unacceptable risk for participating in the  study 
[10] Serious concomitant illness that could require the use of systemic 
corticosteroids or otherwise interfere with study participation or require active 
frequent monitoring (e.g., unstable chronic  asthma) 
[11] Organ transplant(s) (corneal transplant performed >3 months prior to 
screening may be allowed) 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 332 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 19 
 
[12] Clinically important deviation, in the opinion of the investigator, from normal 
limits in physical examination, vital sign measurements, and/or 
electrocardiograms, that is not associated with a chronic, well-controlled 
medical condition 
[13] Electrocardiogram (ECG) abnormalities at Visit 1 that, in the opinion of the 
investigator or the sponsor, are clinically significant and indicate an 
unacceptable risk for the patient’s participation in the study (Bazett’s 
corrected QT interval >470 msec for men and  women) 
[14] Have evidence of active or latent TB as documented by a positive PPD test   
(≥5 mm induration between approximately 2 and 3 days after application, 
regardless of vaccination history), medical history, or chest x-ray at screening. 
Exceptions are patients with a history of latent TB who have documented 
evidence of completing a course of appropriate  treatment. 
 If the PPD test is positive or not conducted and the patient has no medical 
history or chest x-ray findings consistent with active or latent TB, the 
patient should have a QuantiFERON®-TB Gold test or the T-SPOT.TB® 
test. If either of these tests is positive or indeterminate (a single re-test is 
allowed), the patient is excluded from the  study. 
[15] Active or latent granulomatous disorders or a non-tuberculous mycobacterial 
infection or opportunistic systemic infection (e.g., Pneumocystis carinii, and 
aspergillosis) within 6 months prior to  screening 
[16] Uncompensated heart failure, fluid overload, myocardial infarction, or 
evidence of ischemic heart disease or other serious cardiac disease within 12 
weeks of Visit 1 
[17] Uncontrolled arterial hypertension characterized by a repeated systolic blood 
pressure >160mm Hg or diastolic blood pressure >100mm Hg at the time of 
Visit 1 
[18] Malignancy (except for basal or squamous cell carcinoma completely excised 
without evidence of recurrence) or lymphoproliferative diseases or have signs 
or symptoms suggestive of possible lymphoproliferative disease, including 
lymphadenopathy or splenomegaly including  lymphoma 
Note: Patients with cervical carcinoma in situ that has been resected with no 
evidence of recurrence or metastatic disease, or with basal cell or squamous 
epithelial skin cancers that have been completely resected with no evidence of 
recurrence for at least 3 years may participate in the  study. 
[19] Evidence of HIV infection or are positive for HIV antibodies (based on 
history or point-of-care testing (POCT)) at Visit  1 
[20] Positive test for hepatitis B defined  as: 
a) positive for hepatitis B surface antigen (HbsAg),  or 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 333 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 20 
 
b) positive for anti-hepatitis B core antibody (HbcAb), but negative for hepatitis B 
surface antibody (HBsAb) or 
c) HBcAb positive and are HBV DNA positive  or 
d) for patients enrolled in Japan, positive for HBcAb and/or anti-hepatitis B surface 
antibody (HbsAb) and positive for hepatitis B deoxyribonucleic acid (HBV  
DNA). If any of the hepatitis B tests have an indeterminate result, confirmatory 
testing will be performed by an alternate  method. 
 
[21] Positive for anti-hepatitis C antibody with confirmed presence of hepatitis C 
virus, or chronic liver disease with the most recent available AST or ALT >2X 
the ULN 
[22] Serious and/or unstable mental and/or physical illness that, in the opinion of 
the investigator, poses an unacceptable risk for the patient’s participation in 
the study 
Prior/Concomitant Therapy 
[23] Received any oral JAK inhibitor (e.g., Xeljianz) within the past 6  months 
[24] Currently receiving any immunosuppressive therapy (e.g.,  cyclosporine) 
[25] Received any monoclonal antibody intended for AD (e.g., ustekinumab or 
dupilumab) within the past 6 months. 
[26] Currently using or expected to use concomitant medications or treatments for 
AD other than those allowed for use in the  protocol 
[27] Exposed to a live vaccine, including the nasal flu vaccine, within 12 weeks 
prior to planned enrollment (with the exception of herpes zoster vaccination; 
patients will be excluded if they were exposed to herpes zoster vaccination 
within 30 days of planned enrollment) or are expected to need/receive a live 
vaccine during the course of the study. 
Prior/Concurrent Clinical Trial Experience 
[28] Currently enrolled in any other clinical study involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this  study 
[29] Participated, within the last 30 days (for Japan, 4 months) in a clinical study 
involving an investigational product. If the previous investigational product 
has a long half-life (2 weeks or longer), at least 3 months or 5 half-lives 
(whichever is longer) should have passed. 
[30] Previously completed or withdrawn from this  study 
Diagnostics Assessments 
Have any of the following specific abnormalities on screening laboratory  tests: 
[31] AST or ALT >2X the ULN 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 334 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 21 
 
[32] Total bilirubin ≥1.5X the ULN 
[33] Hemoglobin <11.0 g/dL (100.0 g/L) 
[34] Total white blood cell count <2500  cells/µL 
[35] Neutropenia (absolute neutrophil count <1200  cells/µL) 
[36] Lymphopenia (lymphocyte count <750  cells/µL) 
[37] Thrombocytopenia  (platelets <100,000/µL) 
[38] eGFR <50 mL/min/1.73 m2 (based on CKD  EPI) 
Note: In the case of any of the aforementioned laboratory abnormalities, they may 
be repeated once within 1 week of the initial values, and values resulting from  
repeat testing may be used to assess enrollment  eligibility. 
Other Exclusions 
[39] Donated blood of more than 500 mL or blood products within 4 weeks prior to 
entry. 
[40] Unwilling to commit to refrain from donating blood or blood products during 
the study. 
[41] History of substance abuse (drug or alcohol) within the two years before 
screening. 
[42] Unable or unwilling to be available for the duration of the study and/or are 
unwilling to follow study  restrictions/procedures. 
[43] Unable or unwilling to have skin biopsies performed, unless exempted by the 
investigator. 
[44] Investigator site personnel directly affiliated with this study and/or their 
immediate families; immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally  adopted. 
[45] Employees of the sponsor. 
[46] Unwilling or unable to comply with the use of all potential data collection 
devices. 
 
5.3. Screen Failures 
Individuals who do not meet the criteria for participation in this study (screen failure) may be re- 
screened. Individuals may be re-screened once (time period from screen fail to re-screen to be 
determined by the investigator). If re-screening is performed, the individual must sign a new 
informed consent form (ICF) and will be assigned a new identification number. Additionally, all 
screening procedures must be conducted at re-screen to ensure all eligibility criteria are   met. 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 335 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 22 
 
6. Treatment 
6.1. Treatments Administered 
This study includes the treatment regimens outlined in Table JAHG.2 below. Doses of baricitinib 
or placebo will be administered orally. 
 
 
Table JAHG.2. 
Treatment Regimens 
 
    Treatment Group 
Dose (QD) 
Day 1 through Day 112 
 
2 mg LY 
(1  2-mg LY tab; 1  4-mg placebo tab) 
4 mg LY 
(1  2-mg placebo tab; 1  4-mg LY tab) 
Placebo 
(1  2-mg placebo tab; 1  4-mg placebo tab) 
Abbreviations: tab = tablet; LY = baricitinib 
 
 
The investigator or his/her designee is responsible for the  following: 
 explaining and verifying the correct use of the investigational agent(s) to the 
patient and site personnel 
 maintaining accurate records of investigational product dispensing and  collection 
 returning, at the end of the study, all unused investigational product to the 
sponsor, or its designee, unless the sponsor and sites have agreed all unused 
medication is to be destroyed by the site, as allowed by local  law 
 
6.2. Method of Treatment Assignment 
Patients who meet all criteria for enrollment will be randomized to double-blind treatment at   
Visit 2. Assignment to treatment groups will be determined by a computer-generated random 
sequence using an interactive response technology (IRT) system. The IRT system will be used to 
assign blister packs containing double-blind investigational product to each patient. The IRT 
system will dispense a number of blister packs adequate for each visit   interval. 
The randomization will be stratified by  country. 
 
6.2.1. Selection and Timing of Doses 
Patient treatment assignments will be based on the randomization scheme as described   above. 
On PK sample collection days (Appendix 2), specific fasting and dose timing requirements are 
outlined in Table JAHG.5 (Section  8.5.1). 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 336 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 23 
 
6.3. Blinding 
This is a double-blind study in which the patients, investigator, and study site personnel will be 
blinded to treatment allocation. 
To preserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is  complete. 
Emergency unblinding for AEs may be performed through an IRT system, which may  
supplement or take the place of emergency codes generated by a computer drug-labeling system. 
This option may be used ONLY if the patient’s well-being requires knowledge of the patient’s 
treatment assignment. All calls resulting in an unblinding event are recorded and reported by the 
IRT system. 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding  
of a patient’s treatment assignment is warranted. Patient safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the sponsor CRP prior to  
unblinding a patient’s treatment  assignment. 
If an investigator, site personnel performing assessments, or patient is unblinded to the treatment 
code assignment, the sponsor must be contacted  immediately. 
 
6.4. Packaging and Labelling 
The sponsor (or its designee) will provide the following investigational   products: 
 tablets containing 2 mg of baricitinib 
 tablets containing 4 mg of baricitinib 
 placebo to match baricitinib 2 mg tablets 
 placebo to match baricitinib 4 mg tablets 
Additionally, the sponsor (or its designee) will also provide the following concomitant therapy 
product: 
 triamcinolone 0.1% cream which should be used according to the labeling provided 
by the manufacturer or as directed by the  investigator 
Investigational products and triamcinolone 0.1% cream will be dispensed to the patient at the 
investigator’s study site. 
Investigational product will be packaged in blister packs. Investigational product packaging will 
be labeled with a unique identifier for drug dispensing by the IRT system. Blister packs will 
contain additional tablets to allow for sufficient administration of investigational product within 
the allowed visit internal window. 
Investigational product will be labeled according to the country’s regulatory requirements. All 
investigational products will be stored, inventoried, reconciled, and destroyed according to 
applicable regulations. Investigational products will be manufactured and tested by the sponsor 
or its representative in accordance with current Good Manufacturing Practices   (cGMP) 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 337 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 24 
 
requirements for clinical studies, and will be supplied with lot numbers, expiry dates, and 
certificates of analysis (as applicable). 
6.5. Investigational Products Storage and  Handling 
Investigational products should be stored between 15°C and 30°C. All investigational products 
should be stored in a secure and locked area with strictly limited access and monitored for 
temperature and will be allocated and dispensed by appropriately trained   personnel. 
Investigational products will be packaged in blister packs. Patients will be provided with enough 
blister packs for their visit intervals. Detailed records of the amounts of study drug received, 
dispensed and remaining at the end of the study will be  maintained. 
 
Investigational products will be labeled according to the country’s regulatory requirements. All 
investigational products will be stored, inventoried, reconciled, and destroyed according to 
applicable regulations. Investigational products will be supplied by the sponsor or its 
representative in accordance with current Good Manufacturing Practices, and will be supplied 
with lot numbers, expiry dates, and certificates of analysis (as  applicable). 
 
6.6. Dose Modification 
No dose modifications will be allowed. 
 
6.7. Treatment Compliance 
Patient compliance with study medication will be assessed at each visit. Compliance will be 
assessed by counting returned tablets. Deviation(s) from the prescribed dosage regimen should  
be recorded in the CRF. 
The patient will be considered significantly noncompliant if he or she misses more than 20% of 
the prescribed doses during the study. Similarly, a patient will be considered significantly 
noncompliant if he or she is judged by the investigator to have intentionally or repeatedly taken 
more than the prescribed amount of  medication. 
Patients found to be noncompliant with investigational product should be assessed to determine 
the reason for noncompliance, and educated and/or managed as deemed appropriate by the 
investigator to improve compliance. 
 
6.8. Concomitant Therapy 
The use of triamcinolone 0.1% cream will be allowed throughout the trial. Patients will be 
instructed to apply the triamcinolone 0.1% cream according to the labeling provided by the 
manufacturer or as directed by the investigator. The triamcinolone 0.1% cream container will be 
weighed at each visit to assess usage. 
All concomitant medication taken during the study must be recorded on the Concomitant 
Medication case report form (CRF). Treatment with concomitant atopic dermatitis therapies 
during the study is permitted only as outlined in the inclusion/exclusion criteria (Section 5.1 and 
Section 5.2) and as described in the paragraphs  below. 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 338 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 25 
 
Additional systemic drugs are to be avoided during the study, unless required to treat an   AE. 
Non-live seasonal vaccinations and/or emergency vaccination (such as rabies or tetanus 
vaccinations) are allowed. 
The following will be allowed as needed: use of topical antibiotics in the event of secondary 
infections of lesions; nonprescription shampoos; NSAIDs; diphenhydramine (50 mg); and 
topical moisturizers/emollients, bath oils, oatmeal bath preparations, bleach baths if using a  
stable regimen prior to enrollment, and salicylic acid preparations. Patients will be instructed to 
consult the investigator or other appropriate study personnel at the site before taking any new 
medications or supplements. 
 
6.9. Treatment after Study Completion 
6.9.1.   Continued Access 
The Investigational Product will not be made available to patients after the conclusion of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 339 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 26 
 
7. Discontinuation Criteria 
7.1. Discontinuation of Investigational  Product 
7.1.1. Temporary Interruption of Investigational  Product 
In some circumstances, it may be necessary to temporarily interrupt treatment as a result of AEs   
or abnormal laboratory values as described in Table JAHG.3.that may have an unclear  
relationship to investigational product. Except in cases of emergency, it is recommended that the 
investigator consult with the sponsor (or its designee) before temporarily interrupting   therapy. 
The investigator must obtain approval from the sponsor (or its designee) before restarting 
investigational product that was temporarily discontinued because of an AE or abnormal 
laboratory value. Investigational product must be held in the following situations involving 
laboratory abnormalities and may be resumed as noted in Table  JAHG.3. 
Table JAHG.3. 
Criteria for Temporary Interruption from Study Treatment 
 
 
Hold Investigational Product if the Following 
Laboratory Test Results Occur: 
Investigational Product May Be Resumed after 
Approval from Lilly (or its Designee) and When: 
WBC count <2000 cells/µL 
WBC count 2500 cells/µL 
ANC <1000 cells/L 
ANC >1200 cells/µL 
Lymphocyte count <500 cells/µL 
Lymphocyte count 750 cells/µL 
Platelet count <75,000/µL 
Platelet count 100,000/µL 
eGFR <40 mL/min/1.73 m2 (from serum 
 creatinine) 
eGFR 50 mL/min/1.73 m2 
ALT or AST >5 times the ULN 
ALT and AST return to <2 times the ULN, and 
investigational product is not considered to be the cause 
of enzyme elevation 
Hemoglobin <9 g/dL 
Hemoglobin 10 g/dL 
Symptomatic herpes zoster 
All skin lesions have crusted and are resolving 
Severe infection that, in the opinion of the 
investigator, merits the investigational product 
being discontinued 
Resolution of infection 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; eGFR = estimated glomerular filtration rate; min = minute; ULN = upper limit of normal; 
WBC = white blood cell. 
 
 
7.1.2. Permanent Discontinuation of Investigational  Product 
Any patient who is permanently discontinued from investigational product for an AE or  
abnormal laboratory result should have the reason for investigational product discontinuation 
reported as the AE or abnormal laboratory value. If any of the criteria listed in Section 7.1.1. 
above recur after investigational product is restarted, the investigator must obtain approval from 
the sponsor (or its designee) before restarting investigational product.  In addition, patients   will 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 340 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 27 
 
be permanently discontinued from investigational product if they experience any of the criteria 
listed in Table JAHG.4. 
Table JAHG.4 
Criteria for Permanent Discontinuation of Investigational Product 
 
Permanently Discontinue Investigational Product if any of the Following are Observed: 
ALT or AST >8 times the ULN 
ALT or AST >5 times the ULN persisting for more than 2 weeks after temporary interruption of investigational 
product 
ALT or AST >3 times the ULN and total bilirubin level >2 times the ULN 
ALT or AST >3 times the ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%) 
WBC count <1000 cells/L 
ANC <500 cells/L 
Lymphocyte count <200 cells/L 
Hemoglobin <8 g/dL 
Pregnancy 
Malignancy (except for successfully treated basal cell or squamous epithelial skin cancers) 
HBV DNA ≥29 IU/mLa 
 
Abbreviations: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate 
aminotransferase; HBV DNA = hepatitis B virus deoxyribonucleic acid; ULN = upper limit of normal; 
WBC = white blood cell. 
a If a HBV DNA result of ‘target detected’ 29 IU/mL or greater, then the patient should be referred to a hepatology 
specialist immediately. In selected cases, investigators may temporarily continue study drug in accordance with 
current immunomodulator management in the setting of HBV DNA positivity. This option may be considered in 
consultation with the sponsor (or its designee) and evaluation of individual patient risks and benefits. Refer to 
Section 8.4.5 for additional instruction on HBV DNA monitoring. 
 
7.1.3. Discontinuation of Inadvertently Enrolled  Patients 
If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the sponsor CRP and the investigator to 
determine if the patient may continue in the study. If both agree it is medically appropriate to 
continue, the investigator must obtain documented approval from the sponsor CRP to allow the 
inadvertently enrolled patient to continue in the study with or without treatment with 
investigational product. 
 
7.1.4. Permanent Discontinuation from the  Study 
Some possible reasons that may lead to permanent discontinuation  include: 
 Enrollment in any other clinical study involving an investigational product or enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this study 
 Participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical practice  (GCP) 
 Investigator Decision 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 341 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 28 
 
o the investigator decides that the patient should be discontinued from the   study 
o if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study indication, 
discontinuation from the study occurs prior to introduction of the new  agent 
 Patient  Decision 
Patients who discontinue the study early will have early termination (ET) procedures performed 
as shown in the Schedule of Activities (Appendix  2). 
7.1.5. Patients Lost to Follow-Up 
A patient will be considered lost to follow-up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.  Site personnel are expected to make   
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by the site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 342 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 29 
 
8. Study Assessments and  Procedures 
Appendix 2 lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for  timing). 
Appendix 3 lists the laboratory tests that will be performed for this  study. 
Appendix 4 provides the hepatic monitoring tests for treatment-emergent   abnormalities. 
Additionally, a study addendum will be compiled to detail the capture of photographs from 
selected lesions for patients enrolled at up to three selected study sites. These photographs will 
permit documentation of the clinical response through sequential photography of a selected 
lesion or involved area before and following study drug  treatment. 
 
Unless otherwise stated in the subsections below, all samples collected for specified laboratory 
tests will be destroyed within 60 days of receipt of confirmed test results. Certain samples may  
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards. 
8.1. Efficacy Assessments 
Study procedures and their timing are summarized in the Schedule of Activities (Appendix   2). 
 
8.1.1. Primary Efficacy Assessments 
The clinical outcome measure that will be used in this study is the EASI score (specifically, the 
proportion of patients achieving a 50% reduction in EASI or  EASI-50). 
 Eczema Area and Severity Index (EASI) scores: The EASI assesses extent of disease 
at four body sites and measures four clinical signs: (1) erythema, (2) 
induration/papulation, (3) excoriation, and (4) lichenification each on a scale of 0 to 3. 
EASI confers a maximum score of 72. EASI evaluates two dimensions of atopic 
dermatitis: disease extent and clinical signs.
 
8.1.2. Secondary Efficacy Assessments 
 Mean and Percentage change in Eczema Area and Severity Index (EASI) scores: See 
above.
 
 SCORing Atopic Dermatitis (SCORAD): The SCORAD index uses the rule of nines to 
assess disease extent and evaluates five clinical characteristics to determine disease 
severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation and (5) 
lichenification. SCORAD also assesses subjective symptoms of pruritus and sleep loss 
with Visual Analogue Scales (VAS). These three aspects: extent of disease, disease 
severity and subjective symptoms combine to give a maximum possible score of 103.
 
 
Investigator’s Global Assessment (IGA): The IGA consists of a 6-point severity scale 
from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate 
disease, 4 = severe disease and 5 = very severe disease). IGA uses clinical characteristics
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 343 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 30 
 
of erythema, infiltration, papulation, oozing and crusting as guidelines for the overall 
severity assessment. 
 
 
Dermatology Life Quality Index (DLQI): The DLQI is a simple, patient-administered, 
10-question, validated, quality-of-life questionnaire that covers 6 domains including 
symptoms and feelings, daily activities, leisure, work and school, personal relationships, 
and treatment. The recall period of this scale is over the “last week.” Response categories 
include “not at all,” “a lot,” and “very much,” with corresponding scores of 1, 2, and 3 
respectively and unanswered (“not relevant”) responses scored as 0. A DLQI total score 
of 0 to 1 is considered as having no effect on a patient’s health-related quality of life, and 
a 5-point change from baseline is considered as the minimal clinically important 
difference threshold (Khilji, 2002; Hongbo, 2005).
 
 
Itch Numerical Rating Scale (NRS): The Itch NRS is a patient-administered, 11 point 
horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 
representing “worst itch imaginable.”  Overall severity of a patient’s itching is  
indicated by circling the number that best describes the worst level of itching in the 
past 24 hours. Analyses were performed to support a responder definition that was 
defined as proportion of patients achieving an Itch NRS ≥4-point reduction from 
baseline for patients who had baseline Itch NRS  ≥4.
8.1.2.2 Exploratory Efficacy Assessments 
Data on the following exploratory efficacy measures will be collected at the times shown in the 
Schedule of Activities (Appendix 2): 
 Patient-Oriented Eczema Measure (POEM): The Patient-Oriented Eczema Measure 
(POEM) was originally developed to help address the imbalance between physician and 
patient-based outcome measures in eczema research. Patients answer simple questions 
about the frequency of seven symptoms: itch, sleep disturbance, skin bleeding, skin 
weeping/oozing, skin cracking, skin flaking, and skin dryness/roughness over the last 
week. The total score from this assessment reflects overall disease activity. The POEM 
utilizes a 5-point Likert scale for each question and is intended for ages 1-60 years. 
POEM scores can range from 0 to 28 where lower total scores reflect lower disease 
activity and higher scores reflect higher disease activity (Charman, 2004).
 
 Actigraphy Device: A hypoallergenic wrist watch-like device that is used to collect 
sleep/wake patterns and quantify nocturnal scratching events (Ferguson, 2015).
 
8.1.3. Appropriateness of Primary Efficacy  Measure 
 Eczema Area and Severity Index (EASI): The EASI is one of the best instruments 
available to measure clinical signs of AD. EASI utilizes objective physician estimates of 
disease extent and severity. The EASI is valid and internally consistent and has adequate 
intraobserver reliability, intermediate interobserver reliability, and adequate 
responsiveness. One advantage of the EASI is its unidimensionality; that is, it only 
measures clinical signs of AD and does not include symptoms. Another advantage of the
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 344 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 31 
 
EASI is that it measures the intensity of the lesions at multiple body parts (rather than 
relying on a representative lesion) (Schmitt, 2013). 
 
8.2. Adverse Events 
The investigator remains responsible for following, through an appropriate health care option,   
AEs that are (1) serious or otherwise medically important, (2) considered related to the 
investigational product or the study, or that (3) caused the patient to discontinue the  
investigational product before completing the study. The patient should be followed until the  
event resolves, stabilizes with appropriate diagnostic evaluation, or is reasonably explained. The 
frequency of follow-up evaluations of the AE is left to the discretion of the   investigator. 
The sponsor has standards for reporting AEs that are to be followed regardless of applicable 
regulatory requirements that may be less stringent. Study site personnel will record the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. All AEs collected in the study 
CRF will be validated and reported in the final study  report. 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect. 
After the ICF is signed, study site personnel will record, via the CRF/electronic data entry, the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study. In addition, site personnel will 
record any change in the condition(s) and any new conditions as AEs. Investigators should  
record their assessment of the potential relatedness of each AE to protocol procedure or 
investigational product. 
Investigators must document their review of each laboratory safety  report. 
Any clinically significant findings from ECGs, laboratory tests, vital sign measurements, and 
other procedures that result in a diagnosis should be reported to the sponsor or its designee. In 
addition, all AEs occurring after the patient receives the first dose of the investigational product 
must be reported to the sponsor or its  designee. 
Investigators will be instructed to report to the sponsor or its designee their assessment of the 
potential relatedness of each AE to protocol procedure or investigational product via the case 
report form. 
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the  study. 
Cases of pregnancy that occur during maternal or paternal exposures to the investigational   
product should be reported. Data on fetal outcome and breast-feeding are collected for regulatory 
reporting and drug safety evaluation. 
Study site personnel must alert the sponsor or its designee immediately of the investigator 
unblinding a patient’s treatment group assignment for any  reason. 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 345 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 32 
 
If a patient’s treatment is discontinued as a result of an AE, study site personnel must clearly 
report to the sponsor or its designee the circumstances and data leading to any such 
discontinuation of treatment. 
8.2.1. Adverse Events/Laboratory Results of Special Interest  
Adverse events or laboratory results of special interest include infections; myelosuppressive 
events of anemia, leukopenia, neutropenia, lymphopenia, thrombocytopenia; thrombocytosis; 
hyperlipidemia; hypercholesterolemia; and elevations in ALT/AST (≥3X ULN) and total 
bilirubin (≥2X ULN). 
8.2.2. Serious Adverse Events 
Study site personnel must alert the sponsor or its designee of any SAE within 24 hours of 
investigator awareness of the event via a sponsor-approved method. Alerts issued via telephone 
are to be immediately followed with official notification on study-specific SAE   forms. 
All SAEs will be reported in the study CRF and on the approved study-specific SAE form by the 
study site personnel. In addition, the study-specific SAE forms will be collected by 
sponsor/designee and subsequently entered into the clinical study database and the study safety 
database. Investigators will be required to update the study-specific SAE forms when new 
information becomes available, and address questions from the sponsor/designee until the SAE 
has been fully resolved or explained to the satisfaction of the sponsor. The SAE data from both 
CRF and study-specific SAE forms will be validated and included in the final CSR. If the SAE 
cases are closed after the completion of database lock, such information may not be included in  
the final study report. Such additional information will continue to be collected in the study- 
specific SAE form, and be reported either in an amendment to study report if such information  
lead to a clinically significant changes in the conclusion of the study; or in the annual 
Development Safety Update Report (DSUR) or IB update if the information from the SAE does 
not alter the overall conclusion of the study. 
An SAE is any AE from this study that results in one of the following  outcomes: 
 death 
 initial or prolonged inpatient hospitalization 
 a life-threatening experience (that is, immediate risk of  dying) 
 persistent or significant  disability/incapacity 
 congenital anomaly/birth defect 
 considered significant by the investigator for any other  reason 
 
Important medical events that may not result in death, be life-threatening, or require  
hospitalization may be considered SAEs when, based upon appropriate medical judgment, they 
may jeopardize the patient and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Previously planned (prior to signing of ICF) surgeries should   
not be reported as SAEs unless the underlying medical condition has worsened during the course 
of the study. 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 346 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 33 
 
SAEs occurring after a patient has taken the last dose of the investigational product will be 
collected in the pharmacovigilance system and clinical data collection database for 30 days after 
the last dose of the investigational product, regardless of the investigator’s opinion of causation. 
Thereafter, SAEs are not required to be reported unless the investigator feels the events were 
related to either investigational product, drug delivery system, or a protocol  procedure. 
Sponsor/designee has the option to request follow up information or clarification of existing 
information from the investigators up to closure of the case. SAEs should be followed by the 
investigator until resolution of all queries, clinical recovery is complete or until a stable clinical 
endpoint has been reached. Follow up may therefore continue after the patient has been  
discharged from the study. The type and extent of follow up undertaken will be determined for 
each individual case and depends upon the nature, severity, and medical significance of the  
report. The follow up may include supplemental investigations, additional laboratory tests, 
histopathological examinations, or consultations with other health care professionals. If a patient 
dies during participation in the study, the follow up may include a copy of any post-mortem 
findings, if available. 
The investigator site will be required to contact the patient in accordance with their procedures to 
obtain necessary information to provide updates to the study-specific SAE forms. Requests for 
outstanding information from the investigational site to patients should be maintained as part of  
the clinical study documents. 
8.2.2.1. 
Suspected Unexpected Serious Adverse  Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed  
in the IB and that the investigator identifies as related to investigational product or procedure. 
United States 21 CFR 312.32 and European Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participating countries  
require the reporting of SUSARs. The sponsor has procedures that will be followed for the 
recording and expedited reporting of SUSARs that are consistent with global regulations and the 
associated detailed guidances. 
 
8.2.3.   Complaint Handling 
The Sponsor collects product complaints on investigational products and drug delivery systems 
used in clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product improvements. 
Patients will be instructed to contact the investigator as soon as possible if he or she has a 
complaint or problem with the investigational product so that the situation can be   assessed. 
 
8.3. Treatment of Overdose 
Refer to the baricitinib Investigator’s  Brochure. 
 
8.4. Safety Assessments 
Safety assessments include vital signs, physical examination, electrocardiograms, AEs, patient- 
reported scale data, and safety laboratory  testing. 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 347 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 34 
 
 
 
8.4.1. Physical examination 
A complete physical examination will be performed during Visit 1 (screening). Directed physical 
examinations will be performed according to the Schedule of Activities (Appendix 2) and may    
be repeated at the investigator’s discretion any time a patient presents with physical   complaints. 
 
8.4.2. Electrocardiograms 
For each patient, an electrocardiogram (ECG) should be performed according to the Schedule of 
Activities (Appendix 2) and as deemed necessary by the  investigator. 
Any clinically significant findings from ECGs that result in a diagnosis and that occur after the 
patient receives the first dose of the investigational treatment should be reported to Lilly or its 
designee as an AE via the  CRF. 
8.4.3. Vital Signs 
For each patient, vital signs measurements should be conducted according to the Schedule of 
Activities (Appendix 2) and following study specific recommendations provided by the sponsor 
for the study. 
Any clinically significant findings from vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
 
8.4.4. Laboratory Tests 
For each patient, laboratory tests detailed in (Appendix 3) should be conducted according to the 
Schedule of Activities (Appendix 2). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of investigational product should be reported to the 
sponsor or its designee as an AE via designated data transmission   methods. 
8.4.5. Hepatitis B virus (HBV) DNA  monitoring 
Patients who are HBcAb positive and HBV DNA negative (undetectable) at Visit 1 will require 
HBV DNA monitoring every 3 months and at the patient’s last visit (V8 or ET), regardless of 
their HBsAb status. If the HBV DNA result is ‘target detected’ ≥29 IU/mL, then the patient 
should be referred to a hepatology specialist immediately. In selected cases, investigators may 
temporarily continue study drug in accordance with current immunomodulator management in 
the setting of HBV DNA positivity. This option may be considered in consultation with the 
sponsor (or its designee) and evaluation of individual patient risks and benefits. The following 
actions should be taken in response to HBV DNA test  results: 
 If a result of “target detected” is obtained at any time during the study with a value   of 
≥29 IU/mL, refer to Table  JAHG.4. 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 348 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 35 
 
 
For patients enrolled at study sites in Japan only, if a patient is HbsAb positive and negative for 
HBV DNA at Visit 1, HBV DNA needs to be checked at least monthly and at the patient’s last 
visit (V8 or ET). 
 
8.4.6. Quick Inventory of Depressive Symptomatology-Self Report 16 
(QIDS-SR16) 
For each patient, the QIDS-SR16 should be taken according to the Schedule of Activities 
(Appendix 2). 
The QIDS-SR16 is a self-administered 16-item instrument intended to assess the existence and 
severity of symptoms of depression as listed in the American Psychiatric Association’s 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) (American 
Psychiatry Association [APA] 1994). The QIDS-SR16 scale is used to assess the potential  
impact of treatment on new onset or changes in depression, thoughts of death, and /or suicidal 
ideation severity. A patient is asked to consider each statement as it relates to the way they have 
felt for the past 7 days. There is a 4-point scale for each item ranging from 0 to 3. The 16   items 
corresponding to 9 depression domains are summed to give a single score ranging from 0 to 27, 
with higher scores denoting greater symptom severity. The domains assessed by the instrument 
include: (1) sad mood, (2) concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) 
energy/fatigue, (7) sleep disturbance (initial, middle, and late insomnia or   hypersomnia), 
(8) decrease/increase in appetite/weight, and (9) psychomotor agitation/retardation (Rush,   2003). 
 
8.4.7. Safety Monitoring 
The sponsor will periodically review evolving aggregate safety data within the study by 
appropriate methods. 
If a patient experiences elevated ALT ≥3X ULN, ALP ≥3X ULN, or elevated TBL ≥2X ULN, 
clinical and laboratory monitoring should be initiated by the investigator. Details for hepatic 
monitoring depend upon the severity and persistence of observed laboratory test abnormalities.  
To ensure patient safety and comply with regulatory guidance, the investigator is to consult with 
the sponsor CRP regarding collection of specific recommended clinical information and follow- 
up laboratory tests (Appendix 4). 
8.5. Pharmacokinetics 
8.5.1. PK sample collection 
A total of 6 venous blood samples (approximately 5 mL per sample) for the measurement of 
baricitinib concentrations will be drawn at visits scheduled within the time windows specified in 
the Schedule of Activities (Appendix 2). Specific dosing and fasting requirements for each PK 
visit are described in Table JAHG.5  below. 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 349 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 36 
 
Table JAHG.5. 
Timing of Dosing and Fasting Requirements for PK Sample 
Collection Visits 
 
Events 
Visit 
2 
4 
5 
6 
7 
ET 
Overnight 
(8-hr) fast 
Yes 
No 
No 
No 
Yes 
No 
Take study 
drug 
At clinic 
At home 
At home 
At clinic 
At clinic 
N/A 
Morning Fast 
Until PK 
samples are 
taken 
N/A 
N/A 
N/A 
Until PK 
sample is 
taken 
N/A 
Sample time 
windows 
relative to dose 
 
Pre-dose 
 
15-30min 
post-dose 
1.5 – 4 hr 
post-dose 
4 – 8 hr 
post-dose 
Pre-dose 
30-90 min 
post-dose 
N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 350 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 37 
 
On all PK sample collection days, patients should take all study medication within 5   minutes. 
At Visits 2 and 7, patients will be asked to arrive at the study site after an overnight fast. Patients 
will receive an oral dose of placebo or baricitinib at the study site and will remain fasted until PK 
blood samples have been collected. A light snack will be provided after PK samples have been 
collected. 
At Visits 4 and 5, patients will be advised to take the study drug at home. Patients will then go  
to the study site in the scheduled time window for study  assessments. 
At Visit 6, patients will be advised to NOT take study drug prior to visiting the study site. A 
single blood sample will be collected prior to the patient taking their drug at the study   site. 
A single PK sample will be obtained, whenever possible, at the early termination visit. In the 
event of an SAE, up to 2 additional blood samples may be taken at the investigator’s discretion, 
up to 6 hours after the reported event and within 24 hours of the patient’s last  dose. 
For any PK sample taken, the actual date and time (24-hour clock) of PK sample collection as 
well as the date and time of the last 2 dose administrations prior to the PK sample should be 
recorded. 
The sponsor, or its designee, will provide instructions for the collection and handling of blood 
samples. 
8.5.2. PK sample assay 
Plasma samples will be assayed for baricitinib using a validated liquid chromatography with 
tandem mass spectrometry (LC/MS/MS) method at a laboratory approved by the sponsor. 
Samples from patients receiving baricitinib will be assayed. PK samples from patients on 
placebo are not planned to be assayed. 
8.5.3. PK sample storage and retention 
Bioanalytical samples collected to measure investigational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study. Pharmacokinetic samples will  
be kept in storage at a laboratory facility designated by the sponsor and may also be assayed for 
additional exploratory analyses. Pharmacokinetic results will not be provided to investigative   
sites or blinded personnel until the study has been  unblinded. 
 
8.6. Pharmacodynamics 
Further pharmacodynamic data, beyond efficacy and biomarker data, will not be   collected. 
 
8.7. Genetics 
A blood sample (approximately 10 mL) will be collected for pharmacogenetic analysis as 
specified in the Schedule of Activities (Appendix 2) where local regulations and ethical review 
boards (ERBs) allow. 
Samples will not be used to conduct unspecified disease or population genetic research either 
now or in the future.  Samples will be used to investigate variable response to baricitinib and   to 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 351 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 38 
 
investigate genetic variants thought to play a role in atopic dermatitis or other inflammatory skin 
disorders. Assessment of variable response may include evaluation of AEs or differences in 
efficacy.  These studies may include but are not limited to evaluate their association with  
observed response to baricitinib. 
All pharmacogenetic samples will be coded with the patient number. Only investigator site 
personnel can link these samples, and any data generated, back to the patient. Samples will be 
destroyed according to a process consistent with local  regulations. 
Samples will be retained for a maximum of 15 years after the last patient visit for the study, or  
for a shorter period if local regulations and/or ERBs impose shorter time limits, at a facility 
selected by the sponsor. This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in drug development or when the drug is commercially  available. 
Molecular technologies are expected to improve during the 15-year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or exome 
sequencing, genome wide association studies, candidate gene studies, and epigenetic analyses. 
Regardless of technology utilized genotyping data generated will be used only for the specific 
research scope described here. 
8.8. Biomarkers 
Skin biopsies, serum, plasma, and whole blood ribonucleic acid (RNA) samples for non-genetic 
biomarker research will be collected at the times specified in the Schedule of Activities 
(Appendix 2) where local regulations and ERBs  allow. 
Samples may be used for research on the drug target, disease process, pathways associated with 
atopic dermatitis, mechanism of action of baricitinib, and/or research method or in validating 
diagnostic tools or assay(s) related to atopic  dermatitis. 
All biomarker samples will be coded with the patient number. Only investigator site personnel 
can link these samples, and any data generated, back to the patient. Samples will be destroyed 
according to a process consistent with local  regulations. 
Samples will be retained for a maximum 15 years after the last patient visit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by  
the sponsor. This retention period enables use of new technologies, response to regulatory 
questions, and investigation of variable response that may not be observed until later in drug 
development or when the drug is commercially  available. 
8.8.1. Skin Biopsies 
Patients will be required to provide skin punch biopsy samples collected per the Schedule of 
Activities (Appendix 2), unless exempted by the  investigator. 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
and used to study biomarkers related to atopic dermatitis and/or related to the mechanism of 
action of baricitinib.  Techniques used may include but are not limited to   immunohistochemistry 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 352 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 39 
 
and microarray expression profiling. Samples will be de-identified as described in International 
Conference on Harmonisation (ICH) guideline E15, and may be used for exploratory microarray 
expression profiling or transcriptome sequencing. Detailed instructions for sample collection and 
handling will be provided by the sponsor. Samples will be sent to a sponsor-designated lab for 
immunohistochemistry. 
. 
 
8.8.2. Nonpharmacogenetic Biomarkers 
Peripheral serum samples (approximately 10 mL) will be collected at pre- and post-treatment 
time points for the assessment of biomarkers expected to be mechanistically related to JAK 1/2 
inhibition and/or the atopic dermatitis disease state. A blood sample for genotyping of filaggrin 
will also be collected. Sample processing and handling instructions will be provided by the 
sponsor. Samples will be sent to a sponsor-designated lab for   evaluation. 
Exploratory biomarker serum, plasma, and blood for mRNA samples will also be collected and 
stored at a sponsor-designated vendor. 
 
8.9.    Health Economics 
The self-reported questionnaires will be administered according to the Schedule of Activities 
(Appendix 2). The questionnaires will be administered in countries where they have been 
translated into the native language of the region and linguistically  validated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 353 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 40 
 
9. Statistical Considerations and Data  Analysis 
9.1. Determination of Sample Size 
Approximately 90 patients will be enrolled using a 4:3:3 randomization scheme of placebo, 2 mg 
baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 20%, 
approximately 72 patients will complete the  study. 
This sample size provides 80% power to see a difference in EASI-50 between placebo and either 
baricitinib treatment group of 35%, assuming a placebo response rate of 40%, using a 1-sided chi-
square test with alpha =  0.05. 
An interim analysis may be conducted to assess variability, effect size, and placebo effect to 
evaluate the need for an increase in the number of patients randomized up to a total of 120 and/or  
a possible change in randomization ratio. Details around this potential interim analysis will be 
described in the statistical analysis plan (SAP) or in interim analysis planning documentation, as 
appropriate. 
9.2. General Statistical Considerations 
Statistical analysis of this study will be the responsibility of the sponsor or its designee. A 
detailed statistical analysis plan (SAP) will be provided by the sponsor or its designee, and will 
be finalized prior to database lock and  unblinding. 
Investigator site data will be pooled for statistical analysis  purposes. 
All tests of treatment effects will be conducted at a 1-sided alpha level of 0.05, unless otherwise 
stated. 
Data analyses will be provided by treatment groups and for all study patients combined wherever 
appropriate. For continuous variables, summary statistics will include number of patients, mean, 
median, standard deviation, minimum, and maximum.   Categorical endpoints will be   
summarized using number of patients, frequency, and  percentages. 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making the change, will be described 
in the clinical study report. Additional exploratory analyses of the data will be conducted as 
deemed appropriate. 
9.3. Treatment Group Comparability 
9.3.1. Patient Disposition 
All patients who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation will be 
given.  Data tabulations will summarize the following patient numbers, per treatment   group: 
 Enrolled 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 354 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 41 
 
 Received treatment 
 Violated the protocol 
 Completed the protocol 
 Withdrew because of: 
o Adverse event 
o Lack of efficacy 
o Consent withdrawal 
o Other reasons, as applicable 
A detailed description of patient disposition will be provided at the end of the   study. 
 
9.3.2. Patient Characteristics 
Baseline and demographic characteristics will be summarized descriptively by treatment group 
and overall. 
9.3.3. Concomitant Therapy 
Concomitant use of topical corticosteroids will be summarized by treatment  group. 
 
9.4. Primary and Secondary Analyses 
9.4.1. Primary Analyses 
The primary outcome will be the proportion of patients achieving EASI-50 in each treatment 
arm. The primary analysis will be performed using all randomized patients utilizing a Non- 
Responder Imputation (NRI) analysis. The proportion of patients achieving EASI-50 in the 
placebo arm will be compared to proportion of patients in each of the baricitinib arms using a 
one-sided chi-square test with alpha=0.05. As this is a proof of concept study, there will not be 
any adjustment of alpha for  multiple comparisons. 
For EASI-50 endpoint, all Non-Responders, as well as all patients who discontinue study 
treatment at any time prior to the time point of interest or discontinue from the study for any 
reason, will be defined as Non-Responders for the NRI analysis. Randomized patients without at 
least 1 post-baseline observation will also be defined as Non-Responders for the   NRI analysis. 
9.4.2. Secondary Analyses 
Continuous secondary endpoints will be summarized and analyzed using treatment groups by use 
of a mixed effects model with treatment as the main factor and baseline values as covariates. The 
treatment (intercept) effects and their standard errors from the mixed effects model will be used   
to produce p-values and 90% confidence intervals for the treatment   comparison. 
For continuous endpoints collected longitudinally, missing data will assumed to be missing at 
random and a mixed model repeated measures (MMRM) approach will be used. Other 
imputation techniques, such as multiple imputation, may be utilized in sensitivity   analyses. 
Categorical secondary endpoints will be summarized and analyzed using a chi-square test or 
Fisher’s exact test, if needed. 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 355 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 42 
 
9.4.3. Tertiary/Exploratory Analyses 
Continuous secondary endpoints will be summarized and may be analyzed by use of a mixed 
effects model with treatment as the main factor and baseline values as covariates. The treatment 
(intercept) effects and their standard errors from the mixed effects model will be used to produce 
p-values and 90% confidence intervals for the treatment  comparison. 
Categorical secondary endpoints will be summarized and may be analyzed using a chi-square 
test or Fisher’s exact test, if needed. 
 
9.5. Safety Analyses 
Safety analyses will be conducted on all patients who received at least one dose of study drug. 
No statistical comparisons of treatment groups will be completed for safety   endpoints. 
All adverse events will be summarized and listed. The incidence of symptoms for each treatment 
will be presented by severity and by association with study drug as perceived by the investigator. 
Symptoms reported to occur prior to enrollment will be distinguished from those reported as new 
or increased in severity during the study. 
Additional safety parameters that will be assessed include safety lab parameters and vital signs. 
The parameters will be listed, and summarized using standard descriptive statistics. Additional 
analysis will be performed if warranted upon review of the  data. 
9.6. Pharmacokinetic/Pharmacodynamic  Analyses 
The pharmacokinetics of baricitinib will be assessed using population PK analysis techniques. 
The relationship between the primary and secondary efficacy endpoints and plasma exposure, 
race, and age of onset may be explored. PK and PD data may be combined with prior data for an 
integrated analysis. 
 
9.7. Other Analyses 
9.7.1. Health Economics 
Patient reported outcome endpoints will be summarized and analyzed using treatment groups by 
use of a mixed effects model with treatment as the main factor and baseline values as covariates. 
The treatment (intercept) effects and their standard errors from the mixed effects model will be 
used to produce p-values and 90% confidence intervals for the treatment   comparison. 
 
9.7.2. Biomarkers 
Biomarker data from all patients undergoing biomarker assessments will be analyzed. Biomarker 
data will be summarized and listed, and may be displayed  graphically. 
 
9.8.    Interim Analyses 
A limited number of pre-identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan, prior to the interim or final database lock, in order to initiate the 
final population pharmacokinetics/pharmacodynamics (PK/PD) model development   processes 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 356 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 43 
 
for interim or final analyses. Information that may unblind the study during the analyses will not  
be reported to study sites or blinded study team until the study has been  unblinded. 
An interim analysis may be conducted to assess variability of response, effect size, and placebo 
effect during the course of the study in order to evaluate the potential need for an increase in the 
number of patients randomized up to a total of 120 and/or a possible change in randomization 
ratio. Details around this potential interim analysis will be described in the statistical analysis 
plan (SAP) or in interim analysis planning documentation, as  appropriate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 357 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 44 
 
10. Study Governance  Considerations 
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process 
10.1.1. Informed Consent 
The investigator is responsible for ensuring  that: 
 the patient understands the potential risks and benefits of participating in the 
study 
 informed consent is given by each patient or legal representative.  This  
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol procedures and prior to the administration of 
investigational product. 
 any questions the patient may have throughout the study are answered and 
shares, in a timely manner, any new information that may be relevant to the 
patient’s willingness to continue his or her participation in the  study. 
 
10.1.2. Ethical Review 
The investigator or designee must give assurance that the ethical review board (ERB) was 
properly constituted and convened as required by International Conference on Harmonisation 
(ICH) guidelines and other applicable laws and  regulations. 
Documentation of ERB approval of the protocol and the ICF must be provided to the sponsor 
before the study may begin at the investigative site(s). The sponsor or its representatives must 
approve the ICF, including any changes made by the ERBs, before it is used at the investigative 
site(s).  All ICFs must be compliant with the ICH guideline on   GCP. 
The study site’s ERB(s) should be provided with the  following: 
 current IB and updates during the course of the  study 
 ICF 
 relevant curricula vitae 
10.1.3. Regulatory Considerations 
This study will be conducted in accordance  with: 
 consensus ethics principles derived from international ethics guidelines, including 
the Declaration of Helsinki and Council for International Organizations of   
Medical Sciences (CIOMS) International Ethical  Guidelines 
 applicable ICH GCP  Guidelines 
 applicable laws and regulations 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 358 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 45 
 
The investigator or designee will promptly submit the protocol to applicable   ERB(s). 
All or some of the obligations of the Sponsor may be assigned to a Contract Research 
Organization (CRO). 
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and/or other study-related 
data. 
 
10.1.4. Investigator Information 
Physicians with a specialty in dermatology will participate as investigators in this clinical   study. 
 
10.1.5. Protocol Signatures 
The sponsor’s responsible medical officer will approve the protocol, confirming that, to the best  
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a sponsor  representative. 
 
10.1.6. Final Report Signature 
The CSR coordinating investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study. 
The investigator with the most enrolled patients will be requested to serve as the CSR 
coordinating investigator. If this investigator is unable to fulfill this function, another 
investigator will be chosen by the sponsor to serve as the CSR coordinating   investigator. 
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study. 
 
10.2. Data Quality Assurance 
To ensure accurate, complete, and reliable data, the sponsor/designee will perform the   following: 
 provide instructional material to the study sites, as  appropriate 
 sponsor start-up training to instruct the investigators and study coordinators. This 
training will give instruction on the protocol, the completion of the CRFs, and 
study procedures. 
 make periodic visits to the study site 
 be available for consultation and stay in contact with the study site personnel by 
mail, telephone, and/or fax 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 359 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 46 
 
 review and evaluate CRF data and use standard computer edits to detect errors in 
data collection 
 conduct a quality review of the database 
In addition, the sponsor/designee will periodically check a sample of the patient data recorded 
against source documents at the study site. The sponsor/designee and/or regulatory agencies 
may audit the study at any time.  Investigators will be given notice before an audit   occurs. 
The investigator will keep records of all original source data.  This might include laboratory  
tests, medical records, and clinical notes. If requested, the investigator will provide the sponsor, 
applicable regulatory agencies, and applicable ERBs with direct access to original source 
documents. 
 
10.2.1. Data Capture System 
An electronic data capture (EDC) system will be used in this study. The site maintains a source 
for the data entered into the sponsor-designated EDC system, if collected external to the EDC 
system. 
Electronic patient-reported outcome (ePRO) measures (for example, a rating scale) or other data 
reported directly by the patient (for example, daily dosing schedule, event diary) may be entered 
into an ePRO instrument (for example, personal digital assistant [PDA]), or by means of an 
interactive response technology system (IRT) at the time the information is obtained. In these 
instances where there is no prior written or electronic source data at the site, the ePRO  
instrument record will serve as the  source. 
If ePRO records are stored at a third party site, investigator sites will have continuous access to 
the source documents during the study and will receive an archival copy at the end of the study 
for retention. 
Any data for which the ePRO instrument record will serve to collect source data will be 
identified and documented by each site in that site’s study  file. 
Case report form data will be encoded and stored in a clinical study  database. 
Case report form data collected by a third-party will be encoded by the third-party and stored 
electronically in the third-party’s database system. Validated data will subsequently be 
transferred to the sponsor designated database. 
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system. Data will subsequently be transferred from the central 
vendor to the sponsor designated database. 
Any data for which paper documentation provided by the patient will serve as the source  
document will be identified and documented by each site in that site’s study file. Paper 
documentation provided by the patient may include, for example, a paper diary to collect patient- 
reported outcome (PRO) measures (for example, a rating scale), a daily dosing schedule, or an 
event diary. 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 360 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 47 
 
Data from complaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management system. 
10.3. Study and Site Closure 
10.3.1. Discontinuation of Study Sites 
Study site participation may be discontinued if the sponsor or its designee, the investigator, or 
the ERB of the study site judges it necessary for medical, safety, regulatory, or other reasons 
consistent with applicable laws, regulations, and  GCP. 
10.3.2. Discontinuation of the Study 
The study will be discontinued if the sponsor or its designee judges it necessary for medical, 
safety, regulatory, or other reasons consistent with applicable laws, regulations, and   GCP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 361 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 48 
 
11. References 
[APA] American Psychiatry Association. 1994. Diagnostic and Statistical Manual of Mental 
Disorders. 4th ed. Washington DC. 
Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic 
inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul  1;2(3):e24137. 
Beck, LA, Thaçi, D, Hamilton, JD, Graham, NM, Bieber, T, Rocklin, R, Ming, JE, Ren, H, Kao, 
R, Simpson, E, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. 
New Engl. J. Med. 2014, 371,  130–139. 
Bieber, T. Atopic Dermatitis. Ann Derm. 2010,  125-137. 
Bissonnette R, Poulin Y, Zhou Y, Tan J, Hong HC, Webster J, Ip W, Tang L, Lyle M. Efficacy 
and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 
12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 
Apr;166(4):853-60. 
Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients' 
perspective. Arch Dermatol. 2004  Dec;140(12):1513-9. 
Epstein E, Pinski JB. A blind study. Arch Dermatol 1964; 89:  548–549. 
Ferguson T, Rowlands AV, Olds T, Maher C. Validity of consumer-level, activity monitors in 
healthy adults worn in free-living conditions: a cross-sectional study. International Journal of 
Behavioral Nutrition and Physical Activity (2015)  12:42. 
 
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for 
routine clinical use. Clin Exp Dermatol. 1994  May;19(3):210-6. 
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, 
Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of 
tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug   9;367(6):495-507. 
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality 
of life into practice: What do dermatology life quality index scores mean? J Invest   Dermatol. 
2005 Oct;125(4):659-64. 
Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus- 
Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety and efficacy of baricitinib    
at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to 
methotrexate. Ann Rheum Dis. 2015  Feb;74(2):333-40. 
Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality 
Index scores. Br J Dermatol 2002; 147 (Suppl 62):  50. 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 362 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 49 
 
Klingmüller U, Wu H, Hsiao JG, Toker A, Duckworth BC, Cantley LC, Lodish HF. 
Identification of a novel pathway important for proliferation and differentiation of primary 
erythroid progenitors. Proc Natl Acad Sci U S A. 1997 Apr  1;94(7):3016-21. 
Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik 
KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging 
study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with 
background methotrexate in patients with active rheumatoid arthritis and an inadequate response  
to methotrexate alone. Arthritis Rheum. 2012  Apr;64(4):970-81. 
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus 
kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015  Sep;73(3):395-9. 
Muto T, Hsieh SD, Sakurai Y, Yoshinaga H, Suto H, Okumura K, Ogawa H. Brit J Derm. 2003; 
148: 117–121. 
Mallinckrodt C, Tamura RN, Tanaka Y. Recent developments in improving signal detection and 
reducing placebo response in psychiatric clinical trials. J Psychiatric Research 45 (2011) 1202- 
1207. 
Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of 
Biomarkers through Broad and Targeted Therapeutics. J Clin Med. 2015 Apr   29;4(5):858-73. 
Menter A, Disch D, Clemens J, Janes J, Papp K, Macias W. A phase 2b trial of baricitinib, an 
oral JAK inhibitor, in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2014 
May;70(5, Suppl 1): AB162. 
Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, 
Colamonici OR, van Deursen JM, Grosveld G, Ihle JN. Jak2 is essential for signaling through a 
variety of cytokine receptors. Cell. 1998 May  1;93(3):385-95. 
Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus 
kinases. Immunol Rev. 2008  Jun;223:132-42. 
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan   
PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of 
Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a 
psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 
1;54(5):573-83. 
Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, Spuls P; 
Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative. Assessment of 
clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin 
Immunol. 2013 Dec;132(6):1337-47. 
Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, Punwani N, Williams WV, Yeleswaram S.   
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in 
healthy volunteers. J Clin Pharmacol. 2014  Dec;54(12):1354-61. 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 363 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 50 
 
Vera J, Bachmann J, Pfeifer AC, Becker V, Hormiga JA, Darias NV, Timmer J, Klingmüller U, 
Wolkenhauer O. A systems biology approach to analyse amplification in the JAK2-STAT5 
signalling pathway. BMC Syst Biol. 2008 Apr  25;2:38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 364 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 51 
 
Appendix 1. 
Abbreviations and Definitions 
 
 
 
 
 
Term 
Definition 
AD 
Atopic Dermatitis 
AE 
adverse event: Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product. 
ALT 
alanine aminotransferase 
AST 
aspartate aminotransferase 
Audit 
A systematic and independent examination of the study-related activities and 
documents to determine whether the evaluated study-related activities were conducted, 
and the data were recorded, analyzed, and accurately reported according to the protocol, 
applicable standard operating procedures (SOPs), good clinical practice (GCP), and the 
applicable regulatory requirement(s). 
Blinding/masking 
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not. 
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received. 
BSA 
body surface area 
Chorus 
A semi-autonomous clinical development organization within Eli Lilly and Company. 
CIOMS 
Council for International Organizations of Medical Sciences 
CKD EPI 
Chronic Kidney Disease Epidemiology  Collaboration 
Complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system. 
Compliance 
Adherence to all the study-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements. 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 365 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 52 
 
 
Confirmation 
A process used to confirm that laboratory test results meet the quality requirements 
defined by the laboratory generating the data and that Lilly is confident that results are 
accurate. Confirmation will either occur immediately after initial testing or will require 
that samples be held to be retested at some defined time point, depending on the steps 
required to obtain confirmed results. 
CRF/eCRF 
case report form/electronic case report form (sometimes referred to as clinical report 
form): A printed or electronic form for recording study participants’ data during a 
clinical study, as required by the protocol. 
CRO 
contract research organization 
CRP 
Clinical research physician: individual responsible for the medical conduct of the 
study. Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer. 
CRU 
clinical research unit 
CS 
corticosteroid 
CSE 
clinically significant event. A moderate-to-severe adverse event (AE), abnormal 
clinical sign, or clinical laboratory finding that may pose a risk to the well-being of the 
patient. 
CSR 
clinical study report 
DLQI 
Dermatologic Life Quality Index 
DMC 
data monitoring committee 
DN 
Diabetic Nephropathy 
DNA 
deoxyribonucleic acid 
DSUR 
Development Safety Update Report 
EASI 
Eczema Area and Severity Index 
ECG 
electrocardiogram 
EDC 
Electronic data capture 
eGFR 
estimated glomerular filtration rate 
End of study 
Date of the last visit or last scheduled procedure shown in the Study Schedule for the 
last active patient in the study 
Enroll 
The act of assigning a patient to a treatment. Patients who are enrolled in the study are 
those who have been assigned to a treatment. 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 366 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 53 
 
 
Enter 
Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptable representatives. 
ePRO 
electronic patient-reported outcome 
ERB/IRB 
ethical review board/institutional review board: a board or committee (institutional, 
regional, or national) composed of medical professionals and nonmedical members 
whose responsibility is to verify that the safety, welfare, and human rights of the 
patients participating in a clinical study are protected. 
e-source 
electronic source documentation 
FSH 
follicle stimulating hormone 
GCP 
good clinical practice 
GGT 
gamma glutamyltransferase 
H2 receptor 
histamine H2 receptor 
HBcAb 
hepatitis B core antibody 
HBsAb 
hepatitis B surface antibody 
HBsAg 
hepatitis B surface antigen 
HBV DNA 
hepatitis B virus DNA 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
IB 
Investigator’s Brochure 
IC50 
half-maximal  inhibitory concentration 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IFN-γ 
interferon-gamma 
IGA 
Investigator’s Global Assessment 
IgE 
immunoglobulin E 
IL 
interleukin 
INR 
international normalized ratio 
Informed consent 
A process by which a subject voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the subject's decision to participate. Informed consent is documented by 
means of a written, signed and dated informed consent form. 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 367 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 54 
 
 
Interim analysis 
An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked. 
Investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical study, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form. 
Investigator 
A person responsible for the conduct of the clinical study at a study site. If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal investigator. 
ITT 
intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that treatment group irrespective of their 
compliance to the planned course of treatment. 
IRT 
interactive response technology system 
JAK 
Janus kinase 
JAK1, JAK2, JAK3 
kinases belonging to the Janus kinase family 
Legal  Representative 
An individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective subject, to the subject’s participation in the clinical study. 
Lilly 
Eli Lilly and Company 
LRL 
Lilly Research Laboratories 
MMRM 
mixed model repeated measures 
MOS 
margin of safety 
NRI 
non-responder imputation 
NRS 
numerical rating scale 
PASI 
Psoriasis Area and Severity Index 
Patient 
A study participant who has the disease or condition for which the investigational 
product is targeted. 
PK/PD 
pharmacokinetics/pharmacodynamics 
PO 
per os; oral administration 
POCT 
point-of-care testing 
POEM 
Patient-Oriented Eczema Measure 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 368 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 55 
 
 
PPD 
purified protein derivate 
PRO/ePRO 
patient-reported outcomes/electronic patient-reported  outcomes 
QIDS-SR16 
Quick Inventory of Depressive Symptomatology-Self Report 16 
QD 
once daily 
Randomize 
the process of assigning subjects to an experimental treatment group according to the 
randomization schedule for the study. 
RA 
Rheumatoid Arthritis 
RNA 
ribonucleic acid 
SAE 
serious adverse event; any untoward medical occurrence that at any dose results in 
death, is life threatening, requires inpatient hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability/incapacity, or is a 
congenital anomaly/birth defect. 
SAP 
statistical analysis plan 
SCORAD 
SCORing of Atopic Dermatitis 
Screening 
The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SUSARs 
suspected unexpected serious adverse reactions 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event: Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and that does not necessarily have to 
have a causal relationship with this treatment. 
Th1, Th 2 
subsets of T helper cells; T lymphocytes expressing CD4 are also known as helper T 
cells 
TSH 
thyroid stimulating hormone. 
ULN 
upper limit of normal 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY 3009104 
I4V-MC-JAHG CSR Appendix Protocol 
Page 369 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 56 
 
Appendix 2. 
Schedule of Activities 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 370 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 57 
Study Schedule of Activities Protocol  I4V-MC-JAHG 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Study Site/CRU Visit 
X 
X (applicable for 
PPD only) 
X 
X 
X 
X 
X 
X 
X 
X 
ICF 
X 
Clinical Assessments 
Demographics, Height 
X 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
QuantiFERON®-TB Gold, or 
T-SPOT.TB® test or PPD (read 48-72 hrs later) 
X 
Read PPD (if applicable) 
X 
ECG (single)-Taken prior to all other 
assessments at V1 
X 
Chest x-ray
b (posterior-anterior view) 
X 
Inclusion/Exclusion Review for Entry 
X 
Inclusion/Exclusion Review for Enrollment 
X 
Randomization 
X 
Medical History and PE 
X 
Symptom Directed PE 
X 
X 
X 
X 
X 
X 
X 
X 
Previous AD Therapy 
X 
Habits 
X 
continued on next page 
 
a If the QuantiFERON-TB Gold test or T-SPOT.TB test is available and, if, in the judgment of the investigator, it is preferred as an alternative to the PPD skin test for the evaluation of tuberculosis     
infection, it may be used instead of the PPD skin test and may be read locally. If the QuantiFERON-TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient will be 
excluded from the study. 
b A posterior-anterior chest x-ray will be performed at screening unless one has been performed within the past 6 months and the x-ray and reports are available. 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 371 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 58 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
Vital Signs (BP and pulse) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
X 
X 
X 
X 
Dispense topical corticosteroid (as needed) 
X 
X 
X 
X 
X 
X 
X 
Weigh and record topical corticosteroid 
container with cap 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Discontinue all excluded AD medications 
X 
Pre-existing Conditions 
X 
AEs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigational Product Package Dispensed 
X 
X 
X 
X 
X 
Investigational Product Package 
Returned/Compliance  Assessed 
X 
X 
X 
X 
X 
X 
Dose administration at site 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
Itch NRS 
X 
X 
X 
X 
X 
X 
X 
DLQI 
X 
X 
X 
X 
X 
X 
X 
POEM 
X 
X 
X 
X 
X 
X 
X 
continued on next page 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 372 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 59 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 
(LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of 
Investigational Product 
-38 to 
-28 
1 to 3 
days 
after V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Clinical Assessments (continued) 
QIDS-SR16 
X 
X 
X 
X 
X 
X 
X 
Actigraphy Device Download 
X 
X 
X 
X 
X 
X 
Biopsy performed (NL: non-lesion and L: lesion to 
be performed following Investigator and Patient rating 
scale assessments) 
X 
(NL, L) 
X 
(L) 
X 
(NL, L) 
Laboratory Assessments-(collect all non- 
PK samples pre-dose, as applicable) 
Hematology 
X 
X 
X 
X 
X 
X 
X 
Serum Chemistry 
X 
X 
X 
X 
X 
X 
X 
Lipids (fasting) 
X 
X 
eGFR (CKD EPI) 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
X 
HBsAg, HBcAb, HbsAb (including 
Quantitative HBsAb load assessment) 
X 
HBV DNA 
X 
 
continued on next page 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 373 
LY3009104 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 60 
 
Procedure 
Screening 
Treatment Period 
Washout 
Period 
Early 
Term 
Study Visit 
V1 
V1a 
V2 
V3 
V4 
V5 
V6 
V7 
V8 (LPV) 
Study Week relative to Start of 
Investigational Product 
0 
1 
4 
8 
12 
16 
20 
ET 
Study Day Relative to Start of Investigational 
Product 
-38 to 
-28 
1 to 3 
days 
after 
V1 
0 
7 
28 
56 
84 
112 
140 
ET 
Visit Tolerance Window (days) 
±2 
±4 
±4 
±4 
±4 
±4 
Laboratory Assessments (cont.-collect all 
non-PK samples pre-dose, as applicable) 
Hep C Antibody 
X 
HIV 
X 
Thyroid Function Tests 
X 
Serum Pregnancy Test 
X 
Urine Pregnancy Test 
X 
X 
X 
X 
X 
X 
X 
FSH 
X 
Stored serum and plasma for /Exploratory 
Biomarkers 
X 
X 
X 
X 
Stored blood for RNA and Exploratory 
Biomarkers 
X 
X 
X 
X 
Blood for DNA (filaggrin genotyping) 
X 
Plasma for baricitinib Concentration (See PK 
Sample Collection Visits Table JAHG.5) 
X 
X 
X 
X 
X 
X 
Stored blood for pharmacogenetics 
X 
Serum for Disease State Biomarkers 
X 
X 
X 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 374 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 61 
 
Appendix 3. 
Clinical Laboratory Tests 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 375 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 62 
 
 
Clinical Laboratory Tests 
 
Hematologya,b 
Clinical Chemistrya,b 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume 
Total bilirubin 
Mean cell hemoglobin concentration 
Direct bilirubin 
Leukocytes (WBC) 
Alkaline phosphatase 
Reticulocyte 
Alanine aminotransferase (ALT/SGPT) 
Absolute counts of: 
Aspartate aminotransferase (AST/SGOT) 
Neutrophils, segmented 
Blood urea nitrogen (BUN) 
Neutrophils, juvenile (bands) 
Creatinine 
Lymphocytes 
Uric acid 
Monocytes 
Calcium 
Eosinophils 
Glucose 
Basophils 
Albumin 
Platelets 
Total protein 
Cell morphology 
Estimated glomerular filtration rate (eGFR)e 
Creatine phosphokinase (CPK) 
Urinalysisa,b,d 
Color 
Other Testsa 
Specific gravity 
Hepatitis B Surface antigenf 
pH 
Anti-Hepatitis B Core antibodyf 
Protein 
Quantitative HBsAb load assessmenta 
Glucose 
Hepatitis B Surface antibodyf 
Ketones 
Human immunodeficiency virusf 
Bilirubin 
Hepatitis C antibodyf,g 
Urobilinogen 
Thyroid-stimulating hormonef 
Blood 
Thyroxinef 
Leukocyte esterase 
Pregnancy Testh 
Nitrite 
FSHf,i 
Serum immunoglobulin (IgA, IgG, and IgM) 
Lipid (Fasting) a,c 
PPD, QuantiFERON®-TB Gold or T-SPOT.TB® j 
Total cholesterol 
Low-density lipoprotein 
baricitinib 
High-density lipoprotein 
HBV DNA 
Triglycerides 
 
Abbreviations: CKD-EPI= Chronic Kidney Disease Epidemiology Collaboration; DNA = deoxyribonucleic acid; 
FSH = folliclestimulatinghormone; HBV = Hepatitis B virus;; RBC = red 
blood cells; RNA = ribonucleic acid; SGOT = serum glutamic oxaloacetic transaminase; SGPT = serum glutamic 
pyruvic transaminase; TB = tuberculosis; WBC = white blood cells. 
a Assayed by sponsor-designated laboratory. 
b Unscheduled or repeat blood chemistry, hematology, and urinalysis panels may be performed at the discretion of 
the investigator, as needed. 
c Fasting lipid profile. Patients should not eat or drink anything except water for 12 hours prior to test. 
d Microscopic examination of sediment performed only if abnormalities are noted on the routine urinalysis. 
e eGFR for serum creatinine calculated by the central laboratory using the -CKD EPI method. 
f Test required at Visit 1 only to determine eligibilityof patient for the study. 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 376 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 63 
 
g A positive hepatitis C antibody (Hep C antibody) result will be confirmed with an alternate hepatitis C method. 
h For all women of childbearing potential, a serum pregnancy test will be performed at Visit 1 and a local urine 
pregnancy test will be performed at all visits thereafter. 
i To confirm postmenopausal status for women ≥40 and <60 years of age who have had a cessation of menses, an 
FSH test will be performed. Non-childbearing potential is defined as an FSH ≥40 mIU/mL and a cessation of 
menses for at least 12 months. 
j The QuantiFERON®-TB Gold test is the preferred alternative to the PPD test for the evaluation of TB infection, 
and it may be used instead of the PPD test or T-SPOT.TB® test and may be read locally. If the QuantiFERON®- 
TB Gold test is indeterminate, 1 retest is allowed. If the retest is indeterminate, then the patient is excluded from 
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


I4V-MC-JAHG CSR Appendix Protocol 
Page 377 
LY3009104 
 
 
 
 
 
 
 
 
 
 
I4V-MC-JAHG Clinical Protocol 
Page 64 
 
Appendix 4. 
Hepatic Monitoring Tests for  Treatment- 
Emergent Abnormality 
 
 
 
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may be required in 
follow-up with patients in consultation with the sponsor, its designee, or clinical research physician. 
 
Hepatic Monitoring Tests 
 
Hepatic Hematologya 
Haptoglobina 
Hemoglobin 
Hematocrit 
Hepatic Coagulationa 
RBC 
Prothrombin Time 
WBC 
Prothrombin Time, INR 
Neutrophils, segmented 
Lymphocytes 
Hepatic Serologiesa,b 
Monocytes 
Hepatitis A antibody, total 
Eosinophils 
Hepatitis A antibody, IgM 
Basophils 
Hepatitis B surface antigen 
Platelets 
Hepatitis B surface antibody 
Hepatitis B Core antibody 
Hepatic Chemistrya 
Hepatitis C antibody 
Total bilirubin 
Hepatitis E antibody, IgG 
Direct bilirubin 
Hepatitis E antibody, IgM 
Alkaline phosphatase 
ALT 
Anti-nuclear antibodya 
AST 
GGT 
Anti-smooth muscle antibodya 
 
Abbreviations: ALT = alanine aminotransferase; AST = aspirate aminotransferase; GGT = gamma-glutamyl 
transferase; Ig = immunoglobulin; INR = international normalised ratio; RBC = red blood cells; WBC = white 
blood cells. 
a Assayed by sponsor-designated or local laboratory. 
b Reflex/confirmation dependent on regulatory requirements and/or testing availability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LY3009104 


LY3009104 
 
 
14V-MC-JAHG  CSR Appendix Protocol 
Page 378 
 
 
 
 
 
 
14V-MC.JAHG Clinical Protocol 
Page 65 
 
Appendix 5. 
Protocol 14V-MC-JAHG Signature Page 
 
 
I confirm that I have read this protocol; I understand it and I will work according to this protocol. 
I will also work consistentlywith the ethical principles that have their 01igin in tlte Declaration 
of Helsinki and that are consistent with good clinical practices and applicable laws and 
regulations. I will accept the monitor's overseeing of the study. I will abide by the publication 
plan set forth in my Agreement with the sponsor (Choms, Eli Lilly and Company) or designee. I 
will promptly submit the protocol to applicable ethical review board(s). I confirm that ifl or any 
of mystaff are members of tlte ethical review board, we will abstain from voting on this 
protocol. 
 
 
Signatme of Investigator 
Date 
 
 
Investigator Name (Title) 
 
 
Name of Facility 
 
 
Location of Facility 
(City, State (if applicable), Country) 
 
 
 
Signatme of sponsor 
Date (dd-mmm-yyyy) 
 
PD 
(Chief Medical Officer, Choms-Eli 
  Lilly and Company) 
 
Sponsor name (Title) 
 
Eli Lilly and Company 
Name 
Lilly Corporate Center, Indianapolis. Indiana, USA 
Location (City, State (if applicable), Country) 
 
 
LY3009104 
Instructionsto the Investigator. Please SIGN and DATE this signature page. PRINT your 
name, title andthe nameof thefacility in which thestudy willbe cooducted oo bothcopies. 
Return 1 ot the ·s  nedc  ·esto the s 

SAP_000.pdf: 
Statistical Analysis Plan I4V-MC-JAHG
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and 
Efficacy of Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis
NCT02576938
Approved:  11 Jan 2017


Statistical Analysis Plan v1_0 Final.pdf
Electronic Signature Page
  Workflow History
The following individuals have electronically signed this document.
Assigned To
Purpose
Date Signed
Status
Outcome
Approve
11 Jan 2017 11:47:12 AM
Completed
Approved
Author
11 Jan 2017 11:12:58 AM
Completed
Author
Review
11 Jan 2017 11:24:07 AM
Completed
Reviewed
Review
11 Jan 2017 11:35:19 AM
Completed
Reviewed
Review
11 Jan 2017 11:37:44 AM
Completed
Reviewed
PPD


Confidential 
 
Statistical Analysis Plan 
I4V-MC-JAHG 
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 
Study to Evaluate the Safety and Efficacy of Baricitinib in 
Patients with Moderate-to-Severe Atopic Dermatitis 
 
 
Version 1.0 
 
10 January, 2017 
 
Prepared for 
 
Lilly l CHORUS 
 
Eli Lilly and Company 
Lilly Corporate Center, Indianapolis IN 46285 U.S.A 
 
 
Prepared by 
 
 
 
55 Corporate Woods 
 
9300 West 110th Street, Suite 550 
 
Overland Park, Kansas  66210 
 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 2 of 29 
Table of Contents 
Description 
Page 
ABBREVIATIONS/DEFINITIONS .............................................................................. 5 
1 
INTRODUCTION AND OBJECTIVES ............................................................ 7 
1.1 
Introduction .................................................................................................................7 
1.2 
Study Objectives ..........................................................................................................7 
1.3 
Determination of Sample Size ....................................................................................9 
2 
General Statistical Methodology and Conventions ........................................... 9 
2.1 
Randomization Schedule and Unblinding Plan ........................................................9 
2.2 
Analysis Populations .................................................................................................10 
2.3 
Handling of Dropouts and Missing Data ................................................................10 
2.4 
Adjustment for Multiple Centers ............................................................................11 
2.5 
Interim Analysis and Adjustment for Multiplicity ................................................11 
2.6 
Coding of Concomitant Medications and Adverse Events ....................................12 
2.7 
Definition of Study Time Points ...............................................................................12 
2.8 
Reporting Conventions .............................................................................................12 
2.9 
Changes to the Planned Analyses ............................................................................13 
2.9.1 
Changes to the Planned Analyses in the Protocol .............................................13 
3 
Patient Accounting and Disposition .................................................................. 13 
3.1 
Patient Accounting ....................................................................................................13 
3.2 
Study Disposition .......................................................................................................13 
4 
Baseline Characteristics ..................................................................................... 13 
4.1 
Demographics ............................................................................................................14 
4.2 
Baseline Anthropometrics ........................................................................................14 
4.3 
Baseline Habits ..........................................................................................................14 
4.4 
Atopic Dermatitis History ........................................................................................14 
5 
Concomitant Medications .................................................................................. 15 
6 
Efficacy Analyses ................................................................................................ 15 
6.1 
Primary Efficacy Analysis ........................................................................................15 
6.1.1 
Analyses in Support of Primary Efficacy ...........................................................16 
6.1.2 
Sensitivity Analyses for the Primary Efficacy Variable ...................................16 
6.2 
Secondary Efficacy Analyses ....................................................................................17 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 3 of 29 
6.2.1 
Change and Percentage Change in EASI ...........................................................17 
6.2.2 
SCORing Atopic Dermatitis (SCORAD) ...........................................................17 
6.2.3 
Investigator’s Global Assessment .......................................................................18 
6.2.4 
Dermatology Life Quality Index .........................................................................18 
6.2.5 
Itch Numerical Rating Scale ................................................................................19 
6.3 
Exploratory Efficacy Analyses .................................................................................20 
6.3.1 
Patient-Oriented Eczema Measure .....................................................................20 
6.3.2 
Analyses for Actigraphy Device data .................................................................21 
6.3.2.1 
Analyses for Sleep/Wake Patterns .....................................................................21 
6.3.2.2 
Analyses for Nocturnal Scratching ....................................................................21 
6.3.3 
Analyses for Quick Inventory of Depressive Symptomatology – 
Self Report 16 .......................................................................................................21 
6.3.4 
Exploratory Subgroup Assessment of Response ...............................................22 
7 
Safety Analyses ................................................................................................... 22 
7.1 
Study Medication Exposure and Treatment Compliance .....................................23 
7.1.1 
Extent of Exposure ...............................................................................................23 
7.1.2 
Treatment Compliance ........................................................................................23 
7.2 
Adverse Events ..........................................................................................................24 
7.2.1. 
Treatment-Emergent Adverse Events ................................................................24 
7.2.2. 
Treatment Related TEAE ....................................................................................24 
7.2.3 
Serious Treatment-Emergent Adverse Events ..................................................24 
7.2.4 
TEAE Resulting in Death ....................................................................................25 
7.2.5 
TEAE Leading to Study Drug Discontinuation .................................................25 
7.2.6 
TEAE by Maximal Severity ................................................................................25 
7.2.7 
Adverse Events of Special Interest .....................................................................25 
7.3 
Clinical Laboratory Results .....................................................................................25 
7.3.1 
Descriptive Statistics over Time ..........................................................................26 
7.3.2 
Shift tables and Categorical variables ................................................................26 
7.4 
Vital Signs and Weight .............................................................................................26 
7.5 
Biomarker Results .....................................................................................................27 
7.5.1 
Skin biopsies ..........................................................................................................27 
7.5.2 
Blood biomarkers .................................................................................................27 
7.5.3 
Filaggrin genotyping ............................................................................................27 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 4 of 29 
7.5.4 
Correlation between Baseline Biomarkers ........................................................27 
7.5.5 
Biomarkers as Measures of Disease Severity .....................................................28 
8 
Pharmacokinetic Analyses ................................................................................. 28 
9 
Health Outcome Psychometric Analyses .......................................................... 28 
References ....................................................................................................................... 29 
 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 5 of 29 
ABBREVIATIONS/DEFINITIONS 
Abbreviations 
AE 
adverse event 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase  
ANCOVA 
analysis of covariance 
ANOVA 
analysis of variance 
AST 
alanine aminotransferase  
BMI 
body mass index 
CMH 
Cochran-Mantel-Haenszel 
CSR 
clinical study report 
DLQI 
Dermatologic Life Quality Index 
eCRF 
electronic case report form 
EASI 
Eczema Area and Severity Index 
EASI-50 
50% reduction in EASI score 
EASI-75 
75% reduction in EASI score 
EASI-90 
90% reduction in EASI score 
GPORWE 
(Lilly) Global Patient Outcomes and Real World Evidence 
IFN-g 
interferon-gamma 
IGA 
Investigator’s Global Assessment 
IGA [0] 
post-baseline IGA Score of 0 (clear) 
IGA [0,1] 
post-baseline IGA Score of 0 (clear) or 1 (almost clear) 
IRT 
Interactive response technology 
Itch NRS 
Itch Numeric Rating Scale 
ITT 
intent to treat 
LDH 
lactate dehydrogenase 
LOCF 
last observed carried forward 
LY 
baricitinib (LY3009104) 
MedDRA™ 
Medical Dictionary for Regulatory Activities 
MMRM 
mixed effects model repeated measures 
NRI 
non-responder imputation 
PK 
pharmacokinetic 
POEM 
Patient-Oriented Eczema Measure 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 6 of 29 
PT 
preferred term 
QIDS-SR16 
Quick Inventory Depressive Symptomatology – Self Report 16 
QOL 
quality of life 
SAE 
serious adverse event 
SAP 
Statistical analysis plan 
SCORAD 
SCORing Atopic Dermatitis 
SDTM 
Study Data Tabulation Model 
SOC 
system organ class 
TBili 
total bilirubin 
TEAE 
treatment emergent adverse event 
ULN 
upper limit of the normal range 
VAS 
visual analog scale 
WASO 
Wake after sleep onset 
WHODD 
World Health Organization Drug Dictionary 
 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 7 of 29 
1 
INTRODUCTION AND OBJECTIVES 
1.1 Introduction 
The purpose of this statistical analysis plan (SAP) is to describe the analysis variables and 
statistical procedures that will be used to analyze and report the results from a Phase 2 study 
evaluating the safety and efficacy of baricitinib, a JAK1/JAK2 selective inhibitor, in patients 
with moderate-to-severe atopic dermatitis. This SAP is based on the amended protocol, Protocol 
I4V-MC-JAHG(d), which was approved on 24 June 2016.  
Changes to the protocol that impact the design, the data collected, or the statistical methods and 
that occur after the finalization of this SAP may require amendment of the approved SAP. 
Similarly, changes to the planned analysis variables and/or statistical methods described in the 
approved SAP may also require amendment of the SAP.  
The formats for the tables, listings, and figures described in this SAP are provided in a 
companion document. Changes to the formats of these reports that are decided after the 
finalization of the SAP will not require an amendment. In addition, any additional supportive or 
exploratory analyses requested after SAP approval will not require amendment of the SAP. 
These additional analyses will be described in the clinical study report (CSR).  
Please see the study protocol for details about the study design, procedures, and schedule of 
assessments and see the electronic case report form (eCRF) for details about variables collected 
and their possible values. 
1.2 
Study Objectives 
Table JAHG.1 shows the objectives and endpoints of the study that were defined in the protocol. 
Additional endpoints will be defined in this SAP. 
Table JAHG.1. 
Objectives and Endpoints 
Objectives 
Endpoints 
Primary 
• To compare the proportion of moderate-
to-severe atopic dermatitis patients 
achieving a 50% or greater reduction in 
the Eczema Area and Severity Index 
(EASI-50) between each baricitinib dose 
group (2 mg and 4 mg) and placebo when 
treated daily for 16 weeks 
 
• EASI-50 at 16 weeks 
Secondary 
 
• To evaluate the absolute and percent 
change from baseline of the EASI with 
baricitinib compared to placebo 
• EASI at Weeks 1, 4, 8, 12, and 16 
 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 8 of 29 
• To evaluate the mean change from 
baseline compared to placebo for the 
SCORing Atopic Dermatitis (SCORAD) 
• SCORAD at  Weeks 1, 4, 8, 12, and 16 
 
• To evaluate the mean change from 
baseline compared to placebo for the 
Investigator’s Global Assessment (IGA) 
• IGA at Weeks 1, 4, 8, 12, and 16 
 
• To assess quality of life based on the 
Dermatologic Life Quality Index (DLQI) 
• DLQI at Weeks 1, 4, 8, 12, and 16 
• 
To assess itch based on the Itch 
Numerical Rating Scale (NRS) 
• Itch Numerical Rating Scale at Weeks 1, 
4, 8, 12, and 16 
 
• To characterize the pharmacokinetics of 
baricitinib in patients with moderate-to-
severe atopic dermatitis 
• Plasma pharmacokinetic data 
Exploratory 
 
• To evaluate EASI response in patients 
based on their baseline total serum IgE 
 
• EASI at Weeks 1, 4, 8, 12 and 16; baseline 
total serum IgE 
 
• To evaluate total serum IgE over the 
course of treatment 
 
• Total serum IgE at baseline, Weeks 4, and 
16 
 
Exploratory (continued) 
• To evaluate changes in disease activity 
over the course of treatment 
• Patient-Oriented Eczema Measure (POEM)  
at  Weeks 1, 4, 8, 12, and 16  
 
• To evaluate changes in sleep quality over 
the course of treatment 
• Change from baseline with data from a 
wearable actigraphy device 
• To evaluate changes in nocturnal itch 
patterns over the course of treatment 
• Change from baseline with data from a 
wearable actigraphy device 
• To evaluate EASI response relative to  
filaggrin genotype 
 
• EASI-50 and filaggrin genotype data from 
peripheral baseline blood sample 
 
• To assess tissue biomarkers from biopsies  
 
• K16, Ki-67, and IL-4 will be assessed from 
each tissue biopsy (collected at baseline 
(lesion and non-lesion), at Week 4 (lesion), 
and at Week 16 (lesion and non-lesion) 
 
• To assess peripheral biomarkers 
mechanistically related to inhibition of 
JAK 1/2 mechanism 
• Peripheral biomarkers collected at baseline, 
Weeks 4 and 16 
 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 9 of 29 
• To perform subgroup  assessments of 
response based on patient and disease 
characteristics 
• Ad hoc evaluation of potential prognostic 
and predictive disease characteristics   
 
 
1.3 Determination of Sample Size 
Approximately 120 patients will be enrolled using a 4:3:3 randomization scheme for placebo, 
2 mg baricitinib, or 4 mg baricitinib, respectively. Assuming a drop-out rate no greater than 20%, 
approximately 96 patients will complete the study.  
This sample size provides 90% power to detect a 35% difference in EASI-50 between placebo 
and either the 4-mg baricitinib using a 2-sided chi-square test with alpha = 0.05. 
2 
General Statistical Methodology and Conventions 
CHORUS will designate a provider to generate the statistical analyses detailed in this SAP. All 
computations for statistical analyses will be performed using SAS® software, Version 9.3 or 
later. All SAS programs used in the production of statistical summary outputs will be validated 
with independent programming prior to finalization. In addition, all program outputs will be 
independently reviewed. The validation process will be used to confirm that all data 
manipulations and calculations were accurately done. Once validation is complete, a senior 
statistical reviewer should perform a final review of the documents to ensure the accuracy and 
consistency with this plan and consistency within tables. Upon completion of validation and 
quality review procedures, all documentation will be collected and filed by the project statistician 
or designee. 
Before implementation of parametric methods of analysis, the distribution of analysis variables 
will be examined to determine if model assumptions are satisfied. Transformations or 
nonparametric methods of analysis may be used if warranted. However, in some cases, 
nonparametric analysis may be the initially proposed method due to the expected distribution of 
response. Whenever alternative methods of analysis are required, the description of the new 
method along with the rationale for its use will be documented in the CSR. 
The eCRF data for all patients will be provided in Standard Data Tabulation Model (SDTM) 
datasets. Any additional data listing supplied as part of the CSR will be sorted by investigative 
site and patient identification number, and patients will be identified in the listings by the 
investigator number concatenated with the patient number. 
2.1 Randomization Schedule and Unblinding Plan 
This is a double-blind study in which the patients, investigator, and study site personnel will be 
blinded to treatment allocation. PAREXEL International will be responsible for building the 
interactive response technology (IRT) system that randomly assigns study treatments to patients.  
To preserve the blinding of the study, only a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is complete. A limited group 
may have access to unblinded treatment information to ensure the safety of patients in the study. 
Another small team of Lilly scientists (project statistician, statistical analyst, pharmacokineticist, 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 10 of 29 
research physician, medical director, and global patient outcome scientist) will have access to the 
unblinded treatment information just before the last patient has completed their Week 12 visit. 
Their review of the unblinded data will facilitate planning of future studies. They may 
communicate unblinded findings to a small number of other Lilly personnel to facilitate business 
decisions, but not to those who are involved in the conduct of the study who would be involved 
in direct site contact and assessment of blinded clinical outcomes. A list of all those individuals 
who become unblinded prior to study completion will be maintained by the unblinded 
statistician. This process will ensure that data integrity is maintained while patients are still 
receiving blinded therapy.  
Once the last patient completes Week 16, thus blinded study treatment, and all data management 
data activities have been completed – data entered, coding completed, and all queries resolved – 
the Chorus Asset Manager and Statistician will approve PAREXEL to release the randomization 
schedule to the reporting team. Additional Lilly personnel as well as steering committee 
members may also be unblinded to commence reporting of results from the treatment period. Site 
personnel and those Lilly personnel who are involved in the conduct of the study who would be 
involved in direct site contact and assessment of blinded clinical outcomes and patients will 
remain blinded until the study completes. 
Emergency unblinding of site personnel may be performed through the IRT system. This option 
may be used ONLY if the patient’s well-being requires knowledge of the patient’s treatment 
assignment. All calls resulting in an unblinding event are recorded and reported by the IRT 
system. 
2.2 Analysis Populations 
The analyses for efficacy will be based on the intention-to-treat (ITT) principle (Gillings and 
Koch 1991), which seeks to preserve the benefits of randomization and avoid the issue of 
selection bias. The ITT population is defined as all randomized patients, and analyses based on 
the ITT population will utilize the treatments assigned at randomization.  
Safety will be analyzed using the Safety Population. The Safety population is defined as all 
randomized patients who received at least one dose of a randomly assigned study treatment. 
Safety analyses will utilize the treatment that the patient received. 
Pharmacokinetic (PK) data will be analyzed using the PK Population. The PK population is 
defined as all patients who received at least one dose of baricitinib and provided at least one 
post-dose PK sample. Pharmacokinetic analyses will be performed using the treatment that the 
patient received. 
2.3 
Handling of Dropouts and Missing Data 
Analysis of the primary response endpoint, EASI-50, will include all randomized patients and 
utilize a non-responder imputation (NRI) analysis. All patients who discontinue study treatment 
at any time prior to the time point of interest, or discontinue from the study for any reason, will 
be defined as non-responders for the NRI analysis.  Randomized patients without at least 1 post-
baseline observation will also be defined as non-responders for the NRI analysis. Secondary and 
exploratory efficacy responder analyses will also utilize NRI analyses and all randomized 
patients.  


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 11 of 29 
For the secondary and exploratory efficacy endpoints and clinical laboratory endpoints that are 
collected longitudinally, a last observation analysis will be performed by carrying forward the 
last post-baseline assessment. These last observation carried forward (LOCF) analyses guarantee 
the maximum number of randomized patients who were assessed post-baseline, will be included 
in the analyses. In addition, for many of the efficacy endpoints, mixed effect model repeated 
measures (MMRM) analyses will be performed to mitigate the impact of missing data, which 
will be assumed to be missing at random during the study. 
If only a missing or partial date for AEs or concomitant medications is available and a complete 
date is required for calculations, the following algorithms will be applied:  
• 
For the start date:  
− 
If year, month, and day are missing then use the minimum of the patient's first visit date or the consent date.  
− 
If either only month or month and day are missing then use January 1.  
− 
If only day is missing, impute the first day of the month.  
• 
For the end date:  
− 
If year, month, and day are missing then use the patient's last visit date.  
− 
If either only month or month and day are missing then use December 31.  
− 
If only day is missing then use the last day of the month.  
− 
Do not expand the record past the patient's last visit.  
The original missing or partial date, the imputed complete date, and the indicator variable that 
indicates which dates were imputed will be retained in the database. 
Analyses of the safety endpoints, many of which are incidence based, will include all patients in 
the safety population, unless specifically stated otherwise.  
2.4 
Adjustment for Multiple Centers 
The study randomization is stratified by country of the investigative site, and only investigative 
centers from Japan and the United States are included in the study. The number of patients to be 
randomized in each country is not fixed, so there may be low enrollment in one of the countries. 
The stratification variable “country” will not be included in the statistical model by default. If 
there are at least 15 patients enrolled in each country, analyses that include a fixed effect for 
country may be performed as exploratory analyses. 
2.5 
Interim Analysis and Adjustment for Multiplicity 
There were no planned formal interim analyses for this study. The interim review of the ongoing 
study data, that is described in Section 2.1, does not include any alpha-spending nor will any 
modifications of the current study be contemplated. 
The primary efficacy analyses include separate comparisons of each baricitinib arm to the 
placebo arm. To control the type 1 error rate for the primary efficacy analyses, these separate 
comparisons will be performed in a stepwise fashion. The 4-mg baricitinib arm will be compared 
with the placebo arm; if this test is statistically significant at level α = 5%, then the 2-mg 
baricitinib arm will be compared with the placebo arm; again using α = 5%.  


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 12 of 29 
Because this is a phase 2 study, no other adjustments for multiplicity will be made for statistical 
tests. 
2.6 
Coding of Concomitant Medications and Adverse Events 
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA™), and concomitant medications will be coded using the World Health Organization 
Drug Dictionary. The most recent version of these dictionaries at the time of database lock will 
be used for reporting. The version of the dictionary used for reporting will be provided in the 
CSR. 
2.7 
Definition of Study Time Points 
Study baseline for a patient will extend from the date of informed consent until the date of first 
dose of randomly assigned study medication. For efficacy, safety and background characteristics, 
the baseline value of a parameter will be the last measurement of that parameter during the 
baseline period.  
The post-baseline period will start on the date of first dose of randomly assigned study 
medication. Study day will be defined as  
Study Day = Date –Date of 1st dose+1*if (Date >= Date of 1st dose). 
The last part of the equation indicates that 1 is added if the date of collection/observation is 
greater than or equal to the date of first dose of randomly assigned study medication. This forces 
all post-baseline events to have a positive value and all dates prior to first dose to have a value 
less than 0. 
2.8 Reporting Conventions 
This section details the general conventions to be used for the statistical analyses. Departures 
from these general conventions will be provided in the specific detailed sections of this analysis 
plan. The following conventions will be applied to all data presentations and analyses:   
• 
Data will be summarized for the following groups: 
− 
Overall, Placebo, 2mg LY, 4mg LY will be used for patient accounting and disposition 
− 
Placebo, 2mg LY, and 4mg LY for all presentations except patient accounting and disposition 
• 
Continuous variables will generally be summarized by the number of patients, mean, standard deviation, 
median, minimum, and maximum.  Exceptions to these conventions will be specifically noted. Categorical 
variables will be summarized by the number and percentage of patients within each category. 
• 
All mean and median values will be formatted to one more decimal place than the measured value. 
• 
Standard deviation values will be formatted to two more decimal places than the measured value. 
• 
Minimum and maximum values will be presented with the same number of decimal places as the measured 
value. 
• 
The number and percent of responses will be presented in the form XX (XX %), where the percentage is in 
parentheses. Percentages will be rounded to the nearest percent. In the case of a frequency of zero, the 
frequency and percentage will be presented as 0 rather than 0 (0%). 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 13 of 29 
• 
All summary tables will include the analysis population sample size (i.e., number of patients) in each treatment 
group. 
• 
Date variables will be formatted as ddMMMYY for presentation. 
2.9 Changes to the Planned Analyses 
2.9.1 Changes to the Planned Analyses in the Protocol 
• 
There was a typo for the analyses of continuous secondary efficacy endpoints. The level for the confidence 
intervals should have been 95%, rather than 90%. The correction has been implemented in this SAP. 
3 
Patient Accounting and Disposition 
3.1 Patient Accounting 
For each study center the number of patients in the ITT, Safety and PK populations will be 
provided overall and by randomized assignment. The date of the first patient visit and the last 
patient visit for each study center will also be provided. These dates and patient totals will also 
be summarized for the whole study and by country.  
A list of protocol violations that could potentially impact the analysis of the study will be 
determined during the conduct of the study by study team members who are blinded to assigned 
study treatment. The number and percentage of patients with each violation will be tabulated 
overall and by randomized treatment assignment. 
3.2 Study Disposition 
The disposition of all randomized patients will be presented. The number of patients randomized 
and the number of patients in the Safety Population will be presented overall and by treatment 
group. In addition, the reason for study discontinuation will be tabulated by treatment group 
using the list of reasons provided in the eCRF. This report will be generated for both the overall 
population and for patients enrolled in Japan. 
4 
Baseline Characteristics 
Demographic data, baseline characteristics, and atopic dermatitis history will be summarized 
using descriptive statistics by randomized treatment assignment. These summaries will be based 
on the ITT population and will be generated using both the overall population and for patients 
enrolled in Japan. Randomized patients who are missing measurements of the baseline variable 
being analyzed will not be included in the summary for that variable. 
Unless otherwise specified, F-tests from the analysis of variance (ANOVA) model with a fixed 
effect for randomized treatment group will be conducted for continuous variables. These tests 
will be based on the Type 3 sum of squares. Categorical variables will be analyzed using the 
general association chi-square tests. If the number of patients in a category is less than 5 for 
either randomized group, Freeman-Halton exact tests will be used instead of the chi-square test. 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 14 of 29 
4.1 
Demographics 
Demographic variables collected prior to randomization include date of birth, sex, race, and 
ethnicity. Age at study entry, age group (Age < 65 years, Age ≥ 65 years), sex, and race will be 
summarized and reported. Age at study entry will be based on the age of the patient on the date 
the informed consent is signed. Age at study entry will be analyzed as a continuous variable 
while age group is analyzed as a categorical variable. Sex will also be analyzed as a categorical 
variable. Patient race will be captured using multiple racial categories (i.e., American Indian or 
Alaskan Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, 
and White), and Race will be reported using a chi-square test and these categories along with a 
‘Multiple’ category for those patients who identify more than one race category. The response 
for ethnicity could be Hispanic or Latino, or Non-Hispanic or Latino. Ethnicity will be analyzed 
as a categorical variable.  
4.2 
Baseline Anthropometrics 
Patient height and weight will also be collected prior to randomization. Both variables will be 
reported in metric units (height in cm and weight in kg) and will be analyzed as continuous 
variables along with Body Mass Index (BMI; in kg/m2). Body mass index will also be analyzed 
categorically using the categories obese (BMI ≥ 30 kg/m2) and non-obese (BMI < 30 kg/m2). 
4.3 
Baseline Habits 
The alcohol, tobacco, and caffeine habits for each patient will be collected during the baseline 
period. The number and percentage of patients who consume alcohol, tobacco and caffeine will 
be tabulated for each treatment group using the ITT population. In addition, among those patients 
who currently smoke descriptive statistics of the number of cigarettes per day will be provided 
by treatment group. No statistical inference will be performed for the habits variables, and this 
report will only be produced for the overall population.  
4.4 
Atopic Dermatitis History 
The date of atopic dermatitis diagnosis along with the types of prior therapies received will be 
collected during the screening period. The types of prior therapy will be collected using the 
following categories:  hydration plus topical steroids and/or antibiotics (Category 1), systemic 
steroids and/or phototherapy (Category 2), cyclosporine and/or other immunomodulators 
(Category 3). Patients could have received treatments from more than one category.  
Time since diagnosis of atopic dermatitis, in months, will be descriptively summarized and 
analyzed as a continuous variable. Since patients could have received treatments from multiple 
categories, each category will be analyzed separately as a categorical variable. In addition, the 
number and percent of patients who reported alopecia areata in their medical history will be 
compared between treatments using the general association Mantel-Haenszel or Freeman-Halton 
statistic.  


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 15 of 29 
5 
Concomitant Medications 
Concomitant medications will be defined as medications, other than triamcinolone 0.1% cream, 
taken on or after the date of first dose of randomly assigned study treatment. This includes all 
medications initially taken prior to the date of first dose of randomly assigned study medication 
but with a stop date that is either missing or after the date of first dose of randomly assigned 
study medication. Those medications where the stop date is documented as prior to the date of 
first dose of randomly assigned study medication will be classified as prior medications. The 
prior medications will not be included in any summary reports. 
The reporting of concomitant medications will be by WHODD preferred drug name (often the 
generic drug name). The report of all concomitant medications taken during the study will be 
prepared by treatment using the safety population, and the number and percentage of patients 
who received each concomitant medication will be presented.  
6 
Efficacy Analyses 
Efficacy analyses for this study will be based on the findings from clinical tools (EASI, 
SCORAD, and IGA) and patient reported outcomes (DLQI, Itch NRS, and POEM) that assess 
the extent and severity of atopic dermatitis, the symptoms related to atopic dermatitis, or the 
impact on the patient’s quality of life (QOL). In addition, data from wearable actigraphy devices 
will be analyzed to assess sleep/wake patterns and changes in nocturnal itch patterns. All of these 
assessments will be collected longitudinally during the study. 
All efficacy analyses will be performed using the ITT population. Reports will be generated for 
the overall population, and many of the reports will also be produced using only patients enrolled 
in Japan. The method of analysis or statistical technique employed to address missing data will 
be described separately for each variable. Presentations of efficacy will include the number of 
patients with data at each time point plus related statistics derived from the analysis. 
Assessments performed at Visit 2 will be considered the baseline measurements. If the Visit 2 
assessment for a clinical tool or patient reported outcome is missing, then the Visit 1 assessment, 
if it exists, will be considered the baseline measurement. If a patient has no assessment of a 
clinical tool or patient reported outcome prior to the initiation of study treatment, then the patient 
will be excluded from the efficacy analysis of that variable at the given time point. 
6.1 Primary Efficacy Analysis 
The primary efficacy analysis will be the based on the Eczema Area and Severity Index (EASI), 
which is a valid and internally consistent clinical observation tool that has adequate intra-
observer reliability, intermediate inter-observer reliability, and adequate responsiveness. 
The EASI assesses objective physician estimates of two dimensions of atopic dermatitis – 
disease extent and clinical signs – by scoring the extent of disease (percentage of skin affected: 0 
= 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the 
severity of four clinical signs (erythema, induration/papulation, excoriation, and lichenification) 
each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at four body sites 
(head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. Each body site 
will have a score that ranges from 0 to 72, and the final EASI score will be obtained by weight-


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 16 of 29 
averaging these four scores (using multipliers 0.2 for head and neck and upper limbs and 0.3 for 
trunk and lower limbs). Hence, the final EASI score will range from 0 to 72 for each time point. 
The EASI will be assessed at baseline and at Weeks 1, 4, 8, 12, and 16 post-randomization, plus 
at the early termination visit, if applicable. At each of the post-baseline visits the EASI will be 
computed, and the EASI score will be compared with the EASI score obtained at baseline to 
obtain the proportion of reduction.  
The primary efficacy measure will be the proportion of moderate-to-severe atopic dermatitis 
patients achieving a 50% reduction in the Eczema Area and Severity Index, or EASI-50, after 16 
weeks of treatment. The primary analysis will be performed using a Non-Responder Imputation 
(NRI) analysis. All patients with a less than 50% reduction in the EASI at Week 16, plus all 
patients who either discontinue study treatment or discontinue from the study for any reason at 
any time prior to Week 16 will be defined as non-responders for the NRI analysis. Randomized 
patients without at least 1 post-baseline observation of EASI will also be defined as non-
responders for the NRI analysis. 
The proportion of patients achieving EASI-50 in the placebo arm will be compared to the 
proportion of patients in each of the baricitinib arms (2 mg and 4 mg) using a two-sided chi-
square test with alpha=0.05. To control for multiplicity testing will be performed in a stepwise 
fashion. First, the 4-mg baricitinib arm will be compared with the placebo arm; if this test is 
statistically significant, then the 2-mg baricitinib arm will be compared with the placebo arm. 
The number and percent of patients, based on an NRI analysis, with a 50% reduction in EASI 
will be presented for each treatment arm at each time point including the patient’s last 
assessment, which should be either Week 16 or the early termination visit. The p-values for the 
pairwise chi-square tests from the NRI analyses will also be tabulated. In addition, a bar chart 
that shows the percentage of patients with a 50% reduction in EASI for each treatment arm at 
each time point including the patient’s last assessment will be presented. The figure displays will 
be generated for the overall population and by country – United States and Japan.  
6.1.1 Analyses in Support of Primary Efficacy 
Non-responder imputation analyses that assess the EASI-75 and EASI-90, i.e., proportion of 
moderate-to-severe atopic dermatitis patients achieving a 75% (or 90%) reduction in the EASI, 
will also be conducted. P-values from Fisher’s exact test may be used due to the potential for low 
response rates. 
Observed cases analyses of EASI-50, EASI-75 and EASI-90 will also be conducted using Chi-
square of Fisher’s Exact Test. 
6.1.2 Sensitivity Analyses for the Primary Efficacy Variable 
The NRI analysis of EASI-50, as well as EASI-75 and EASI-90, will be repeated using a logistic 
regression model with fixed effects for treatment and country. Odds ratio estimates and the Wald 
95% confidence intervals will be provided for the pairwise comparisons of baricitinib to placebo.  


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 17 of 29 
6.2 
Secondary Efficacy Analyses 
6.2.1 Change and Percentage Change in EASI 
Change and percentage change from baseline for EASI will be derived for each patient at each 
post-baseline visit (Weeks 1, 4, 8, 12, and 16). Descriptive statistics for the value, change and 
percentage change will be tabulated for each time point. 
Missing assessments will assumed to be missing at random and separate mixed effects model 
repeated measures (MMRM) analyses will be performed to compare the baricitinib treatment 
arms and placebo for the actual and percent change from baseline. For both change and percent 
change from baseline the MMRM model will contain fixed effects for treatment, visit, and 
country and the treatment-by-visit interaction plus the baseline value and baseline-by-visit term 
as covariates. Patient will be nested within treatment, and the covariance structure among the 
repeated measurements for a patient will be assumed to be common across patients and modeled 
using an unstructured 5x5 matrix. Satterthwaite’s approximation will be used to estimate 
denominator degrees of freedom. The significance of differences in least-square means will be 
based on Type III tests using the observed population margins. The analyses will be performed 
using the SAS procedure PROC MIXED.  
The tabular output for these MMRM analyses will present the least squares means, standard 
errors and 95% confidence intervals and p-values for each main effect marginal. Pairwise 
contrasts of the least squares means between the randomized treatment arms will also be 
provided at each time point using LSMESTIMATE statements.  
For both endpoints plots of the least squares mean ± standard error estimates for changes in 
EASI over time will be provided by randomized treatment. These plots will be provided for the 
overall population and for each country.  
Finally, a last observation analysis will be performed for both change and percent change using 
an analysis of covariance (ANCOVA) model with fixed effects for treatment and country plus 
the baseline value as a covariate. Tabular output for these ANCOVA analyses will present the 
least squares means, standard errors and 90% confidence intervals and p-values for each main 
effect marginal. Pairwise contrasts of the least squares means will also be provided for 
randomized treatment arms at each time point.  
6.2.2 SCORing Atopic Dermatitis (SCORAD) 
To determine disease severity the SCORing Atopic Dermatitis (SCORAD) index uses the rule of 
nines to assess disease extent (head and neck 9%; upper limbs 9% each; lower limbs 18% each; 
anterior trunk 18%; back 18%; genitals 1%; and hands 2%) and evaluates six clinical 
characteristics – erythema, edema/papulation, oozing/crusts, excoriation, lichenification and 
dryness – each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe). 
SCORAD also assesses subjective symptoms of pruritus and sleep loss with visual analogue 
scales (VAS) where 0 is no itch (or no sleeplessness) and 10 is the worst imaginable itch (or 
sleeplessness). These three aspects: extent of disease (A: range 0-102), disease severity (B; range 
0-18) and subjective symptoms (C: range 0-20) will be combined using, A/5 + 7*B/2 + C, to 
give a maximum possible score of 103.4.  


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 18 of 29 
The SCORAD will be assessed at baseline and at Weeks 1, 4, 8, 12, and 16 post-randomization, 
plus at the early termination visit, if applicable. At each of the post-baseline visits the SCORAD 
will be computed, and the SCORAD score will be compared with the SCORAD score obtained 
at baseline to obtain change and percent change from baseline. Descriptive statistics for the 
SCORAD value and the subjective assessments of pruritus and sleep loss and the respective 
changes from baseline will be tabulated for each time point using the overall and by-country 
populations. 
The MMRM and ANCOVA analyses described in Section 6.2.1 will be performed to compare 
the baricitinib treatment arms and placebo for change and percent change from baseline in the 
SCORAD score, and change from baseline in the pruritus and insomnia assessments. The tabular 
outputs for the MMRM and ANCOVA analyses described will be provided. 
6.2.3 Investigator’s Global Assessment 
The Investigator’s Global Assessment (IGA) uses the clinical characteristics – erythema, 
infiltration, papulation, oozing and crusting – as guidelines for the overall severity assessment. 
The IGA consists of a 6-point severity scale from clear to very severe disease (0 = clear, 1 = 
almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease and 5 = very severe 
disease).  
The IGA will be assessed at baseline and at Weeks 1, 4, 8, 12, and 16 post-randomization, plus at 
the early termination visit, if applicable. At each of the post-baseline visits the IGA will be 
computed, and the IGA score will be compared with the IGA score obtained at baseline to obtain 
change from baseline. Descriptive statistics for the value and change from baseline will be 
tabulated for each time point using the overall and by-country populations. 
An IGA [0,1] responder is defined as a patient with a post-baseline score of 0 (clear) or 1 (almost 
clear), and an IGA [0,1] responder with a 2-point drop is a responder whose change from 
baseline is at least 2 points. An IGA [0] responder is defined as a patient with a post-baseline 
score of 0 (clear). At each post-baseline time point and the last observation the number and 
percent of IGA [0,1] responders both overall and those with at least a 2-point drop from baseline 
will be compared between each baricitinib arm and placebo using a two-sided Fisher’s Exact test 
at level α = 0.05. A similar analysis will be performed for IGA [0].  
In addition, a bar chart that shows the percentage of IGA [0,1] responders with a 2-point drop in 
each treatment arm and at each time point including the patient’s last assessment will be 
presented. The figure will be generated for the overall population and by country. 
Analyses will also be performed for change from baseline at each post-baseline time point and 
for the last observation. Comparisons between each baricitinib arm with placebo will be based on 
chi-square statistics using the row mean scores option. The number and percentage of patients 
having change from baseline scores (range: -5 to 5) will be tabulated for each treatment arm and 
each time point. The associated p-values at each time point will also be presented for each 
pairwise comparison. 
6.2.4 Dermatology Life Quality Index 
The Dermatology Life Quality Index (DLQI) is a simple, patient-administered, 10-question, 
validated, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 19 of 29 
daily activities, leisure, work and school, personal relationships, and treatment. The recall period 
of this scale is over the “last week.” Response categories include “not at all,”, “a little”, “a lot,” 
and “very much,” with corresponding scores of 0, 1, 2, and 3 respectively and unanswered or 
“not relevant” responses scored as 0. For question 7 the response category ‘yes’ is scored 3, 
while a ‘no’ response’ is scored as 2, 1, or 0 based on the follow-up question response “a lot”, “a 
little”, or “not at all” respectively. The DLQI total score will be obtained by summing the scores 
from the 10 questions with a minimum score of 0 and a maximum score of 30. If any one of the 
10 questions is unanswered, that question is scored as 0. However, if 2 or more questions are not 
answered then the DLQI score will not be calculated. 
The DLQI will be assessed at baseline and at Weeks 1, 4, 8, 12, and 16 post-randomization, plus 
at the early termination visit, if applicable. At each of the post-baseline visits the DLQI total 
score will be computed along with the change from baseline. Descriptive statistics for the value, 
change from baseline will be tabulated for each time point.  
The MMRM and ANCOVA analyses described in Section 6.2.1 will be performed to compare 
the baricitinib treatment arms and placebo for change from baseline in the DLQI total score. 
A DLQI responder is defined as a patient with a 4-point or greater decrease from baseline in the 
DLQI total score. At each post-baseline time point and the last observation the number and 
percent of DLQI responders will be compared between each baricitinib arm and placebo using a 
two-sided Fisher’s Exact test at level α = 0.05. This analysis will be performed using only 
patients with a baseline DLQI total score greater than or equal to 4 points.  
Individual domain DLQI scores may be analyzed in post-hoc analyses. 
6.2.5 Itch Numerical Rating Scale 
The Itch Numerical Rating Scale (NRS): The Itch NRS is a patient-administered, 11 point 
horizontal scale anchored at 0 and 10, with 0 representing “no itch” and 10 representing “worst 
itch imaginable.” The patient indicates the overall severity of itching that best describes the 
worst level of itching in the past 24 hours.  
The Itch NRS will be assessed at baseline and at Weeks 1, 4, 8, 12, and 16 post-randomization, 
plus at the early termination visit, if applicable. At each of the post-baseline visits the Itch NRS 
score will be computed along with the change and percent change from baseline. Descriptive 
statistics for the value and changes from baseline will be tabulated for each time point.  
The number and percent of patients with an Itch NRS score of 0 “no itch” will be compared 
between the baricitinib arms and the placebo arm at each time point including baseline using an 
NRI analysis. Patients who either discontinue study treatment or discontinue from the study for 
any reason will be defined as non-responders for the NRI analysis for all assessments that were 
not collected. Randomized patients without at least 1 post-baseline observation of Itch NRS will 
also be defined as non-responders for the NRI analysis. The proportion of patients with no itch in 
the placebo arm will be compared to the proportion of patients in each of the baricitinib arms (2 
mg and 4 mg) using two-sided Fisher’s exact tests with alpha=0.05. The number and percentage 
of patients with no itch will be presented for each treatment arm at each time point including the 
patient’s last assessment. The p-values for the pairwise Fisher’s Exact tests will also be 
tabulated.  


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 20 of 29 
In addition, a bar chart that shows the percent of patients with no itch for each treatment arm at 
each time point including the patient’s last assessment will be presented. The figure display will 
be generated for the overall population and by country.  
The MMRM and ANCOVA analyses described in Section 6.2.1 will be performed to compare 
the baricitinib treatment arms and placebo for change from baseline in the Itch NRS scores. The 
tabular outputs for the MMRM and ANCOVA analyses described will be provided. 
6.3 Exploratory Efficacy Analyses 
6.3.1 Patient-Oriented Eczema Measure 
The Patient Oriented Eczema Measure (POEM) is seven-item patient-administered tool that 
focuses on the atopic dermatitis experienced by the patient. This tool has a one week recall 
period. Each question is scored on a five point scale (0 = no days; 1 = 1-2 days; 2 = 3-4 days; 3 = 
5-6 days; 4 = every day), with a total score ranging from 0 to 28. If a single question is left 
unanswered, then that question is scored as 0. If more than one question is unanswered, then the 
tool is not scored. 
The POEM score will be calculated at baseline and at Weeks 1, 4, 8, 12, and 16 post-
randomization, plus at the early termination visit, if applicable. At each of the post-baseline visits 
the POEM score will be compared with the POEM score obtained at baseline to obtain change 
and percent change from baseline. Descriptive statistics for the value, change and percent change 
from baseline will be tabulated for each time point. 
The MMRM and ANCOVA analyses described in Section 6.2.1 will be performed to compare 
the baricitinib treatment arms and placebo for change from baseline in the POEM score. The 
tabular outputs for the MMRM and ANCOVA analyses described therein will be provided. 
The POEM score can be banded as follows: 
• 
0 to 2 = Clear or almost clear 
• 
3 to 7 = Mild eczema 
• 
8 to 16 = Moderate eczema 
• 
17 to 24 = Severe eczema 
• 
25 to 28 = Very severe eczema 
At each time point, baseline and post-baseline, the banded POEM score will be compared 
between each baricitinib arm and placebo using chi-square statistics with the row mean scores 
option. The number and percentage of patients in each band on the scale will be tabulated for 
each treatment arm and each time point. The associated p-values at each time point will be 
presented for each pairwise comparison. A bar chart that shows the distribution of patients 
among the bands for each treatment arm at each time point including the patient’s last 
assessment will be presented.  
Exploratory analyses may examine individual POEM items. 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 21 of 29 
6.3.2 Analyses for Actigraphy Device data 
Hypoallergenic wrist watch-like devices will be worn by the patients throughout the study. A 
total of three devices will be worn – one device captures activity and sleep while two high-
resolution devices, one worn on each arm, determine nocturnal scratching. Data from the devices 
will be used to summarize sleep/wake patterns and quantify nocturnal scratching events.  
Data from the actigraphy devices will be downloaded at Weeks 1, 4, 8, 12, and 16 post-
randomization, plus at the early termination visit, if applicable. Reproducibility of the data from 
day-to-day is fairly high, so results from the seven days prior to each download will be averaged 
to derive the response variables. Data from baseline will be available as part of the Week 1 
download. At each of the post-baseline visits change from baseline will be computed for each of 
the response variables.  
Additional exploratory analyses may be done, for example evaluating area under the curve to 
compare treatment groups. 
6.3.2.1 Analyses for Sleep/Wake Patterns 
At each time point the following parameters will be analyzed: average number of sleep 
disturbances per night-hour, duration of sleep, time of initial disturbance after sleep onset (WASO), 
onset latency, wake time, percent of time awake, number of wake bouts, fragmentation and sleep 
efficiency. The MMRM analysis described in Section 6.2.1 will be performed to compare the 
baricitinib treatment arms and placebo for change from baseline for each of the variables. The 
tabular outputs for the MMRM analyses will be provided. 
6.3.2.2 Analyses for Nocturnal Scratching 
Three variables will be computed to assess nocturnal scratching – the average number of 
scratching events per night, the average time spent actively scratching during the night, and the 
average number of scratching events per hour. The MMRM analysis described in Section 6.2.1 
will be performed to compare the baricitinib treatment arms and placebo for change from 
baseline for each of the nocturnal itching variables. The tabular outputs for the MMRM analyses 
will be provided. 
6.3.3 Analyses for Quick Inventory of Depressive Symptomatology – Self Report 16 
The Quick Inventory Depressive Symptomatology - Self Report 16 (QIDS-SR16) is a self-
administered 16-item instrument intended to assess the existence and severity of symptoms of 
depression. The QIDS-SR16 scale is used to assess the potential impact of treatment on new 
onset or changes in depression, thoughts of death, and /or suicidal ideation severity. A patient is 
asked to consider each statement as it relates to the way they have felt for the past 7 days. There 
is a 4-point scale for each item ranging from 0 to 3. The 16 items corresponding to 9 depression 
domains are summed to give a single score ranging from 0 to 27, with higher scores denoting 
greater symptom severity. The domains assessed by the instrument include: (1) sad mood, (2) 
concentration, (3) self-criticism, (4) suicidal ideation, (5) interest, (6) energy/fatigue, (7) sleep 
disturbance (initial, middle, and late insomnia or hypersomnia), (8) decrease/increase in 
appetite/weight, and (9) psychomotor agitation/retardation. The score is derived by adding the 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 22 of 29 
following nine numbers – results from questions 5 (depressed mood), 10 (concentration), 11 
(worthlessness/guilt), 12 (suicidal ideation), 13 (decreased interest), 14 (decreased energy) plus 
the highest scores from questions 1-4 (sleep), 6-9 (weight/appetite changes), and 15-16 
(psychomotor changes), respectively.  If any single question is left unanswered, then that 
question is scored as 0. 
The QIDS-SR16 will be assessed at baseline and at Weeks 1, 4, 8, 12, and 16 post-
randomization, plus at the early termination visit, if applicable. At each of the post-baseline visits 
the QIDS-SR16 domain scores and total score will be calculated, and the scores will be 
compared with the respective baseline score to obtain change and percent from baseline. 
Descriptive statistics for the value and changes from baseline will be tabulated for each domain 
and total score and at each time point. 
The QIDS-SR16 total score will be categorized as follows: 
• 
0 to 5 = No depression 
• 
6 to 10 = Mild depression 
• 
11 to 15 = Moderate depression 
• 
16 to 20 = Severe depression 
• 
21 to 27 = Very severe depression 
At each time point, baseline and post-baseline, the level of depression will be compared between 
each baricitinib arm and placebo using chi-square statistics with the row mean scores option. The 
number and percentage of patients in each depression level will be tabulated for each treatment 
arm and each time point. The associated p-values at each time point will be presented for each 
pairwise comparison. A bar chart that shows the distribution of patients among the bands for 
each treatment arm at each time point including the patient’s last assessment will be presented. 
The table and figure displays will be generated for the overall population and for patients 
enrolled in Japan. 
6.3.4 Exploratory Subgroup Assessment of Response 
Subgroup assessments of response based on patient and disease characteristics will be performed 
on an ad hoc basis. Reviews of the data will include evaluations of potential prognostic and 
predictive disease characteristics with specific interest in how these prognostic factors impact the 
EASI score. If a potential prognostic factor merits further consideration the exploratory analyses 
will at least include an NRI logistic regression analysis of the EASI-50 after 16 weeks where 
treatment, country and the potential factor are included in the model. 
7 
Safety Analyses 
All analyses of safety including the extent of exposure to study medication will be performed 
using the safety population. Reports will be generated using the overall population, and some 
reports will be repeated using only patients enrolled in Japan. 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 23 of 29 
7.1 Study Medication Exposure and Treatment Compliance 
7.1.1 Extent of Exposure 
Extent of exposure will be derived as: 
Extent of Exposure = Date of 1st dose of study medication –Date of last dose of study medication +1, 
where study medication considers only the study tablets. Extent of exposure will be descriptively 
summarized for each treatment arm.  
Patients in this trial will also be given triamcinolone 0.1% cream as a concomitant therapy. The 
use of the cream will commence at the time of the first study visit and will continue throughout 
the treatment period of the study. The amount of triamcinolone 0.1% cream used will be derived 
for both the baseline period and the treatment period. In both cases the usage will be normalized 
to a 30 day period, i.e.  
Triamcinolone average monthly usage = 
total weight (in grams)dispensed−total weight(in grams) returned
duration (in days)of study period/30 days
. 
The baseline period will commence on the date that the triamcinolone 0.1% cream is first 
dispensed and end on the day prior to the date of first dose of randomly assigned study treatment. 
The treatment period will commence on the date of first dose of randomly assigned study 
treatment and end on the date of last treatment period visit, i.e. usually the earlier of the date of 
the Week 16 clinic visit or the date of the early termination visit. For both study periods, 
triamcinolone average monthly usage will be descriptively summarized for each treatment arm 
using the overall and by-country populations. If warranted after review of the data, additional 
analyses of select efficacy variables that incorporate the triamcinolone average monthly usage as 
a covariate in the statistical model may be considered.  
7.1.2 Treatment Compliance 
Treatment compliance with the randomly assigned study medication will be evaluated at every 
clinic visit, so that the clinical site can reinforced the importance of treatment compliance with 
the patient. A patient will be considered significantly noncompliant if he or she misses more than 
20% of the prescribed doses during the study, i.e. compliance < 80%. Similarly, a patient will be 
considered significantly noncompliant if he or she is judged by the investigator to have 
intentionally or repeatedly taken more than the prescribed amount of medication, i.e. compliance 
≥ 120%. Persistent non-compliance can result in the patient being discontinued from the study. 
For the purpose of analysis only the overall treatment compliance will be summarized. Treatment 
compliance will be derived as 
Treatment Compliance = 
total number of tablets dispensed−total number of tablets returned
total number of tablets expected
. 
The total number of tablets expected will be equal to the number of days between the date of first 
dose of randomly assigned study treatment and the date of the patient’s last treatment period 
visit.  
Treatment compliance will be descriptively summarized for each treatment arm. In addition, the 
number and percentage of patients whose compliance < 80% or ≥ 120% will also be presented 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 24 of 29 
for each treatment arm. Treatment compliance summaries will be produced using the ITT 
population. 
7.2 Adverse Events 
AEs will be collected from the day the patient gives informed consent until 30 days after the 
final dose of study drug or until resolution of all serious adverse events (SAEs). Only those AEs 
that emerge or worsen after the date of first dose of randomly assigned study medication, i.e. 
treatment emergent adverse events (TEAE), will be reported. Adverse events with a missing start 
date will also be classified as TEAE. 
Summaries of TEAE will include the number of patients with at least one TEAE for each 
treatment arm. When reporting by system organ class (SOC) and preferred term (PT), the reports 
will present the SOC in alphabetical order; while PTs within the SOC will be presented in order 
of overall decreasing frequency of occurrence in the combined baricitinib arms. A patient with 
multiple TEAEs (different PTs) coded to the same SOC will be counted only once for that SOC, 
but will be counted each time for different PTs within that SOC. A patient with separate events 
of the same PT (different start/stop dates) will be counted only once in the frequency tables for 
that PT. 
TEAEs will be reported using the treatment that the patient received.  
No statistical testing will be performed for comparisons of TEAEs. 
An overview of all TEAEs will also be provided by treatment group using the types of AEs 
defined in the following subsections. 
7.2.1. Treatment-Emergent Adverse Events 
TEAEs will be summarized by SOC and PT for each treatment arm. In addition, a presentation of 
TEAE preferred terms in decreasing frequency in the combined baricitinib treatment arms will 
be provided.  
7.2.2. Treatment Related TEAE 
Every AE will be assessed by the investigator for its relationship to the randomly assigned study 
medication. The subset of TEAE considered by the investigator as related to study treatment will 
be called treatment related TEAE. 
Treatment related TEAE will be summarized for each treatment arm by SOC and PT and by 
decreasing frequency in the combined baricitinib arms.  
7.2.3 Serious Treatment-Emergent Adverse Events 
An SAE is an AE that met one or more of the following criteria: 
• 
death 
• 
initial or prolonged inpatient hospitalization 
• 
a life-threatening experience (that is, immediate risk of dying) 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 25 of 29 
• 
persistent or significant disability/incapacity 
• 
congenital anomaly/birth defect or 
• 
considered significant by the investigator for any other reason 
Serious TEAEs will be summarized for each treatment arm by SOC and. A listing of all SAE 
will also be provided. The listing will be sorted by treatment arm, country, patient ID and study 
day of onset. 
7.2.4 TEAE Resulting in Death 
If there are any TEAE that result in death, then a listing of all deaths will be provided. The listing 
will be sorted by treatment arm, country, patient ID and study day of onset. 
7.2.5 TEAE Leading to Study Drug Discontinuation 
For every AE in the eCRF the investigator indicates whether the action taken with respect to the 
study medication was dose not changed or drug withdrawn.  
The TEAE that lead to study drug discontinuation will be summarized for each treatment arm by 
SOC and PT and by decreasing frequency in the combined baricitinib. A listing of the TEAE that 
lead to study drug discontinuation will also be provided. 
7.2.6 TEAE by Maximal Severity 
Every AE will be graded by the investigator as mild, moderate, or severe, so for each patient the 
greatest severity observed can be obtained by comparing the severity of all of a patient’s TEAE 
that share the same SOC or PT. A table of TEAE by maximal severity will be prepared for each 
treatment arm by SOC and PT.  
7.2.7 Adverse Events of Special Interest 
Adverse events or laboratory results of special interest include infections; myelosuppressive 
events of anaemia (haemoglobin decreased), leukopenia (white blood cell count decreased), 
neutropenia (neutrophil count decreased), lymphopenia (lymphocyte count decreased), 
thrombocytopenia (red blood cell count decreased), thrombocythaemia (platelet count increased); 
hyperlipidaemia (lipids increased); hypercholesterolemia (cholesterol increased); and elevations 
in hypertransaminasaemia (aminotransferase increased) and hyperbilirubinemia (bilirubin 
increased). All TEAE for which the PT contains any of the above terms or that belong to the 
SOC ‘Infections and infestations’ will be considered an AE of special interest. The TEAE of 
special interest will be summarized for each treatment arm by SOC and PT and by decreasing 
frequency in the combined baricitinib arms.  
7.3 Clinical Laboratory Results 
Blood samples for hematology and serum chemistry and urine samples for urinalysis will be 
collected at baseline and Weeks 4, 8, 12, and 16 post-randomization. Blood samples for fasting 
lipid profiles will be collected at baseline and Week 16 post-randomization, and blood samples 
for immunoglobulins will be collected at baseline and Weeks 8 and 16 post-randomization. If a 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 26 of 29 
patient decides to discontinue early from the study, samples for each of the parameters will be 
collected prior to discontinuation. 
Analyses of laboratory values will be produced using the measurements collected the scheduled 
time points. The unscheduled assessments will only appear in data listings. An exception will be 
made for the analyses of the last measured values which for patients who do not have a 
measurement at Week 16 will be derived using the last collected scheduled or unscheduled 
measurement.   
7.3.1 Descriptive Statistics over Time 
At each of the post-baseline visits the change and percent change from baseline for each every 
quantitative clinical laboratory parameter will be derived. Descriptive statistics for the value and 
changes from baseline will be tabulated for each time point for each treatment arm. 
7.3.2 Shift tables and Categorical variables 
The grading of each laboratory parameter as low, normal or high will be compared from baseline 
to Week 16 and to the last observation, which should be the Week 16 or early termination visit, 
Shift tables will present the number and percent of patients who started in a category (low, 
normal, high) at baseline and category at the end of the study. Similarly, shift tables for the 
categorical urinalysis parameter will also be produced.  
Shift tables comparing baseline to the other time points in the study may be generated if 
warranted after data review. 
Additional shift tables will be constructed for the liver parameters – alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin 
(TBili). For each of the transaminases the number of patients with any post-baseline elevation 
exceeding 3 times the upper limit of the normal range (3xULN) will be counted by treatment 
arm. The counts of patients will be reported using subsets defined by the patients’ baseline 
transaminase values; i.e. ALT ≤ 1xULN, 1xULN < ALT ≤ 2xULN. The analyses of ALT and 
AST elevations will also be performed using 5xULN and 10xULN For TBili the number of 
patients with any post-baseline elevation exceeding 2xULN will be counted by treatment arm 
using the subsets TBili ≤ 1xULN and TBili > 1xULN. For ALP the number of patients with any 
post-baseline elevation exceeding 1.5xULN (also 2xULN and 3xULN) will be counted by 
treatment arm. 
7.4 Vital Signs and Weight 
The vital signs pulse and blood pressure will be assessed at baseline and at Weeks 1, 4, 8, 12, 
and 16 post-randomization, plus at the early termination visit, if applicable. Except for the Week 
1 visit, weight will also be collected. At each of the post-baseline visits the vital signs and weight 
change from baseline will be computed. Descriptive statistics for the value and change from 
baseline will be tabulated for each time point. In addition, the number and percentage of patients 
with a systolic blood pressure reading either ≤ 90 mmHg or ≥ 160 mmHg or a change 
≥20 mmHg, with a diastolic blood pressure reading either ≤ 50 mmHg or ≥ 100 mmHg or a 
change ≥10 mmHg, or with a pulse either < 50 bpm or > 100 bpm or a change ≥15 bpm will also 
be presented by treatment group at each time point. 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 27 of 29 
No statistical analyses are planned. Any clinically significant findings should result in a 
diagnosis to be reported as an AE. If warranted by additional review of the data further analyses 
will be performed. 
7.5 Biomarker Results 
Skin biopsies, serum, plasma, and whole blood ribonucleic acid (RNA) samples for non-genetic 
biomarker research will be collected where local regulations and external review boards allow. 
The analyses of biomarkers will be presented for the overall population and by country. Analyses 
of biomarkers are exploratory objectives, so additional post-hoc analyses may be added if review 
of the data indicates such analyses are warranted. 
7.5.1 Skin biopsies 
Skin biopsy samples from atopic dermatitis lesions and adjacent normal tissue will be collected 
to study biomarkers related to atopic dermatitis and/or related to the mechanism of action of 
baricitinib. Samples will be collected at baseline and at Week 16. An additional sample from the 
lesion will be collected at Week 4. The tissue biomarkers to be collected include IL-4, Ki67, 
K16, and epidermal thickness. Change and percentage change from baseline for each parameter 
will be derived for each patient at each post-baseline visit for each type of tissue for each patient. 
Descriptive statistics for the value, change and percentage change will be tabulated for each time 
point.  
7.5.2 Blood biomarkers 
Peripheral blood and serum samples will be collected at baseline and at Weeks 4 and 16. The 
blood biomarkers to be collected include eosinophils, IL-4, IL-5, IL-10, IL-12, IL-13, IL-19, IL-
31, CCL17/TARC, IgE, lactate dehydrogenase (LDH), and interferon gamma (IFH-g). Change 
and percentage change from baseline for each parameter will be derived for each patient at each 
post-baseline visit for each type of tissue for each patient. Descriptive statistics for the value, 
change and percentage change will be tabulated for each time point. Descriptive statistics for the 
maximal post-baseline change and percent change will also be presented. 
7.5.3 Filaggrin genotyping 
A blood sample for genotyping of filaggrin will be collected at baseline (Visit 2). The percent 
wild type will be descriptively summarized for the overall population. Scatterplots of filaggrin 
genotype with the change and percent change in EASI after 16 weeks of treatment will be 
presented along with the associated Pearson’s correlation coefficient will be provided for the 
overall population. In addition, for each treatment group side-by-side box plots of the filaggrin 
genotype will be produced for the patients who did/did not achieve EASI-50 after 16 weeks of 
treatment.  
7.5.4 Correlation between Baseline Biomarkers 
Pearson correlation coefficients will be calculated for each pair of biomarkers. The baseline 
values of these biomarkers will be used for this analysis, and all patients with baseline biomarker 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 28 of 29 
data will be included. A table of all pairwise correlations will be generated for the overall 
population. The pairwise scatterplots may also be produced if warranted based on review of the 
data and results. 
7.5.5 Biomarkers as Measures of Disease Severity 
Pearson correlation coefficients will be calculated for each biomarker and efficacy variable 
pairing. The baseline values of the biomarkers (skin biopsy, blood biomarker, and filaggrin 
genotype) and the efficacy variables (EASI, SCORAD, IGA, DLQI, Itch NRS, and POEM) will 
be used for this analysis. All patients with baseline biomarker data and efficacy data will be 
included. A table of all pairwise correlations will be generated for the overall population. The 
pairwise scatterplots may also be produced if warranted based on review of the data and results. 
8 
Pharmacokinetic Analyses 
Venous blood samples (approximately 5 mL per sample) for the measurement of baricitinib 
concentrations will be drawn at baseline (pre-dose and at 15-30 minutes post-dose) and Weeks 4 
(1.5-4 hours post-dose), 8 (4-8 hours post-dose), 12 (pre-dose), and 16 (30-90 minutes post-dose) 
post-randomization, plus at the early termination visit, if applicable. Plasma samples from 
patients on active treatment will be assayed for baricitinib using liquid chromatography and 
tandem mass spectrometry (LC/MS/MS).  
Baricitinib concentrations will be summarized by treatment and time window using summary 
statistics (n, mean, standard deviation, coefficient of variation [CV], minimum, median, 
maximum, geometric mean, and geometric CV). 
A population PK analysis will be performed separately and reported in a population PK report.  
Exposure-response relationships between the primary and select secondary efficacy endpoints 
and plasma exposure may also be explored. 
9 
Health Outcome Psychometric Analyses 
A separate analysis plan (GPORWE 2016-0067) describing the psychometric analyses of the Itch 
NRS and POEM as well as responder definition will be provided by Lilly Global Patient 
Outcomes and Real World Evidence. 


Lilly l CHORUS  
I4V-MC-JAHG 
Baricitinib  
Statistical Analysis Plan 
Version 1.0 
Confidential 
Page 29 of 29 
References 
1 Gillings D, Koch G. The application of the principle of intention to treat to the analysis of 
clinical trial. Drug Inf J. 1991;25:411–424.